assay_id,src_assay_id,description,assay_category,bao_format,chembl_id,doc_id,assay_tax_id,curated_by,src_id,cell_id,assay_type,assay_test_type,assay_organism,assay_strain,assay_tissue,assay_cell_type
1,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,BAO_0000019,CHEMBL615117,11087,,Autocuration,1,,B,,,,,
2,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,BAO_0000219,CHEMBL615118,684,,Autocuration,1,,F,,,,,
3,,,,BAO_0000019,CHEMBL615119,15453,,Autocuration,1,,B,,,,,
4,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,BAO_0000249,CHEMBL615120,17841,9913.0,Autocuration,1,,B,,Bos taurus,,,
5,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,BAO_0000219,CHEMBL615121,17430,9606.0,Intermediate,1,163.0,F,,Homo sapiens,,,143B
6,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,BAO_0000219,CHEMBL615122,17430,9606.0,Intermediate,1,163.0,F,,Homo sapiens,,,143B
7,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,BAO_0000219,CHEMBL615123,13799,10090.0,Intermediate,1,163.0,F,,Mus musculus,,,143B
8,,In vitro cell cytotoxicity was determined against 143B cell line,,BAO_0000219,CHEMBL615124,17774,9606.0,Expert,1,163.0,F,,Homo sapiens,,,143B
9,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,BAO_0000219,CHEMBL615125,3801,9606.0,Intermediate,1,163.0,F,,Homo sapiens,,,143B
10,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,BAO_0000219,CHEMBL615126,17430,9606.0,Intermediate,1,163.0,F,,Homo sapiens,,,143B
11,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,BAO_0000219,CHEMBL615127,17430,9606.0,Intermediate,1,163.0,F,,Homo sapiens,,,143B
12,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,BAO_0000219,CHEMBL615128,17774,9606.0,Expert,1,163.0,F,,Homo sapiens,,,143B
13,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,CHEMBL857900,11324,1280.0,Intermediate,1,,F,,Staphylococcus aureus,,,
14,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,CHEMBL615129,11324,1280.0,Intermediate,1,,F,,Staphylococcus aureus,,,
15,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,CHEMBL615130,11324,1280.0,Intermediate,1,,F,,Staphylococcus aureus,,,
16,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,CHEMBL615131,11324,1280.0,Intermediate,1,,F,,Staphylococcus aureus,,,
17,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,BAO_0000357,CHEMBL884521,11347,10116.0,Expert,1,,A,,Rattus norvegicus,,,
18,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,CHEMBL615132,16474,,Autocuration,1,,B,,,,,
19,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,BAO_0000019,CHEMBL615133,10091,,Autocuration,1,,B,,,,,
20,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,CHEMBL615134,16474,,Autocuration,1,,B,,,,,
21,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,CHEMBL615135,16474,,Autocuration,1,,B,,,,,
22,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,CHEMBL615136,16474,,Autocuration,1,,B,,,,,
23,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,CHEMBL615137,16474,,Autocuration,1,,B,,,,,
24,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,CHEMBL615138,16474,,Autocuration,1,,B,,,,,
25,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,BAO_0000219,CHEMBL836324,14352,,Autocuration,1,,B,,,,,
26,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,BAO_0000357,CHEMBL615139,5646,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
27,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,BAO_0000357,CHEMBL615140,5646,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
28,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,CHEMBL615141,10997,,Autocuration,1,,B,,,,,
29,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,BAO_0000357,CHEMBL615142,6309,3847.0,Autocuration,1,,B,,soya bean,,,
30,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,BAO_0000357,CHEMBL615143,167,3847.0,Autocuration,1,,B,,Glycine max,,,
31,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,BAO_0000357,CHEMBL615144,167,3847.0,Autocuration,1,,B,,Glycine max,,,
32,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,BAO_0000357,CHEMBL872867,11087,3847.0,Autocuration,1,,B,,Glycine max,,,
33,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,BAO_0000357,CHEMBL615145,11087,3847.0,Autocuration,1,,B,,Glycine max,,,
34,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,CHEMBL615146,13622,3847.0,Autocuration,1,,B,,Glycine max,,,
35,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,CHEMBL615147,13622,3847.0,Autocuration,1,,B,,Glycine max,,,
36,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,BAO_0000019,CHEMBL615148,11347,10116.0,Autocuration,1,,A,,Rattus norvegicus,,,
37,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,BAO_0000019,CHEMBL615149,5926,562.0,Autocuration,1,,B,,Escherichia coli,,,
38,,Dissociation constant with dimeric 16S rRNA RNA construct B,,BAO_0000019,CHEMBL615150,4567,,Autocuration,1,,B,,,,,
39,,Dissociation constant towards 16S rRNA construct A,,BAO_0000225,CHEMBL615151,3782,,Intermediate,1,,B,,,,,
40,,Dissociation constant towards 16S rRNA construct B,,BAO_0000225,CHEMBL615152,3782,,Intermediate,1,,B,,,,,
41,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,BAO_0000225,CHEMBL615153,4466,562.0,Expert,1,,B,,Escherichia coli,,,
42,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,BAO_0000225,CHEMBL615154,6592,562.0,Expert,1,,B,,Escherichia coli,,,
43,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,CHEMBL615155,898,,Autocuration,1,,B,,,,,
44,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,CHEMBL615156,898,,Autocuration,1,,B,,,,,
45,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,CHEMBL615157,13163,9606.0,Autocuration,1,,B,,Homo sapiens,,,
46,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,CHEMBL615158,13163,9606.0,Autocuration,1,,B,,Homo sapiens,,,
47,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,CHEMBL615159,10691,10116.0,Expert,1,,B,,Rattus norvegicus,,,
48,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,CHEMBL615172,10691,10116.0,Expert,1,,B,,Rattus norvegicus,,,
49,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,CHEMBL615173,10691,10116.0,Expert,1,,B,,Rattus norvegicus,,,
50,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,CHEMBL615174,10691,10116.0,Expert,1,,B,,Rattus norvegicus,,,
51,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,CHEMBL884518,898,,Autocuration,1,,B,,,,,
52,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,BAO_0000357,CHEMBL615175,912,,Autocuration,1,,B,,,,,
53,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,BAO_0000357,CHEMBL615176,912,,Autocuration,1,,B,,,,,
54,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,BAO_0000357,CHEMBL615177,912,,Autocuration,1,,B,,,,,
55,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,BAO_0000249,CHEMBL615178,15103,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
56,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,BAO_0000219,CHEMBL615179,5116,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
57,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,BAO_0000219,CHEMBL615180,14578,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,Oocytes
58,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,BAO_0000219,CHEMBL615181,14578,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,Oocytes
59,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,BAO_0000219,CHEMBL615182,14578,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,Oocytes
60,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,BAO_0000219,CHEMBL615183,4787,9606.0,Expert,1,506.0,F,,Homo sapiens,,,1A9
61,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,BAO_0000219,CHEMBL615184,4787,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
62,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,BAO_0000219,CHEMBL615185,3547,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
63,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,BAO_0000219,CHEMBL615186,3547,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
64,,Effective dose of compound against replication of 1A9 cell line was evaluated,,BAO_0000219,CHEMBL615187,6726,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
65,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,BAO_0000219,CHEMBL885343,3455,9606.0,Expert,1,506.0,F,,Homo sapiens,,,1A9
66,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,BAO_0000219,CHEMBL615188,5726,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
67,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,BAO_0000219,CHEMBL615189,5726,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
68,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,BAO_0000219,CHEMBL615190,5726,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
69,,Inhibitory activity against Taxol resistant 1A9 cell lines,,BAO_0000219,CHEMBL615191,3395,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
70,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,BAO_0000219,CHEMBL615192,3415,9606.0,Expert,1,506.0,F,,Homo sapiens,,,1A9
71,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,BAO_0000219,CHEMBL827083,3415,9606.0,Expert,1,506.0,F,,Homo sapiens,,,1A9
72,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,BAO_0000219,CHEMBL615193,17099,9606.0,Expert,1,506.0,F,,Homo sapiens,,,1A9
73,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,BAO_0000219,CHEMBL615194,17099,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
74,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,BAO_0000219,CHEMBL615195,17099,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
75,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,BAO_0000219,CHEMBL615196,17099,9606.0,Intermediate,1,506.0,F,,Homo sapiens,,,1A9
76,,Inhibitory concentration against Jurkat cells,,BAO_0000219,CHEMBL615197,17721,9606.0,Intermediate,1,503.0,F,,Homo sapiens,,,Jurkat
77,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,BAO_0000019,CHEMBL615198,1229,,Intermediate,1,,F,,,,,
78,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,BAO_0000357,CHEMBL615199,11347,10116.0,Expert,1,,A,,Rattus norvegicus,,,
79,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,CHEMBL615200,17117,,Expert,1,,B,,,,,
80,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,CHEMBL615201,17117,,Expert,1,,B,,,,,
81,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,BAO_0000357,CHEMBL615202,17117,,Expert,1,,B,,,,,
82,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,BAO_0000251,CHEMBL615203,11375,5476.0,Autocuration,1,,B,,Candida albicans,,,
83,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,BAO_0000251,CHEMBL615204,11375,5476.0,Autocuration,1,,B,,Candida albicans,,,
84,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,BAO_0000251,CHEMBL615205,11375,4932.0,Autocuration,1,,B,,Saccharomyces cerevisiae,,,
85,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,BAO_0000251,CHEMBL615206,11375,4932.0,Autocuration,1,,B,,Saccharomyces cerevisiae,,,
86,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,BAO_0000251,CHEMBL615207,11375,9823.0,Autocuration,1,,B,,Sus scrofa,,Liver,
87,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,BAO_0000019,CHEMBL827084,791,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
88,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,BAO_0000019,CHEMBL615208,791,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
89,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,BAO_0000019,CHEMBL615209,791,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
90,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,BAO_0000251,CHEMBL615210,11375,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
91,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,BAO_0000251,CHEMBL615211,11375,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
92,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,BAO_0000251,CHEMBL615212,153,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
93,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,BAO_0000357,CHEMBL615213,8269,,Expert,1,,B,,,,,
94,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,BAO_0000357,CHEMBL615273,8269,,Expert,1,,B,,,,,
95,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000219,CHEMBL615274,17653,9606.0,Expert,1,726.0,F,,Homo sapiens,,,HepG2
96,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,BAO_0000219,CHEMBL615275,14277,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
97,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,BAO_0000219,CHEMBL615276,1717,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
98,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,BAO_0000219,CHEMBL615277,14091,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
99,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,BAO_0000219,CHEMBL615326,14091,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
100,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000218,CHEMBL883130,17653,10407.0,Expert,1,,F,,Hepatitis B virus,,,
101,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,BAO_0000219,CHEMBL884519,13105,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
102,,Concentration required to inhibit 50% of 2.2.15 cell line,,BAO_0000219,CHEMBL615327,1717,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
103,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,BAO_0000219,CHEMBL615328,13105,9606.0,Intermediate,1,726.0,A,,Homo sapiens,,,HepG2
104,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,BAO_0000218,CHEMBL615329,13600,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
105,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,BAO_0000218,CHEMBL615330,13467,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
106,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,BAO_0000218,CHEMBL615331,17477,10407.0,Expert,1,,F,,Hepatitis B virus,,,2.2.15
107,,In vitro anti-HBV activity in 2.2.15 cells,,BAO_0000218,CHEMBL615332,1593,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
108,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,BAO_0000218,CHEMBL615333,1593,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
109,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,BAO_0000218,CHEMBL615334,15089,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
110,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,BAO_0000218,CHEMBL615335,15089,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
111,,Cytotoxicity in 2.2.15 cells,,BAO_0000218,CHEMBL615336,1593,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
112,,Cytotoxicity in 2.2.15 cells; Not determined,,BAO_0000218,CHEMBL615337,1593,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
113,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,BAO_0000218,CHEMBL615338,13600,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
114,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,BAO_0000218,CHEMBL615339,13467,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
115,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,BAO_0000218,CHEMBL615340,13467,9606.0,Intermediate,1,,F,,Homo sapiens,,,2.2.15
116,,Antiviral activity against HBV was determined in 2.215 cell line,,BAO_0000219,CHEMBL615341,14764,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
117,,Inhibition of 20-HETE synthesis in human renal microsomes,,BAO_0000251,CHEMBL615342,6531,9606.0,Autocuration,1,,B,,Homo sapiens,,,
118,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,BAO_0000019,CHEMBL615343,17322,,Autocuration,1,,B,,,,,
119,,Inhibitory concentration against 2008 (ovarian) cells,,BAO_0000219,CHEMBL615344,17072,9606.0,Intermediate,1,388.0,F,,Homo sapiens,,,2008
120,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,BAO_0000219,CHEMBL615345,16936,9606.0,Intermediate,1,388.0,F,,Homo sapiens,,,2008
121,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,BAO_0000219,CHEMBL615346,16936,9606.0,Intermediate,1,388.0,F,,Homo sapiens,,,2008
122,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,BAO_0000219,CHEMBL615347,17146,9606.0,Intermediate,1,388.0,F,,Homo sapiens,,,2008
123,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,BAO_0000219,CHEMBL615348,17146,9606.0,Intermediate,1,388.0,F,,Homo sapiens,,,2008
124,,In vitro inhibition of 2008/R ovarian cancer cell line,,BAO_0000219,CHEMBL827085,10797,9606.0,Intermediate,1,561.0,F,,Homo sapiens,,,2008/R
125,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,BAO_0000219,CHEMBL615349,10797,9606.0,Intermediate,1,561.0,F,,Homo sapiens,,,2008/R
126,,In vitro inhibition of 2008/S ovarian cancer cell line,,BAO_0000219,CHEMBL615350,10797,9606.0,Intermediate,1,389.0,F,,Homo sapiens,,,2008/S
127,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,BAO_0000219,CHEMBL615351,10797,9606.0,Intermediate,1,389.0,F,,Homo sapiens,,,2008/S
128,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,BAO_0000220,CHEMBL615352,4823,9606.0,Expert,1,,B,,Homo sapiens,,,
129,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,BAO_0000220,CHEMBL615353,12912,9606.0,Intermediate,1,,B,,Homo sapiens,,,
130,,Inhibition of chymotrypsin-like activity of 20S proteasome,,BAO_0000220,CHEMBL615354,2957,,Expert,1,,B,,,,,
131,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,BAO_0000220,CHEMBL615355,2957,,Expert,1,,B,,,,,
132,,Inhibitory activity against 20S proteosome,,BAO_0000220,CHEMBL615356,3260,,Intermediate,1,,B,,,,,
133,,Compound was tested for inhibitory activity against tryptase,,BAO_0000019,CHEMBL615357,3451,9606.0,Autocuration,1,,B,,Homo sapiens,,,
134,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,BAO_0000219,CHEMBL615358,13885,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
135,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,BAO_0000219,CHEMBL827086,13885,9606.0,Intermediate,1,726.0,F,,Homo sapiens,,,HepG2
136,,Compound was tested for the inhibition of Alpha-glucosidase,,BAO_0000019,CHEMBL615359,3676,,Autocuration,1,,B,,,,,
137,,Inhibitory concentration against human neutrophil elastase (HNE),,BAO_0000357,CHEMBL615360,6043,,Autocuration,1,,B,,,,,
138,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,BAO_0000218,CHEMBL615361,11140,10116.0,Autocuration,1,,F,,Rattus norvegicus,,Heart,
139,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,CHEMBL615362,10543,,Autocuration,1,,F,,,,,
140,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,CHEMBL615363,10543,,Expert,1,,F,,,,,
141,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000357,CHEMBL615364,10543,,Autocuration,1,,B,,,,,
142,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,CHEMBL615365,10543,,Expert,1,,F,,,,,
143,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,BAO_0000219,CHEMBL615366,11365,10090.0,Intermediate,1,524.0,F,,Mus musculus,,,P338
144,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,BAO_0000219,CHEMBL615367,11365,10090.0,Intermediate,1,524.0,F,,Mus musculus,,,P338
145,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,BAO_0000219,CHEMBL615368,11803,9606.0,Intermediate,1,554.0,F,,Homo sapiens,,,PBL
146,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,BAO_0000019,CHEMBL615369,11803,9940.0,Autocuration,1,,F,,Ovis aries,,,
147,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,BAO_0000019,CHEMBL615370,11803,9940.0,Autocuration,1,,F,,Ovis aries,,,
148,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,BAO_0000357,CHEMBL615673,12278,,Autocuration,1,,B,,,,,
149,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,BAO_0000019,CHEMBL615674,8249,9606.0,Autocuration,1,,F,,Homo sapiens,,,
150,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,BAO_0000019,CHEMBL615675,8249,9606.0,Autocuration,1,,F,,Homo sapiens,,,
151,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,BAO_0000219,CHEMBL615676,8249,9606.0,Autocuration,1,635.0,F,,Homo sapiens,,,CCRF-CEM
152,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,BAO_0000219,CHEMBL615677,8249,9606.0,Autocuration,1,635.0,F,,Homo sapiens,,,CCRF-CEM
153,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,BAO_0000219,CHEMBL615678,8249,9606.0,Autocuration,1,635.0,F,,Homo sapiens,,,CCRF-CEM
154,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,BAO_0000219,CHEMBL615679,8249,9606.0,Autocuration,1,635.0,F,,Homo sapiens,,,CCRF-CEM
155,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,BAO_0000019,CHEMBL615680,8249,9606.0,Autocuration,1,,F,,Homo sapiens,,,
156,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,BAO_0000019,CHEMBL615681,8249,9606.0,Autocuration,1,,F,,Homo sapiens,,,
157,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,BAO_0000249,CHEMBL857972,16992,,Autocuration,1,,B,,,,,
158,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,BAO_0000218,CHEMBL857899,10543,1314.0,Intermediate,1,,F,,Streptococcus pyogenes,,,
159,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,BAO_0000218,CHEMBL615371,17833,10335.0,Intermediate,1,,F,,Human herpesvirus 3,,,
160,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,BAO_0000218,CHEMBL615372,17290,10335.0,Expert,1,468.0,F,,vericilla zoster virus,,,HEL
161,,Antiviral activity against 07/1 strain of VZV; ND: No data,,BAO_0000218,CHEMBL615373,17290,10335.0,Intermediate,1,,F,,vericilla zoster virus,,,
162,,Antiviral activity against 07/1 strain of VZV; ND=No data,,BAO_0000218,CHEMBL615374,17290,10335.0,Intermediate,1,,F,,vericilla zoster virus,,,
163,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,BAO_0000218,CHEMBL615375,10932,561.0,Intermediate,1,,F,,escherichia cloac,,,
164,,Ratio of Ki at A2 to Ki at A1 receptors,,BAO_0000019,CHEMBL615376,9707,,Autocuration,1,,B,,,,,
165,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,BAO_0000249,CHEMBL615377,2346,5476.0,Expert,1,,B,,Candida albicans,,,
166,,"Inhibition of 1,3-beta-glucan synthase",,BAO_0000357,CHEMBL615378,2205,284593.0,Expert,1,,B,,Candida glabrata CBS 138,,,
167,,Inhibition of growth of 1-87 human tumor cell line,,BAO_0000219,CHEMBL615379,11900,9606.0,Intermediate,1,832.0,F,,Homo sapiens,,,1-87 tumor cell line
168,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,BAO_0000219,CHEMBL615380,14864,10116.0,Expert,1,,B,,Rattus norvegicus,,,
169,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,BAO_0000357,CHEMBL615381,16474,3847.0,Autocuration,1,,B,,Glycine max,,,
170,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,BAO_0000357,CHEMBL615382,16474,3847.0,Autocuration,1,,B,,Glycine max,,,
171,,% inhibition against soybean 1-lipoxygenase (SLO),,BAO_0000357,CHEMBL615383,16474,3847.0,Autocuration,1,,B,,Glycine max,,,
172,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,BAO_0000357,CHEMBL615384,16474,3847.0,Autocuration,1,,B,,Glycine max,,,
173,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,BAO_0000357,CHEMBL615385,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
174,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,BAO_0000357,CHEMBL615386,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
175,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,BAO_0000357,CHEMBL615387,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
176,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,BAO_0000357,CHEMBL615388,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
177,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,BAO_0000357,CHEMBL615214,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
178,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,BAO_0000357,CHEMBL827087,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
179,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,BAO_0000357,CHEMBL615215,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
180,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,BAO_0000357,CHEMBL615216,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
181,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,BAO_0000357,CHEMBL615217,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
182,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,BAO_0000357,CHEMBL615218,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
183,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,BAO_0000357,CHEMBL615219,3094,3847.0,Autocuration,1,,B,,Glycine max,,,
184,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,BAO_0000019,CHEMBL615220,10413,10090.0,Autocuration,1,,B,,Mus musculus,,,
185,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,BAO_0000219,CHEMBL615221,16929,10090.0,Intermediate,1,294.0,F,,Mus musculus,,,C3H 10T1/2
186,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,BAO_0000019,CHEMBL615222,1229,,Intermediate,1,,F,,,,,
187,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,CHEMBL615223,16587,,Autocuration,1,,B,,,,,
188,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,CHEMBL615224,16587,,Autocuration,1,,B,,,,,
189,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,BAO_0000357,CHEMBL615225,16587,,Autocuration,1,,B,,,,,
190,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,BAO_0000357,CHEMBL615226,16587,,Autocuration,1,,B,,,,,
191,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,BAO_0000357,CHEMBL615227,16587,,Autocuration,1,,B,,,,,
192,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,BAO_0000019,CHEMBL615228,8058,9913.0,Expert,1,,F,,Bos taurus,,,
193,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,BAO_0000357,CHEMBL615229,9065,10116.0,Expert,1,,B,,Rattus norvegicus,,,
194,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,BAO_0000357,CHEMBL615230,8865,10116.0,Expert,1,,B,,Rattus norvegicus,,Adrenal gland,
195,,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,CHEMBL615231,9066,10116.0,Expert,1,,B,,Rattus norvegicus,,,
196,,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,CHEMBL884520,8394,10116.0,Expert,1,,B,,Rattus norvegicus,,,
197,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,BAO_0000357,CHEMBL615232,8394,10116.0,Expert,1,,B,,Rattus norvegicus,,,
198,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,BAO_0000019,CHEMBL615233,6431,,Autocuration,1,,B,,,,,
199,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,CHEMBL827088,6431,,Autocuration,1,,B,,,,,
200,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,CHEMBL615234,6431,,Autocuration,1,,B,,,,,
201,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,BAO_0000019,CHEMBL615235,9295,,Autocuration,1,,F,,,,,
202,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,CHEMBL615236,10193,,Autocuration,1,,B,,,,,
203,,Compound was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,CHEMBL615237,13622,,Autocuration,1,,B,,,,,
204,,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,CHEMBL615238,12079,,Autocuration,1,,F,,,,,
205,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,CHEMBL615239,13622,,Autocuration,1,,B,,,,,
206,,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,CHEMBL615240,12079,9606.0,Autocuration,1,,F,,Homo sapiens,,,
207,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,BAO_0000019,CHEMBL615241,13500,,Expert,1,,B,,,,,
208,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,BAO_0000357,CHEMBL615242,13723,,Expert,1,,B,,,,,
209,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,CHEMBL615243,16474,,Autocuration,1,,B,,,,,
210,,Inhibitory activity against human platelet 12-lipoxygenase,,BAO_0000019,CHEMBL615244,1630,,Autocuration,1,,B,,,,,
211,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,BAO_0000019,CHEMBL615245,167,,Autocuration,1,,B,,,,,
212,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,CHEMBL615246,16474,,Autocuration,1,,B,,,,,
213,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,BAO_0000019,CHEMBL615247,167,,Autocuration,1,,B,,,,,
214,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,BAO_0000019,CHEMBL615248,16474,,Autocuration,1,,B,,,,,
215,,Inhibitory activity towards porcine 12-lipoxygenase,,BAO_0000357,CHEMBL615249,10091,,Autocuration,1,,B,,,,,
216,,Tested for inhibition against porcine 12-LO,,BAO_0000357,CHEMBL615250,11966,,Autocuration,1,,B,,,,,
217,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,BAO_0000019,CHEMBL615251,951,,Autocuration,1,,B,,,,,
218,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,BAO_0000019,CHEMBL615252,10997,,Autocuration,1,,B,,,,,
219,,In vitro inhibition of rat platelet 12-lipoxygenase,,BAO_0000019,CHEMBL828340,10193,,Expert,1,,B,,,,,
220,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,CHEMBL615253,10193,,Autocuration,1,,B,,,,,
221,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,BAO_0000019,CHEMBL615254,10193,,Autocuration,1,,B,,,,,
222,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,BAO_0000019,CHEMBL615255,10193,,Autocuration,1,,B,,,,,
223,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,CHEMBL615256,10193,,Autocuration,1,,B,,,,,
224,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,BAO_0000019,CHEMBL615257,10193,,Autocuration,1,,B,,,,,
225,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,BAO_0000019,CHEMBL615258,11087,,Autocuration,1,,B,,,,,
226,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,BAO_0000219,CHEMBL615259,15569,9606.0,Intermediate,1,621.0,F,,Homo sapiens,,,41M
227,,In vitro antitumor activity against 41M cell line.,,BAO_0000219,CHEMBL615260,12989,9606.0,Expert,1,621.0,F,,Homo sapiens,,,41M
228,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,BAO_0000219,CHEMBL615261,16745,9606.0,Intermediate,1,621.0,F,,Homo sapiens,,,41M
229,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,BAO_0000219,CHEMBL615262,15569,9606.0,Intermediate,1,621.0,F,,Homo sapiens,,,41M
230,,In vitro antitumor activity against 41McisR cell line.,,BAO_0000219,CHEMBL615263,12989,9606.0,Expert,1,621.0,F,,Homo sapiens,,,41M
231,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,BAO_0000219,CHEMBL838393,12989,9606.0,Expert,1,621.0,F,,Homo sapiens,,,41M
232,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,BAO_0000219,CHEMBL615264,16745,9606.0,Intermediate,1,621.0,F,,Homo sapiens,,,41M
233,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,BAO_0000357,CHEMBL615265,6210,9606.0,Expert,1,,B,,Homo sapiens,,,
234,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,CHEMBL615266,6210,9606.0,Expert,1,,B,,Homo sapiens,,,
235,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,CHEMBL615267,6226,,Expert,1,,B,,,,,
236,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,CHEMBL615268,17855,,Expert,1,,B,,,,,
237,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,BAO_0000357,CHEMBL615269,17855,,Expert,1,,B,,,,,
238,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,CHEMBL615270,17855,,Expert,1,,B,,,,,
239,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,CHEMBL615271,10413,,Autocuration,1,,B,,,,,
240,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,CHEMBL615272,10413,562.0,Autocuration,1,,B,,Escherichia coli,,,
241,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,CHEMBL615103,10413,562.0,Autocuration,1,,B,,Escherichia coli,,,
242,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,BAO_0000357,CHEMBL615104,10413,562.0,Autocuration,1,,B,,Escherichia coli,,,
243,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,CHEMBL615105,10413,,Autocuration,1,,B,,,,,
244,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,CHEMBL872866,10413,,Autocuration,1,,B,,,,,
245,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,CHEMBL615106,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
246,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,BAO_0000019,CHEMBL615107,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
247,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,BAO_0000357,CHEMBL615108,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
248,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,BAO_0000357,CHEMBL615109,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
249,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,CHEMBL615110,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
250,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,CHEMBL840105,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
251,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,BAO_0000019,CHEMBL615111,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
252,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,BAO_0000019,CHEMBL615112,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
253,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,BAO_0000019,CHEMBL615113,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
254,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,BAO_0000019,CHEMBL615114,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
255,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,CHEMBL615115,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
256,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,CHEMBL615116,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
257,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,BAO_0000357,CHEMBL615698,7323,,Autocuration,1,,B,,,,,
258,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,CHEMBL615699,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
259,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,BAO_0000019,CHEMBL615700,7587,9823.0,Autocuration,1,,B,,Sus scrofa,,,
260,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,BAO_0000357,CHEMBL615701,13750,4932.0,Expert,1,,B,,Saccharomyces cerevisiae,,,
261,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,CHEMBL615702,7662,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
262,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,CHEMBL615703,7662,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
263,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,BAO_0000019,CHEMBL615704,7662,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
264,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,CHEMBL615705,12211,,Autocuration,1,,F,,,,,
265,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,CHEMBL615706,12211,,Autocuration,1,,F,,,,,
266,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,BAO_0000221,CHEMBL615707,12211,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
267,,Stimulatory activity of intragastric pressure was tested in the rat,,BAO_0000019,CHEMBL615708,12211,,Expert,1,,F,,,,,
268,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,BAO_0000357,CHEMBL615709,15453,,Autocuration,1,,B,,,,,
269,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,BAO_0000218,CHEMBL615710,11884,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
270,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,CHEMBL615711,7185,,Autocuration,1,,F,,,,,
271,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,BAO_0000357,CHEMBL615712,6876,9606.0,Expert,1,,B,,Homo sapiens,,,
272,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,BAO_0000357,CHEMBL836325,6876,9606.0,Expert,1,,B,,Homo sapiens,,,
273,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,BAO_0000019,CHEMBL615713,11863,,Autocuration,1,,F,,,,,
274,,Inhibition constant of high-affinity 5-HT uptake,,BAO_0000357,CHEMBL615714,11863,,Autocuration,1,,B,,,,,
275,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,BAO_0000019,CHEMBL615715,11863,,Autocuration,1,,F,,,,,
276,,Maximum rate was determined for high affinity transport of 5-HT,,BAO_0000019,CHEMBL615716,11863,,Autocuration,1,,F,,,,,
277,,Compound was tested for agonistic activity against 5-HT uptake,,BAO_0000019,CHEMBL615717,4639,,Autocuration,1,,F,,,,,
278,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,BAO_0000019,CHEMBL881818,15796,,Expert,1,,B,,,,,
279,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,BAO_0000357,CHEMBL884540,15796,9913.0,Expert,1,,B,,Bos taurus,,,
280,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000224,CHEMBL615718,12801,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
281,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,BAO_0000224,CHEMBL615719,12801,,Autocuration,1,,B,,,,,
282,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,BAO_0000249,CHEMBL615720,12120,,Autocuration,1,,B,,,,,
283,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,BAO_0000249,CHEMBL615721,12120,,Autocuration,1,,B,,,,,
284,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,CHEMBL615722,11963,,Autocuration,1,,B,,,,,
285,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,BAO_0000019,CHEMBL615723,11701,,Autocuration,1,,F,,,,,
286,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615724,9995,,Autocuration,1,,B,,,,Hippocampus,
287,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615725,9995,,Autocuration,1,,B,,,,Hippocampus,
288,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615726,9995,,Autocuration,1,,B,,,,Hippocampus,
289,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,BAO_0000218,CHEMBL615727,16394,,Autocuration,1,,F,In vivo,,,,
290,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,BAO_0000019,CHEMBL615728,11574,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
291,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,CHEMBL857971,15779,,Autocuration,1,449.0,B,,,,,CHO
292,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL615729,15363,,Autocuration,1,,B,,,,,
293,,Efficacy against 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL615730,15363,10116.0,Expert,1,,F,,Rattus norvegicus,,,
294,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,BAO_0000019,CHEMBL615731,15329,,Expert,1,,F,,,,,
295,,Relative potency towards 5-HT2A receptor of rat tail artery,,BAO_0000019,CHEMBL615732,15329,,Expert,1,,F,,,,,
296,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,CHEMBL615733,15329,,Expert,1,,F,,,,,
297,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,BAO_0000019,CHEMBL615734,15329,,Expert,1,,F,,,,,
298,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,BAO_0000019,CHEMBL615735,15329,,Autocuration,1,,F,,,,,
299,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,CHEMBL615736,15329,,Expert,1,,F,,,,,
300,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,CHEMBL615737,273,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
301,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,BAO_0000221,CHEMBL615738,273,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
302,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,CHEMBL615739,273,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
303,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,BAO_0000357,CHEMBL615278,12092,,Autocuration,1,,B,,,,,
304,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,CHEMBL615279,1317,10116.0,Expert,1,,F,,Rattus norvegicus,,,
305,,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL615280,12409,,Expert,1,,B,,,,,
306,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,BAO_0000019,CHEMBL615281,11126,9031.0,Autocuration,1,,B,,Gallus gallus,,,
307,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,BAO_0000019,CHEMBL615282,11126,9606.0,Autocuration,1,,F,,Homo sapiens,,,
308,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,CHEMBL615283,11126,9606.0,Autocuration,1,,F,,Homo sapiens,,,
309,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,BAO_0000219,CHEMBL615284,11126,9606.0,Autocuration,1,649.0,B,,Homo sapiens,,,HL-60
310,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,BAO_0000019,CHEMBL615285,11126,9606.0,Autocuration,1,,B,,Homo sapiens,,,
311,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,CHEMBL615286,11126,9606.0,Autocuration,1,,B,,Homo sapiens,,,
312,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,BAO_0000219,CHEMBL615287,17807,9606.0,Autocuration,1,,B,,Homo sapiens,,,Oocytes
313,,Chymotryptic inhibitory activity against 26S proteasome,,BAO_0000220,CHEMBL615288,16575,,Intermediate,1,,F,,,,,
314,,Inhibitory activity against 26S proteasome degradation of IkB,,BAO_0000220,CHEMBL615289,15407,,Intermediate,1,,B,,,,,
315,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,BAO_0000219,CHEMBL615290,10797,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
316,,In vitro inhibition of 2780/S ovarian cancer cell line,,BAO_0000219,CHEMBL884522,10797,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
317,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,BAO_0000019,CHEMBL615291,3469,9606.0,Autocuration,1,,F,,Homo sapiens,,,
318,,Association constant for binding to AATT 28-mer AATT hairpin,,BAO_0000225,CHEMBL615292,16037,,Intermediate,1,,B,,,,,
319,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,BAO_0000225,CHEMBL615293,16037,,Intermediate,1,,B,,,,,
320,,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,CHEMBL615294,16037,,Intermediate,1,,B,,,,,
321,,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,CHEMBL615295,16037,,Intermediate,1,,B,,,,,
322,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,BAO_0000019,CHEMBL825021,16524,9606.0,Autocuration,1,,F,,Homo sapiens,,,
323,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,BAO_0000019,CHEMBL615296,16524,9606.0,Autocuration,1,,F,,Homo sapiens,,,
324,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,BAO_0000019,CHEMBL615297,16524,9606.0,Autocuration,1,,F,,Homo sapiens,,,
325,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,BAO_0000019,CHEMBL615298,16758,10029.0,Autocuration,1,,F,,Cricetulus griseus,,,
326,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,BAO_0000019,CHEMBL615299,16758,10029.0,Autocuration,1,,F,,Cricetulus griseus,,,
327,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,BAO_0000019,CHEMBL615300,16758,10029.0,Autocuration,1,,F,,Cricetulus griseus,,,
328,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,BAO_0000357,CHEMBL615301,14360,,Autocuration,1,,B,,,,,
329,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,BAO_0000357,CHEMBL615302,14360,9606.0,Expert,1,,B,,Homo sapiens,,,
330,,Selectivity ratio of ID50 in liver and heart,,BAO_0000019,CHEMBL615303,9964,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
331,,"Selectivity, ratio of relative ID50 in liver and heart",,BAO_0000019,CHEMBL615304,9964,,Autocuration,1,,B,,,,,
332,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,BAO_0000019,CHEMBL615305,9964,,Autocuration,1,,B,,,,,
333,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,CHEMBL615306,9964,,Autocuration,1,,B,,,,,
334,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,CHEMBL615307,9964,,Autocuration,1,,B,,,,,
335,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,CHEMBL615308,9964,,Autocuration,1,,B,In vivo,,,,
336,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,CHEMBL615309,9964,,Autocuration,1,,F,In vivo,,,,
337,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,BAO_0000019,CHEMBL615310,9964,,Autocuration,1,,B,,,,,
338,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,BAO_0000019,CHEMBL615311,9964,,Autocuration,1,,B,,,,,
339,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,BAO_0000019,CHEMBL615312,9964,9606.0,Autocuration,1,,B,,Homo sapiens,,,
340,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,CHEMBL615313,9964,,Autocuration,1,,B,,,,,
341,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,CHEMBL615314,9964,,Autocuration,1,,F,,,,,
342,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,CHEMBL615315,9964,,Autocuration,1,,B,,,,,
343,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,BAO_0000218,CHEMBL615316,9964,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
344,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,BAO_0000218,CHEMBL615317,9964,,Autocuration,1,,B,In vivo,,,,
345,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,CHEMBL615318,9964,,Autocuration,1,,B,,,,,
346,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,BAO_0000218,CHEMBL615319,9964,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
347,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,CHEMBL615320,9964,,Autocuration,1,,B,,,,,
348,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,CHEMBL615321,9964,,Autocuration,1,,F,,,,,
349,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,BAO_0000019,CHEMBL615322,3796,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
350,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,CHEMBL615323,4251,562.0,Autocuration,1,,B,,Escherichia coli,,,
351,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,CHEMBL615407,4251,562.0,Autocuration,1,,B,,Escherichia coli,,,
352,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,CHEMBL857267,4251,562.0,Autocuration,1,,B,,Escherichia coli,,,
353,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,CHEMBL615408,4251,562.0,Autocuration,1,,B,,Escherichia coli,,,
354,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,BAO_0000357,CHEMBL615409,166,,Autocuration,1,,B,,,,,
355,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,BAO_0000357,CHEMBL615410,17861,,Autocuration,1,,B,,,,,
356,,Inhibition constant against 3-dehydroquinate synthase,,BAO_0000357,CHEMBL615411,166,,Autocuration,1,,B,,,,,
357,,Association rate constant against 3-dehydroquinate synthase,,BAO_0000357,CHEMBL615412,166,,Autocuration,1,,B,,,,,
358,,Rate constant against 3-dehydroquinate synthase,,BAO_0000357,CHEMBL615413,166,,Autocuration,1,,B,,,,,
359,,Inhibitory activity against fuc-TVII,,BAO_0000019,CHEMBL615414,3548,,Autocuration,1,,B,,,,,
360,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,CHEMBL615415,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
361,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,CHEMBL615416,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
362,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,CHEMBL615417,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
363,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,CHEMBL615418,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
364,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,CHEMBL615419,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
365,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,BAO_0000251,CHEMBL615420,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
366,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,BAO_0000251,CHEMBL615421,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
367,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,BAO_0000251,CHEMBL615422,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
368,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,BAO_0000251,CHEMBL615423,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
369,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,BAO_0000251,CHEMBL872868,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
370,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,BAO_0000251,CHEMBL615424,9877,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
371,,Inhibitory activity against 3-phosphoglycerate kinase.,,BAO_0000224,CHEMBL825022,3003,,Autocuration,1,,B,,,,,
372,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,BAO_0000224,CHEMBL615425,3003,,Autocuration,1,,B,,,,,
373,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,BAO_0000224,CHEMBL615426,3003,,Autocuration,1,,B,,,,,
374,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,BAO_0000357,CHEMBL615427,17185,9606.0,Expert,1,,B,,Homo sapiens,,,
375,,Cytotoxicity on 3677 melanoma cells,,BAO_0000219,CHEMBL615428,6072,9606.0,Intermediate,1,844.0,F,,Homo sapiens,,,3677 melanoma cell line
376,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,BAO_0000219,CHEMBL615429,6072,9606.0,Intermediate,1,844.0,F,,Homo sapiens,,,3677 melanoma cell line
377,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,BAO_0000219,CHEMBL615430,5018,10090.0,Intermediate,1,700.0,F,,Mus musculus,,,MC-38
378,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,BAO_0000019,CHEMBL615431,2852,9606.0,Intermediate,1,,F,,Homo sapiens,,,
379,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,BAO_0000218,CHEMBL615432,8663,,Autocuration,1,798.0,F,,,,,B16
380,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,BAO_0000218,CHEMBL615433,8663,,Autocuration,1,798.0,F,,,,,B16
381,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,BAO_0000019,CHEMBL615434,3245,12131.0,Expert,1,,F,,Human rhinovirus 14,,,
382,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,BAO_0000218,CHEMBL615435,3245,169066.0,Intermediate,1,,F,,Human rhinovirus sp.,,,
383,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,BAO_0000218,CHEMBL615436,3877,169066.0,Intermediate,1,,F,,human rhinovirus type 14,,,
384,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,BAO_0000218,CHEMBL615437,3877,169066.0,Intermediate,1,,F,,human rhinovirus type 14,,,
385,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,CHEMBL615438,5861,12131.0,Expert,1,,F,,Human rhinovirus 14,,,
386,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,CHEMBL615439,5861,12131.0,Expert,1,,F,,Human rhinovirus 14,,,
387,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,CHEMBL615440,5861,12131.0,Expert,1,,F,,Human rhinovirus 14,,,
388,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,BAO_0000019,CHEMBL615441,5861,12131.0,Expert,1,,F,,Human rhinovirus 14,,,
389,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,BAO_0000218,CHEMBL615641,13748,12059.0,Intermediate,1,,F,,Enterovirus,,,
390,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,BAO_0000218,CHEMBL872065,13748,12059.0,Intermediate,1,,F,,Enterovirus,,,
391,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,BAO_0000218,CHEMBL825023,13748,12059.0,Intermediate,1,,F,,Enterovirus,,,
392,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,BAO_0000218,CHEMBL615642,13748,12059.0,Intermediate,1,,F,,Enterovirus,,,
393,,Inhibition of human rhinovirus 3C protease,,BAO_0000357,CHEMBL615643,13748,147712.0,Expert,1,,B,,Human rhinovirus B,,,
394,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,BAO_0000019,CHEMBL615644,17699,9606.0,Autocuration,1,,B,,Homo sapiens,,,
395,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,BAO_0000218,CHEMBL615645,7145,10090.0,Intermediate,1,833.0,F,,Mus musculus,,,3EM 37
396,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,BAO_0000218,CHEMBL615646,7145,10090.0,Intermediate,1,833.0,F,,Mus musculus,,,3EM 37
397,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,BAO_0000218,CHEMBL615647,7145,10090.0,Intermediate,1,833.0,F,,Mus musculus,,,3EM 37
398,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,BAO_0000218,CHEMBL615648,7145,10090.0,Intermediate,1,833.0,F,,Mus musculus,,,3EM 37
399,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,BAO_0000218,CHEMBL615649,7145,10090.0,Intermediate,1,833.0,F,,Mus musculus,,,3EM 37
400,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,BAO_0000218,CHEMBL615650,7145,10090.0,Intermediate,1,833.0,F,,Mus musculus,,,3EM 37
401,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,BAO_0000218,CHEMBL615651,5325,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
402,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,BAO_0000218,CHEMBL615652,5325,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
403,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,BAO_0000218,CHEMBL615653,5325,10090.0,Expert,1,847.0,F,,Mus musculus,,,3LL cell line
404,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,BAO_0000219,CHEMBL615654,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
405,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,BAO_0000219,CHEMBL615655,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
406,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,BAO_0000219,CHEMBL825024,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
407,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,BAO_0000219,CHEMBL615656,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
408,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,BAO_0000219,CHEMBL615657,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
409,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,BAO_0000219,CHEMBL615658,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
410,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,BAO_0000219,CHEMBL615659,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
411,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,BAO_0000219,CHEMBL615660,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
412,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,BAO_0000219,CHEMBL615661,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
413,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,BAO_0000219,CHEMBL615662,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
414,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,BAO_0000219,CHEMBL615663,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
415,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,BAO_0000219,CHEMBL615664,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
416,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,BAO_0000219,CHEMBL615665,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
417,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,BAO_0000219,CHEMBL615666,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
418,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,CHEMBL615667,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
419,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,CHEMBL615668,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
420,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,CHEMBL615669,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
421,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,CHEMBL615670,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
422,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,CHEMBL836739,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
423,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,CHEMBL615671,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
424,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,CHEMBL615672,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
425,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,CHEMBL615791,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
426,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,CHEMBL615792,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
427,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,CHEMBL615793,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
428,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,CHEMBL615794,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
429,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,CHEMBL615795,16169,10090.0,Intermediate,1,847.0,F,,Mus musculus,,,3LL cell line
430,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,BAO_0000219,CHEMBL615590,15547,9606.0,Intermediate,1,971.0,F,,Homo sapiens,,,3LLD122
431,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,BAO_0000218,CHEMBL615591,8663,,Autocuration,1,,F,,,,,
432,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,BAO_0000218,CHEMBL615592,8663,,Autocuration,1,,F,,,,,
433,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,BAO_0000218,CHEMBL615593,8663,,Autocuration,1,,F,,,,,
434,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,BAO_0000218,CHEMBL615594,8663,,Autocuration,1,,F,,,,,
435,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,BAO_0000219,CHEMBL615595,4504,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
436,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,BAO_0000219,CHEMBL615596,4504,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
437,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,BAO_0000219,CHEMBL615597,12695,,Expert,1,723.0,F,,,,,NIH3T3
438,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,BAO_0000219,CHEMBL615598,12695,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
439,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,BAO_0000219,CHEMBL615599,12695,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
440,,Effective dose against murine 3T3 fibroblasts cells,,BAO_0000219,CHEMBL615600,17642,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
441,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,BAO_0000219,CHEMBL615601,17642,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
442,,Cytotoxic effect on 3T3 cells,,BAO_0000219,CHEMBL615602,12340,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
443,,Cytotoxic effect on 3T3 cells,,BAO_0000219,CHEMBL615603,12340,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
444,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,BAO_0000219,CHEMBL615604,12716,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
445,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,BAO_0000219,CHEMBL615605,6277,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
446,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,BAO_0000219,CHEMBL615606,6277,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
447,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,BAO_0000219,CHEMBL884526,6277,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
448,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,BAO_0000219,CHEMBL615607,6277,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
449,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,BAO_0000219,CHEMBL615608,6277,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
450,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,BAO_0000219,CHEMBL615609,6277,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
451,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,BAO_0000219,CHEMBL615682,6277,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
452,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,BAO_0000219,CHEMBL615683,6277,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
453,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,BAO_0000218,CHEMBL615684,17780,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
454,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,BAO_0000219,CHEMBL615685,12751,10090.0,Autocuration,1,,F,,Mus musculus,,,
455,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,BAO_0000219,CHEMBL615686,12380,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
456,,Inhibitory activity against 3T3 cell line,,BAO_0000219,CHEMBL615687,14892,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
457,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,BAO_0000219,CHEMBL884523,12695,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
458,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,BAO_0000019,CHEMBL615688,12695,,Expert,1,,F,,,,,
459,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,BAO_0000219,CHEMBL615689,12695,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
460,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,BAO_0000219,CHEMBL615690,12695,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
461,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,BAO_0000019,CHEMBL615691,12695,,Expert,1,,F,,,,,
462,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,BAO_0000019,CHEMBL615692,12695,,Expert,1,,F,,,,,
463,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,BAO_0000219,CHEMBL615693,6277,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
464,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,BAO_0000219,CHEMBL615324,6277,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
465,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,BAO_0000219,CHEMBL615325,4959,9606.0,Expert,1,723.0,F,,Homo sapiens,,,NIH3T3
466,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,BAO_0000219,CHEMBL615490,4959,9606.0,Expert,1,723.0,F,,Homo sapiens,,,NIH3T3
467,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,BAO_0000219,CHEMBL615491,4959,9606.0,Expert,1,723.0,F,,Homo sapiens,,,NIH3T3
468,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,BAO_0000219,CHEMBL615492,4959,9606.0,Expert,1,723.0,F,,Homo sapiens,,,NIH3T3
469,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,BAO_0000219,CHEMBL615493,12082,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
470,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,BAO_0000219,CHEMBL615494,12082,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
471,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,BAO_0000219,CHEMBL615495,12082,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
472,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,BAO_0000219,CHEMBL615496,12082,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
473,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,BAO_0000219,CHEMBL615497,2643,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
474,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,BAO_0000219,CHEMBL615498,11926,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
475,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,BAO_0000219,CHEMBL615499,15204,10090.0,Intermediate,1,723.0,A,,Mus musculus,,,NIH3T3
476,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,BAO_0000219,CHEMBL835522,15992,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
477,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,BAO_0000219,CHEMBL615500,16279,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
478,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,CHEMBL615501,16279,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
479,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,CHEMBL615502,16279,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
480,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,CHEMBL615503,16279,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
481,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,CHEMBL615504,16279,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
482,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,CHEMBL615505,16279,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
483,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,BAO_0000219,CHEMBL615506,12831,10090.0,Expert,1,723.0,F,,Mus musculus,,,NIH3T3
484,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,BAO_0000219,CHEMBL615507,13497,10090.0,Intermediate,1,723.0,F,,Mus musculus,,,NIH3T3
485,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,CHEMBL615508,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
486,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,BAO_0000219,CHEMBL615509,13618,10090.0,Intermediate,1,620.0,F,,Mus musculus,,,3T3-L1
487,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,BAO_0000219,CHEMBL615510,11902,10090.0,Intermediate,1,620.0,F,,Mus musculus,,,3T3-L1
488,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,BAO_0000219,CHEMBL615511,11902,10090.0,Intermediate,1,620.0,F,,Mus musculus,,,3T3-L1
489,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,BAO_0000219,CHEMBL615512,11902,10090.0,Intermediate,1,620.0,F,,Mus musculus,,,3T3-L1
490,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,BAO_0000218,CHEMBL615513,14840,10090.0,Intermediate,1,620.0,F,,Mus musculus,,,3T3-L1
491,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,BAO_0000218,CHEMBL615514,14840,10090.0,Intermediate,1,620.0,F,,Mus musculus,,,3T3-L1
492,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,BAO_0000219,CHEMBL615515,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
493,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,BAO_0000219,CHEMBL615516,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
494,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,CHEMBL615517,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
495,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,BAO_0000219,CHEMBL615518,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
496,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,CHEMBL615519,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
497,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,BAO_0000218,CHEMBL615520,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
498,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,BAO_0000218,CHEMBL615521,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
499,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,BAO_0000218,CHEMBL615522,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
500,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,CHEMBL615523,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
501,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,BAO_0000218,CHEMBL615524,13715,,Expert,1,620.0,F,,,,,3T3-L1
502,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,CHEMBL615525,13715,,Expert,1,620.0,F,,,,,3T3-L1
503,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,BAO_0000218,CHEMBL615526,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
504,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,CHEMBL615527,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
505,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,BAO_0000218,CHEMBL615528,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
506,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,CHEMBL615529,13715,,Expert,1,620.0,F,,,,,3T3-L1
507,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,CHEMBL615530,13715,,Expert,1,620.0,F,,,,,3T3-L1
508,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,BAO_0000218,CHEMBL615531,13715,,Expert,1,620.0,F,,,,,3T3-L1
509,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,BAO_0000219,CHEMBL615532,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
510,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,CHEMBL615533,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
511,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,BAO_0000219,CHEMBL615534,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
512,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,BAO_0000218,CHEMBL615535,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
513,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,CHEMBL615536,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
514,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,CHEMBL615537,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
515,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,CHEMBL615538,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
516,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,BAO_0000218,CHEMBL836166,13715,,Intermediate,1,620.0,F,,,,,3T3-L1
517,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,BAO_0000219,CHEMBL615539,6411,,Expert,1,620.0,F,,,,,3T3-L1
518,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,BAO_0000219,CHEMBL615540,6411,10090.0,Intermediate,1,620.0,F,,Mus musculus,,,3T3-L1
519,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,BAO_0000219,CHEMBL615541,6411,,Expert,1,620.0,F,,,,,3T3-L1
520,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,BAO_0000219,CHEMBL615542,3966,10090.0,Expert,1,620.0,F,,Mus musculus,,,3T3-L1
521,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,BAO_0000219,CHEMBL615543,3966,10090.0,Intermediate,1,620.0,F,,Mus musculus,,,3T3-L1
522,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,BAO_0000219,CHEMBL615544,15556,10090.0,Expert,1,620.0,F,,Mus musculus,,,3T3-L1
523,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,BAO_0000219,CHEMBL615545,5845,10090.0,Expert,1,620.0,F,,Mus musculus,,,3T3-L1
524,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,BAO_0000219,CHEMBL615546,14422,10090.0,Expert,1,620.0,F,,Mus musculus,,,3T3-L1
525,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,BAO_0000219,CHEMBL615547,5845,10090.0,Expert,1,620.0,F,,Mus musculus,,,3T3-L1
526,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,BAO_0000219,CHEMBL615548,14508,10090.0,Expert,1,620.0,F,,Mus musculus,,,3T3-L1
527,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,BAO_0000219,CHEMBL615549,14508,10090.0,Expert,1,620.0,F,,Mus musculus,,,3T3-L1
528,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,BAO_0000219,CHEMBL615550,14508,10090.0,Expert,1,620.0,F,,Mus musculus,,,3T3-L1
529,,Inhibitory activity against rat fibroblast (3Y1) cell line,,BAO_0000219,CHEMBL615551,6349,10116.0,Intermediate,1,1118.0,F,,Rattus norvegicus,,,3Y1 cell line
530,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,BAO_0000219,CHEMBL615552,15899,10116.0,Expert,1,1118.0,F,,Rattus norvegicus,,,3Y1 cell line
531,,Cytotoxicity in 3Y1 cells.,,BAO_0000219,CHEMBL615553,15899,10116.0,Expert,1,1118.0,F,,Rattus norvegicus,,,3Y1 cell line
532,,Cytostatic effect in 3Y1 cells.,,BAO_0000219,CHEMBL615554,15899,10116.0,Expert,1,1118.0,F,,Rattus norvegicus,,,3Y1 cell line
533,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,BAO_0000219,CHEMBL615555,15899,10116.0,Intermediate,1,1118.0,F,,Rattus norvegicus,,,3Y1 cell line
534,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,BAO_0000219,CHEMBL615556,17038,10116.0,Expert,1,1118.0,F,,Rattus norvegicus,,,3Y1 cell line
535,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,BAO_0000019,CHEMBL615557,12421,,Autocuration,1,,B,,,,,
536,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,CHEMBL615558,12947,,Autocuration,1,,B,,,,,
537,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,CHEMBL872066,12947,,Autocuration,1,,B,,,,,
538,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,BAO_0000019,CHEMBL615559,4896,9823.0,Expert,1,,B,,Sus scrofa,,,
539,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,BAO_0000019,CHEMBL615560,6148,,Autocuration,1,,B,,,,,
540,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,BAO_0000019,CHEMBL615561,16432,,Autocuration,1,,B,,,,,
541,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,BAO_0000019,CHEMBL857062,4978,,Expert,1,,B,,,,,
542,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,BAO_0000019,CHEMBL615562,4978,,Expert,1,,B,,,,,
543,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,BAO_0000019,CHEMBL615563,3723,,Autocuration,1,,B,,,,,
544,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,BAO_0000357,CHEMBL615564,3518,,Autocuration,1,,B,,,,,
545,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,BAO_0000019,CHEMBL615565,4164,,Autocuration,1,,B,,,,,
546,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,BAO_0000019,CHEMBL615566,3518,,Autocuration,1,,B,,,,,
547,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,BAO_0000019,CHEMBL615567,4164,9823.0,Expert,1,,B,,Sus scrofa,,,
548,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,BAO_0000019,CHEMBL615568,3518,,Autocuration,1,,B,,,,,
549,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,BAO_0000357,CHEMBL615569,3518,,Autocuration,1,,B,,,,,
550,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,BAO_0000019,CHEMBL615570,4978,,Autocuration,1,,B,,,,,
551,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,BAO_0000019,CHEMBL615571,4978,,Autocuration,1,,B,,,,,
552,,Binding affinity against melatonin (MT1) receptor (pC1),,BAO_0000224,CHEMBL615572,6455,,Autocuration,1,,B,,,,,
553,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,BAO_0000019,CHEMBL615573,2222,,Autocuration,1,,B,,,,,
554,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,BAO_0000019,CHEMBL615574,13020,,Autocuration,1,,B,,,,,
555,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,BAO_0000019,CHEMBL615575,13021,,Autocuration,1,,B,,,,,
556,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,BAO_0000357,CHEMBL615576,14532,,Autocuration,1,,B,,,,,
557,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL615577,14118,,Autocuration,1,,B,,,,,
558,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,BAO_0000221,CHEMBL615578,11884,,Autocuration,1,,B,,,,Hippocampus,
559,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615579,13969,,Expert,1,,B,,,,,
560,,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615580,13392,,Expert,1,,B,,,,,
561,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,BAO_0000019,CHEMBL615581,14430,,Expert,1,,B,,,,,
562,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,CHEMBL615582,12248,,Autocuration,1,,B,,,,Hippocampus,
563,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,CHEMBL615583,12249,,Autocuration,1,,B,,,,Hippocampus,
564,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615584,9995,,Autocuration,1,,B,,,,Hippocampus,
565,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL833691,9995,,Autocuration,1,,B,,,,Hippocampus,
566,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615585,9995,,Autocuration,1,,B,,,,Hippocampus,
567,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615586,9995,,Autocuration,1,,B,,,,Hippocampus,
568,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL884524,9995,,Autocuration,1,,B,,,,Hippocampus,
569,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,CHEMBL615587,12249,,Autocuration,1,,B,,,,Hippocampus,
570,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,BAO_0000221,CHEMBL615588,11799,,Autocuration,1,,B,,,,Hippocampus,
571,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,BAO_0000249,CHEMBL615589,14331,10116.0,Expert,1,,B,,Rattus norvegicus,,,
572,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,BAO_0000221,CHEMBL615442,11884,9913.0,Expert,1,,B,,Bos taurus,,Hippocampus,
573,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,BAO_0000221,CHEMBL615443,14331,,Autocuration,1,,B,,,,Hippocampus,
574,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,BAO_0000221,CHEMBL615444,11701,,Autocuration,1,,B,,,,Hippocampus,
575,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,BAO_0000221,CHEMBL615445,11701,,Expert,1,,B,,,,Hippocampus,
576,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,BAO_0000221,CHEMBL615446,12248,,Autocuration,1,,B,,,,Hippocampus,
577,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,BAO_0000219,CHEMBL615447,12248,,Autocuration,1,449.0,B,,,,,CHO
578,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,CHEMBL615448,12248,,Expert,1,,B,,,,Hippocampus,
579,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,CHEMBL615449,12249,,Expert,1,,B,,,,Hippocampus,
580,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,CHEMBL615450,12248,,Autocuration,1,449.0,B,,,,,CHO
581,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,BAO_0000221,CHEMBL615451,11799,,Expert,1,,B,,,,Hippocampus,
582,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,CHEMBL615452,634,,Autocuration,1,,B,,,,,
583,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615453,9995,,Autocuration,1,,B,,,,Hippocampus,
584,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615454,9995,,Autocuration,1,,B,,,,Hippocampus,
585,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615455,9995,,Autocuration,1,,B,,,,Hippocampus,
586,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615456,9995,,Autocuration,1,,B,,,,Hippocampus,
587,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615457,9995,,Autocuration,1,,B,,,,Hippocampus,
588,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,BAO_0000218,CHEMBL615458,12210,,Expert,1,,B,,,,Hippocampus,
589,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL615459,13311,,Expert,1,,B,,,,Hippocampus,
590,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,BAO_0000219,CHEMBL615460,2331,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
591,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,BAO_0000019,CHEMBL615461,1375,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
592,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,BAO_0000019,CHEMBL615462,1375,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
593,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,BAO_0000221,CHEMBL615463,11574,10141.0,Autocuration,1,,F,,Cavia porcellus,,Hippocampus,
594,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,BAO_0000221,CHEMBL615464,12867,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
595,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,CHEMBL615465,12867,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
596,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,BAO_0000221,CHEMBL615466,12867,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
597,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,CHEMBL615467,12867,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
598,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,CHEMBL615468,12867,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
599,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,BAO_0000221,CHEMBL615469,12867,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
600,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615470,11574,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
601,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615471,13114,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
602,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615472,13181,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
603,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,BAO_0000221,CHEMBL883242,10639,10141.0,Autocuration,1,,B,,Cavia porcellus,,Hippocampus,
604,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,BAO_0000221,CHEMBL615473,10639,10141.0,Autocuration,1,,F,,Cavia porcellus,,Hippocampus,
605,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,BAO_0000218,CHEMBL615474,11883,10029.0,Autocuration,1,449.0,B,,Cricetulus griseus,,,CHO
606,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615475,17785,,Autocuration,1,,B,,,,,
607,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,BAO_0000219,CHEMBL615476,1558,,Autocuration,1,308.0,F,,,,,HeLa
608,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,BAO_0000219,CHEMBL615477,1558,,Autocuration,1,308.0,F,,,,,HeLa
609,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL615478,15740,,Autocuration,1,,F,,,,,
610,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000219,CHEMBL615160,17624,,Autocuration,1,449.0,F,,,,,CHO
611,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000219,CHEMBL615161,17624,,Expert,1,449.0,F,,,,,CHO
612,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,BAO_0000219,CHEMBL615162,17624,,Autocuration,1,449.0,F,,,,,CHO
613,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,BAO_0000219,CHEMBL615163,17624,,Autocuration,1,449.0,F,,,,,CHO
614,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,CHEMBL615164,17624,,Expert,1,449.0,B,,,,,CHO
615,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,CHEMBL615165,17624,,Expert,1,449.0,B,,,,,CHO
616,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,BAO_0000219,CHEMBL615166,17624,,Autocuration,1,449.0,B,,,,,CHO
617,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,BAO_0000219,CHEMBL615167,14256,,Autocuration,1,,F,,,,,
618,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,BAO_0000219,CHEMBL615168,3445,9606.0,Expert,1,308.0,B,,Homo sapiens,,,HeLa
619,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,BAO_0000219,CHEMBL615169,3445,9606.0,Expert,1,308.0,B,,Homo sapiens,,,HeLa
620,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000219,CHEMBL615170,17200,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
621,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000219,CHEMBL615171,17200,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
622,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL615694,15180,,Autocuration,1,,F,,,,,
623,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL615695,15180,,Autocuration,1,,F,,,,,
624,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,CHEMBL615696,16026,,Autocuration,1,,F,,,,,
625,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,CHEMBL615697,2759,,Autocuration,1,449.0,F,,,,,CHO
626,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,BAO_0000219,CHEMBL859410,2759,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
627,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,BAO_0000219,CHEMBL615841,2759,,Autocuration,1,449.0,F,,,,,CHO
628,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,BAO_0000219,CHEMBL615842,2759,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
629,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,CHEMBL835003,2759,,Autocuration,1,449.0,F,,,,,CHO
630,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,BAO_0000219,CHEMBL615843,2759,,Autocuration,1,449.0,F,,,,,CHO
631,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,BAO_0000219,CHEMBL615979,2759,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
632,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,BAO_0000219,CHEMBL615980,2759,,Autocuration,1,449.0,F,,,,,CHO
633,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,BAO_0000219,CHEMBL615981,2759,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
634,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,BAO_0000019,CHEMBL615982,3445,9606.0,Expert,1,,F,,Homo sapiens,,,
635,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,CHEMBL615983,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
636,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,CHEMBL615984,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
637,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,CHEMBL615985,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
638,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,CHEMBL615986,17624,,Autocuration,1,449.0,F,,,,,CHO
639,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,CHEMBL615987,17624,,Autocuration,1,449.0,F,,,,,CHO
640,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,BAO_0000219,CHEMBL615988,17624,,Autocuration,1,449.0,F,,,,,CHO
641,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,CHEMBL615989,17624,,Expert,1,449.0,F,,,,,CHO
642,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,BAO_0000219,CHEMBL615990,17624,,Autocuration,1,449.0,F,,,,,CHO
643,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,BAO_0000219,CHEMBL615991,17624,,Autocuration,1,449.0,F,,,,,CHO
644,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,CHEMBL615992,17624,,Autocuration,1,449.0,F,,,,,CHO
645,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,BAO_0000219,CHEMBL615993,17624,,Autocuration,1,449.0,F,,,,,CHO
646,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,CHEMBL615994,17624,,Expert,1,449.0,F,,,,,CHO
647,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,BAO_0000219,CHEMBL615995,17624,,Autocuration,1,449.0,F,,,,,CHO
648,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,CHEMBL615996,17624,,Autocuration,1,449.0,F,,,,,CHO
649,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,BAO_0000219,CHEMBL615997,17624,,Autocuration,1,449.0,F,,,,,CHO
650,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,CHEMBL615998,6563,,Autocuration,1,,F,,,,,
651,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,CHEMBL615999,6563,,Autocuration,1,,F,,,,,
652,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,CHEMBL616000,6563,,Autocuration,1,,F,,,,,
653,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,CHEMBL616001,17296,,Autocuration,1,722.0,F,,,,,HEK293
654,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,BAO_0000019,CHEMBL616002,6876,9606.0,Expert,1,,F,,Homo sapiens,,,
655,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,BAO_0000019,CHEMBL616003,6876,,Expert,1,,F,,,,,
656,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616004,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
657,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,BAO_0000019,CHEMBL616005,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
658,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,CHEMBL616006,5548,,Autocuration,1,,F,,,,,
659,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,CHEMBL616007,5548,,Expert,1,,F,,,,,
660,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,CHEMBL616008,5548,,Autocuration,1,,F,,,,,
661,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,CHEMBL616009,5548,,Autocuration,1,,F,,,,,
662,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,BAO_0000019,CHEMBL616010,5929,,Expert,1,,F,,,,,
663,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,BAO_0000019,CHEMBL616011,5929,9606.0,Expert,1,,F,,Homo sapiens,,,
664,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,BAO_0000019,CHEMBL615740,5929,9606.0,Expert,1,,F,,Homo sapiens,,,
665,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,BAO_0000019,CHEMBL615741,16245,,Autocuration,1,,F,,,,,
666,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,CHEMBL615742,5640,,Expert,1,,F,,,,,
667,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,BAO_0000019,CHEMBL615743,5640,,Autocuration,1,,F,,,,,
668,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,BAO_0000219,CHEMBL615744,14509,,Autocuration,1,449.0,F,,,,,CHO
669,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,BAO_0000219,CHEMBL615745,14509,,Expert,1,449.0,F,,,,,CHO
670,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,CHEMBL615746,15331,,Autocuration,1,,B,,,,,
671,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,CHEMBL615747,15331,,Autocuration,1,,B,,,,,
672,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,CHEMBL615748,6563,,Autocuration,1,,F,,,,,
673,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,BAO_0000019,CHEMBL615749,6563,,Autocuration,1,,F,,,,,
674,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,CHEMBL615750,6563,,Autocuration,1,,F,,,,,
675,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616259,6563,9606.0,Expert,1,,F,,Homo sapiens,,,
676,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,CHEMBL616260,6563,,Autocuration,1,,F,,,,,
677,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,BAO_0000019,CHEMBL616261,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
678,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,CHEMBL616262,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
679,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,CHEMBL616263,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
680,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,BAO_0000019,CHEMBL616264,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
681,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,BAO_0000019,CHEMBL616265,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
682,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,CHEMBL616266,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
683,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,CHEMBL616267,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
684,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,BAO_0000019,CHEMBL616268,5272,9606.0,Expert,1,,F,,Homo sapiens,,,
685,,Inhibition of human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616269,16146,9606.0,Expert,1,,B,,Homo sapiens,,,
686,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,CHEMBL884528,17624,,Autocuration,1,449.0,B,,,,,CHO
687,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,BAO_0000219,CHEMBL616270,13706,,Expert,1,722.0,B,,,,,HEK293
688,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL616271,15250,,Autocuration,1,449.0,B,,,,,CHO
689,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,CHEMBL616272,17624,,Autocuration,1,449.0,F,,,,,CHO
690,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,BAO_0000357,CHEMBL616273,6861,,Expert,1,,B,,,,,
691,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616274,17200,9606.0,Expert,1,,B,,Homo sapiens,,,
692,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,CHEMBL616275,17624,,Autocuration,1,449.0,B,,,,,CHO
693,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,CHEMBL616276,17624,,Autocuration,1,449.0,B,,,,,CHO
694,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,CHEMBL616277,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
695,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,BAO_0000218,CHEMBL616278,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
696,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,BAO_0000218,CHEMBL616279,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
697,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,CHEMBL616280,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
698,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,BAO_0000218,CHEMBL616281,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
699,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,CHEMBL616282,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
700,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,BAO_0000218,CHEMBL616283,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
701,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,BAO_0000218,CHEMBL616284,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
702,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,BAO_0000218,CHEMBL616285,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
703,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,BAO_0000218,CHEMBL616286,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
704,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,BAO_0000218,CHEMBL616287,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
705,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,BAO_0000218,CHEMBL616288,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
706,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,BAO_0000218,CHEMBL616289,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
707,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,BAO_0000218,CHEMBL615610,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
708,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,BAO_0000218,CHEMBL615611,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
709,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,BAO_0000218,CHEMBL615612,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
710,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,BAO_0000218,CHEMBL615613,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
711,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,BAO_0000218,CHEMBL615614,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
712,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,CHEMBL615615,12058,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
713,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,BAO_0000019,CHEMBL615616,11440,,Autocuration,1,,B,,,,,
714,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,BAO_0000249,CHEMBL615617,6238,,Autocuration,1,,B,,,,Hypothalamus,
715,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,BAO_0000019,CHEMBL615618,10046,,Autocuration,1,,B,,,,,
716,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,BAO_0000019,CHEMBL615619,10046,,Autocuration,1,,B,,,,,
717,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,CHEMBL615620,10046,,Expert,1,,B,,,,,
718,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,CHEMBL615621,167,,Autocuration,1,,B,,,,,
719,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,CHEMBL615622,167,,Autocuration,1,,B,,,,,
720,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,BAO_0000019,CHEMBL615623,11520,,Autocuration,1,,F,,,,,
721,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,CHEMBL615624,11520,,Autocuration,1,,F,,,,,
722,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,CHEMBL615625,11520,,Autocuration,1,,F,,,,,
723,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,CHEMBL767045,11520,,Autocuration,1,,F,,,,,
724,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,BAO_0000019,CHEMBL615626,135,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
725,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,BAO_0000019,CHEMBL615627,135,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
726,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,BAO_0000019,CHEMBL615628,11311,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
727,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,CHEMBL615629,10193,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
728,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,BAO_0000357,CHEMBL615630,12281,9606.0,Expert,1,,B,,Homo sapiens,,,
729,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,CHEMBL615631,11311,,Autocuration,1,,B,,,,,
730,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,CHEMBL615632,12576,,Autocuration,1,,F,,,,,
731,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,BAO_0000357,CHEMBL615633,12281,,Autocuration,1,,B,,,,,
732,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,CHEMBL615634,12576,,Autocuration,1,,F,,,,,
733,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,CHEMBL615635,11089,9823.0,Expert,1,,B,,Sus scrofa,,,
734,,In vitro inhibition of rat 5-Lipoxygenase,,BAO_0000357,CHEMBL615636,11006,,Expert,1,,B,,,,,
735,,Inhibitory activity against 5-Lipoxygenase,,BAO_0000357,CHEMBL615637,11481,10116.0,Expert,1,,B,,Rattus norvegicus,,,
736,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,BAO_0000219,CHEMBL615638,10864,,Expert,1,702.0,B,,,,,RBL-1
737,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,CHEMBL615639,3595,,Autocuration,1,702.0,B,,,,,RBL-1
738,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,BAO_0000219,CHEMBL615640,11311,,Autocuration,1,702.0,B,,,,,RBL-1
739,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,BAO_0000019,CHEMBL615796,11311,,Autocuration,1,,B,,,,,
740,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,CHEMBL615845,11311,,Autocuration,1,,B,,,,,
741,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,CHEMBL615846,11006,,Autocuration,1,,B,,,,,
742,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,BAO_0000219,CHEMBL615847,3595,,Autocuration,1,702.0,B,,,,,RBL-1
743,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,BAO_0000357,CHEMBL615848,11311,,Autocuration,1,,B,,,,,
744,,Ratio of IC50 against 5-LO and COX,,BAO_0000019,CHEMBL615849,11481,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
745,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,CHEMBL615850,11006,,Autocuration,1,,B,,,,,
746,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,BAO_0000357,CHEMBL615851,11006,,Autocuration,1,,B,,,,,
747,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,BAO_0000219,CHEMBL615852,11311,,Autocuration,1,,B,,,,,
748,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,BAO_0000019,CHEMBL615853,11006,,Autocuration,1,,F,,,,,
749,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,BAO_0000357,CHEMBL884527,4288,,Autocuration,1,,B,,,,Prostate gland,
750,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,BAO_0000019,CHEMBL872871,7587,8932.0,Autocuration,1,,B,,Columba livia,,,
751,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,BAO_0000019,CHEMBL615854,7587,8932.0,Autocuration,1,,B,,Columba livia,,,
752,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,BAO_0000019,CHEMBL767046,7587,8932.0,Autocuration,1,,B,,Columba livia,,,
753,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,BAO_0000357,CHEMBL615855,11249,,Autocuration,1,,B,,,,,
754,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,BAO_0000019,CHEMBL615856,8003,10116.0,Expert,1,,F,,Rattus norvegicus,,,
755,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,CHEMBL615857,8003,10116.0,Expert,1,,F,,Rattus norvegicus,,,
756,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,CHEMBL615858,8003,10116.0,Expert,1,,F,,Rattus norvegicus,,,
757,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,BAO_0000221,CHEMBL615859,12416,,Expert,1,,B,,,,Hippocampus,
758,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,BAO_0000357,CHEMBL615860,16293,,Autocuration,1,,B,,,,,
759,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL615861,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
760,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL615862,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
761,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL615863,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
762,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL615864,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
763,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,CHEMBL615865,10085,,Autocuration,1,,B,,,,Hippocampus,
764,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,CHEMBL615866,10085,,Autocuration,1,,B,,,,Hippocampus,
765,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,CHEMBL615867,10085,,Autocuration,1,,B,,,,Hippocampus,
766,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,BAO_0000249,CHEMBL615868,9841,,Autocuration,1,,B,,,,,
767,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,BAO_0000249,CHEMBL615869,8822,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
768,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,BAO_0000019,CHEMBL615870,9806,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
769,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,BAO_0000019,CHEMBL615871,9806,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
770,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,BAO_0000224,CHEMBL615872,8868,,Autocuration,1,,B,,,,,
771,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,BAO_0000221,CHEMBL833492,9036,,Autocuration,1,,B,,,,Hippocampus,
772,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,BAO_0000221,CHEMBL615873,11374,,Autocuration,1,,B,,,,Hippocampus,
773,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,BAO_0000224,CHEMBL615479,10881,,Autocuration,1,,B,,,,,
774,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,BAO_0000019,CHEMBL615480,8822,,Autocuration,1,,B,,,,,
775,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,BAO_0000249,CHEMBL615481,9806,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
776,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,CHEMBL872869,15463,,Autocuration,1,,B,,,,,
777,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,CHEMBL615482,15463,,Autocuration,1,,B,,,,,
778,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,CHEMBL615483,14542,,Autocuration,1,,B,,,,Brain,
779,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,CHEMBL615484,14542,,Autocuration,1,,B,,,,Brain,
780,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,BAO_0000019,CHEMBL615485,8569,,Autocuration,1,,B,,,,,
781,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,BAO_0000224,CHEMBL615486,10062,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
782,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,BAO_0000224,CHEMBL615487,4771,,Autocuration,1,,B,,,,,
783,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,CHEMBL615488,10062,,Autocuration,1,,B,,,,,
784,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,CHEMBL615489,10062,,Autocuration,1,,B,,,,,
785,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,CHEMBL615389,10062,,Autocuration,1,,B,,,,,
786,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,CHEMBL615390,15463,,Autocuration,1,,B,,,,,
787,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,CHEMBL615391,15463,,Autocuration,1,,B,,,,,
788,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,BAO_0000224,CHEMBL615392,9098,,Autocuration,1,,B,,,,,
789,,Affinity for 5-hydroxytryptamine 1 receptor,,BAO_0000019,CHEMBL615393,3070,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
790,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,BAO_0000221,CHEMBL615394,14542,,Autocuration,1,,B,,,,Brain,
791,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,CHEMBL615395,14542,,Autocuration,1,,B,,,,Brain,
792,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,BAO_0000224,CHEMBL615396,6398,,Autocuration,1,,B,,,,,
793,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,BAO_0000221,CHEMBL615397,1344,,Autocuration,1,,B,,,,Brain,
794,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,CHEMBL615398,11963,,Autocuration,1,,B,,,,,
795,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,BAO_0000019,CHEMBL615399,8908,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
796,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,BAO_0000019,CHEMBL615400,9098,,Autocuration,1,,B,,,,,
797,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,BAO_0000019,CHEMBL615401,8841,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
798,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,BAO_0000019,CHEMBL615402,8814,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
799,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,BAO_0000019,CHEMBL615403,11752,,Autocuration,1,,B,,,,,
800,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,BAO_0000221,CHEMBL615404,11642,,Autocuration,1,,B,,,,Brain,
801,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,BAO_0000019,CHEMBL615781,11642,,Autocuration,1,,B,,,,,
802,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,BAO_0000220,CHEMBL615782,9231,,Autocuration,1,,B,,,,Brain,
803,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,BAO_0000221,CHEMBL615783,11351,,Autocuration,1,,B,,,,Brain,
804,,Compound was tested for binding affinity against 5-HT1 receptor,,BAO_0000019,CHEMBL873481,4639,,Autocuration,1,,B,,,,,
805,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,BAO_0000019,CHEMBL615784,1205,,Autocuration,1,,B,,,,,
806,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,CHEMBL615785,10025,,Expert,1,,B,,,,,
807,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,CHEMBL615786,13241,,Autocuration,1,,F,,,,,
808,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,CHEMBL615787,16245,,Autocuration,1,,F,In vivo,,,,
809,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,CHEMBL615788,16245,,Autocuration,1,,F,In vivo,,,,
810,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL767044,12438,,Autocuration,1,,F,,,,,
811,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,CHEMBL615789,16245,,Autocuration,1,,F,In vivo,,,,
812,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,CHEMBL615790,16245,,Autocuration,1,,F,In vivo,,,,
813,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,BAO_0000019,CHEMBL615813,15740,,Autocuration,1,,F,,,,,
814,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,BAO_0000219,CHEMBL615814,15535,,Autocuration,1,,F,,,,,
815,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,BAO_0000219,CHEMBL615815,15535,,Expert,1,,F,,,,,
816,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,BAO_0000219,CHEMBL615816,15535,,Autocuration,1,,F,,,,,
817,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,BAO_0000249,CHEMBL615817,9888,,Expert,1,,B,,,,,
818,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,BAO_0000221,CHEMBL615818,10085,,Autocuration,1,,B,,,,Hippocampus,
819,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,BAO_0000221,CHEMBL615819,10085,,Autocuration,1,,B,,,,Hippocampus,
820,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,BAO_0000249,CHEMBL615820,17331,,Expert,1,,B,,,,,
821,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,BAO_0000221,CHEMBL615821,10845,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
822,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,BAO_0000221,CHEMBL615822,10845,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
823,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL615823,10845,,Expert,1,,B,,,,Hippocampus,
824,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,BAO_0000221,CHEMBL615824,10845,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
825,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,BAO_0000221,CHEMBL615825,10845,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
826,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615826,13730,,Expert,1,,B,,,,,
827,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,CHEMBL615827,13508,,Expert,1,,B,,,,,
828,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,BAO_0000249,CHEMBL615828,13508,,Expert,1,,B,,,,Hippocampus,
829,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL615829,12073,,Expert,1,,B,,,,Hippocampus,
830,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL615830,4671,,Autocuration,1,,B,,,,Hippocampus,
831,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,BAO_0000221,CHEMBL615831,13631,,Expert,1,,B,,,,Hippocampus,
832,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615832,12438,,Autocuration,1,,B,,,,,
833,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,BAO_0000019,CHEMBL615833,10483,,Autocuration,1,,B,,,,,
834,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,BAO_0000221,CHEMBL615834,10483,,Autocuration,1,,B,,,,Hippocampus,
835,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,BAO_0000249,CHEMBL615835,12352,,Intermediate,1,,B,,,,,
836,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,BAO_0000249,CHEMBL615836,14732,,Autocuration,1,,B,,,,Hippocampus,
837,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,BAO_0000019,CHEMBL615837,11049,10116.0,Expert,1,,B,,Rattus norvegicus,,,
838,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,BAO_0000019,CHEMBL615838,11049,10116.0,Expert,1,,B,,Rattus norvegicus,,,
839,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,BAO_0000249,CHEMBL615839,13657,,Expert,1,,B,,,,,
840,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,CHEMBL884525,11473,,Autocuration,1,,B,,,,,
841,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,CHEMBL615840,2014,,Autocuration,1,,B,,,,,
842,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL615405,3086,,Expert,1,,B,,,,Hippocampus,
843,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,CHEMBL615406,15854,,Expert,1,,B,,,,,
844,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,BAO_0000221,CHEMBL615900,10922,,Expert,1,,B,,,,Hippocampus,
845,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,BAO_0000221,CHEMBL615901,13346,,Expert,1,,B,,,,Hippocampus,
846,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,BAO_0000357,CHEMBL615902,15311,,Expert,1,,B,,,,,
847,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,BAO_0000221,CHEMBL615903,10922,,Autocuration,1,,B,,,,Hippocampus,
848,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,BAO_0000357,CHEMBL615904,10025,,Autocuration,1,,B,,,,,
849,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,CHEMBL615905,10025,,Expert,1,,B,,,,,
850,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,CHEMBL615906,9742,,Autocuration,1,,B,,,,,
851,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,CHEMBL615907,9742,,Autocuration,1,,F,,,,,
852,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,CHEMBL615908,12304,,Expert,1,,B,,,,,
853,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,BAO_0000221,CHEMBL615909,15789,,Autocuration,1,,B,,,,Hippocampus,
854,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,BAO_0000019,CHEMBL615910,9912,,Autocuration,1,,B,,,,,
855,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000019,CHEMBL615911,9912,,Autocuration,1,,B,,,,,
856,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,BAO_0000019,CHEMBL615912,9912,,Autocuration,1,,B,,,,,
857,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,CHEMBL615913,16693,,Expert,1,,B,,,,,
858,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,CHEMBL615914,13276,,Expert,1,,B,,,,,
859,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,BAO_0000221,CHEMBL615915,12678,,Autocuration,1,,B,,,,Hippocampus,
860,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,BAO_0000357,CHEMBL615916,11825,,Autocuration,1,,B,,,,,
861,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,BAO_0000357,CHEMBL615917,12443,,Expert,1,,B,,,,,
862,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615918,13830,,Expert,1,,B,,,,,
863,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,BAO_0000249,CHEMBL615919,14286,,Expert,1,,B,,,,Hippocampus,
864,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,CHEMBL615920,14356,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
865,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615921,15306,,Autocuration,1,,B,,,,,
866,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,BAO_0000357,CHEMBL615922,15306,,Expert,1,,B,,,,,
867,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,CHEMBL881290,16616,10116.0,Expert,1,,F,,Rattus norvegicus,,,
868,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,BAO_0000221,CHEMBL615923,3651,,Autocuration,1,,B,,,,Hippocampus,
869,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL615924,14331,,Autocuration,1,,F,,,,Hippocampus,
870,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL615925,14331,,Autocuration,1,,F,,,,Hippocampus,
871,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615926,14178,10116.0,Expert,1,,B,,Rattus norvegicus,,,
872,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL615927,10639,10116.0,Expert,1,,B,,Rattus norvegicus,,,
873,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,CHEMBL615928,12306,,Autocuration,1,,B,,,,Hippocampus,
874,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,CHEMBL615929,1348,10116.0,Expert,1,,B,,Rattus norvegicus,,,
875,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,BAO_0000221,CHEMBL615930,13605,,Autocuration,1,,B,,,,Hippocampus,
876,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,CHEMBL615931,17624,,Autocuration,1,449.0,B,,,,,CHO
877,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,CHEMBL615932,17624,,Autocuration,1,449.0,F,,,,,CHO
878,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,CHEMBL615933,17624,,Autocuration,1,449.0,F,,,,,CHO
879,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615934,15267,,Autocuration,1,,B,,,,,
880,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,BAO_0000357,CHEMBL615935,16532,,Autocuration,1,,B,,,,,
881,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,CHEMBL615936,6563,,Autocuration,1,,F,,,,,
882,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,BAO_0000219,CHEMBL615937,4751,,Autocuration,1,449.0,B,,,,,CHO
883,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615938,15463,,Autocuration,1,,B,,,,,
884,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,BAO_0000357,CHEMBL615797,3805,,Autocuration,1,,B,,,,,
885,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615798,5640,,Autocuration,1,,B,,,,,
886,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,BAO_0000357,CHEMBL872870,6563,,Autocuration,1,,B,,,,,
887,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,BAO_0000357,CHEMBL615799,5548,,Autocuration,1,,B,,,,,
888,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615800,6347,,Autocuration,1,,B,,,,,
889,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,CHEMBL615801,17296,,Autocuration,1,722.0,F,,,,,HEK293
890,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,BAO_0000019,CHEMBL615802,13047,,Autocuration,1,,B,,,,,
891,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,CHEMBL615803,15740,,Autocuration,1,,B,,,,,
892,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,CHEMBL835002,5640,,Expert,1,,F,,,,,
893,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,BAO_0000019,CHEMBL615804,5640,,Autocuration,1,,F,,,,,
894,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,BAO_0000219,CHEMBL615805,17211,,Expert,1,308.0,B,,,,,HeLa
895,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,BAO_0000219,CHEMBL615806,4751,,Autocuration,1,449.0,B,,,,,CHO
896,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,BAO_0000357,CHEMBL615807,6491,9606.0,Expert,1,,B,,Homo sapiens,,,
897,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,BAO_0000357,CHEMBL615808,4707,,Autocuration,1,,B,,,,,
898,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615809,13910,9606.0,Expert,1,,B,,Homo sapiens,,,
899,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,BAO_0000219,CHEMBL615810,16190,,Autocuration,1,308.0,B,,,,,HeLa
900,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615811,16633,,Autocuration,1,,B,,,,,
901,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,BAO_0000219,CHEMBL615812,11898,,Autocuration,1,449.0,B,,,,,CHO
902,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,CHEMBL615751,11898,,Autocuration,1,449.0,B,,,,,CHO
903,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615752,14331,,Autocuration,1,,B,,,,,
904,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,BAO_0000219,CHEMBL615753,17624,,Expert,1,449.0,B,,,,,CHO
905,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,BAO_0000219,CHEMBL615754,17624,,Autocuration,1,449.0,B,,,,,CHO
906,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615755,3307,,Autocuration,1,,B,,,,,
907,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,CHEMBL615756,6563,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
908,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,BAO_0000019,CHEMBL615757,14165,,Autocuration,1,,B,,,,,
909,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,CHEMBL615758,5732,,Autocuration,1,,B,,,,,
910,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,CHEMBL615759,13366,,Expert,1,,B,,,,,
911,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615760,17626,,Autocuration,1,,B,,,,,
912,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,BAO_0000219,CHEMBL615761,6588,,Expert,1,308.0,B,,,,,HeLa
913,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,BAO_0000357,CHEMBL872104,16209,,Autocuration,1,,B,,,,,
914,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615762,15463,,Autocuration,1,,B,,,,,
915,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615763,15463,,Autocuration,1,,B,,,,,
916,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,BAO_0000357,CHEMBL615764,14770,,Autocuration,1,,B,,,,,
917,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,BAO_0000219,CHEMBL615765,16245,,Autocuration,1,1167.0,B,,,,,Cell line
918,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,BAO_0000019,CHEMBL615766,16245,,Autocuration,1,,B,,,,,
919,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615767,5548,,Autocuration,1,,B,,,,,
920,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615768,5548,,Expert,1,,B,,,,,
921,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615769,5548,,Autocuration,1,,B,,,,,
922,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,BAO_0000357,CHEMBL615770,6876,,Expert,1,,B,,,,,
923,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615771,2598,,Autocuration,1,,B,,,,,
924,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,BAO_0000357,CHEMBL615772,17785,,Expert,1,,B,,,,,
925,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL615773,6013,,Autocuration,1,,B,,,,,
926,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615774,5929,,Expert,1,,B,,,,,
927,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615775,16633,,Autocuration,1,,B,,,,,
928,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,CHEMBL615776,1558,,Autocuration,1,,B,,,,,
929,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615777,16026,,Expert,1,,B,,,,,
930,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,BAO_0000219,CHEMBL615778,12469,,Autocuration,1,,B,,,,,
931,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,CHEMBL615779,15874,9606.0,Expert,1,,B,,Homo sapiens,,,
932,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,CHEMBL615780,15874,,Autocuration,1,,B,,,,,
933,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616298,3935,,Autocuration,1,,B,,,,,
934,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616299,15818,,Autocuration,1,,B,,,,,
935,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,BAO_0000219,CHEMBL616300,13706,,Autocuration,1,485.0,B,,,,,CHO-K1
936,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,BAO_0000219,CHEMBL616301,13729,,Expert,1,485.0,F,,,,,CHO-K1
937,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616302,15413,,Autocuration,1,,B,,,,,
938,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,BAO_0000019,CHEMBL616117,15413,,Autocuration,1,,B,,,,,
939,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,BAO_0000019,CHEMBL616118,15413,,Autocuration,1,,B,,,,,
940,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,BAO_0000019,CHEMBL616119,15413,,Autocuration,1,,B,,,,,
941,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,BAO_0000219,CHEMBL616120,3445,9606.0,Expert,1,308.0,B,,Homo sapiens,,,HeLa
942,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616121,15740,,Autocuration,1,,B,,,,,
943,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,CHEMBL616122,15740,,Autocuration,1,,B,,,,,
944,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616123,17626,,Autocuration,1,,B,,,,,
945,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616124,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
946,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,CHEMBL616125,5640,,Expert,1,,B,,,,,
947,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,BAO_0000357,CHEMBL616126,5272,10116.0,Expert,1,,B,,Rattus norvegicus,,,
948,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,BAO_0000219,CHEMBL616127,4622,,Autocuration,1,449.0,B,,,,,CHO
949,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616128,17085,,Expert,1,,B,,,,,
950,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,CHEMBL616129,3025,,Autocuration,1,,B,,,,,
951,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616130,15315,,Expert,1,,B,,,,,
952,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,BAO_0000357,CHEMBL616131,15267,,Autocuration,1,,B,,,,,
953,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,BAO_0000219,CHEMBL616132,17158,,Autocuration,1,308.0,B,,,,,HeLa
954,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,BAO_0000219,CHEMBL616133,14214,9606.0,Expert,1,308.0,B,,Homo sapiens,,,HeLa
955,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616134,17133,,Autocuration,1,,B,,,,,
956,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,BAO_0000357,CHEMBL616135,16532,,Autocuration,1,,B,,,,,
957,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,CHEMBL616136,2391,9606.0,Expert,1,,B,,Homo sapiens,,,
958,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,BAO_0000019,CHEMBL616137,14447,,Autocuration,1,,B,,,,,
959,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,BAO_0000019,CHEMBL872105,14447,,Autocuration,1,,B,,,,,
960,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,CHEMBL616138,15086,,Autocuration,1,,B,,,,,
961,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616139,13051,9606.0,Expert,1,,B,,Homo sapiens,,,
962,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,BAO_0000019,CHEMBL616140,16026,,Autocuration,1,,F,,,,,
963,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,BAO_0000019,CHEMBL616141,17085,,Expert,1,,B,,,,,
964,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616142,17133,,Autocuration,1,,B,,,,,
965,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,BAO_0000357,CHEMBL616143,17133,,Autocuration,1,,B,,,,,
966,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,CHEMBL616144,17211,,Autocuration,1,308.0,B,,,,,HeLa
967,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,BAO_0000219,CHEMBL616145,17211,,Autocuration,1,308.0,B,,,,,HeLa
968,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,CHEMBL616012,17211,,Autocuration,1,308.0,B,,,,,HeLa
969,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,CHEMBL616013,17211,,Autocuration,1,308.0,B,,,,,HeLa
970,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,CHEMBL616014,16394,,Autocuration,1,,F,,,,,
971,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,CHEMBL616015,16394,,Autocuration,1,,F,,,,,
972,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,CHEMBL616016,16394,,Autocuration,1,,F,,,,,
973,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,BAO_0000218,CHEMBL616017,16394,,Autocuration,1,,F,In vivo,,,,
974,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,BAO_0000019,CHEMBL616018,16394,,Autocuration,1,,B,,,,,
975,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,BAO_0000019,CHEMBL616019,15740,,Autocuration,1,,F,,,,,
976,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,BAO_0000019,CHEMBL616020,15740,,Autocuration,1,,F,,,,,
977,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL858018,15740,,Autocuration,1,,B,,,,,
978,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,CHEMBL616021,17296,,Autocuration,1,722.0,F,,,,,HEK293
979,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,BAO_0000019,CHEMBL616022,5640,,Expert,1,,F,,,,,
980,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,BAO_0000019,CHEMBL616023,5640,,Autocuration,1,,F,,,,,
981,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,BAO_0000019,CHEMBL616024,5640,,Autocuration,1,,F,,,,,
982,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,BAO_0000019,CHEMBL616025,5640,,Autocuration,1,,F,,,,,
983,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,CHEMBL616026,2759,,Autocuration,1,449.0,F,,,,,CHO
984,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,BAO_0000019,CHEMBL616027,16394,,Autocuration,1,,F,,,,,
985,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,BAO_0000019,CHEMBL616028,16394,9606.0,Expert,1,,F,,Homo sapiens,,,
986,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,BAO_0000019,CHEMBL616029,3445,9606.0,Expert,1,,F,,Homo sapiens,,,
987,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,BAO_0000219,CHEMBL616030,4316,,Expert,1,449.0,B,,,,,CHO
988,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,BAO_0000019,CHEMBL616031,4316,,Expert,1,,B,,,,,
989,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,CHEMBL616032,15180,9606.0,Expert,1,,F,,Homo sapiens,,,
990,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,CHEMBL616033,15180,9606.0,Expert,1,,F,,Homo sapiens,,,
991,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,CHEMBL616034,15042,,Autocuration,1,,F,,,,,
992,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,CHEMBL616035,15042,,Autocuration,1,,F,,,,,
993,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616036,15042,,Autocuration,1,,F,,,,,
994,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,CHEMBL616037,15042,,Autocuration,1,,F,,,,,
995,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,CHEMBL616038,15042,,Autocuration,1,,F,,,,,
996,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,CHEMBL616039,15042,,Autocuration,1,,F,,,,,
997,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616040,15042,,Autocuration,1,,F,,,,,
998,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,CHEMBL616041,15180,9606.0,Expert,1,308.0,F,,Homo sapiens,,,HeLa
999,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,CHEMBL616042,15180,9606.0,Expert,1,308.0,F,,Homo sapiens,,,HeLa
1000,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,CHEMBL616043,15180,9606.0,Expert,1,308.0,F,,Homo sapiens,,,HeLa
1001,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,BAO_0000019,CHEMBL616044,16245,,Autocuration,1,,F,,,,,
1002,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,CHEMBL616045,16026,,Autocuration,1,,F,,,,,
1003,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,CHEMBL616046,17296,,Autocuration,1,722.0,F,,,,,HEK293
1004,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,BAO_0000219,CHEMBL616047,2759,,Autocuration,1,449.0,F,,,,,CHO
1005,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,CHEMBL616048,2759,,Autocuration,1,449.0,F,,,,,CHO
1006,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,BAO_0000219,CHEMBL616049,2759,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
1007,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,BAO_0000219,CHEMBL616050,2759,,Autocuration,1,449.0,F,,,,,CHO
1008,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,BAO_0000219,CHEMBL616051,15419,,Expert,1,,F,,,,,
1009,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,BAO_0000219,CHEMBL616212,15419,,Autocuration,1,,F,,,,,
1010,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,CHEMBL616213,16026,,Autocuration,1,,F,,,,,
1011,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,BAO_0000219,CHEMBL616214,1414,,Expert,1,,B,In vitro,,,,
1012,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,BAO_0000219,CHEMBL616215,1414,,Expert,1,,B,In vitro,,,,
1013,,Binding activity radioligand.,,BAO_0000357,CHEMBL616216,12861,,Autocuration,1,,B,,,,,
1014,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,CHEMBL616217,12861,,Autocuration,1,,B,,,,,
1015,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616218,5104,,Autocuration,1,,B,,,,,
1016,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616219,5105,,Autocuration,1,,B,,,,,
1017,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616220,16312,,Autocuration,1,,B,,,,,
1018,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL833493,15180,9606.0,Expert,1,,B,,Homo sapiens,,,
1019,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616221,5033,,Autocuration,1,,B,,,,,
1020,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,BAO_0000219,CHEMBL616222,16909,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1021,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616223,2590,,Autocuration,1,,F,,,,,
1022,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000019,CHEMBL616224,2590,,Autocuration,1,,F,,,,,
1023,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,BAO_0000019,CHEMBL616225,16394,,Expert,1,,B,,,,,
1024,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,BAO_0000219,CHEMBL616226,4540,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
1025,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,BAO_0000219,CHEMBL616227,17296,,Autocuration,1,722.0,B,,,,,HEK293
1026,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,BAO_0000219,CHEMBL616228,17296,,Autocuration,1,722.0,B,,,,,HEK293
1027,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,BAO_0000219,CHEMBL616229,15779,,Autocuration,1,722.0,B,,,,,HEK293
1028,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,BAO_0000219,CHEMBL616230,15779,,Autocuration,1,722.0,B,,,,,HEK293
1029,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,BAO_0000219,CHEMBL616231,15779,,Autocuration,1,722.0,B,,,,,HEK293
1030,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616232,6166,,Autocuration,1,,B,,,,,
1031,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,BAO_0000219,CHEMBL616233,15779,,Autocuration,1,722.0,B,,,,,HEK293
1032,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,BAO_0000219,CHEMBL857973,4199,,Autocuration,1,722.0,B,,,,,HEK293
1033,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,BAO_0000219,CHEMBL616234,15316,,Autocuration,1,,B,,,,,
1034,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616235,14875,,Autocuration,1,,B,,,,,
1035,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000219,CHEMBL616236,14727,,Expert,1,308.0,B,,,,,HeLa
1036,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000019,CHEMBL616237,14727,,Expert,1,,B,,,,,
1037,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,BAO_0000219,CHEMBL616238,15146,,Autocuration,1,722.0,B,,,,,HEK293
1038,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,BAO_0000219,CHEMBL616239,5213,,Autocuration,1,722.0,B,,,,,HEK293
1039,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,BAO_0000219,CHEMBL616240,16429,,Autocuration,1,,B,,,,,
1040,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,BAO_0000219,CHEMBL616241,15042,9606.0,Expert,1,308.0,B,,Homo sapiens,,,HeLa
1041,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,BAO_0000219,CHEMBL616242,14818,,Autocuration,1,722.0,B,,,,,HEK293
1042,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,BAO_0000219,CHEMBL616243,4829,,Autocuration,1,722.0,B,,,,,HEK293
1043,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616244,17200,,Expert,1,,B,,,,,
1044,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616245,13051,9606.0,Autocuration,1,,B,,Homo sapiens,,,
1045,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,CHEMBL616246,5486,,Autocuration,1,,B,,,,,
1046,,Binding affinity against 5-HT1D receptor,,BAO_0000357,CHEMBL616247,5254,,Autocuration,1,,B,,,,,
1047,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616248,5254,,Autocuration,1,,B,,,,,
1048,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,CHEMBL616249,15331,,Autocuration,1,,B,,,,,
1049,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,CHEMBL616250,13506,9606.0,Autocuration,1,,B,,Homo sapiens,,,
1050,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616251,15267,,Autocuration,1,,B,,,,,
1051,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,BAO_0000218,CHEMBL616252,16616,,Autocuration,1,,F,In vivo,,,,
1052,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,BAO_0000218,CHEMBL616253,16616,,Autocuration,1,,F,In vivo,,,,
1053,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,BAO_0000218,CHEMBL616254,16616,,Autocuration,1,,F,In vivo,,,,
1054,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,BAO_0000218,CHEMBL616255,16616,10090.0,Expert,1,,F,,Mus musculus,,,
1055,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,BAO_0000218,CHEMBL832872,16616,10090.0,Expert,1,,F,,Mus musculus,,,
1056,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,BAO_0000218,CHEMBL616256,16616,10090.0,Expert,1,,F,,Mus musculus,,,
1057,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,BAO_0000218,CHEMBL616257,16616,10090.0,Expert,1,,F,,Mus musculus,,,
1058,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,BAO_0000218,CHEMBL616258,16616,10090.0,Expert,1,,F,,Mus musculus,,,
1059,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,BAO_0000218,CHEMBL616384,16616,10090.0,Expert,1,,F,,Mus musculus,,,
1060,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,BAO_0000221,CHEMBL616385,10297,,Autocuration,1,,B,,,,Hippocampus,
1061,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,BAO_0000357,CHEMBL616386,13704,,Expert,1,,B,,,,,
1062,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,BAO_0000221,CHEMBL616387,10297,10090.0,Expert,1,,B,,Mus musculus,,Hippocampus,
1063,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,BAO_0000221,CHEMBL616388,10297,,Autocuration,1,,B,,,,Hippocampus,
1064,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,BAO_0000221,CHEMBL616389,10297,10090.0,Expert,1,,B,,Mus musculus,,Hippocampus,
1065,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,BAO_0000221,CHEMBL616390,10297,,Autocuration,1,,B,,,,Hippocampus,
1066,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,BAO_0000357,CHEMBL616391,217,,Autocuration,1,,B,,,,,
1067,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,BAO_0000221,CHEMBL616392,10297,10090.0,Expert,1,,B,,Mus musculus,,Hippocampus,
1068,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616393,4921,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1069,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,BAO_0000357,CHEMBL616394,4921,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1070,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,BAO_0000019,CHEMBL616395,4996,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1071,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,BAO_0000357,CHEMBL616396,12918,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1072,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,CHEMBL872907,5333,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1073,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,CHEMBL616397,4437,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1074,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,BAO_0000019,CHEMBL616398,1742,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1075,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616399,16688,9823.0,Expert,1,,B,,Sus scrofa,,,
1076,,Binding activity radioligand.,,BAO_0000357,CHEMBL857065,12861,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1077,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,CHEMBL616400,12861,9823.0,Expert,1,,B,,Sus scrofa,,,
1078,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,CHEMBL616401,12861,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1079,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,BAO_0000019,CHEMBL616402,12490,,Expert,1,,B,,,,,
1080,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616403,11828,9823.0,Expert,1,,B,,Sus scrofa,,,
1081,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,BAO_0000221,CHEMBL616404,11866,9823.0,Autocuration,1,,B,,Sus scrofa,,Hippocampus,
1082,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,BAO_0000249,CHEMBL616405,12827,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1083,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,BAO_0000019,CHEMBL616406,12918,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1084,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,BAO_0000019,CHEMBL616407,12919,9823.0,Expert,1,,F,,Sus scrofa,,,
1085,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,BAO_0000019,CHEMBL616408,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
1086,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,BAO_0000249,CHEMBL616409,15796,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1087,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,BAO_0000221,CHEMBL616410,3651,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1088,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,BAO_0000357,CHEMBL616411,188,,Autocuration,1,,B,,,,,
1089,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,BAO_0000249,CHEMBL616412,16616,10116.0,Expert,1,,F,,Rattus norvegicus,,,
1090,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,BAO_0000249,CHEMBL616413,16616,10116.0,Expert,1,,F,,Rattus norvegicus,,Hippocampus,
1091,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,CHEMBL616414,12306,,Autocuration,1,,B,,,,Hippocampus,
1092,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,BAO_0000221,CHEMBL616415,17167,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1093,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,BAO_0000019,CHEMBL616416,14776,,Autocuration,1,,B,,,,,
1094,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,BAO_0000357,CHEMBL616417,12158,,Expert,1,,B,,,,,
1095,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,CHEMBL616418,13481,,Autocuration,1,,B,,,,,
1096,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,CHEMBL616419,13427,,Autocuration,1,,B,In vitro,,,,
1097,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,BAO_0000357,CHEMBL616420,10210,,Autocuration,1,,B,,,,,
1098,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,BAO_0000249,CHEMBL616421,10205,,Autocuration,1,,B,,,,,
1099,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,BAO_0000249,CHEMBL616422,10205,,Autocuration,1,,B,,,,,
1100,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,BAO_0000249,CHEMBL616423,10205,,Expert,1,,B,,,,,
1101,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,BAO_0000357,CHEMBL616424,12280,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1102,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616425,17386,,Expert,1,,B,,,,,
1103,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,BAO_0000357,CHEMBL616426,13654,,Expert,1,,B,,,,,
1104,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,BAO_0000221,CHEMBL616427,14423,,Autocuration,1,,B,,,,Hippocampus,
1105,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,BAO_0000221,CHEMBL616428,15412,,Autocuration,1,,B,,,,Hippocampus,
1106,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL616290,12073,,Autocuration,1,,B,,,,Hippocampus,
1107,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616052,4101,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1108,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616053,10062,,Autocuration,1,,B,,,,,
1109,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,CHEMBL616054,6238,,Autocuration,1,,B,,,,,
1110,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616055,16273,,Autocuration,1,,B,,,,,
1111,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,BAO_0000357,CHEMBL616056,11139,,Autocuration,1,,B,,,,,
1112,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,CHEMBL616057,16796,,Expert,1,,B,,,,,
1113,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,CHEMBL616058,9548,10116.0,Expert,1,,B,,Rattus norvegicus,,Brain,
1114,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,CHEMBL616059,10381,,Autocuration,1,,B,,,,Brain,
1115,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,BAO_0000249,CHEMBL616060,13408,,Autocuration,1,,B,,,,,
1116,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,BAO_0000221,CHEMBL616061,13825,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1117,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,BAO_0000221,CHEMBL616062,11147,,Expert,1,,B,,,,Hippocampus,
1118,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,CHEMBL616063,10552,,Autocuration,1,,B,,,,,
1119,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,BAO_0000249,CHEMBL616064,10552,,Autocuration,1,,B,,,,Striatum,
1120,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,BAO_0000249,CHEMBL616065,17136,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1121,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,BAO_0000249,CHEMBL616066,5778,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1122,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL616067,13481,,Autocuration,1,,B,,,,Hippocampus,
1123,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,BAO_0000221,CHEMBL616068,13481,,Autocuration,1,,B,,,,Hippocampus,
1124,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL616069,13630,,Intermediate,1,,B,,,,Hippocampus,
1125,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,CHEMBL616070,16245,,Expert,1,,B,,,,,
1126,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL616071,14509,,Autocuration,1,,B,,,,Hippocampus,
1127,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,BAO_0000221,CHEMBL616072,14509,,Expert,1,,B,,,,Hippocampus,
1128,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,BAO_0000221,CHEMBL616073,14509,,Autocuration,1,,B,,,,Hippocampus,
1129,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,BAO_0000221,CHEMBL616074,14509,,Autocuration,1,,B,,,,Hippocampus,
1130,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,BAO_0000019,CHEMBL616075,14256,,Expert,1,,B,,,,,
1131,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616076,11139,,Autocuration,1,,B,,,,,
1132,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,BAO_0000019,CHEMBL616077,11047,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1133,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,BAO_0000019,CHEMBL616078,11047,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1134,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,BAO_0000019,CHEMBL616079,11047,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1135,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,BAO_0000219,CHEMBL616080,2395,10116.0,Expert,1,485.0,B,,Rattus norvegicus,,,CHO-K1
1136,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616081,9699,,Autocuration,1,,B,,,,,
1137,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,BAO_0000221,CHEMBL616082,12028,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1138,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,BAO_0000221,CHEMBL616083,12028,,Autocuration,1,,B,,,,Hippocampus,
1139,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,CHEMBL616084,5815,,Autocuration,1,,B,,,,,
1140,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,BAO_0000019,CHEMBL616085,16616,,Expert,1,,B,,,,,
1141,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,BAO_0000019,CHEMBL616086,5815,,Autocuration,1,,B,,,,,
1142,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,BAO_0000221,CHEMBL616087,2761,,Autocuration,1,,B,,,,Hippocampus,
1143,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,BAO_0000357,CHEMBL616088,13133,,Expert,1,,B,,,,,
1144,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,CHEMBL616089,10444,,Autocuration,1,,B,,,,,
1145,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,BAO_0000357,CHEMBL616090,13278,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1146,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,CHEMBL616091,15874,,Autocuration,1,,B,,,,,
1147,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,BAO_0000249,CHEMBL616092,10552,,Autocuration,1,,B,,,,Striatum,
1148,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,BAO_0000357,CHEMBL616093,11130,,Autocuration,1,,B,,,,,
1149,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,BAO_0000218,CHEMBL616094,11130,,Autocuration,1,,B,In vivo,,,,
1150,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,BAO_0000221,CHEMBL616095,14542,,Autocuration,1,,B,,,,Brain,
1151,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616096,13670,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1152,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,BAO_0000249,CHEMBL616097,9888,,Expert,1,,B,,,,,
1153,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,BAO_0000249,CHEMBL616098,3678,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1154,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL616099,11332,,Autocuration,1,,B,,,,Hippocampus,
1155,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL616100,11332,,Autocuration,1,,B,,,,Hippocampus,
1156,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616101,1185,,Expert,1,,B,,,,,
1157,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,CHEMBL616102,2014,,Expert,1,,B,,,,,
1158,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616103,1185,,Autocuration,1,,B,,,,,
1159,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,BAO_0000019,CHEMBL616104,14429,,Expert,1,,B,,,,,
1160,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,BAO_0000019,CHEMBL616105,16288,,Expert,1,,B,,,,,
1161,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616106,5432,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1162,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,BAO_0000019,CHEMBL616107,14429,,Autocuration,1,,B,,,,,
1163,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,BAO_0000357,CHEMBL616108,13672,,Expert,1,,B,,,,,
1164,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,CHEMBL616109,11296,,Expert,1,,B,,,,Hippocampus,
1165,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,BAO_0000357,CHEMBL616110,11296,,Autocuration,1,,B,,,,,
1166,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,BAO_0000219,CHEMBL616111,14749,,Expert,1,449.0,B,,,,,CHO
1167,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,CHEMBL616112,15086,,Expert,1,,B,,,,,
1168,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,BAO_0000221,CHEMBL616113,13462,,Autocuration,1,,B,,,,Hippocampus,
1169,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616114,15363,,Autocuration,1,,B,,,,,
1170,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616115,15363,,Autocuration,1,,B,,,,,
1171,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616116,10796,,Autocuration,1,,B,,,,,
1172,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL615844,12816,,Expert,1,,B,,,,Brain,
1173,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,CHEMBL615939,13542,,Expert,1,,B,,,,Hippocampus,
1174,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,BAO_0000019,CHEMBL615940,13308,,Expert,1,,B,,,,,
1175,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,BAO_0000221,CHEMBL615941,13541,,Expert,1,,B,,,,Hippocampus,
1176,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,BAO_0000221,CHEMBL615942,10058,,Autocuration,1,,B,,,,Hippocampus,
1177,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,CHEMBL615943,10058,,Autocuration,1,,B,,,,Hippocampus,
1178,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,BAO_0000221,CHEMBL615944,10058,,Autocuration,1,,B,,,,Hippocampus,
1179,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,BAO_0000221,CHEMBL615945,10058,,Autocuration,1,,B,,,,Hippocampus,
1180,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,BAO_0000221,CHEMBL615946,10058,,Autocuration,1,,B,,,,Hippocampus,
1181,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,BAO_0000221,CHEMBL615947,10058,,Autocuration,1,,B,,,,Hippocampus,
1182,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,BAO_0000221,CHEMBL615948,10058,,Autocuration,1,,B,,,,Hippocampus,
1183,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,BAO_0000221,CHEMBL615949,10058,,Autocuration,1,,B,,,,Hippocampus,
1184,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,BAO_0000221,CHEMBL615950,10058,,Autocuration,1,,B,,,,Hippocampus,
1185,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,BAO_0000221,CHEMBL615951,10058,,Autocuration,1,,B,,,,Hippocampus,
1186,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,BAO_0000221,CHEMBL615952,10058,,Autocuration,1,,B,,,,Hippocampus,
1187,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,BAO_0000221,CHEMBL615953,10058,,Autocuration,1,,B,,,,Hippocampus,
1188,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,BAO_0000221,CHEMBL615954,10058,,Autocuration,1,,B,,,,Hippocampus,
1189,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,CHEMBL615955,10058,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1190,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,BAO_0000221,CHEMBL615956,10058,,Autocuration,1,,B,,,,Hippocampus,
1191,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,BAO_0000221,CHEMBL615957,10058,,Autocuration,1,,B,,,,Hippocampus,
1192,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,BAO_0000019,CHEMBL615958,12879,,Expert,1,,B,,,,,
1193,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,BAO_0000019,CHEMBL615959,11964,,Expert,1,,B,,,,,
1194,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,BAO_0000019,CHEMBL615960,11964,,Autocuration,1,,B,,,,,
1195,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,BAO_0000019,CHEMBL615961,11964,,Autocuration,1,,B,,,,,
1196,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,CHEMBL615962,9548,,Expert,1,,B,,,,Brain,
1197,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,BAO_0000019,CHEMBL615963,9098,,Expert,1,,B,,,,,
1198,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,BAO_0000019,CHEMBL615964,9098,,Autocuration,1,,B,,,,,
1199,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,BAO_0000019,CHEMBL615965,9098,,Autocuration,1,,B,,,,,
1200,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,BAO_0000219,CHEMBL615966,13248,,Expert,1,449.0,B,,,,,CHO
1201,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,BAO_0000249,CHEMBL615967,3147,,Expert,1,,B,,,,,
1202,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,CHEMBL615968,13949,,Expert,1,,B,,,,,
1203,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,BAO_0000218,CHEMBL615969,11883,,Autocuration,1,449.0,B,,,,,CHO
1204,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,BAO_0000218,CHEMBL615970,11883,,Autocuration,1,,B,,,,,
1205,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,BAO_0000357,CHEMBL615971,11883,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1206,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,CHEMBL615972,15535,,Expert,1,,B,,,,,
1207,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,BAO_0000249,CHEMBL615973,15535,,Autocuration,1,,B,,,,,
1208,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,BAO_0000249,CHEMBL615974,15535,,Autocuration,1,,B,,,,,
1209,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,CHEMBL615975,16372,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1210,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,BAO_0000249,CHEMBL615976,14608,,Expert,1,,B,,,,,
1211,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,CHEMBL872106,4795,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1212,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL615977,13863,,Autocuration,1,,B,,,,,
1213,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,BAO_0000357,CHEMBL615978,13863,,Autocuration,1,,B,,,,,
1214,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,BAO_0000357,CHEMBL616166,13863,,Autocuration,1,,B,,,,,
1215,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,BAO_0000357,CHEMBL616167,13863,,Autocuration,1,,B,,,,,
1216,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,BAO_0000357,CHEMBL616168,13863,,Autocuration,1,,B,,,,,
1217,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,BAO_0000357,CHEMBL616169,13863,,Autocuration,1,,B,,,,,
1218,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,BAO_0000357,CHEMBL616170,13863,,Autocuration,1,,B,,,,,
1219,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,BAO_0000357,CHEMBL616171,13863,,Autocuration,1,,B,,,,,
1220,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,BAO_0000357,CHEMBL616172,13863,,Autocuration,1,,B,,,,,
1221,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,BAO_0000357,CHEMBL616173,13863,,Autocuration,1,,B,,,,,
1222,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,BAO_0000357,CHEMBL616174,13863,,Autocuration,1,,B,,,,,
1223,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,BAO_0000357,CHEMBL616175,13863,,Autocuration,1,,B,,,,,
1224,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,BAO_0000357,CHEMBL616176,13863,,Autocuration,1,,B,,,,,
1225,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,BAO_0000357,CHEMBL616177,13863,,Autocuration,1,,B,,,,,
1226,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,BAO_0000357,CHEMBL616178,13863,,Autocuration,1,,B,,,,,
1227,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,CHEMBL616179,9742,,Autocuration,1,,B,,,,,
1228,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616180,12073,,Autocuration,1,,B,,,,,
1229,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,BAO_0000357,CHEMBL616181,4101,,Autocuration,1,,B,,,,,
1230,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,BAO_0000019,CHEMBL616182,15360,,Autocuration,1,,B,,,,,
1231,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,CHEMBL616183,11576,,Autocuration,1,,B,,,,Hippocampus,
1232,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,BAO_0000019,CHEMBL615874,5834,,Expert,1,,B,,,,,
1233,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,BAO_0000219,CHEMBL615875,2395,10116.0,Expert,1,485.0,B,,Rattus norvegicus,,,CHO-K1
1234,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,BAO_0000019,CHEMBL615876,1375,,Autocuration,1,,B,,,,,
1235,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,BAO_0000019,CHEMBL615877,1375,,Autocuration,1,,B,,,,,
1236,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,BAO_0000357,CHEMBL615878,3967,,Autocuration,1,,B,,,,,
1237,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,BAO_0000357,CHEMBL615879,12884,,Expert,1,,B,,,,,
1238,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,BAO_0000357,CHEMBL615880,2343,,Expert,1,,B,,,,,
1239,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,CHEMBL615881,11511,,Autocuration,1,,B,,,,,
1240,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,CHEMBL615882,11511,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1241,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,BAO_0000218,CHEMBL615883,16394,,Autocuration,1,,F,In vivo,,,,
1242,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,BAO_0000218,CHEMBL615884,16394,,Autocuration,1,,F,In vivo,,,,
1243,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,BAO_0000218,CHEMBL615885,16394,,Autocuration,1,,F,In vivo,,,,
1244,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,BAO_0000218,CHEMBL615886,16394,,Autocuration,1,,F,In vivo,,,,
1245,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,BAO_0000218,CHEMBL615887,16394,,Autocuration,1,,F,In vivo,,,,
1246,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,BAO_0000218,CHEMBL615888,16394,,Autocuration,1,,F,In vivo,,,,
1247,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,BAO_0000218,CHEMBL615889,16394,,Autocuration,1,,F,In vivo,,,,
1248,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,BAO_0000218,CHEMBL615890,16394,,Autocuration,1,,F,In vivo,,,,
1249,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,BAO_0000218,CHEMBL615891,16394,,Autocuration,1,,F,In vivo,,,,
1250,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,BAO_0000218,CHEMBL615892,16394,,Autocuration,1,,F,In vivo,,,,
1251,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,BAO_0000218,CHEMBL615893,16394,,Autocuration,1,,F,In vivo,,,,
1252,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,BAO_0000218,CHEMBL615894,16394,,Autocuration,1,,F,In vivo,,,,
1253,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,BAO_0000218,CHEMBL615895,16394,,Autocuration,1,,F,In vivo,,,,
1254,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,BAO_0000218,CHEMBL615896,16394,,Autocuration,1,,F,In vivo,,,,
1255,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,BAO_0000218,CHEMBL615897,16394,,Autocuration,1,,F,In vivo,,,,
1256,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,BAO_0000249,CHEMBL615898,16616,10116.0,Expert,1,,F,,Rattus norvegicus,,,
1257,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,BAO_0000019,CHEMBL615899,16796,,Autocuration,1,,B,,,,,
1258,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,CHEMBL616291,16796,,Autocuration,1,,B,,,,,
1259,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,BAO_0000357,CHEMBL616292,15629,,Autocuration,1,,B,,,,,
1260,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,CHEMBL616293,13241,,Autocuration,1,,F,,,,,
1261,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL616294,12073,,Expert,1,,B,,,,Hippocampus,
1262,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,BAO_0000249,CHEMBL616295,14286,,Autocuration,1,,B,,,,Hippocampus,
1263,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,BAO_0000221,CHEMBL616296,14542,,Autocuration,1,,B,,,,Brain,
1264,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,CHEMBL616297,13630,,Autocuration,1,,F,,,,,
1265,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,BAO_0000019,CHEMBL616605,13630,,Autocuration,1,,F,,,,,
1266,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,BAO_0000019,CHEMBL616606,13630,,Autocuration,1,,F,,,,,
1267,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,CHEMBL616607,13630,,Autocuration,1,,F,,,,,
1268,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,CHEMBL616608,13630,,Expert,1,,F,,,,,
1269,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,BAO_0000019,CHEMBL616609,13630,,Autocuration,1,,F,,,,,
1270,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,BAO_0000019,CHEMBL616610,13630,10116.0,Expert,1,,F,,Rattus norvegicus,,,
1271,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,CHEMBL616611,13630,,Autocuration,1,,F,,,,,
1272,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,BAO_0000019,CHEMBL616612,13630,,Expert,1,,F,,,,,
1273,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,BAO_0000019,CHEMBL616613,13630,,Autocuration,1,,F,,,,,
1274,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,BAO_0000019,CHEMBL616614,13630,,Expert,1,,F,,,,,
1275,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,BAO_0000019,CHEMBL616615,13630,,Autocuration,1,,F,,,,,
1276,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,CHEMBL616616,13630,,Expert,1,,F,,,,,
1277,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,BAO_0000019,CHEMBL616617,13630,,Autocuration,1,,F,,,,,
1278,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,CHEMBL616618,13630,,Autocuration,1,,F,,,,,
1279,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,BAO_0000019,CHEMBL616619,13630,,Autocuration,1,,F,,,,,
1280,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,BAO_0000019,CHEMBL616620,13630,,Expert,1,,F,,,,,
1281,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,CHEMBL616621,13630,,Expert,1,,F,,,,,
1282,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,BAO_0000019,CHEMBL616622,13630,,Autocuration,1,,F,,,,,
1283,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,BAO_0000019,CHEMBL616146,13630,,Expert,1,,F,,,,,
1284,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,BAO_0000019,CHEMBL832873,13630,,Autocuration,1,,F,,,,,
1285,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,BAO_0000019,CHEMBL616147,13630,,Autocuration,1,,F,,,,,
1286,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,CHEMBL872872,13630,,Autocuration,1,,F,,,,,
1287,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,CHEMBL616148,13630,,Autocuration,1,,F,,,,,
1288,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,BAO_0000221,CHEMBL616149,9783,,Autocuration,1,,B,,,,Hippocampus,
1289,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,BAO_0000221,CHEMBL616150,9783,,Expert,1,,B,,,,Hippocampus,
1290,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,BAO_0000249,CHEMBL616151,14331,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1291,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,BAO_0000221,CHEMBL872873,15260,,Expert,1,,B,,,,Hippocampus,
1292,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,BAO_0000221,CHEMBL616670,15260,,Autocuration,1,,B,,,,Hippocampus,
1293,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,BAO_0000221,CHEMBL616671,15260,,Autocuration,1,,B,,,,Hippocampus,
1294,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,CHEMBL884861,16616,10116.0,Expert,1,,F,,Rattus norvegicus,,,
1295,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,BAO_0000357,CHEMBL616672,15629,,Autocuration,1,,B,,,,,
1296,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,CHEMBL616673,15086,,Autocuration,1,,B,,,,,
1297,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,CHEMBL616674,5717,,Expert,1,,F,,,,,
1298,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,CHEMBL616675,12652,,Autocuration,1,,B,,,,,
1299,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,BAO_0000221,CHEMBL616676,14608,,Autocuration,1,,B,,,,Hippocampus,
1300,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,CHEMBL616677,12306,,Autocuration,1,,B,,,,Hippocampus,
1301,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,CHEMBL616678,12306,,Autocuration,1,,B,,,,Hippocampus,
1302,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616679,15247,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1303,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,BAO_0000221,CHEMBL616680,17529,,Expert,1,,B,,,,Hippocampus,
1304,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL616681,14826,,Autocuration,1,,B,,,,Hippocampus,
1305,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL616682,14826,,Autocuration,1,,B,,,,Hippocampus,
1306,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,CHEMBL616683,13241,,Autocuration,1,,B,,,,Hippocampus,
1307,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,BAO_0000221,CHEMBL616684,14093,,Autocuration,1,,B,,,,Hippocampus,
1308,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,BAO_0000221,CHEMBL616685,14093,,Autocuration,1,,B,,,,Hippocampus,
1309,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,BAO_0000221,CHEMBL616686,14442,,Autocuration,1,,B,,,,Brain,
1310,,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,CHEMBL616687,9919,,Autocuration,1,,B,,,,,
1311,,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,CHEMBL616688,9919,,Autocuration,1,,B,,,,,
1312,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,BAO_0000221,CHEMBL616689,11440,,Autocuration,1,,B,,,,Hippocampus,
1313,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,BAO_0000357,CHEMBL616690,11257,,Autocuration,1,,B,,,,,
1314,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616691,10330,,Expert,1,,B,,,,,
1315,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,BAO_0000221,CHEMBL616692,17331,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1316,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,BAO_0000249,CHEMBL616693,16567,,Expert,1,,B,,,,,
1317,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,CHEMBL616694,12058,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1318,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,BAO_0000221,CHEMBL616695,9699,,Autocuration,1,,B,,,,Hippocampus,
1319,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,BAO_0000357,CHEMBL616696,9547,,Autocuration,1,,B,,,,,
1320,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,BAO_0000357,CHEMBL616697,10330,,Autocuration,1,,B,,,,,
1321,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616698,14331,,Autocuration,1,,B,,,,,
1322,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616949,14060,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1323,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,BAO_0000221,CHEMBL616950,14744,,Autocuration,1,,B,,,,Hippocampus,
1324,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,CHEMBL832875,13506,,Autocuration,1,,B,,,,,
1325,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,CHEMBL616951,10862,,Expert,1,,B,,,,Brain,
1326,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,CHEMBL616952,10862,,Expert,1,,B,,,,Brain,
1327,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,BAO_0000357,CHEMBL616953,10062,,Expert,1,,B,,,,,
1328,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,BAO_0000357,CHEMBL616954,12073,,Autocuration,1,,B,,,,,
1329,,GTPgammaS radioligand binding assay,,BAO_0000357,CHEMBL616955,14875,,Autocuration,1,,B,,,,,
1330,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,CHEMBL616956,2391,,Autocuration,1,,B,,,,,
1331,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,BAO_0000019,CHEMBL616957,2391,,Autocuration,1,,F,,,,,
1332,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,BAO_0000019,CHEMBL616958,2391,,Autocuration,1,,F,,,,,
1333,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616959,2391,,Autocuration,1,,B,,,,,
1334,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,CHEMBL616960,2391,,Autocuration,1,,B,,,,,
1335,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,BAO_0000019,CHEMBL616961,2391,,Autocuration,1,,F,,,,,
1336,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,BAO_0000219,CHEMBL616962,17211,,Expert,1,308.0,B,,,,,HeLa
1337,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,BAO_0000219,CHEMBL616963,17211,,Autocuration,1,308.0,B,,,,,HeLa
1338,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,BAO_0000357,CHEMBL616524,6491,9606.0,Expert,1,,B,,Homo sapiens,,,
1339,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL616525,16190,,Autocuration,1,449.0,B,,,,,CHO
1340,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,CHEMBL872908,14165,,Autocuration,1,,B,,,,,
1341,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,BAO_0000019,CHEMBL616526,14165,,Autocuration,1,,B,,,,,
1342,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616527,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
1343,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,CHEMBL616528,6328,,Expert,1,,B,,,,,
1344,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,CHEMBL616529,14770,,Autocuration,1,,B,,,,,
1345,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,BAO_0000357,CHEMBL616530,2598,,Autocuration,1,,B,,,,,
1346,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616531,6897,,Expert,1,,B,,,,,
1347,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616532,6897,,Autocuration,1,,B,,,,,
1348,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616533,6013,,Autocuration,1,,B,,,,,
1349,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616534,5843,,Expert,1,,B,,,,,
1350,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,CHEMBL616535,14454,,Expert,1,,B,,,,,
1351,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,BAO_0000357,CHEMBL616536,16209,,Autocuration,1,,B,,,,,
1352,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616537,3935,,Autocuration,1,,B,,,,,
1353,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,BAO_0000219,CHEMBL616538,13729,,Expert,1,485.0,F,,,,,CHO-K1
1354,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000019,CHEMBL616539,14251,,Expert,1,,F,,,,,
1355,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,BAO_0000019,CHEMBL616540,17085,,Expert,1,,B,,,,,
1356,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,CHEMBL616429,3025,,Autocuration,1,,B,,,,,
1357,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616430,15315,,Expert,1,,B,,,,,
1358,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,BAO_0000219,CHEMBL616431,14214,9606.0,Expert,1,,B,,Homo sapiens,,,
1359,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616432,3804,9606.0,Expert,1,,B,,Homo sapiens,,,
1360,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,BAO_0000357,CHEMBL616433,2391,9606.0,Expert,1,,B,,Homo sapiens,,,
1361,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616434,4175,9606.0,Expert,1,,B,,Homo sapiens,,,
1362,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,BAO_0000219,CHEMBL616435,17296,,Autocuration,1,449.0,B,,,,,CHO
1363,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,BAO_0000019,CHEMBL616436,17085,,Expert,1,,B,,,,,
1364,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,BAO_0000219,CHEMBL616437,17211,,Autocuration,1,308.0,B,,,,,HeLa
1365,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,BAO_0000219,CHEMBL616438,17211,,Autocuration,1,308.0,B,,,,,HeLa
1366,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,BAO_0000219,CHEMBL616439,17211,,Autocuration,1,308.0,B,,,,,HeLa
1367,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,BAO_0000357,CHEMBL616440,15926,9606.0,Expert,1,,B,,Homo sapiens,,,
1368,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,BAO_0000219,CHEMBL616441,16312,,Autocuration,1,485.0,B,,,,,CHO-K1
1369,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,BAO_0000357,CHEMBL616442,5843,,Expert,1,,B,,,,,
1370,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616443,5843,,Autocuration,1,,B,,,,,
1371,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000219,CHEMBL616444,16312,,Expert,1,485.0,B,,,,,CHO-K1
1372,,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616445,15926,9606.0,Expert,1,,B,,Homo sapiens,,,
1373,,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616446,15926,9606.0,Expert,1,,B,,Homo sapiens,,,
1374,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL616447,4540,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1375,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,CHEMBL616448,6166,,Autocuration,1,,B,,,,,
1376,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,BAO_0000219,CHEMBL616449,17296,,Autocuration,1,449.0,B,,,,,CHO
1377,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,BAO_0000219,CHEMBL616450,17296,,Autocuration,1,449.0,B,,,,,CHO
1378,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,BAO_0000219,CHEMBL857974,17296,,Autocuration,1,449.0,B,,,,,CHO
1379,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL616451,15779,,Autocuration,1,449.0,B,,,,,CHO
1380,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL616452,15779,,Autocuration,1,449.0,B,,,,,CHO
1381,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,BAO_0000219,CHEMBL616453,15779,,Autocuration,1,449.0,B,,,,,CHO
1382,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,CHEMBL616454,4199,,Autocuration,1,449.0,B,,,,,CHO
1383,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616455,14875,9606.0,Expert,1,,B,,Homo sapiens,,,
1384,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,BAO_0000219,CHEMBL616456,15146,,Autocuration,1,449.0,B,,,,,CHO
1385,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,CHEMBL616457,5213,,Autocuration,1,,B,,,,,
1386,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,BAO_0000219,CHEMBL616458,14818,,Autocuration,1,449.0,B,,,,,CHO
1387,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL616459,4829,,Autocuration,1,449.0,B,,,,,CHO
1388,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,BAO_0000019,CHEMBL616460,14454,,Expert,1,,F,,,,,
1389,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,BAO_0000019,CHEMBL616461,14454,,Expert,1,,F,,,,,
1390,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,BAO_0000219,CHEMBL616462,14875,,Autocuration,1,449.0,F,,,,,CHO
1391,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,BAO_0000219,CHEMBL616463,14875,,Autocuration,1,449.0,F,,,,,CHO
1392,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,BAO_0000019,CHEMBL616464,15250,,Autocuration,1,,F,,,,,
1393,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,BAO_0000219,CHEMBL616465,15250,,Autocuration,1,449.0,B,,,,,CHO
1394,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL832874,15086,,Autocuration,1,,B,,,,,
1395,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,BAO_0000019,CHEMBL616184,3025,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,,
1396,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,BAO_0000019,CHEMBL616185,14998,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
1397,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,BAO_0000019,CHEMBL616186,14998,9986.0,Intermediate,1,,B,,Oryctolagus cuniculus,,,
1398,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,BAO_0000019,CHEMBL616187,14998,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
1399,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616188,13969,,Expert,1,,B,,,,,
1400,,Binding affinity for 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL873475,13392,,Intermediate,1,,B,,,,,
1401,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,BAO_0000019,CHEMBL616189,3651,10116.0,Expert,1,,B,,Rattus norvegicus,,Striatum,
1402,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,CHEMBL616190,10025,,Expert,1,,B,,,,,
1403,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,BAO_0000357,CHEMBL616191,13863,,Autocuration,1,,B,,,,,
1404,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,BAO_0000357,CHEMBL616192,13863,,Autocuration,1,,B,,,,,
1405,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,BAO_0000357,CHEMBL616193,13863,,Autocuration,1,,B,,,,,
1406,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,BAO_0000357,CHEMBL616194,13863,,Autocuration,1,,B,,,,,
1407,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,BAO_0000357,CHEMBL616195,13863,,Autocuration,1,,B,,,,,
1408,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,BAO_0000357,CHEMBL616196,13863,,Autocuration,1,,B,,,,,
1409,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,BAO_0000249,CHEMBL616197,4622,,Autocuration,1,,B,,,,Hippocampus,
1410,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,CHEMBL616198,14911,,Intermediate,1,,B,,,,,
1411,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,BAO_0000221,CHEMBL616199,12678,,Autocuration,1,,B,,,,Hippocampus,
1412,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,BAO_0000221,CHEMBL616200,12678,,Expert,1,,B,,,,Hippocampus,
1413,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL616201,14235,,Expert,1,,B,,,,Hippocampus,
1414,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,BAO_0000221,CHEMBL616202,14949,,Expert,1,,B,,,,Hippocampus,
1415,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,BAO_0000221,CHEMBL616203,14949,,Expert,1,,B,,,,Hippocampus,
1416,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,BAO_0000221,CHEMBL616204,14949,,Expert,1,,B,,,,Hippocampus,
1417,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,BAO_0000221,CHEMBL616205,14949,,Expert,1,,B,,,,Hippocampus,
1418,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,BAO_0000221,CHEMBL616206,14949,,Expert,1,,B,,,,Hippocampus,
1419,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,CHEMBL616207,16118,,Expert,1,,B,,,,,
1420,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,BAO_0000249,CHEMBL616208,3268,,Autocuration,1,,B,,,,,
1421,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,BAO_0000249,CHEMBL616209,3268,,Autocuration,1,,B,,,,,
1422,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,BAO_0000357,CHEMBL616210,16117,,Expert,1,,B,,,,,
1423,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,BAO_0000221,CHEMBL616211,9783,,Expert,1,,B,,,,Hippocampus,
1424,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,BAO_0000221,CHEMBL616504,9783,,Autocuration,1,,B,,,,Hippocampus,
1425,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,CHEMBL616505,14356,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1426,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,CHEMBL616506,15740,,Autocuration,1,,F,,,,,
1427,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,CHEMBL872107,12306,,Autocuration,1,,B,,,,Hippocampus,
1428,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,BAO_0000221,CHEMBL616507,13348,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1429,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,BAO_0000249,CHEMBL616303,10394,,Autocuration,1,,B,,,,,
1430,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,BAO_0000221,CHEMBL616304,15260,,Autocuration,1,,B,,,,Hippocampus,
1431,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,CHEMBL616305,10046,,Expert,1,,B,,,,Hippocampus,
1432,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,BAO_0000221,CHEMBL616306,15260,,Intermediate,1,,F,,,,Hippocampus,
1433,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616307,12851,,Autocuration,1,,B,,,,,
1434,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,BAO_0000221,CHEMBL881829,2148,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1435,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,BAO_0000357,CHEMBL616308,13134,,Expert,1,,B,,,,,
1436,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,BAO_0000019,CHEMBL616309,12462,,Autocuration,1,,B,,,,,
1437,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,BAO_0000019,CHEMBL616310,12462,,Expert,1,,B,,,,,
1438,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,BAO_0000219,CHEMBL616311,12462,,Autocuration,1,449.0,B,,,,,CHO
1439,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616312,11933,,Expert,1,,B,,,,,
1440,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,BAO_0000357,CHEMBL616313,11933,,Autocuration,1,,B,,,,,
1441,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,CHEMBL616314,403,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1442,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL616315,15538,,Autocuration,1,,B,,,,Hippocampus,
1443,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,BAO_0000221,CHEMBL616567,15538,,Autocuration,1,,B,,,,Hippocampus,
1444,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,BAO_0000221,CHEMBL616568,15538,,Autocuration,1,,B,,,,Hippocampus,
1445,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,BAO_0000019,CHEMBL616569,12464,,Intermediate,1,,B,,,,,
1446,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,BAO_0000357,CHEMBL616570,1455,,Expert,1,,B,,,,,
1447,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,CHEMBL616571,12652,,Autocuration,1,,B,,,,,
1448,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,BAO_0000221,CHEMBL616572,12639,,Autocuration,1,,B,,,,Hippocampus,
1449,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,BAO_0000249,CHEMBL616573,13949,,Expert,1,,B,,,,,
1450,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,BAO_0000357,CHEMBL616574,12463,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1451,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,BAO_0000221,CHEMBL616575,14829,,Expert,1,,B,,,,Hippocampus,
1452,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,BAO_0000221,CHEMBL872108,14829,,Autocuration,1,,B,,,,Hippocampus,
1453,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,BAO_0000357,CHEMBL616576,12092,,Autocuration,1,,B,,,,,
1454,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,BAO_0000249,CHEMBL616577,403,,Autocuration,1,,B,,,,,
1455,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,BAO_0000249,CHEMBL616578,403,,Autocuration,1,,B,,,,,
1456,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,BAO_0000357,CHEMBL616579,3967,,Expert,1,,B,,,,,
1457,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,BAO_0000019,CHEMBL616580,12771,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1458,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,CHEMBL616581,15086,,Autocuration,1,,B,,,,,
1459,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL616582,14909,,Autocuration,1,,B,,,,Hippocampus,
1460,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,CHEMBL616583,14949,,Expert,1,,B,,,,Hippocampus,
1461,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,BAO_0000221,CHEMBL616584,2309,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1462,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616585,4170,,Expert,1,,B,,,,,
1463,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,BAO_0000221,CHEMBL616586,11642,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1464,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,BAO_0000221,CHEMBL616587,11642,,Autocuration,1,,B,,,,Hippocampus,
1465,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL616588,12953,,Autocuration,1,,B,,,,Hippocampus,
1466,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,BAO_0000221,CHEMBL616589,12953,,Autocuration,1,,B,,,,Hippocampus,
1467,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,CHEMBL616590,12953,,Expert,1,,B,,,,Hippocampus,
1468,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,BAO_0000219,CHEMBL616591,12903,,Expert,1,449.0,B,,,,,CHO
1469,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616592,12536,,Expert,1,,B,,,,,
1470,,The inhibition activity of 5-HT1A at 1 uM,,BAO_0000357,CHEMBL616593,10058,,Autocuration,1,,B,,,,,
1471,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000219,CHEMBL616594,12902,,Expert,1,485.0,B,,,,,CHO-K1
1472,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,BAO_0000249,CHEMBL616595,14057,,Expert,1,,B,,,,,
1473,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,BAO_0000357,CHEMBL616596,11296,,Autocuration,1,,B,,,,,
1474,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,CHEMBL616597,11296,,Autocuration,1,,B,,,,Hippocampus,
1475,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,CHEMBL616598,11296,,Expert,1,,B,,,,Hippocampus,
1476,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,BAO_0000249,CHEMBL616599,16616,10116.0,Expert,1,,F,,Rattus norvegicus,,,
1477,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,BAO_0000249,CHEMBL616600,16616,10116.0,Expert,1,,F,,Rattus norvegicus,,Hippocampus,
1478,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,BAO_0000019,CHEMBL616601,16567,,Autocuration,1,,B,,,,,
1479,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,BAO_0000019,CHEMBL616602,16567,,Autocuration,1,,B,,,,,
1480,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,BAO_0000019,CHEMBL616603,16567,,Autocuration,1,,B,,,,,
1481,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,BAO_0000019,CHEMBL616604,16567,,Autocuration,1,,B,,,,,
1482,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,BAO_0000249,CHEMBL616316,17136,,Autocuration,1,,B,,,,,
1483,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,BAO_0000249,CHEMBL616317,17136,,Autocuration,1,,B,,,,,
1484,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,BAO_0000019,CHEMBL616318,16616,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1485,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,BAO_0000221,CHEMBL616319,17331,,Autocuration,1,,B,,,,Hippocampus,
1486,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,BAO_0000221,CHEMBL616320,17331,,Autocuration,1,,B,,,,Hippocampus,
1487,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,BAO_0000221,CHEMBL616321,17167,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1488,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,CHEMBL616322,15740,,Autocuration,1,,F,,,,,
1489,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,BAO_0000019,CHEMBL616323,15740,,Autocuration,1,,F,,,,,
1490,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,BAO_0000357,CHEMBL616324,4671,,Autocuration,1,,B,,,,,
1491,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,BAO_0000221,CHEMBL616325,10058,,Autocuration,1,,B,,,,Hippocampus,
1492,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,BAO_0000221,CHEMBL616326,10058,,Autocuration,1,,B,,,,Hippocampus,
1493,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,BAO_0000221,CHEMBL616327,10058,,Autocuration,1,,B,,,,Hippocampus,
1494,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616328,12073,,Autocuration,1,,B,,,,,
1495,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,CHEMBL858110,2759,,Autocuration,1,,B,,,,,
1496,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,CHEMBL616329,2759,,Autocuration,1,,F,,,,,
1497,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,CHEMBL616330,2759,,Autocuration,1,,B,,,,,
1498,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,CHEMBL616331,2759,,Autocuration,1,,F,,,,,
1499,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,CHEMBL616332,2759,,Autocuration,1,,F,,,,,
1500,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,CHEMBL857063,9737,,Autocuration,1,,B,,,,Brain,
1501,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,CHEMBL616333,9737,,Autocuration,1,,B,,,,,
1502,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,BAO_0000019,CHEMBL616334,5717,,Expert,1,,F,,,,,
1503,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,CHEMBL616335,12253,,Autocuration,1,,B,,,,Hippocampus,
1504,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,BAO_0000019,CHEMBL616336,14025,,Autocuration,1,,B,,,,,
1505,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,BAO_0000249,CHEMBL616337,10425,,Expert,1,,B,,,,,
1506,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,BAO_0000019,CHEMBL616338,14998,,Autocuration,1,,B,,,,,
1507,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,BAO_0000221,CHEMBL616339,13694,,Autocuration,1,,B,,,,Hippocampus,
1508,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,BAO_0000221,CHEMBL616340,13694,,Autocuration,1,,B,,,,Hippocampus,
1509,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,CHEMBL616341,4342,,Autocuration,1,,B,,,,,
1510,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616342,12936,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1511,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,BAO_0000019,CHEMBL616343,13144,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1512,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,BAO_0000019,CHEMBL616344,13343,,Expert,1,,B,,,,,
1513,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,CHEMBL616345,12132,,Expert,1,,B,,,,,
1514,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,CHEMBL616346,15419,,Expert,1,,B,,,,,
1515,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,CHEMBL616347,1479,,Autocuration,1,,B,,,,Hippocampus,
1516,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,BAO_0000019,CHEMBL616348,14287,,Expert,1,,B,,,,,
1517,,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616349,13116,,Expert,1,,B,,,,,
1518,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,BAO_0000249,CHEMBL616152,2759,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1519,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,CHEMBL616153,2759,,Autocuration,1,,B,,,,,
1520,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,BAO_0000019,CHEMBL616154,14748,,Expert,1,,B,,,,,
1521,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,CHEMBL616155,12304,,Autocuration,1,,B,,,,,
1522,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,BAO_0000221,CHEMBL616156,12409,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1523,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,BAO_0000221,CHEMBL616157,12409,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
1524,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,BAO_0000221,CHEMBL616158,13267,,Autocuration,1,,B,,,,Hippocampus,
1525,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,CHEMBL616159,15194,,Autocuration,1,,B,,,,,
1526,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,BAO_0000357,CHEMBL616160,14256,,Expert,1,,B,,,,,
1527,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,BAO_0000019,CHEMBL616161,16567,,Autocuration,1,,B,,,,,
1528,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,CHEMBL616162,15740,,Autocuration,1,,F,,,,,
1529,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,CHEMBL616163,13278,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1530,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,CHEMBL616164,1970,,Expert,1,,B,,,,,
1531,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,BAO_0000221,CHEMBL616165,10034,,Autocuration,1,,B,,,,Brain,
1532,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,BAO_0000019,CHEMBL616355,13348,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1533,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,CHEMBL616356,13630,,Autocuration,1,,F,,,,,
1534,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,CHEMBL616357,10862,,Autocuration,1,,B,,,,Brain,
1535,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,CHEMBL616358,12058,,Autocuration,1,,B,,,,,
1536,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616359,4639,,Autocuration,1,,B,,,,,
1537,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,BAO_0000357,CHEMBL616360,15453,,Expert,1,,B,,,,,
1538,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616361,4820,,Expert,1,,B,,,,,
1539,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616362,1089,,Autocuration,1,,B,,,,,
1540,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,BAO_0000249,CHEMBL616363,386,,Autocuration,1,,B,,,,,
1541,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,BAO_0000357,CHEMBL616364,6011,,Autocuration,1,,B,,,,,
1542,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616365,5014,,Autocuration,1,,B,,,,,
1543,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616366,4402,,Expert,1,,B,,,,,
1544,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL872906,17066,,Expert,1,,B,,,,,
1545,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,BAO_0000357,CHEMBL616367,17515,,Autocuration,1,,B,,,,,
1546,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616368,2474,,Autocuration,1,,B,,,,,
1547,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,CHEMBL616369,4775,,Autocuration,1,,B,,,,,
1548,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,BAO_0000357,CHEMBL616370,14294,9606.0,Expert,1,,B,,Homo sapiens,,,
1549,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,BAO_0000357,CHEMBL616371,14294,9606.0,Expert,1,,B,,Homo sapiens,,,
1550,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,CHEMBL616372,12249,,Autocuration,1,449.0,B,,,,,CHO
1551,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,BAO_0000219,CHEMBL616373,11376,,Expert,1,,B,,,,,
1552,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000218,CHEMBL616374,2474,,Autocuration,1,,B,In vivo,,,,
1553,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,CHEMBL616375,13311,,Autocuration,1,,B,,,,Hippocampus,
1554,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,CHEMBL616376,4373,,Autocuration,1,,B,,,,,
1555,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,BAO_0000357,CHEMBL857064,1633,,Expert,1,,B,,,,,
1556,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,CHEMBL616377,11866,,Autocuration,1,,B,,,,,
1557,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,CHEMBL616378,4373,,Autocuration,1,,B,,,,,
1558,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616379,4687,,Autocuration,1,,B,,,,,
1559,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616380,16946,,Autocuration,1,,B,,,,,
1560,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,BAO_0000357,CHEMBL616381,13291,,Autocuration,1,,B,,,,,
1561,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616382,14159,,Autocuration,1,,B,,,,,
1562,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,BAO_0000357,CHEMBL616383,10812,,Autocuration,1,,B,,,,,
1563,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,BAO_0000219,CHEMBL616350,3032,10090.0,Expert,1,449.0,B,,Mus musculus,,,CHO
1564,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616351,16655,,Autocuration,1,,B,,,,,
1565,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,BAO_0000357,CHEMBL616352,14532,,Autocuration,1,,B,,,,,
1566,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616353,13944,,Autocuration,1,,B,,,,,
1567,,Binding affinity against serotonergic 5-HT1a receptor,,BAO_0000357,CHEMBL616354,13033,,Autocuration,1,,B,,,,,
1568,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616508,10321,,Autocuration,1,,B,,,,,
1569,,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616559,2968,10090.0,Expert,1,,B,,Mus musculus,,,
1570,,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616560,13964,,Autocuration,1,,B,,,,,
1571,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,BAO_0000357,CHEMBL616561,15527,,Autocuration,1,,B,,,,,
1572,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,CHEMBL616562,12248,,Autocuration,1,449.0,B,,,,,CHO
1573,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,CHEMBL616563,12249,,Autocuration,1,449.0,B,,,,,CHO
1574,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616564,15120,,Autocuration,1,,B,,,,,
1575,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616565,13313,,Autocuration,1,,B,,,,,
1576,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,BAO_0000218,CHEMBL616566,2613,,Autocuration,1,,B,,,,,
1577,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,BAO_0000357,CHEMBL616989,16700,,Autocuration,1,,B,,,,,
1578,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL857975,2201,,Autocuration,1,,B,,,,,
1579,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616990,1274,10090.0,Expert,1,,B,,Mus musculus,,,
1580,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,CHEMBL616991,1317,,Autocuration,1,,B,,,,,
1581,,Tested against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616992,12146,,Autocuration,1,,B,,,,,
1582,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL616993,14059,,Autocuration,1,,B,,,,,
1583,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,BAO_0000019,CHEMBL616994,14025,9986.0,Expert,1,,B,,Oryctolagus cuniculus,,,
1584,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,BAO_0000019,CHEMBL616995,14025,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
1585,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,BAO_0000219,CHEMBL616996,14447,9593.0,Intermediate,1,722.0,B,,Gorilla gorilla,,,HEK293
1586,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,CHEMBL616997,3025,10141.0,Autocuration,1,,F,In vivo,Cavia porcellus,,,
1587,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,CHEMBL616998,3025,10141.0,Autocuration,1,,F,In vivo,Cavia porcellus,,,
1588,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,BAO_0000019,CHEMBL616999,15329,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
1589,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,BAO_0000019,CHEMBL617000,15329,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
1590,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,BAO_0000019,CHEMBL617001,15847,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
1591,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,BAO_0000019,CHEMBL858111,15847,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
1592,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,BAO_0000019,CHEMBL617002,14165,,Autocuration,1,,F,,,,,
1593,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,BAO_0000019,CHEMBL617003,14214,,Autocuration,1,,F,,,,,
1594,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,BAO_0000019,CHEMBL617004,14214,,Autocuration,1,,F,,,,,
1595,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,BAO_0000019,CHEMBL617005,14214,9606.0,Expert,1,,F,,Homo sapiens,,,
1596,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,BAO_0000219,CHEMBL616623,13729,9606.0,Expert,1,485.0,F,,Homo sapiens,,,CHO-K1
1597,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,BAO_0000219,CHEMBL616624,3025,,Autocuration,1,449.0,F,,,,,CHO
1598,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL883243,2391,,Autocuration,1,,B,,,,,
1599,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,BAO_0000019,CHEMBL616625,2391,,Autocuration,1,,F,,,,,
1600,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,BAO_0000219,CHEMBL616626,14956,,Expert,1,449.0,F,,,,,CHO
1601,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,BAO_0000219,CHEMBL616627,2598,,Autocuration,1,449.0,F,,,,,CHO
1602,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,BAO_0000219,CHEMBL616628,2598,,Autocuration,1,449.0,F,,,,,CHO
1603,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,BAO_0000219,CHEMBL616629,2598,,Autocuration,1,449.0,F,,,,,CHO
1604,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,BAO_0000219,CHEMBL616630,2598,,Autocuration,1,449.0,F,,,,,CHO
1605,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,CHEMBL616631,14956,,Expert,1,,F,,,,,
1606,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,CHEMBL616632,14956,,Autocuration,1,,F,,,,,
1607,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616633,14214,9606.0,Expert,1,,B,,Homo sapiens,,,
1608,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,BAO_0000219,CHEMBL616634,3463,,Expert,1,449.0,B,,,,,CHO
1609,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,BAO_0000357,CHEMBL616635,15331,,Autocuration,1,,B,,,,,
1610,,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL885358,16146,9606.0,Expert,1,,B,,Homo sapiens,,,
1611,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,BAO_0000219,CHEMBL616636,14159,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1612,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,BAO_0000219,CHEMBL616637,14158,,Expert,1,449.0,B,,,,,CHO
1613,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616638,14159,,Autocuration,1,,B,,,,,
1614,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL616639,15250,,Expert,1,449.0,B,,,,,CHO
1615,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,BAO_0000219,CHEMBL616640,15250,,Expert,1,449.0,B,,,,,CHO
1616,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL616641,15331,,Expert,1,449.0,B,,,,,CHO
1617,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,BAO_0000219,CHEMBL616642,15332,,Expert,1,449.0,B,,,,,CHO
1618,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,BAO_0000219,CHEMBL616643,14956,,Expert,1,449.0,B,,,,,CHO
1619,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,BAO_0000357,CHEMBL616644,3805,,Autocuration,1,,B,,,,,
1620,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,BAO_0000357,CHEMBL616645,14875,,Autocuration,1,,B,,,,,
1621,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,CHEMBL616646,14454,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,,
1622,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,CHEMBL616647,14454,9986.0,Expert,1,,F,,Oryctolagus cuniculus,,,
1623,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,BAO_0000357,CHEMBL616509,16288,,Autocuration,1,,B,,,,,
1624,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,BAO_0000357,CHEMBL616510,16288,,Autocuration,1,,B,,,,,
1625,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616511,16312,,Autocuration,1,,B,,,,,
1626,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,CHEMBL616512,1348,9913.0,Expert,1,,B,,Bos taurus,,,
1627,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,BAO_0000357,CHEMBL616513,5834,9913.0,Autocuration,1,,B,,Bos taurus,,,
1628,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,BAO_0000019,CHEMBL616514,13366,9913.0,Autocuration,1,,B,,Bos taurus,,Striatum,
1629,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,BAO_0000357,CHEMBL616515,1414,9913.0,Expert,1,,B,,Bos taurus,,,
1630,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,BAO_0000019,CHEMBL616516,14998,9913.0,Autocuration,1,,B,,Bos taurus,,,
1631,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,CHEMBL616517,11473,9913.0,Autocuration,1,,B,,Bos taurus,,,
1632,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,CHEMBL616518,11473,9913.0,Autocuration,1,,B,,Bos taurus,,,
1633,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,CHEMBL616519,10639,9913.0,Autocuration,1,,B,,Bos taurus,,,
1634,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,CHEMBL616520,10639,9913.0,Autocuration,1,,B,,Bos taurus,,,
1635,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,BAO_0000357,CHEMBL616521,1375,9913.0,Autocuration,1,,B,,Bos taurus,,,
1636,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,BAO_0000357,CHEMBL616522,1375,9913.0,Autocuration,1,,B,,Bos taurus,,,
1637,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,CHEMBL884531,16532,9913.0,Autocuration,1,,B,,Bos taurus,,,
1638,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616523,11147,9913.0,Autocuration,1,,B,,Bos taurus,,,
1639,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,BAO_0000019,CHEMBL616731,13366,9913.0,Autocuration,1,,B,,Bos taurus,,Striatum,
1640,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,BAO_0000019,CHEMBL616732,10444,9913.0,Autocuration,1,,B,,Bos taurus,,,
1641,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,BAO_0000357,CHEMBL616733,16532,9913.0,Autocuration,1,,B,,Bos taurus,,,
1642,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,CHEMBL616734,16532,9913.0,Autocuration,1,,B,,Bos taurus,,,
1643,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,BAO_0000249,CHEMBL616735,12827,9913.0,Autocuration,1,,B,,Bos taurus,,,
1644,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,BAO_0000249,CHEMBL616736,12827,9913.0,Autocuration,1,,B,,Bos taurus,,,
1645,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,CHEMBL616737,12919,9913.0,Expert,1,,F,,Bos taurus,,,
1646,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,BAO_0000019,CHEMBL616738,14025,9913.0,Autocuration,1,,B,,Bos taurus,,,
1647,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,CHEMBL616739,12919,9913.0,Expert,1,,F,,Bos taurus,,,
1648,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,CHEMBL616740,12919,9913.0,Expert,1,,F,,Bos taurus,,,
1649,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,CHEMBL616741,12919,9913.0,Expert,1,,F,,Bos taurus,,,
1650,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,BAO_0000219,CHEMBL616742,14447,9593.0,Autocuration,1,722.0,B,,Gorilla gorilla,,,HEK293
1651,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,BAO_0000019,CHEMBL616743,1375,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
1652,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,BAO_0000019,CHEMBL616744,1375,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
1653,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,BAO_0000019,CHEMBL616745,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1654,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000019,CHEMBL616746,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1655,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,BAO_0000019,CHEMBL616747,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1656,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,BAO_0000019,CHEMBL616748,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1657,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,BAO_0000019,CHEMBL616648,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1658,,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616649,11574,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
1659,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,CHEMBL616650,1558,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
1660,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,CHEMBL616651,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1661,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,CHEMBL616652,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1662,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,CHEMBL616653,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1663,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,BAO_0000218,CHEMBL616654,12409,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
1664,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,BAO_0000019,CHEMBL616655,12253,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
1665,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616656,12936,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
1666,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,BAO_0000019,CHEMBL616657,13181,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
1667,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,BAO_0000357,CHEMBL616658,12409,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
1668,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,BAO_0000357,CHEMBL616659,10639,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
1669,,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616660,5254,,Autocuration,1,,B,,,,,
1670,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,CHEMBL616661,13051,,Autocuration,1,,B,,,,,
1671,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL616662,3463,,Expert,1,,F,,,,,
1672,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL616663,15315,,Autocuration,1,,F,,,,,
1673,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL616664,6011,,Autocuration,1,,F,,,,,
1674,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,BAO_0000219,CHEMBL881820,14159,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
1675,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,BAO_0000219,CHEMBL616665,14159,,Autocuration,1,449.0,F,,,,,CHO
1676,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,BAO_0000219,CHEMBL616666,15250,,Expert,1,449.0,B,,,,,CHO
1677,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,BAO_0000219,CHEMBL616667,15250,,Autocuration,1,449.0,B,,,,,CHO
1678,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,BAO_0000219,CHEMBL616668,15331,,Expert,1,449.0,F,,,,,CHO
1679,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,BAO_0000219,CHEMBL616669,15332,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
1680,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,BAO_0000219,CHEMBL617040,15332,,Expert,1,449.0,F,,,,,CHO
1681,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,BAO_0000219,CHEMBL617041,3294,,Autocuration,1,449.0,F,,,,,CHO
1682,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,BAO_0000219,CHEMBL617042,14158,,Expert,1,449.0,F,,,,,CHO
1683,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,BAO_0000219,CHEMBL617043,14956,,Expert,1,449.0,F,,,,,CHO
1684,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL617044,12469,,Autocuration,1,,F,,,,,
1685,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,BAO_0000219,CHEMBL617045,3463,,Expert,1,449.0,F,,,,,CHO
1686,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,BAO_0000219,CHEMBL617046,15250,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
1687,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,BAO_0000219,CHEMBL617047,15250,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
1688,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,CHEMBL617048,14956,,Expert,1,,F,,,,,
1689,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,BAO_0000019,CHEMBL616897,14159,,Autocuration,1,,F,,,,,
1690,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,BAO_0000019,CHEMBL616898,14159,9606.0,Expert,1,,F,,Homo sapiens,,,
1691,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,BAO_0000219,CHEMBL858201,14499,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
1692,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL616899,15315,,Autocuration,1,,F,,,,,
1693,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,BAO_0000219,CHEMBL616900,3294,,Autocuration,1,,B,In vitro,,,,
1694,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,BAO_0000219,CHEMBL616901,3463,,Expert,1,449.0,B,,,,,CHO
1695,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,BAO_0000357,CHEMBL616902,15331,,Autocuration,1,,B,,,,,
1696,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,CHEMBL616903,14159,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1697,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,BAO_0000219,CHEMBL616904,14158,,Expert,1,449.0,B,,,,,CHO
1698,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616905,14159,,Autocuration,1,,B,,,,,
1699,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,BAO_0000219,CHEMBL616906,15250,,Expert,1,449.0,B,,,,,CHO
1700,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL616907,15250,,Expert,1,449.0,B,,,,,CHO
1701,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL616908,15331,,Expert,1,449.0,B,,,,,CHO
1702,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,CHEMBL616909,15332,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1703,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,CHEMBL616910,14499,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1704,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL616911,15332,,Expert,1,449.0,B,,,,,CHO
1705,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,CHEMBL616912,14956,,Expert,1,449.0,B,,,,,CHO
1706,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,BAO_0000357,CHEMBL616913,3805,,Autocuration,1,,B,,,,,
1707,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,BAO_0000219,CHEMBL616914,6011,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1708,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL616915,16190,,Autocuration,1,449.0,B,,,,,CHO
1709,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,CHEMBL616916,14165,,Autocuration,1,,B,,,,,
1710,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616917,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
1711,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,BAO_0000357,CHEMBL616918,15527,,Autocuration,1,,B,,,,,
1712,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,CHEMBL616919,6328,,Expert,1,,B,,,,,
1713,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616920,16209,,Autocuration,1,,B,,,,,
1714,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,BAO_0000357,CHEMBL872914,14770,,Autocuration,1,,B,,,,,
1715,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,BAO_0000357,CHEMBL616921,2598,,Autocuration,1,,B,,,,,
1716,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616922,6897,,Expert,1,,B,,,,,
1717,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616923,6013,,Autocuration,1,,B,,,,,
1718,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616924,5843,,Expert,1,,B,,,,,
1719,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,CHEMBL875909,14454,,Expert,1,,B,,,,,
1720,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,BAO_0000357,CHEMBL616925,14454,,Autocuration,1,,B,,,,,
1721,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,BAO_0000357,CHEMBL616926,14454,,Autocuration,1,,B,,,,,
1722,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616927,15818,,Autocuration,1,,B,,,,,
1723,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,BAO_0000219,CHEMBL616928,13729,,Expert,1,485.0,F,,,,,CHO-K1
1724,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,BAO_0000219,CHEMBL616929,6011,9606.0,Expert,1,,B,In vitro,Homo sapiens,,,
1725,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616930,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
1726,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL616931,17085,,Expert,1,,B,,,,,
1727,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,CHEMBL616932,3025,,Autocuration,1,,B,,,,,
1728,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616933,15315,,Expert,1,,B,,,,,
1729,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,BAO_0000219,CHEMBL616934,14214,9606.0,Expert,1,,B,,Homo sapiens,,,
1730,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616935,3804,9606.0,Expert,1,,B,,Homo sapiens,,,
1731,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,BAO_0000357,CHEMBL616936,16700,,Autocuration,1,,B,,,,,
1732,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,CHEMBL616937,2391,9606.0,Expert,1,,B,,Homo sapiens,,,
1733,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616938,4175,9606.0,Expert,1,,B,,Homo sapiens,,,
1734,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL616939,17085,,Autocuration,1,,B,,,,,
1735,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,BAO_0000019,CHEMBL616940,17085,,Expert,1,,B,,,,,
1736,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,BAO_0000357,CHEMBL616941,15926,9606.0,Expert,1,,B,,Homo sapiens,,,
1737,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,BAO_0000219,CHEMBL616942,16312,,Autocuration,1,485.0,B,,,,,CHO-K1
1738,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,BAO_0000219,CHEMBL616943,16312,,Autocuration,1,485.0,B,,,,,CHO-K1
1739,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,BAO_0000219,CHEMBL616944,14956,,Autocuration,1,449.0,B,,,,,CHO
1740,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,BAO_0000019,CHEMBL616945,3294,,Autocuration,1,,F,,,,,
1741,,Binding activity radioligand.,,BAO_0000357,CHEMBL616946,12861,,Autocuration,1,,B,,,,,
1742,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,CHEMBL616947,12861,,Autocuration,1,,B,,,,,
1743,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,BAO_0000219,CHEMBL616948,16312,,Expert,1,485.0,B,,,,,CHO-K1
1744,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616851,5104,,Autocuration,1,,B,,,,,
1745,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616852,5105,,Autocuration,1,,B,,,,,
1746,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616853,14499,,Autocuration,1,,B,,,,,
1747,,Binding activity against human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616854,15926,9606.0,Expert,1,,B,,Homo sapiens,,,
1748,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL616855,4540,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
1749,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,BAO_0000219,CHEMBL616856,15779,,Autocuration,1,449.0,B,,,,,CHO
1750,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,CHEMBL616857,15779,,Autocuration,1,449.0,B,,,,,CHO
1751,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616858,6166,,Autocuration,1,,B,,,,,
1752,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,CHEMBL616859,15779,,Autocuration,1,449.0,B,,,,,CHO
1753,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,BAO_0000219,CHEMBL616860,15779,,Autocuration,1,449.0,B,,,,,CHO
1754,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,BAO_0000219,CHEMBL616861,17451,,Autocuration,1,722.0,B,,,,,HEK293
1755,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,BAO_0000219,CHEMBL616541,17451,,Autocuration,1,722.0,B,,,,,HEK293
1756,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,BAO_0000219,CHEMBL616542,17451,,Autocuration,1,722.0,B,,,,,HEK293
1757,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,CHEMBL616543,4199,,Autocuration,1,449.0,B,,,,,CHO
1758,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616544,14875,9606.0,Expert,1,,B,,Homo sapiens,,,
1759,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,BAO_0000219,CHEMBL616545,15146,,Autocuration,1,449.0,B,,,,,CHO
1760,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,CHEMBL616546,5213,,Autocuration,1,,B,,,,,
1761,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,BAO_0000219,CHEMBL616547,14818,,Autocuration,1,449.0,B,,,,,CHO
1762,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL616548,4829,,Autocuration,1,449.0,B,,,,,CHO
1763,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,BAO_0000019,CHEMBL616549,14454,,Expert,1,,F,,,,,
1764,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,BAO_0000019,CHEMBL616550,14454,,Expert,1,,F,,,,,
1765,,Binding affinity against 5-HT2C receptor,,BAO_0000357,CHEMBL857066,5254,,Autocuration,1,,B,,,,,
1766,,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616551,5254,,Autocuration,1,,B,,,,,
1767,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000357,CHEMBL616552,10639,,Autocuration,1,,B,,,,,
1768,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000019,CHEMBL832876,10639,,Autocuration,1,,F,,,,,
1769,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,BAO_0000019,CHEMBL616553,12352,,Expert,1,,B,,,,,
1770,,Binding affinity towards 5-HT1B was determined,,BAO_0000357,CHEMBL616554,9098,,Autocuration,1,,B,,,,,
1771,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,BAO_0000019,CHEMBL616555,14430,,Expert,1,,B,,,,,
1772,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,BAO_0000019,CHEMBL616556,13657,,Expert,1,,B,,,,,
1773,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,BAO_0000019,CHEMBL616557,13657,,Autocuration,1,,B,,,,,
1774,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,CHEMBL616558,15854,,Expert,1,,B,,,,,
1775,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,BAO_0000019,CHEMBL616749,10639,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1776,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,CHEMBL616750,10025,,Autocuration,1,,B,,,,,
1777,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,BAO_0000357,CHEMBL616751,10025,,Autocuration,1,,B,,,,,
1778,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,CHEMBL616752,14286,,Autocuration,1,,B,,,,,
1779,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,BAO_0000019,CHEMBL616753,3651,,Autocuration,1,,B,,,,Striatum,
1780,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616754,14178,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1781,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,BAO_0000019,CHEMBL616755,10639,,Autocuration,1,,B,,,,,
1782,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,BAO_0000019,CHEMBL616756,13605,,Autocuration,1,,B,,,,Striatum,
1783,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,BAO_0000019,CHEMBL616757,5834,,Autocuration,1,,B,,,,Striatum,
1784,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,BAO_0000357,CHEMBL616758,10922,,Autocuration,1,,B,,,,Striatum,
1785,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,CHEMBL616759,14286,,Autocuration,1,,B,,,,,
1786,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,BAO_0000357,CHEMBL616760,11825,,Autocuration,1,,B,,,,,
1787,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,BAO_0000019,CHEMBL616761,14826,,Autocuration,1,,B,,,,Striatum,
1788,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,BAO_0000019,CHEMBL616762,9699,,Autocuration,1,,B,,,,Striatum,
1789,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,BAO_0000019,CHEMBL616763,14423,,Autocuration,1,,B,,,,,
1790,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,BAO_0000357,CHEMBL872909,10062,,Expert,1,,B,,,,,
1791,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616764,10062,,Autocuration,1,,B,,,,,
1792,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616765,12280,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1793,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,BAO_0000357,CHEMBL616766,15412,,Autocuration,1,,B,,,,Striatum,
1794,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,BAO_0000357,CHEMBL616767,15412,,Autocuration,1,,B,,,,Striatum,
1795,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616768,10062,,Autocuration,1,,B,,,,,
1796,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616769,11147,,Autocuration,1,,B,,,,,
1797,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,BAO_0000019,CHEMBL616770,9547,,Autocuration,1,,B,,,,,
1798,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,CHEMBL616771,10444,,Autocuration,1,,B,,,,,
1799,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,BAO_0000019,CHEMBL616772,12469,,Autocuration,1,,B,,,,Striatum,
1800,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,BAO_0000019,CHEMBL616773,9098,,Expert,1,,B,,,,,
1801,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,BAO_0000019,CHEMBL616774,9098,,Autocuration,1,,B,,,,,
1802,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616775,9699,,Autocuration,1,,B,,,,,
1803,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,CHEMBL616776,10394,,Autocuration,1,,B,,,,,
1804,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,BAO_0000357,CHEMBL616777,12092,,Autocuration,1,,B,,,,,
1805,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,BAO_0000357,CHEMBL616778,16700,,Autocuration,1,,B,,,,,
1806,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,BAO_0000249,CHEMBL616779,403,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1807,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616780,12771,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1808,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,BAO_0000019,CHEMBL616781,11642,,Autocuration,1,,B,,,,,
1809,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616782,12953,,Autocuration,1,,B,,,,,
1810,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,BAO_0000357,CHEMBL616783,12953,,Autocuration,1,,B,,,,,
1811,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,BAO_0000019,CHEMBL616784,12953,,Expert,1,,B,,,,Striatum,
1812,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,BAO_0000357,CHEMBL616785,12953,,Autocuration,1,,B,,,,,
1813,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,CHEMBL857067,9737,,Autocuration,1,,B,,,,Brain,
1814,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,BAO_0000019,CHEMBL616786,9737,,Autocuration,1,,B,,,,,
1815,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,CHEMBL616787,9737,,Autocuration,1,,B,,,,Brain,
1816,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,BAO_0000357,CHEMBL616788,12827,,Autocuration,1,,B,,,,,
1817,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616789,5033,,Autocuration,1,,B,,,,,
1818,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,BAO_0000019,CHEMBL616790,9786,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1819,,Binding affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616791,13116,,Expert,1,,B,,,,,
1820,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,BAO_0000019,CHEMBL616792,16429,,Autocuration,1,,B,,,,,
1821,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,BAO_0000249,CHEMBL616793,12409,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1822,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616794,15194,,Autocuration,1,,B,,,,,
1823,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,CHEMBL616795,15194,,Autocuration,1,,B,,,,,
1824,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,BAO_0000019,CHEMBL616796,5486,,Autocuration,1,,B,,,,,
1825,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616797,4639,,Autocuration,1,,B,,,,,
1826,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,BAO_0000249,CHEMBL616798,386,,Autocuration,1,,B,,,,,
1827,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,BAO_0000357,CHEMBL616799,2474,,Autocuration,1,,B,,,,,
1828,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,BAO_0000357,CHEMBL616800,6011,,Autocuration,1,,B,,,,,
1829,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616801,5014,,Autocuration,1,,B,,,,,
1830,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,BAO_0000357,CHEMBL616802,17515,,Autocuration,1,,B,,,,,
1831,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,CHEMBL616803,4373,,Autocuration,1,,B,,,,,
1832,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,BAO_0000357,CHEMBL857068,1633,,Expert,1,,B,,,,,
1833,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,BAO_0000357,CHEMBL616804,1633,,Autocuration,1,,B,,,,,
1834,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,CHEMBL616805,4373,,Autocuration,1,,B,,,,,
1835,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616806,4687,,Autocuration,1,,B,,,,,
1836,,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,CHEMBL616807,11574,,Autocuration,1,,B,,,,,
1837,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616808,10321,,Autocuration,1,,B,,,,,
1838,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,CHEMBL616809,15527,,Autocuration,1,,B,,,,,
1839,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,BAO_0000357,CHEMBL616810,17200,,Autocuration,1,,B,,,,,
1840,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,BAO_0000224,CHEMBL616811,14423,,Autocuration,1,,B,,,,,
1841,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,BAO_0000357,CHEMBL616812,5834,9913.0,Autocuration,1,,B,,Bos taurus,,,
1842,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL616813,11473,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1843,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL616814,11473,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1844,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,CHEMBL616815,10639,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1845,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,CHEMBL616816,10639,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1846,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,BAO_0000357,CHEMBL616817,14331,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1847,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,BAO_0000357,CHEMBL616818,10796,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1848,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,BAO_0000357,CHEMBL616819,9098,9823.0,Expert,1,,B,,Sus scrofa,,,
1849,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,BAO_0000357,CHEMBL616820,14331,9823.0,Expert,1,,B,,Sus scrofa,,,
1850,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,BAO_0000019,CHEMBL616821,11828,9823.0,Expert,1,,B,,Sus scrofa,,,
1851,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,BAO_0000357,CHEMBL616822,11866,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1852,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL616823,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
1853,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,BAO_0000357,CHEMBL616824,188,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1854,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,CHEMBL616825,11825,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1855,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,CHEMBL616826,11825,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1856,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,BAO_0000019,CHEMBL616827,11624,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1857,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,BAO_0000357,CHEMBL616828,11139,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1858,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL616829,11147,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1859,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,CHEMBL616830,10444,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1860,,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,CHEMBL616831,11624,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1861,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,CHEMBL616832,11662,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1862,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,CHEMBL616833,11662,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1863,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,CHEMBL616834,11662,10116.0,Expert,1,,B,,Rattus norvegicus,,,
1864,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,CHEMBL829595,11662,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1865,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,BAO_0000357,CHEMBL616835,9098,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1866,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,BAO_0000249,CHEMBL872910,10394,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1867,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL616836,11933,,Expert,1,,B,,,,,
1868,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,BAO_0000357,CHEMBL616837,12092,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1869,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,CHEMBL616466,12253,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1870,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,BAO_0000219,CHEMBL616467,12253,10116.0,Autocuration,1,722.0,B,,Rattus norvegicus,,,HEK293
1871,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,CHEMBL616468,1558,,Autocuration,1,,B,,,,,
1872,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL616469,2474,,Autocuration,1,,B,,,,,
1873,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL616470,2474,,Autocuration,1,,B,,,,,
1874,,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,CHEMBL616471,11574,,Autocuration,1,,B,,,,,
1875,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,CHEMBL616472,1558,,Autocuration,1,,B,,,,,
1876,,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,CHEMBL616473,13944,,Autocuration,1,,B,,,,,
1877,,Binding affinity against serotonergic 5-HT1c receptor,,BAO_0000357,CHEMBL616474,13033,,Autocuration,1,,B,,,,,
1878,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,BAO_0000357,CHEMBL616475,10321,,Autocuration,1,,B,,,,,
1879,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,BAO_0000357,CHEMBL616476,11866,,Autocuration,1,,B,,,,,
1880,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,CHEMBL616477,14454,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
1881,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,BAO_0000224,CHEMBL616478,11574,,Autocuration,1,,B,,,,,
1882,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,BAO_0000224,CHEMBL616479,11574,,Autocuration,1,,B,,,,,
1883,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,BAO_0000019,CHEMBL616480,13631,,Autocuration,1,,B,,,,,
1884,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,BAO_0000019,CHEMBL616481,9630,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1885,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,BAO_0000249,CHEMBL616482,8822,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1886,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,CHEMBL884713,9064,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Brain,
1887,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,CHEMBL616483,8868,,Autocuration,1,,B,,,,,
1888,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,BAO_0000224,CHEMBL616484,9064,,Autocuration,1,,B,,,,,
1889,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,BAO_0000019,CHEMBL616485,9806,,Autocuration,1,,B,,,,,
1890,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,CHEMBL616486,9098,,Autocuration,1,,B,,,,,
1891,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,CHEMBL616487,8868,,Autocuration,1,,B,,,,,
1892,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,CHEMBL616488,12765,,Autocuration,1,,B,,,,,
1893,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,CHEMBL616489,11049,,Autocuration,1,,B,,,,,
1894,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,CHEMBL616490,11049,,Autocuration,1,,B,,,,,
1895,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,BAO_0000019,CHEMBL616491,11049,,Autocuration,1,,B,,,,,
1896,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,BAO_0000019,CHEMBL616492,11049,,Autocuration,1,,B,,,,,
1897,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,CHEMBL616493,11049,,Autocuration,1,,B,,,,,
1898,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,BAO_0000019,CHEMBL616494,11473,,Autocuration,1,,B,,,,,
1899,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL616495,11473,,Autocuration,1,,B,,,,,
1900,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,BAO_0000019,CHEMBL616496,3086,,Autocuration,1,,B,,,,,
1901,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,CHEMBL616497,11049,,Autocuration,1,,B,,,,,
1902,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,CHEMBL616498,11049,,Autocuration,1,,B,,,,,
1903,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,BAO_0000019,CHEMBL616499,10639,,Autocuration,1,,B,,,,,
1904,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,BAO_0000019,CHEMBL616500,10922,,Autocuration,1,,B,,,,,
1905,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,CHEMBL616501,9064,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Brain,
1906,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,BAO_0000221,CHEMBL616502,10748,,Autocuration,1,,B,,,,Brain,
1907,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,BAO_0000249,CHEMBL884529,11614,,Autocuration,1,,B,,,,,
1908,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,BAO_0000249,CHEMBL616503,11615,,Autocuration,1,,B,,,,,
1909,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL616964,11615,,Autocuration,1,,B,,,,,
1910,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,BAO_0000249,CHEMBL616965,11614,,Autocuration,1,,B,,,,,
1911,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,BAO_0000224,CHEMBL616966,11702,,Autocuration,1,,B,,,,,
1912,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,CHEMBL616967,11702,,Autocuration,1,,B,,,,,
1913,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL616968,11702,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1914,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,CHEMBL616969,11702,,Autocuration,1,,B,,,,,
1915,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,BAO_0000019,CHEMBL884530,13346,,Autocuration,1,,B,,,,,
1916,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL616970,10025,,Autocuration,1,,B,,,,,
1917,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,CHEMBL616971,10025,,Autocuration,1,,B,,,,,
1918,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,CHEMBL616972,10025,,Autocuration,1,,B,,,,,
1919,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,BAO_0000224,CHEMBL616973,9036,,Autocuration,1,,B,,,,,
1920,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,BAO_0000224,CHEMBL616974,9036,,Autocuration,1,,B,,,,,
1921,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,CHEMBL616975,9161,,Autocuration,1,,B,,,,,
1922,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,BAO_0000019,CHEMBL616976,12304,,Autocuration,1,,B,,,,,
1923,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,BAO_0000224,CHEMBL616977,13276,,Autocuration,1,,B,,,,,
1924,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,CHEMBL616978,11825,,Autocuration,1,,B,,,,,
1925,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,BAO_0000224,CHEMBL616979,12443,,Autocuration,1,,B,,,,,
1926,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL616980,13830,,Autocuration,1,,B,,,,,
1927,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,BAO_0000249,CHEMBL616981,9592,,Autocuration,1,,B,,,,,
1928,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,BAO_0000249,CHEMBL616982,9592,,Autocuration,1,,B,,,,,
1929,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,BAO_0000224,CHEMBL616983,10881,,Autocuration,1,,B,,,,,
1930,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,BAO_0000019,CHEMBL616984,13605,,Autocuration,1,,B,,,,,
1931,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL616985,11624,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
1932,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,CHEMBL616986,4101,,Autocuration,1,,B,,,,,
1933,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,CHEMBL616987,4101,,Autocuration,1,,B,,,,,
1934,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,BAO_0000019,CHEMBL616988,15360,,Autocuration,1,,B,,,,,
1935,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,CHEMBL617243,11576,,Autocuration,1,,B,,,,,
1936,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,BAO_0000019,CHEMBL617244,5834,,Autocuration,1,,B,,,,,
1937,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,CHEMBL617245,2395,10116.0,Autocuration,1,485.0,B,,Rattus norvegicus,,,CHO-K1
1938,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,BAO_0000249,CHEMBL617246,11965,,Autocuration,1,,B,,,,,
1939,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,BAO_0000224,CHEMBL617546,3967,,Autocuration,1,,B,,,,,
1940,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,BAO_0000249,CHEMBL617547,11130,,Autocuration,1,,B,,,,,
1941,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,CHEMBL617548,13427,,Autocuration,1,,B,In vitro,,,,
1942,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617549,9443,,Autocuration,1,,B,,,,,
1943,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,CHEMBL617550,9443,,Autocuration,1,,B,,,,,
1944,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,CHEMBL617551,11825,,Autocuration,1,,B,,,,,
1945,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,BAO_0000249,CHEMBL617552,12120,,Autocuration,1,,B,,,,,
1946,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,BAO_0000249,CHEMBL617553,12120,,Autocuration,1,,B,,,,,
1947,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,BAO_0000019,CHEMBL617554,11963,,Autocuration,1,,F,,,,Thoracic aorta,
1948,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL617555,9069,,Autocuration,1,,B,,,,,
1949,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,CHEMBL617556,8868,,Autocuration,1,,B,,,,,
1950,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,CHEMBL617557,17200,,Autocuration,1,,B,,,,,
1951,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,CHEMBL617558,17200,,Autocuration,1,,B,,,,,
1952,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL617559,13969,,Expert,1,,B,,,,,
1953,,Binding affinity for 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL617560,13392,,Expert,1,,B,,,,,
1954,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,CHEMBL617561,1742,,Autocuration,1,,B,,,,,
1955,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,CHEMBL617562,1742,,Autocuration,1,,B,,,,,
1956,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,BAO_0000357,CHEMBL617563,14331,,Autocuration,1,,B,,,,Striatum,
1957,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL617564,12861,,Autocuration,1,,F,,,,,
1958,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,BAO_0000019,CHEMBL617565,12861,,Expert,1,,B,,,,,
1959,,Binding activity radioligand.,,BAO_0000357,CHEMBL856076,12861,,Autocuration,1,,B,,,,,
1960,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,CHEMBL617566,12861,,Autocuration,1,,B,,,,,
1961,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,CHEMBL875911,12861,,Expert,1,,B,,,,,
1962,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,CHEMBL617567,12861,,Autocuration,1,,B,,,,,
1963,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,CHEMBL617568,675,,Autocuration,1,,B,,,,,
1964,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,BAO_0000019,CHEMBL617569,12490,,Expert,1,,B,,,,,
1965,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,BAO_0000249,CHEMBL617570,11828,,Expert,1,,B,,,,,
1966,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,BAO_0000357,CHEMBL617571,11866,,Autocuration,1,,B,,,,,
1967,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,BAO_0000357,CHEMBL617572,773,9823.0,Autocuration,1,,B,,Sus scrofa,,,
1968,,The compound was tested for intrinsic activity against 5-HT1D receptor,,BAO_0000357,CHEMBL617573,13047,9986.0,Expert,1,,B,,Oryctolagus cuniculus,,,
1969,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL617574,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
1970,,The compound was tested for binding affinity against 5-HT1D receptor,,BAO_0000357,CHEMBL617575,13047,9986.0,Expert,1,,B,,Oryctolagus cuniculus,,,
1971,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,BAO_0000357,CHEMBL617576,188,,Autocuration,1,,B,,,,,
1972,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,BAO_0000019,CHEMBL617577,10639,,Autocuration,1,,F,,,,,
1973,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,BAO_0000019,CHEMBL617578,12438,,Autocuration,1,,F,,,,,
1974,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL617579,12438,,Autocuration,1,,B,,,,,
1975,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,CHEMBL617580,15854,,Expert,1,,B,,,,,
1976,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,CHEMBL617581,10394,,Autocuration,1,,B,,,,,
1977,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,BAO_0000357,CHEMBL617582,12092,,Autocuration,1,,B,,,,,
1978,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,BAO_0000019,CHEMBL617583,3389,,Expert,1,,B,,,,,
1979,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,BAO_0000357,CHEMBL617584,6011,,Autocuration,1,,B,,,,,
1980,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL617585,4639,,Autocuration,1,,B,,,,,
1981,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL875912,2474,,Autocuration,1,,B,,,,,
1982,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL617586,5014,,Autocuration,1,,B,,,,,
1983,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,BAO_0000357,CHEMBL617587,17515,,Autocuration,1,,B,,,,,
1984,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,CHEMBL617588,11866,,Autocuration,1,,B,,,,,
1985,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL857980,4687,,Autocuration,1,,B,,,,,
1986,,Tested against 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL617589,12146,,Autocuration,1,,B,,,,,
1987,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL617590,10321,,Autocuration,1,,B,,,,,
1988,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,BAO_0000219,CHEMBL617591,13267,,Autocuration,1,722.0,B,,,,,HEK293
1989,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL617592,1274,9606.0,Expert,1,,B,,Homo sapiens,,,
1990,,,,BAO_0000357,CHEMBL617593,15250,,Autocuration,1,,B,,,,,
1991,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,CHEMBL617594,13706,,Autocuration,1,485.0,B,,,,,CHO-K1
1992,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,CHEMBL617595,13706,,Autocuration,1,485.0,B,,,,,CHO-K1
1993,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,BAO_0000219,CHEMBL617596,13706,,Autocuration,1,722.0,B,,,,,HEK293
1994,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,BAO_0000219,CHEMBL617597,13706,,Autocuration,1,722.0,B,,,,,HEK293
1995,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL617598,13047,,Autocuration,1,,B,,,,,
1996,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,BAO_0000357,CHEMBL872916,13366,,Autocuration,1,,B,,,,,
1997,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,BAO_0000357,CHEMBL617599,13366,,Expert,1,,B,,,,,
1998,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,BAO_0000357,CHEMBL617091,1558,,Autocuration,1,,B,,,,,
1999,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,BAO_0000219,CHEMBL617092,12902,,Expert,1,485.0,B,,,,,CHO-K1
2000,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,CHEMBL617093,13706,,Autocuration,1,485.0,B,,,,,CHO-K1
2001,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,CHEMBL617094,13706,,Autocuration,1,,F,,,,,
2002,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,CHEMBL617095,13706,,Autocuration,1,,F,,,,,
2003,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,CHEMBL617096,14251,,Autocuration,1,,F,,,,,
2004,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,CHEMBL617097,14251,,Autocuration,1,,F,,,,,
2005,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,CHEMBL617098,14251,,Autocuration,1,,F,,,,,
2006,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL617301,13313,,Autocuration,1,,B,,,,,
2007,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL617302,13313,,Autocuration,1,,B,,,,,
2008,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,CHEMBL617303,13366,,Autocuration,1,,B,,,,,
2009,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,CHEMBL617304,13051,,Expert,1,,B,,,,,
2010,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL617305,12903,,Expert,1,449.0,B,,,,,CHO
2011,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,BAO_0000219,CHEMBL617306,12469,9606.0,Autocuration,1,,B,,Homo sapiens,,,
2012,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,BAO_0000357,CHEMBL617307,5619,,Autocuration,1,,B,,,,,
2013,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL617308,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
2014,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,CHEMBL617309,16633,,Autocuration,1,,B,,,,,
2015,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,CHEMBL617310,16633,,Autocuration,1,,B,,,,,
2016,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,CHEMBL617311,16633,,Autocuration,1,,B,,,,,
2017,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL617312,16633,,Autocuration,1,,B,,,,,
2018,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,CHEMBL617313,3269,,Autocuration,1,,B,,,,,
2019,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,CHEMBL617314,12409,,Expert,1,,B,,,,,
2020,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,CHEMBL617315,13706,,Autocuration,1,,F,,,,,
2021,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,BAO_0000219,CHEMBL617316,13706,,Autocuration,1,722.0,B,,,,,HEK293
2022,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,BAO_0000219,CHEMBL617317,13706,,Autocuration,1,722.0,B,,,,,HEK293
2023,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL617318,12903,,Autocuration,1,449.0,B,,,,,CHO
2024,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL617319,13047,,Autocuration,1,,B,,,,,
2025,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,CHEMBL617320,13366,,Expert,1,,B,,,,,
2026,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,CHEMBL617321,13366,,Expert,1,,B,,,,,
2027,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,CHEMBL617322,13366,,Expert,1,,B,,,,,
2028,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616862,13366,,Autocuration,1,,B,,,,,
2029,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,CHEMBL616863,13366,,Autocuration,1,,B,,,,,
2030,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,BAO_0000219,CHEMBL616864,12469,,Autocuration,1,449.0,B,,,,,CHO
2031,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,BAO_0000219,CHEMBL616865,13706,,Autocuration,1,485.0,B,,,,,CHO-K1
2032,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,BAO_0000219,CHEMBL616866,13706,,Autocuration,1,485.0,B,,,,,CHO-K1
2033,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,CHEMBL616867,13706,,Autocuration,1,,F,,,,,
2034,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,BAO_0000219,CHEMBL616868,12902,,Expert,1,485.0,B,,,,,CHO-K1
2035,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,CHEMBL616869,13051,,Expert,1,,B,,,,,
2036,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL616870,12903,,Expert,1,449.0,B,,,,,CHO
2037,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,BAO_0000219,CHEMBL616871,1558,,Autocuration,1,485.0,F,,,,,CHO-K1
2038,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,BAO_0000219,CHEMBL616872,1558,,Autocuration,1,485.0,F,,,,,CHO-K1
2039,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,BAO_0000219,CHEMBL616873,1558,,Autocuration,1,485.0,F,,,,,CHO-K1
2040,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,BAO_0000219,CHEMBL616838,1558,,Autocuration,1,485.0,F,,,,,CHO-K1
2041,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,BAO_0000357,CHEMBL616839,1558,,Autocuration,1,,B,,,,,
2042,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL616840,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
2043,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,BAO_0000357,CHEMBL616841,13313,,Autocuration,1,,B,,,,,
2044,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616842,13313,,Autocuration,1,,B,,,,,
2045,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,CHEMBL857976,12409,,Expert,1,,B,,,,,
2046,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL616843,15250,,Autocuration,1,449.0,B,,,,,CHO
2047,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,BAO_0000357,CHEMBL616844,1348,9606.0,Expert,1,,B,,Homo sapiens,,,
2048,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,BAO_0000357,CHEMBL616845,1348,,Autocuration,1,,B,,,,,
2049,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,BAO_0000357,CHEMBL616846,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
2050,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616847,16209,,Autocuration,1,,B,,,,,
2051,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,BAO_0000019,CHEMBL616848,10444,,Autocuration,1,,B,,,,,
2052,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,BAO_0000357,CHEMBL616849,3935,,Autocuration,1,,B,,,,,
2053,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,BAO_0000357,CHEMBL872911,15818,,Autocuration,1,,B,,,,,
2054,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,BAO_0000019,CHEMBL616850,17085,,Autocuration,1,,B,,,,,
2055,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,BAO_0000219,CHEMBL616699,12936,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
2056,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,CHEMBL616700,6166,,Autocuration,1,,B,,,,,
2057,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,CHEMBL616701,15779,,Autocuration,1,449.0,B,,,,,CHO
2058,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,CHEMBL616702,15779,,Autocuration,1,449.0,B,,,,,CHO
2059,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,BAO_0000219,CHEMBL616703,15779,,Autocuration,1,449.0,B,,,,,CHO
2060,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,BAO_0000357,CHEMBL616704,13181,,Autocuration,1,,B,,,,,
2061,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,CHEMBL616705,4199,,Autocuration,1,449.0,B,,,,,CHO
2062,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,BAO_0000357,CHEMBL616706,14875,,Autocuration,1,,B,,,,,
2063,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,BAO_0000219,CHEMBL616707,15146,,Autocuration,1,449.0,B,,,,,CHO
2064,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,CHEMBL616708,5213,,Autocuration,1,,B,,,,,
2065,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL616709,12146,,Autocuration,1,,B,,,,,
2066,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,BAO_0000219,CHEMBL616710,13267,,Autocuration,1,449.0,B,,,,,CHO
2067,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,BAO_0000219,CHEMBL616711,14818,,Autocuration,1,449.0,B,,,,,CHO
2068,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL616712,4829,,Autocuration,1,449.0,B,,,,,CHO
2069,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,CHEMBL616713,4373,,Autocuration,1,,B,,,,,
2070,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,CHEMBL616714,4373,,Autocuration,1,,B,,,,,
2071,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,BAO_0000357,CHEMBL616715,14159,,Autocuration,1,,B,,,,,
2072,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,BAO_0000357,CHEMBL616716,16633,,Autocuration,1,,B,,,,,
2073,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,BAO_0000019,CHEMBL616717,17085,,Autocuration,1,,F,,,,,
2074,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,BAO_0000019,CHEMBL616718,17085,,Expert,1,,F,,,,,
2075,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,CHEMBL875905,16209,,Autocuration,1,,F,,,,,
2076,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,BAO_0000019,CHEMBL616719,16209,,Autocuration,1,,F,,,,,
2077,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,BAO_0000019,CHEMBL616720,17085,,Expert,1,,F,,,,,
2078,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,BAO_0000357,CHEMBL616721,14159,,Autocuration,1,,B,,,,,
2079,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL616722,15250,,Autocuration,1,449.0,B,,,,,CHO
2080,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,BAO_0000357,CHEMBL616723,3805,,Autocuration,1,,B,,,,,
2081,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,BAO_0000219,CHEMBL616724,16190,,Autocuration,1,449.0,B,,,,,CHO
2082,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,BAO_0000357,CHEMBL616725,16190,,Autocuration,1,,B,,,,,
2083,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,BAO_0000357,CHEMBL616726,16209,,Autocuration,1,,B,,,,,
2084,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,CHEMBL616727,16209,,Autocuration,1,,B,,,,,
2085,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,BAO_0000357,CHEMBL616728,16209,,Autocuration,1,,B,,,,,
2086,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,BAO_0000357,CHEMBL616729,6866,,Autocuration,1,,B,,,,,
2087,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,CHEMBL616730,17085,,Expert,1,,B,,,,,
2088,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,BAO_0000357,CHEMBL617125,16312,,Autocuration,1,,B,,,,,
2089,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,CHEMBL857977,6166,,Autocuration,1,,B,,,,,
2090,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,CHEMBL617126,15779,,Autocuration,1,449.0,B,,,,,CHO
2091,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,BAO_0000219,CHEMBL617127,4199,,Autocuration,1,449.0,B,,,,,CHO
2092,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,BAO_0000357,CHEMBL617128,14875,,Autocuration,1,,B,,,,,
2093,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,BAO_0000219,CHEMBL617129,15146,,Autocuration,1,449.0,B,,,,,CHO
2094,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,CHEMBL617130,5213,,Autocuration,1,,B,,,,,
2095,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,BAO_0000219,CHEMBL617131,14818,,Autocuration,1,449.0,B,,,,,CHO
2096,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL617132,4829,,Autocuration,1,449.0,B,,,,,CHO
2097,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL617133,4829,,Autocuration,1,449.0,B,,,,,CHO
2098,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,CHEMBL617134,4373,,Autocuration,1,,B,,,,,
2099,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,CHEMBL617135,4373,,Autocuration,1,,B,,,,,
2100,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,BAO_0000357,CHEMBL617136,5014,,Autocuration,1,,B,,,,,
2101,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,BAO_0000019,CHEMBL617137,11662,,Autocuration,1,,B,,,,,
2102,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,CHEMBL617138,11662,,Autocuration,1,,B,,,,,
2103,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,CHEMBL617139,11662,,Autocuration,1,,B,,,,,
2104,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617140,14093,,Autocuration,1,,B,,,,,
2105,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,BAO_0000218,CHEMBL617141,11200,,Autocuration,1,,F,In vivo,,,,
2106,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,CHEMBL858112,11200,,Autocuration,1,,F,,,,,
2107,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,BAO_0000019,CHEMBL617142,12352,,Intermediate,1,,B,,,,,
2108,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,BAO_0000019,CHEMBL617143,13657,9913.0,Autocuration,1,,B,,Bos taurus,,,
2109,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,BAO_0000019,CHEMBL617144,14331,9913.0,Autocuration,1,,B,,Bos taurus,,,
2110,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,BAO_0000019,CHEMBL617145,14331,9913.0,Autocuration,1,,B,,Bos taurus,,,
2111,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,BAO_0000019,CHEMBL617146,14331,,Autocuration,1,,B,,,,,
2112,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,BAO_0000019,CHEMBL617147,12685,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
2113,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,BAO_0000019,CHEMBL617148,14389,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
2114,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,BAO_0000019,CHEMBL617149,14386,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
2115,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,CHEMBL617150,5732,,Autocuration,1,,B,,,,,
2116,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,CHEMBL617151,16293,,Autocuration,1,,B,,,,,
2117,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617201,2078,,Autocuration,1,,B,,,,,
2118,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,CHEMBL617202,5486,,Autocuration,1,,B,,,,,
2119,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,CHEMBL617203,11820,,Autocuration,1,,B,In vivo,,,,
2120,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,CHEMBL617204,10297,,Autocuration,1,,B,,,,,
2121,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,BAO_0000224,CHEMBL617205,13704,,Autocuration,1,,B,,,,,
2122,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,BAO_0000019,CHEMBL617206,10297,10090.0,Autocuration,1,,B,,Mus musculus,,,
2123,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,CHEMBL617207,11820,,Autocuration,1,,B,In vivo,,,,
2124,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,BAO_0000019,CHEMBL617208,10297,10090.0,Autocuration,1,,B,,Mus musculus,,,
2125,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617209,11555,,Autocuration,1,,B,,,,,
2126,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,BAO_0000224,CHEMBL617210,11555,,Autocuration,1,,B,,,,,
2127,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,BAO_0000224,CHEMBL617211,11555,,Autocuration,1,,B,,,,,
2128,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,CHEMBL617212,10297,10090.0,Autocuration,1,,B,,Mus musculus,,,
2129,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,BAO_0000224,CHEMBL617213,16688,9823.0,Autocuration,1,,B,,Sus scrofa,,,
2130,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,BAO_0000224,CHEMBL617214,16688,9823.0,Autocuration,1,,B,,Sus scrofa,,,
2131,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,CHEMBL617215,5333,,Autocuration,1,,B,,,,,
2132,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,CHEMBL617216,4437,,Autocuration,1,,B,,,,,
2133,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,BAO_0000357,CHEMBL617217,5033,9823.0,Autocuration,1,,B,,Sus scrofa,,,
2134,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL617218,15267,,Autocuration,1,,B,,,,,
2135,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL872913,15267,,Autocuration,1,,B,,,,,
2136,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,BAO_0000019,CHEMBL617219,11820,,Autocuration,1,,B,,,,,
2137,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL873482,9069,,Autocuration,1,,B,,,,,
2138,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,BAO_0000019,CHEMBL617220,9162,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2139,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,BAO_0000019,CHEMBL617221,9162,,Autocuration,1,,B,,,,,
2140,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,BAO_0000019,CHEMBL617222,9162,,Autocuration,1,,B,,,,,
2141,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,BAO_0000019,CHEMBL875906,10428,,Autocuration,1,,F,,,,,
2142,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,BAO_0000019,CHEMBL617223,9628,,Autocuration,1,,B,,,,,
2143,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617224,12704,,Autocuration,1,,B,,,,,
2144,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,CHEMBL617225,15453,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2145,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,BAO_0000224,CHEMBL617226,188,,Autocuration,1,,B,,,,,
2146,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,CHEMBL617227,10349,,Autocuration,1,,B,,,,,
2147,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,CHEMBL617228,10349,,Autocuration,1,,B,,,,,
2148,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,CHEMBL617229,8868,,Autocuration,1,,B,,,,,
2149,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,CHEMBL617230,10025,,Autocuration,1,,B,,,,,
2150,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,CHEMBL617231,10025,,Autocuration,1,,B,,,,,
2151,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,BAO_0000224,CHEMBL617232,11702,,Autocuration,1,,B,,,,,
2152,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617233,11702,,Autocuration,1,,B,,,,,
2153,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,CHEMBL617234,11702,,Autocuration,1,,B,,,,,
2154,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,BAO_0000019,CHEMBL617235,11702,,Autocuration,1,,F,,,,,
2155,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,BAO_0000019,CHEMBL617236,11702,,Autocuration,1,,F,,,,,
2156,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,BAO_0000221,CHEMBL617237,10085,,Autocuration,1,,B,,,,Hippocampus,
2157,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,BAO_0000221,CHEMBL617238,10085,,Autocuration,1,,B,,,,Hippocampus,
2158,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,BAO_0000221,CHEMBL617239,9630,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Brain,
2159,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,CHEMBL617240,11070,,Autocuration,1,,B,,,,,
2160,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,BAO_0000249,CHEMBL617241,9841,,Autocuration,1,,B,,,,,
2161,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,BAO_0000249,CHEMBL875907,9841,,Autocuration,1,,B,,,,,
2162,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,BAO_0000019,CHEMBL617242,13291,,Autocuration,1,,B,,,,,
2163,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,BAO_0000019,CHEMBL617152,10590,,Autocuration,1,,F,,,,,
2164,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,CHEMBL617153,9064,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Brain,
2165,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,BAO_0000249,CHEMBL617154,12268,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2166,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,BAO_0000221,CHEMBL617155,13508,,Autocuration,1,,B,,,,Brain,
2167,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,CHEMBL617156,11279,,Autocuration,1,,F,,,,,
2168,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,BAO_0000019,CHEMBL617157,11200,,Autocuration,1,,F,,,,,
2169,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,CHEMBL617158,11200,,Autocuration,1,,F,,,,,
2170,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,CHEMBL617159,11200,,Autocuration,1,,F,,,,,
2171,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,CHEMBL617160,11200,,Autocuration,1,,F,,,,,
2172,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,CHEMBL858113,11200,,Autocuration,1,,F,,,,,
2173,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,BAO_0000220,CHEMBL617247,9231,,Autocuration,1,,B,,,,Brain,
2174,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL617248,9737,,Autocuration,1,,B,,,,,
2175,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,CHEMBL617249,9737,,Autocuration,1,,B,,,,Brain,
2176,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,BAO_0000019,CHEMBL617250,9737,,Autocuration,1,,B,,,,,
2177,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL617251,9737,,Autocuration,1,,B,,,,,
2178,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL617252,11828,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2179,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,CHEMBL617006,12253,,Autocuration,1,,B,,,,,
2180,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,BAO_0000019,CHEMBL617007,12253,,Autocuration,1,,B,,,,,
2181,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,BAO_0000019,CHEMBL617008,11279,,Autocuration,1,,F,,,,,
2182,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,BAO_0000019,CHEMBL617009,11866,,Autocuration,1,,B,,,,,
2183,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,BAO_0000224,CHEMBL617010,14424,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2184,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL857978,15180,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2185,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL617011,15180,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2186,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,BAO_0000019,CHEMBL617012,9786,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2187,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,BAO_0000224,CHEMBL617013,12132,,Autocuration,1,,B,,,,,
2188,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,BAO_0000249,CHEMBL617014,5486,,Autocuration,1,,B,,,,,
2189,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL617015,15316,,Autocuration,1,,B,,,,,
2190,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,BAO_0000019,CHEMBL617016,16429,,Autocuration,1,,B,,,,,
2191,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,BAO_0000224,CHEMBL617017,14617,,Autocuration,1,,B,,,,,
2192,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,BAO_0000221,CHEMBL617018,11351,,Autocuration,1,,B,,,,Brain,
2193,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,CHEMBL617019,11279,,Autocuration,1,,F,,,,,
2194,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,CHEMBL617020,9523,,Autocuration,1,,B,,,,,
2195,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,CHEMBL617021,9523,,Autocuration,1,,B,,,,,
2196,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,CHEMBL617022,9523,,Autocuration,1,,B,,,,,
2197,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,CHEMBL617023,9523,,Autocuration,1,,B,,,,,
2198,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,CHEMBL617024,9523,,Autocuration,1,,B,,,,,
2199,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,CHEMBL617025,9523,,Autocuration,1,,B,,,,,
2200,,Hill coefficient of compound was determined,,BAO_0000224,CHEMBL617026,9523,,Autocuration,1,,B,,,,,
2201,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL617027,4771,,Autocuration,1,,B,,,,,
2202,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,BAO_0000019,CHEMBL617028,5033,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2203,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,BAO_0000019,CHEMBL617029,10845,,Expert,1,,B,,,,,
2204,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,BAO_0000019,CHEMBL875908,10845,,Expert,1,,B,,,,,
2205,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,BAO_0000357,CHEMBL617030,16288,,Autocuration,1,,B,,,,,
2206,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,BAO_0000019,CHEMBL617031,16288,,Autocuration,1,,B,,,,,
2207,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,BAO_0000019,CHEMBL617032,16190,,Autocuration,1,,B,,,,,
2208,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,BAO_0000224,CHEMBL617033,12463,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2209,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,BAO_0000224,CHEMBL617034,9699,,Autocuration,1,,B,,,,,
2210,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,BAO_0000224,CHEMBL617035,9699,,Autocuration,1,,B,,,,,
2211,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,CHEMBL617036,11662,,Autocuration,1,,B,,,,,
2212,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617037,1205,,Autocuration,1,,B,,,,,
2213,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,BAO_0000219,CHEMBL617038,11376,,Autocuration,1,,B,,,,,
2214,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,BAO_0000219,CHEMBL617039,11376,,Autocuration,1,,B,,,,,
2215,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617161,4639,,Autocuration,1,,B,,,,,
2216,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617162,2222,,Autocuration,1,,B,,,,,
2217,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617163,1558,,Autocuration,1,,B,,,,,
2218,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617164,1089,,Autocuration,1,,B,,,,,
2219,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,BAO_0000249,CHEMBL617165,386,,Autocuration,1,,B,,,,,
2220,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,BAO_0000224,CHEMBL617166,2474,,Autocuration,1,,B,,,,,
2221,,Binding affinity towards 5-HT2 receptor,,BAO_0000224,CHEMBL617167,17066,,Autocuration,1,,B,,,,,
2222,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL872912,959,,Autocuration,1,,B,,,,,
2223,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,BAO_0000224,CHEMBL617168,6398,,Autocuration,1,,B,,,,,
2224,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,BAO_0000224,CHEMBL617169,11889,,Autocuration,1,,B,,,,,
2225,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617170,4221,,Autocuration,1,,B,,,,,
2226,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,BAO_0000224,CHEMBL617171,11026,,Autocuration,1,,B,,,,,
2227,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,CHEMBL617172,11866,,Autocuration,1,,B,,,,,
2228,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617173,4221,,Autocuration,1,,B,,,,,
2229,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL617174,13950,,Autocuration,1,,B,,,,,
2230,,5-hydroxytryptamine 2 receptor binding affinity,,BAO_0000224,CHEMBL617175,1263,,Autocuration,1,,B,,,,,
2231,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,BAO_0000357,CHEMBL617176,13291,,Autocuration,1,,B,,,,,
2232,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL617177,10812,,Autocuration,1,,B,,,,,
2233,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,CHEMBL617178,13020,,Autocuration,1,,B,,,,,
2234,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,BAO_0000224,CHEMBL617179,13021,,Autocuration,1,,B,,,,,
2235,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,CHEMBL617180,13020,,Autocuration,1,,B,,,,,
2236,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,BAO_0000357,CHEMBL617181,14532,,Autocuration,1,,B,,,,,
2237,,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,CHEMBL617182,13944,,Autocuration,1,,B,,,,,
2238,,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,CHEMBL617183,14331,,Autocuration,1,,B,,,,,
2239,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL617184,14118,,Autocuration,1,,B,,,,,
2240,,Binding affinity against serotonergic 5-HT2 receptor,,BAO_0000357,CHEMBL617185,13033,,Autocuration,1,,B,,,,,
2241,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL617186,10321,,Autocuration,1,,B,,,,,
2242,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,BAO_0000357,CHEMBL617187,12918,,Autocuration,1,,B,,,,,
2243,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,BAO_0000357,CHEMBL617188,15120,,Autocuration,1,,B,,,,,
2244,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,BAO_0000218,CHEMBL617189,2613,,Autocuration,1,,B,,,,,
2245,,Inhibitory activity against cloned human 5-HT2 receptor,,BAO_0000224,CHEMBL617190,13378,9606.0,Autocuration,1,,B,,Homo sapiens,,,
2246,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,BAO_0000219,CHEMBL617191,2331,9606.0,Autocuration,1,449.0,B,,Homo sapiens,,,CHO
2247,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,BAO_0000219,CHEMBL617192,2331,9606.0,Autocuration,1,449.0,B,,Homo sapiens,,,CHO
2248,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,BAO_0000219,CHEMBL617193,2331,9606.0,Autocuration,1,449.0,B,,Homo sapiens,,,CHO
2249,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,BAO_0000219,CHEMBL617194,2331,9606.0,Autocuration,1,449.0,B,,Homo sapiens,,,CHO
2250,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617195,4170,,Autocuration,1,,B,,,,,
2251,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,CHEMBL881830,15453,,Autocuration,1,,B,,,,,
2252,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000357,CHEMBL617196,1479,,Autocuration,1,,B,,,,,
2253,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,BAO_0000224,CHEMBL617197,11139,,Autocuration,1,,B,,,,,
2254,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL617198,13969,,Expert,1,,B,,,,,
2255,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL873476,13392,,Expert,1,,B,,,,,
2256,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,BAO_0000019,CHEMBL617199,14430,,Expert,1,,B,,,,,
2257,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617200,13181,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
2258,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,CHEMBL617484,17200,,Autocuration,1,,B,,,,,
2259,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,CHEMBL617485,17200,,Autocuration,1,,B,,,,,
2260,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,CHEMBL617486,17200,,Autocuration,1,,B,,,,,
2261,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL858022,13463,,Autocuration,1,,B,,,,,
2262,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,BAO_0000219,CHEMBL617049,6347,,Autocuration,1,449.0,B,,,,,CHO
2263,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,CHEMBL617050,6857,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
2264,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,CHEMBL617051,4176,,Autocuration,1,,F,,,,,
2265,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,BAO_0000219,CHEMBL617052,4176,,Autocuration,1,,F,,,,,
2266,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,CHEMBL617053,4176,,Autocuration,1,,F,,,,,
2267,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,BAO_0000219,CHEMBL617054,6347,,Autocuration,1,449.0,B,,,,,CHO
2268,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,BAO_0000219,CHEMBL617055,6347,,Autocuration,1,449.0,B,,,,,CHO
2269,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,BAO_0000357,CHEMBL882924,15331,,Autocuration,1,,B,,,,,
2270,,Inhibition of human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617056,16146,9606.0,Expert,1,,B,,Homo sapiens,,,
2271,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL617057,15250,,Autocuration,1,449.0,B,,,,,CHO
2272,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,BAO_0000219,CHEMBL617058,13631,,Expert,1,,B,,,,,
2273,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,BAO_0000357,CHEMBL617059,3805,,Autocuration,1,,B,,,,,
2274,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,BAO_0000219,CHEMBL617060,4011,,Autocuration,1,449.0,B,,,,,CHO
2275,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,BAO_0000219,CHEMBL617061,4012,,Expert,1,449.0,B,,,,,CHO
2276,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,BAO_0000219,CHEMBL617062,6366,,Expert,1,307.0,B,,,,,L929
2277,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL617063,15949,,Expert,1,449.0,B,,,,,CHO
2278,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,BAO_0000019,CHEMBL617064,14093,,Autocuration,1,,F,,,,,
2279,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000019,CHEMBL617065,13481,,Autocuration,1,,F,,,,,
2280,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,BAO_0000219,CHEMBL617066,6347,,Autocuration,1,449.0,B,,,,,CHO
2281,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,BAO_0000219,CHEMBL617067,6347,,Autocuration,1,449.0,B,,,,,CHO
2282,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,BAO_0000019,CHEMBL617068,14093,,Autocuration,1,,F,,,,,
2283,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,BAO_0000019,CHEMBL617069,14093,,Autocuration,1,,F,,,,,
2284,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL617070,13481,,Autocuration,1,,F,,,,,
2285,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,BAO_0000357,CHEMBL617071,14442,,Autocuration,1,,B,,,,,
2286,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL872915,14442,,Autocuration,1,,B,,,,,
2287,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,BAO_0000357,CHEMBL617072,14755,,Autocuration,1,,B,,,,,
2288,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,BAO_0000357,CHEMBL617073,16441,,Autocuration,1,,B,,,,,
2289,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,BAO_0000357,CHEMBL617074,14744,,Autocuration,1,,B,,,,,
2290,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL617075,16659,,Expert,1,449.0,B,,,,,CHO
2291,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617076,3307,,Autocuration,1,,B,,,,,
2292,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,BAO_0000019,CHEMBL617077,6857,9606.0,Expert,1,,B,,Homo sapiens,,,
2293,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,BAO_0000357,CHEMBL617078,5635,,Expert,1,,B,,,,,
2294,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617079,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
2295,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,CHEMBL617080,15527,,Autocuration,1,,B,,,,,
2296,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,BAO_0000219,CHEMBL617081,6588,,Expert,1,449.0,B,,,,,CHO
2297,,Binding affinity towards human 5-HT2A receptor in BEK cells,,BAO_0000219,CHEMBL617082,13631,,Expert,1,,B,,,,,
2298,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617083,17723,,Autocuration,1,,B,,,,,
2299,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,CHEMBL617084,14770,,Autocuration,1,,B,,,,,
2300,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617085,16293,9606.0,Expert,1,,B,,Homo sapiens,,,
2301,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,CHEMBL617086,16209,,Autocuration,1,,B,,,,,
2302,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,BAO_0000219,CHEMBL617087,12469,,Autocuration,1,,B,,,,,
2303,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617088,15363,,Autocuration,1,,B,,,,,
2304,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617089,15363,,Autocuration,1,,B,,,,,
2305,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,BAO_0000019,CHEMBL617090,16441,,Expert,1,,B,,,,,
2306,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL617513,8,,Autocuration,1,,B,,,,,
2307,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,BAO_0000219,CHEMBL617514,4176,,Autocuration,1,722.0,B,,,,,HEK293
2308,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617515,17085,,Autocuration,1,,B,,,,,
2309,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,CHEMBL617516,17200,,Autocuration,1,,B,,,,,
2310,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,CHEMBL617517,17200,9606.0,Expert,1,,B,,Homo sapiens,,,
2311,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,BAO_0000219,CHEMBL617518,4013,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
2312,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617519,5088,,Autocuration,1,,B,,,,,
2313,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617520,5088,9606.0,Expert,1,,B,,Homo sapiens,,,
2314,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,BAO_0000357,CHEMBL617521,5088,,Autocuration,1,,B,,,,,
2315,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617522,5088,9606.0,Expert,1,,B,,Homo sapiens,,,
2316,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL617523,5088,,Autocuration,1,,B,,,,,
2317,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,CHEMBL617524,5088,,Autocuration,1,,B,,,,,
2318,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,BAO_0000019,CHEMBL617525,9786,,Autocuration,1,,B,,,,,
2319,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,BAO_0000019,CHEMBL617526,9205,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2320,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,BAO_0000224,CHEMBL617527,11257,,Autocuration,1,,B,,,,,
2321,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,CHEMBL617528,9362,,Autocuration,1,,B,,,,,
2322,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,CHEMBL617529,9362,,Autocuration,1,,B,,,,,
2323,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,BAO_0000224,CHEMBL617530,10590,,Autocuration,1,,B,,,,,
2324,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,CHEMBL617531,10468,,Autocuration,1,,B,,,,,
2325,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,BAO_0000019,CHEMBL617532,13050,,Autocuration,1,,B,,,,,
2326,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL617533,11624,,Autocuration,1,,B,,,,,
2327,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,CHEMBL617534,10468,,Autocuration,1,,B,,,,,
2328,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000224,CHEMBL617535,10330,,Autocuration,1,,B,,,,,
2329,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,CHEMBL617536,10062,,Autocuration,1,,B,,,,,
2330,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617537,11642,,Autocuration,1,,B,,,,,
2331,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617538,10062,,Autocuration,1,,B,,,,,
2332,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,CHEMBL617539,13427,,Autocuration,1,,B,In vitro,,,,
2333,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617540,12280,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2334,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,BAO_0000224,CHEMBL617541,4101,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2335,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617542,10062,,Autocuration,1,,B,,,,,
2336,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,BAO_0000224,CHEMBL617543,11147,,Autocuration,1,,B,,,,,
2337,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,CHEMBL617544,2395,10116.0,Autocuration,1,485.0,B,,Rattus norvegicus,,,CHO-K1
2338,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,CHEMBL617545,2395,10116.0,Autocuration,1,485.0,B,,Rattus norvegicus,,,CHO-K1
2339,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,BAO_0000019,CHEMBL617413,9098,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2340,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,BAO_0000019,CHEMBL617414,9098,,Autocuration,1,,B,,,,,
2341,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,BAO_0000019,CHEMBL617415,9098,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2342,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617416,9443,,Autocuration,1,,B,,,,,
2343,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,CHEMBL617417,9443,,Autocuration,1,,B,,,,,
2344,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,BAO_0000019,CHEMBL617418,9699,,Autocuration,1,,B,,,,,
2345,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,BAO_0000019,CHEMBL617419,9699,,Autocuration,1,,B,,,,,
2346,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,CHEMBL617420,9098,,Autocuration,1,,B,,,,,
2347,,Affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617421,3070,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2348,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,BAO_0000224,CHEMBL617422,9547,,Autocuration,1,,B,,,,,
2349,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,BAO_0000019,CHEMBL617423,10444,,Autocuration,1,,B,,,,,
2350,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,BAO_0000019,CHEMBL617424,14617,,Autocuration,1,,B,,,,,
2351,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,BAO_0000019,CHEMBL617425,14617,,Autocuration,1,,B,,,,,
2352,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,BAO_0000224,CHEMBL617426,11130,,Autocuration,1,,B,,,,,
2353,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,BAO_0000218,CHEMBL617427,11130,,Autocuration,1,,B,In vivo,,,,
2354,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,BAO_0000221,CHEMBL617428,14542,,Autocuration,1,,B,,,,Brain,
2355,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,BAO_0000224,CHEMBL617429,2797,,Autocuration,1,,B,,,,,
2356,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,CHEMBL617430,11332,,Autocuration,1,,B,,,,,
2357,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,CHEMBL617431,11332,,Autocuration,1,,B,,,,,
2358,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,BAO_0000019,CHEMBL617432,10752,,Autocuration,1,,B,,,,Frontal cortex,
2359,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617433,1185,,Autocuration,1,,B,,,,,
2360,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617434,1185,,Autocuration,1,,B,,,,,
2361,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,BAO_0000224,CHEMBL617435,11624,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2362,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,BAO_0000019,CHEMBL617436,1344,,Autocuration,1,,B,,,,,
2363,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,BAO_0000019,CHEMBL617437,15453,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Striatum,
2364,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,CHEMBL617438,11662,,Autocuration,1,,B,,,,,
2365,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,CHEMBL617439,11662,,Autocuration,1,,B,,,,,
2366,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617440,10796,,Autocuration,1,,B,,,,,
2367,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617441,9069,,Autocuration,1,,B,,,,,
2368,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,BAO_0000019,CHEMBL872918,8814,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2369,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,BAO_0000019,CHEMBL617442,8908,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2370,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,CHEMBL617443,9098,,Autocuration,1,,B,,,,,
2371,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,BAO_0000019,CHEMBL617444,9098,,Autocuration,1,,B,,,,,
2372,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,CHEMBL617445,9098,,Autocuration,1,,B,,,,,
2373,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,BAO_0000019,CHEMBL617446,9098,,Autocuration,1,,B,,,,,
2374,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,BAO_0000249,CHEMBL617447,9098,,Autocuration,1,,B,,,,,
2375,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,BAO_0000019,CHEMBL617448,9098,,Autocuration,1,,B,,,,,
2376,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,BAO_0000019,CHEMBL617449,9098,,Autocuration,1,,B,,,,,
2377,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,BAO_0000019,CHEMBL617450,9161,,Autocuration,1,,B,,,,,
2378,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,BAO_0000019,CHEMBL617451,9161,,Autocuration,1,,B,,,,,
2379,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,BAO_0000019,CHEMBL617452,9161,,Autocuration,1,,B,,,,,
2380,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,CHEMBL617453,9161,,Autocuration,1,,B,,,,,
2381,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,BAO_0000019,CHEMBL617660,9161,,Autocuration,1,,B,,,,,
2382,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,BAO_0000019,CHEMBL617661,9161,,Autocuration,1,,B,,,,,
2383,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,BAO_0000019,CHEMBL617662,9161,,Autocuration,1,,B,,,,,
2384,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,BAO_0000019,CHEMBL872919,9161,,Autocuration,1,,B,,,,,
2385,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,BAO_0000019,CHEMBL617663,9161,,Autocuration,1,,B,,,,,
2386,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,BAO_0000019,CHEMBL617664,9161,,Autocuration,1,,B,,,,,
2387,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,BAO_0000019,CHEMBL617665,9161,,Autocuration,1,,B,,,,,
2388,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,BAO_0000019,CHEMBL617666,9161,,Autocuration,1,,B,,,,,
2389,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,BAO_0000019,CHEMBL617667,12094,,Autocuration,1,,B,,,,,
2390,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,BAO_0000249,CHEMBL617668,12018,,Autocuration,1,,B,,,,,
2391,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,BAO_0000249,CHEMBL617669,10394,,Autocuration,1,,B,,,,,
2392,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617670,15260,,Autocuration,1,,B,,,,,
2393,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617671,11624,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2394,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617672,13654,,Autocuration,1,,B,,,,,
2395,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,BAO_0000019,CHEMBL617673,9541,,Autocuration,1,,B,,,,,
2396,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,BAO_0000224,CHEMBL617674,11933,,Autocuration,1,,B,,,,,
2397,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,CHEMBL617675,15538,,Autocuration,1,,B,,,,,
2398,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,BAO_0000019,CHEMBL617676,15538,,Autocuration,1,,B,,,,,
2399,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,BAO_0000019,CHEMBL617677,15538,,Autocuration,1,,B,,,,,
2400,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,BAO_0000019,CHEMBL617678,8841,,Autocuration,1,,B,,,,,
2401,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,BAO_0000224,CHEMBL617679,1455,,Autocuration,1,,B,,,,,
2402,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,BAO_0000224,CHEMBL617680,1455,,Autocuration,1,,B,,,,,
2403,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,BAO_0000019,CHEMBL617681,11752,,Autocuration,1,,B,,,,,
2404,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,BAO_0000221,CHEMBL617682,11642,,Autocuration,1,,B,,,,Brain,
2405,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,BAO_0000224,CHEMBL617683,12092,,Autocuration,1,,B,,,,,
2406,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,BAO_0000224,CHEMBL617684,3967,,Autocuration,1,,B,,,,,
2407,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617685,12771,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2408,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,BAO_0000019,CHEMBL617686,11642,,Autocuration,1,,B,,,,,
2409,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,BAO_0000224,CHEMBL617687,11628,,Autocuration,1,,B,,,,,
2410,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,CHEMBL617688,13654,,Autocuration,1,,B,,,,,
2411,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,CHEMBL617689,11200,,Autocuration,1,,F,,,,,
2412,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,CHEMBL617690,11200,,Autocuration,1,,F,,,,,
2413,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,CHEMBL617691,11200,,Autocuration,1,,F,In vivo,,,,
2414,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,CHEMBL617692,11200,,Autocuration,1,,F,In vivo,,,,
2415,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,CHEMBL617693,11200,,Autocuration,1,,F,In vivo,,,,
2416,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,CHEMBL617694,11200,,Autocuration,1,,F,In vivo,,,,
2417,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,BAO_0000221,CHEMBL857985,15436,,Expert,1,,B,,,,Brain,
2418,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,CHEMBL617695,15436,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2419,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,BAO_0000019,CHEMBL617696,14025,,Autocuration,1,,B,,,,,
2420,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,CHEMBL617697,4342,,Autocuration,1,,B,,,,,
2421,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,BAO_0000019,CHEMBL617257,13735,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2422,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,CHEMBL617258,5816,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2423,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,BAO_0000019,CHEMBL617259,14287,,Expert,1,,B,,,,,
2424,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,BAO_0000357,CHEMBL617260,15738,,Autocuration,1,,B,,,,,
2425,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617261,15738,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2426,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,BAO_0000019,CHEMBL617262,15026,,Autocuration,1,,B,,,,,
2427,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,CHEMBL617263,16647,,Expert,1,,B,,,,,
2428,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,BAO_0000019,CHEMBL617264,16647,,Autocuration,1,,B,,,,,
2429,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617265,13345,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2430,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,BAO_0000249,CHEMBL617266,1543,,Autocuration,1,,B,,,,,
2431,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,BAO_0000019,CHEMBL617267,12444,,Autocuration,1,,B,,,,,
2432,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,BAO_0000019,CHEMBL617268,16404,,Expert,1,,B,,,,,
2433,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,BAO_0000219,CHEMBL617269,16404,,Autocuration,1,449.0,B,,,,,CHO
2434,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,BAO_0000357,CHEMBL617323,15577,,Expert,1,,B,,,,,
2435,,Serotonergic activity of the compound.,,BAO_0000357,CHEMBL617324,15577,,Autocuration,1,,B,,,,,
2436,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,BAO_0000249,CHEMBL617325,2495,,Autocuration,1,,B,,,,,
2437,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,BAO_0000019,CHEMBL617326,15042,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2438,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,BAO_0000249,CHEMBL617327,15026,,Expert,1,,B,,,,,
2439,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,CHEMBL617328,12919,10116.0,Expert,1,,F,,Rattus norvegicus,,,
2440,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,CHEMBL617329,12919,10116.0,Expert,1,,F,,Rattus norvegicus,,,
2441,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,CHEMBL617330,12919,10116.0,Expert,1,,F,,Rattus norvegicus,,,
2442,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL617331,15194,,Autocuration,1,,B,,,,,
2443,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,BAO_0000357,CHEMBL617332,15194,,Autocuration,1,,B,,,,,
2444,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617333,4820,,Expert,1,,B,,,,,
2445,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,BAO_0000357,CHEMBL617334,6736,,Autocuration,1,,B,,,,,
2446,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,CHEMBL617335,5163,,Autocuration,1,,B,,,,,
2447,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,CHEMBL617336,5163,,Autocuration,1,,B,,,,,
2448,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,BAO_0000357,CHEMBL617337,6011,,Autocuration,1,,B,,,,,
2449,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,BAO_0000357,CHEMBL617338,14294,9606.0,Expert,1,,B,,Homo sapiens,,,
2450,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617339,5014,,Autocuration,1,,B,,,,,
2451,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617340,17066,,Expert,1,,B,,,,,
2452,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,BAO_0000357,CHEMBL617341,17515,,Autocuration,1,,B,,,,,
2453,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617342,6736,,Expert,1,,B,,,,,
2454,,Affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617343,5163,,Expert,1,,B,,,,,
2455,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,BAO_0000219,CHEMBL617344,16911,,Expert,1,723.0,B,,,,,NIH3T3
2456,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,CHEMBL617345,6841,,Expert,1,,B,,,,,
2457,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,BAO_0000357,CHEMBL617346,6119,,Expert,1,,B,,,,,
2458,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617347,3962,,Autocuration,1,,B,,,,,
2459,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,CHEMBL617348,4373,,Autocuration,1,,B,,,,,
2460,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,CHEMBL617349,4373,,Autocuration,1,,B,,,,,
2461,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617350,3962,,Autocuration,1,,F,,,,,
2462,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,BAO_0000357,CHEMBL872339,1633,,Expert,1,,B,,,,,
2463,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,CHEMBL617351,4373,,Autocuration,1,,B,,,,,
2464,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617352,6576,,Expert,1,,B,,,,,
2465,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617353,4687,,Autocuration,1,,B,,,,,
2466,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617354,16946,,Autocuration,1,,B,,,,,
2467,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617355,14159,,Autocuration,1,,B,,,,,
2468,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,BAO_0000219,CHEMBL617356,3032,10090.0,Expert,1,449.0,B,,Mus musculus,,,CHO
2469,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617357,16655,,Autocuration,1,,B,,,,,
2470,,Binding affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617358,13964,,Autocuration,1,,B,,,,,
2471,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617359,16989,,Expert,1,,B,,,,,
2472,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,CHEMBL617360,16117,,Autocuration,1,,B,,,,,
2473,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,BAO_0000357,CHEMBL875913,16700,,Autocuration,1,,B,,,,,
2474,,Affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617361,3269,,Autocuration,1,,B,,,,,
2475,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617362,1274,9606.0,Expert,1,,B,,Homo sapiens,,,
2476,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,CHEMBL617363,1317,,Autocuration,1,,B,,,,,
2477,,Tested against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617364,12146,,Autocuration,1,,B,,,,,
2478,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,CHEMBL617365,12652,,Autocuration,1,,B,,,,,
2479,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,BAO_0000224,CHEMBL617366,12652,,Autocuration,1,,B,,,,,
2480,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,BAO_0000224,CHEMBL617367,12652,,Autocuration,1,,B,,,,,
2481,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,CHEMBL617368,12652,,Autocuration,1,,B,,,,,
2482,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,BAO_0000357,CHEMBL617369,16647,,Autocuration,1,,B,,,,,
2483,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,BAO_0000219,CHEMBL617370,15851,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2484,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,CHEMBL617371,6857,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
2485,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,BAO_0000357,CHEMBL617372,3805,,Autocuration,1,,B,,,,,
2486,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,BAO_0000357,CHEMBL617373,6491,9606.0,Expert,1,,B,,Homo sapiens,,,
2487,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,BAO_0000019,CHEMBL617374,14093,,Autocuration,1,,F,,,,,
2488,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,BAO_0000019,CHEMBL617375,13481,,Autocuration,1,,F,,,,,
2489,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,BAO_0000019,CHEMBL617376,14093,,Autocuration,1,,F,,,,,
2490,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,BAO_0000019,CHEMBL617377,14093,,Autocuration,1,,F,,,,,
2491,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,BAO_0000019,CHEMBL617378,14093,,Autocuration,1,,F,,,,,
2492,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000019,CHEMBL617379,13481,,Autocuration,1,,F,,,,,
2493,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,BAO_0000357,CHEMBL617380,14442,,Autocuration,1,,B,,,,,
2494,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,BAO_0000357,CHEMBL617381,14442,,Autocuration,1,,B,,,,,
2495,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000357,CHEMBL617382,14442,,Autocuration,1,,B,,,,,
2496,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617383,12369,,Autocuration,1,,B,,,,,
2497,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,BAO_0000357,CHEMBL617384,12369,,Expert,1,,B,,,,,
2498,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,BAO_0000357,CHEMBL617385,12369,,Expert,1,,B,,,,,
2499,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,BAO_0000019,CHEMBL617386,14447,,Autocuration,1,,B,,,,,
2500,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,BAO_0000019,CHEMBL617387,14447,,Autocuration,1,,B,,,,,
2501,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,CHEMBL617388,17451,,Autocuration,1,723.0,B,,,,,NIH3T3
2502,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,CHEMBL617389,6857,,Autocuration,1,449.0,F,,,,,CHO
2503,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,CHEMBL617390,6857,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
2504,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,BAO_0000224,CHEMBL617391,5635,,Autocuration,1,,B,,,,,
2505,,Binding activity radioligand.,,BAO_0000357,CHEMBL617392,12861,,Autocuration,1,,B,,,,,
2506,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,CHEMBL617393,12861,,Autocuration,1,,B,,,,,
2507,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,BAO_0000219,CHEMBL617394,5105,,Autocuration,1,307.0,B,,,,,L929
2508,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,BAO_0000219,CHEMBL617395,5104,,Expert,1,307.0,B,,,,,L929
2509,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,BAO_0000219,CHEMBL617396,5105,,Expert,1,307.0,B,,,,,L929
2510,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,BAO_0000219,CHEMBL617397,5105,,Autocuration,1,307.0,B,,,,,L929
2511,,Binding affinity against 5-HT2A receptor,,BAO_0000357,CHEMBL617398,5254,,Autocuration,1,,B,,,,,
2512,,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617399,5254,,Autocuration,1,,B,,,,,
2513,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,BAO_0000219,CHEMBL617400,13267,,Autocuration,1,722.0,B,,,,,HEK293
2514,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,BAO_0000219,CHEMBL617401,13267,,Autocuration,1,722.0,B,,,,,HEK293
2515,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,BAO_0000219,CHEMBL617402,14157,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2516,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,CHEMBL617403,12936,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2517,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,BAO_0000357,CHEMBL617404,14068,,Expert,1,,B,,,,,
2518,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,CHEMBL857981,12936,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2519,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,CHEMBL617405,12936,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2520,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,BAO_0000219,CHEMBL617253,4540,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2521,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,BAO_0000357,CHEMBL617254,6166,,Expert,1,,B,,,,,
2522,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,CHEMBL617255,17296,,Autocuration,1,722.0,B,,,,,HEK293
2523,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,CHEMBL617256,17296,,Autocuration,1,722.0,B,,,,,HEK293
2524,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,CHEMBL616874,17296,,Autocuration,1,722.0,B,,,,,HEK293
2525,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,BAO_0000219,CHEMBL616875,15779,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2526,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,CHEMBL616876,14391,,Expert,1,722.0,B,,,,,HEK293
2527,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,BAO_0000219,CHEMBL616877,15851,,Expert,1,722.0,B,,,,,HEK293
2528,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,BAO_0000219,CHEMBL616878,15851,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2529,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,BAO_0000219,CHEMBL616879,3832,,Expert,1,722.0,B,,,,,HEK293
2530,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,BAO_0000219,CHEMBL616880,3833,,Expert,1,722.0,B,,,,,HEK293
2531,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,CHEMBL616881,12936,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2532,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL616882,17451,,Autocuration,1,723.0,B,,,,,NIH3T3
2533,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,CHEMBL616883,17451,,Autocuration,1,723.0,B,,,,,NIH3T3
2534,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,CHEMBL616884,17451,,Autocuration,1,723.0,B,,,,,NIH3T3
2535,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,BAO_0000219,CHEMBL616885,4199,,Autocuration,1,722.0,B,,,,,HEK293
2536,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,BAO_0000219,CHEMBL616886,1883,,Autocuration,1,485.0,B,,,,,CHO-K1
2537,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,BAO_0000219,CHEMBL616887,1883,,Expert,1,485.0,B,,,,,CHO-K1
2538,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL616888,14875,9606.0,Expert,1,,B,,Homo sapiens,,,
2539,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,BAO_0000219,CHEMBL616889,15146,,Autocuration,1,722.0,B,,,,,HEK293
2540,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,BAO_0000219,CHEMBL616890,5213,,Autocuration,1,722.0,B,,,,,HEK293
2541,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,BAO_0000219,CHEMBL616891,16404,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
2542,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,BAO_0000219,CHEMBL616892,14818,,Autocuration,1,722.0,B,,,,,HEK293
2543,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,BAO_0000219,CHEMBL616893,4829,,Autocuration,1,722.0,B,,,,,HEK293
2544,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,BAO_0000219,CHEMBL616894,12652,,Autocuration,1,723.0,F,,,,,NIH3T3
2545,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,BAO_0000219,CHEMBL616895,4682,,Expert,1,723.0,B,,,,,NIH3T3
2546,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL616896,12652,,Autocuration,1,,F,,,,,
2547,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617099,4921,,Autocuration,1,,B,,,,,
2548,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,BAO_0000357,CHEMBL617100,4921,,Autocuration,1,,B,,,,,
2549,,Binding affinity against rabbit aorta 5-HT2A receptor,,BAO_0000357,CHEMBL884532,16312,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
2550,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,BAO_0000357,CHEMBL617101,14998,9986.0,Expert,1,,B,,Oryctolagus cuniculus,,,
2551,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,BAO_0000357,CHEMBL617102,14025,9986.0,Expert,1,,B,,Oryctolagus cuniculus,,,
2552,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL617103,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
2553,,The compound was tested for binding affinity against 5-HT2A receptor,,BAO_0000357,CHEMBL617104,13047,9986.0,Expert,1,,B,,Oryctolagus cuniculus,,,
2554,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,BAO_0000219,CHEMBL857979,1883,,Autocuration,1,485.0,B,,,,,CHO-K1
2555,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,BAO_0000019,CHEMBL857502,13463,,Autocuration,1,,B,,,,,
2556,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,CHEMBL617105,13463,,Autocuration,1,,B,,,,,
2557,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,BAO_0000019,CHEMBL858021,13463,,Autocuration,1,,B,,,,Stomach,
2558,,Binding affinity for 5-HT 2A in rat stomach fundus,,BAO_0000019,CHEMBL875910,13463,10116.0,Expert,1,,B,,Rattus norvegicus,,Stomach,
2559,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,CHEMBL617106,13463,,Autocuration,1,,B,,,,,
2560,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000219,CHEMBL617107,16326,,Expert,1,723.0,B,,,,,NIH3T3
2561,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617108,14093,,Autocuration,1,,F,,,,,
2562,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617109,14093,,Autocuration,1,,F,,,,,
2563,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617110,15740,,Autocuration,1,,B,,,,,
2564,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,BAO_0000357,CHEMBL617111,16633,,Autocuration,1,,B,,,,,
2565,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,BAO_0000019,CHEMBL617112,17200,10116.0,Expert,1,,F,,Rattus norvegicus,,,
2566,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617113,17133,,Autocuration,1,,B,,,,,
2567,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617114,17133,,Autocuration,1,,B,,,,,
2568,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617115,17133,,Autocuration,1,,B,,,,,
2569,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,CHEMBL617116,17200,,Autocuration,1,,F,,,,,
2570,,Efficacy at 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617117,15363,,Autocuration,1,,F,,,,,
2571,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,CHEMBL617118,17200,,Autocuration,1,,B,,,,,
2572,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,CHEMBL617119,17200,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2573,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,BAO_0000357,CHEMBL617120,17200,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2574,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,CHEMBL617121,17200,10116.0,Expert,1,,F,,Rattus norvegicus,,,
2575,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,CHEMBL617122,17200,,Autocuration,1,,F,,,,,
2576,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617123,17211,,Autocuration,1,,B,,,,,
2577,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,CHEMBL617124,17331,,Expert,1,,B,,,,,
2578,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,BAO_0000249,CHEMBL617600,13565,,Expert,1,,B,,,,,
2579,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,BAO_0000357,CHEMBL617601,13730,,Expert,1,,B,,,,,
2580,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,BAO_0000019,CHEMBL882923,12416,,Expert,1,,B,,,,,
2581,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617602,15295,,Autocuration,1,,B,,,,,
2582,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,BAO_0000019,CHEMBL617603,1742,,Autocuration,1,,B,,,,,
2583,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617604,15295,,Autocuration,1,,B,,,,,
2584,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL617605,14970,,Expert,1,,B,,,,,
2585,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL617606,16693,,Expert,1,,B,,,,,
2586,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617607,14776,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2587,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,CHEMBL617455,14286,,Autocuration,1,,B,,,,,
2588,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,CHEMBL617456,17200,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2589,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,BAO_0000357,CHEMBL617457,15306,,Expert,1,,B,,,,,
2590,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617458,14178,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2591,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,BAO_0000019,CHEMBL617459,14229,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2592,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,BAO_0000357,CHEMBL617460,12884,,Expert,1,,B,,,,,
2593,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,BAO_0000357,CHEMBL617461,13149,,Expert,1,,B,,,,,
2594,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,BAO_0000019,CHEMBL617462,15295,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2595,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,BAO_0000357,CHEMBL617463,15740,,Autocuration,1,,B,,,,,
2596,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,BAO_0000019,CHEMBL617464,15185,,Autocuration,1,,B,,,,,
2597,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,BAO_0000019,CHEMBL617465,15185,,Autocuration,1,,B,,,,,
2598,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,BAO_0000019,CHEMBL617466,17529,,Expert,1,,B,,,,,
2599,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,CHEMBL617467,14826,,Autocuration,1,,B,,,,,
2600,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,BAO_0000019,CHEMBL617468,17211,,Expert,1,,B,,,,,
2601,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,CHEMBL617469,14826,,Autocuration,1,,B,,,,,
2602,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617470,14093,,Autocuration,1,,B,,,,,
2603,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,BAO_0000019,CHEMBL617471,14093,,Autocuration,1,,B,,,,,
2604,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,BAO_0000219,CHEMBL617472,13246,,Expert,1,723.0,B,,,,,NIH3T3
2605,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,BAO_0000357,CHEMBL617473,13246,,Expert,1,,B,,,,,
2606,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,CHEMBL617474,15436,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2607,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,CHEMBL617475,15436,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2608,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,BAO_0000221,CHEMBL617476,14442,,Autocuration,1,,B,,,,Brain,
2609,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617477,12457,,Expert,1,,B,,,,,
2610,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000219,CHEMBL617478,12457,,Expert,1,723.0,B,,,,,NIH3T3
2611,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,BAO_0000221,CHEMBL617479,14755,,Autocuration,1,,F,,,,,
2612,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,CHEMBL617480,4707,,Autocuration,1,,B,,,,,
2613,,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617481,13297,,Expert,1,,B,,,,,
2614,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,CHEMBL617482,17331,,Expert,1,,B,,,,,
2615,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL617483,4664,,Autocuration,1,,B,,,,,
2616,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,CHEMBL621528,16633,,Autocuration,1,,B,,,,,
2617,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,BAO_0000219,CHEMBL621529,4664,10116.0,Expert,1,723.0,B,,Rattus norvegicus,,,NIH3T3
2618,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,CHEMBL621530,16133,,Expert,1,,B,,,,,
2619,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL621531,16133,,Expert,1,,B,,,,,
2620,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL621532,14060,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2621,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,CHEMBL621533,16326,,Expert,1,,B,,,,,
2622,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL621534,16659,,Expert,1,449.0,B,,,,,CHO
2623,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,BAO_0000019,CHEMBL621535,14776,,Autocuration,1,,B,,,,,
2624,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,CHEMBL621536,13481,,Autocuration,1,,B,,,,,
2625,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL621537,17386,,Autocuration,1,,B,,,,,
2626,,Binding affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL621538,6611,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2627,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,BAO_0000019,CHEMBL621539,14423,,Autocuration,1,,B,,,,,
2628,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,BAO_0000019,CHEMBL621540,15412,,Autocuration,1,,B,,,,,
2629,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,BAO_0000019,CHEMBL621541,15412,,Autocuration,1,,B,,,,,
2630,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL621542,6238,,Autocuration,1,,B,,,,,
2631,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,BAO_0000357,CHEMBL621543,6648,,Expert,1,,B,,,,,
2632,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL621544,5667,,Expert,1,,B,,,,,
2633,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,BAO_0000357,CHEMBL621545,6611,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2634,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL621546,13481,,Autocuration,1,,B,,,,,
2635,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,BAO_0000357,CHEMBL621547,13481,,Autocuration,1,,B,,,,,
2636,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,BAO_0000219,CHEMBL618692,15558,,Expert,1,723.0,B,,,,,NIH3T3
2637,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL618693,6013,,Autocuration,1,,B,,,,,
2638,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,CHEMBL872922,16633,,Autocuration,1,,B,,,,,
2639,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL618694,6013,,Autocuration,1,,B,,,,,
2640,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,BAO_0000357,CHEMBL618695,6013,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2641,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,BAO_0000357,CHEMBL618696,6013,,Autocuration,1,,B,,,,,
2642,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,BAO_0000357,CHEMBL618697,6013,,Expert,1,,B,,,,,
2643,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,BAO_0000357,CHEMBL618892,6013,,Autocuration,1,,B,,,,,
2644,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL618893,6013,,Autocuration,1,,B,,,,,
2645,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL618894,16293,,Autocuration,1,,B,,,,,
2646,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,BAO_0000219,CHEMBL618895,17175,,Expert,1,723.0,B,,,,,NIH3T3
2647,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,CHEMBL618896,13278,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2648,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,BAO_0000019,CHEMBL618897,3682,,Autocuration,1,,B,,,,Caudate-putamen,
2649,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,BAO_0000357,CHEMBL618898,2014,,Autocuration,1,,B,,,,,
2650,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,BAO_0000357,CHEMBL618899,2014,,Autocuration,1,,B,,,,,
2651,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,BAO_0000357,CHEMBL618900,4932,,Autocuration,1,,B,,,,,
2652,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,BAO_0000019,CHEMBL618901,4932,,Autocuration,1,,B,,,,,
2653,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL618902,3935,,Autocuration,1,,B,,,,,
2654,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,BAO_0000221,CHEMBL618903,5432,10116.0,Expert,1,,B,,Rattus norvegicus,,Hippocampus,
2655,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL618904,15818,,Autocuration,1,,B,,,,,
2656,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,BAO_0000357,CHEMBL618905,13672,,Autocuration,1,,B,,,,,
2657,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,BAO_0000357,CHEMBL618906,13672,,Autocuration,1,,B,,,,,
2658,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,BAO_0000219,CHEMBL618907,14749,,Expert,1,723.0,B,,,,,NIH3T3
2659,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,BAO_0000019,CHEMBL618908,13462,,Autocuration,1,,B,,,,,
2660,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617909,15740,,Autocuration,1,,B,,,,,
2661,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,CHEMBL617910,16647,,Expert,1,,B,,,,,
2662,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,BAO_0000221,CHEMBL617911,13345,,Autocuration,1,,B,,,,Brain,
2663,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,CHEMBL872923,16740,,Autocuration,1,,B,,,,,
2664,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,CHEMBL617912,16740,,Autocuration,1,,B,,,,,
2665,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,BAO_0000019,CHEMBL617913,15535,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2666,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,CHEMBL617914,16740,,Expert,1,,B,,,,,
2667,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,CHEMBL617915,16740,,Autocuration,1,,B,,,,,
2668,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,CHEMBL617916,16740,,Autocuration,1,,B,,,,,
2669,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617917,4795,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2670,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,BAO_0000019,CHEMBL617918,8,,Expert,1,,B,,,,,
2671,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,BAO_0000019,CHEMBL617919,8,,Autocuration,1,,B,,,,,
2672,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,CHEMBL617920,17200,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2673,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,BAO_0000019,CHEMBL617921,2148,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2674,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,BAO_0000224,CHEMBL617922,13345,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2675,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,CHEMBL617923,5088,,Autocuration,1,,B,,,,,
2676,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,CHEMBL617924,5088,,Autocuration,1,,B,,,,,
2677,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,BAO_0000357,CHEMBL617925,17133,,Autocuration,1,,B,,,,,
2678,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,BAO_0000357,CHEMBL617926,17133,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2679,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,BAO_0000357,CHEMBL617927,16532,,Autocuration,1,,B,,,,,
2680,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,CHEMBL617928,15086,,Autocuration,1,,B,,,,,
2681,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,CHEMBL617929,2309,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2682,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,BAO_0000019,CHEMBL617930,12953,,Expert,1,,B,,,,,
2683,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,BAO_0000019,CHEMBL617931,12953,,Autocuration,1,,B,,,,,
2684,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,BAO_0000019,CHEMBL617932,12953,,Autocuration,1,,B,,,,,
2685,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,BAO_0000219,CHEMBL617933,16659,,Autocuration,1,449.0,B,,,,,CHO
2686,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,CHEMBL617934,16740,,Autocuration,1,,B,,,,,
2687,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,CHEMBL617935,16740,,Autocuration,1,,B,,,,,
2688,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,BAO_0000357,CHEMBL617936,17133,,Autocuration,1,,B,,,,,
2689,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,BAO_0000019,CHEMBL617937,17211,,Autocuration,1,,B,,,,,
2690,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,BAO_0000019,CHEMBL617938,17331,,Autocuration,1,,B,,,,,
2691,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,BAO_0000218,CHEMBL617939,16633,,Autocuration,1,,B,,,,,
2692,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,BAO_0000218,CHEMBL617940,16633,,Autocuration,1,,B,,,,,
2693,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,BAO_0000218,CHEMBL617941,16633,,Autocuration,1,,B,,,,,
2694,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,BAO_0000357,CHEMBL617942,15026,,Expert,1,,B,,,,,
2695,,Ratio of pKi of 5-HT2A to that of D2 receptor,,BAO_0000357,CHEMBL617943,15026,,Expert,1,,B,,,,,
2696,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,CHEMBL617944,16404,,Expert,1,,B,,,,,
2697,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,CHEMBL617945,16404,,Expert,1,,B,,,,,
2698,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,BAO_0000224,CHEMBL617946,16404,,Expert,1,,B,,,,,
2699,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,BAO_0000357,CHEMBL617947,16404,,Autocuration,1,,B,,,,,
2700,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,BAO_0000357,CHEMBL617948,16326,,Expert,1,,B,,,,,
2701,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,BAO_0000019,CHEMBL858116,15847,,Autocuration,1,,F,,,,,
2702,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,BAO_0000019,CHEMBL617949,15847,,Autocuration,1,,F,,,,,
2703,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,BAO_0000019,CHEMBL617950,15329,,Autocuration,1,,F,,,,,
2704,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,BAO_0000019,CHEMBL617951,16404,,Expert,1,,F,,,,Thoracic aorta,
2705,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,BAO_0000019,CHEMBL617952,16404,,Expert,1,,F,,,,Thoracic aorta,
2706,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,BAO_0000019,CHEMBL617953,16404,,Autocuration,1,,F,,,,Thoracic aorta,
2707,,Binding activity radioligand.,,BAO_0000357,CHEMBL617954,12861,,Autocuration,1,,B,,,,,
2708,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,CHEMBL617955,12861,,Expert,1,,B,,,,,
2709,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,CHEMBL857071,12861,,Autocuration,1,,B,,,,,
2710,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,BAO_0000019,CHEMBL617270,12490,,Expert,1,,B,,,,,
2711,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,BAO_0000219,CHEMBL617271,12827,,Autocuration,1,339.0,B,,,,,N1E-115
2712,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,BAO_0000219,CHEMBL617272,12827,,Autocuration,1,339.0,B,,,,,N1E-115
2713,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,BAO_0000019,CHEMBL617273,12918,,Autocuration,1,,B,,,,,
2714,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,BAO_0000019,CHEMBL617274,12919,10116.0,Expert,1,,F,,Rattus norvegicus,,,
2715,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617275,17723,,Autocuration,1,,B,,,,,
2716,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617276,6013,,Autocuration,1,,B,,,,,
2717,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617277,16293,,Autocuration,1,,B,,,,,
2718,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,CHEMBL617278,3857,,Expert,1,,B,,,,,
2719,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,BAO_0000019,CHEMBL617279,3857,,Expert,1,,B,,,,,
2720,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,CHEMBL617280,3857,,Expert,1,,B,,,,,
2721,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617281,15363,,Autocuration,1,,B,,,,,
2722,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617282,15363,,Autocuration,1,,B,,,,,
2723,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,BAO_0000019,CHEMBL617283,16441,,Expert,1,,B,,,,,
2724,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,BAO_0000019,CHEMBL617284,16441,,Expert,1,,B,,,,,
2725,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,BAO_0000219,CHEMBL617285,4176,,Autocuration,1,722.0,B,,,,,HEK293
2726,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,BAO_0000019,CHEMBL617286,17085,,Autocuration,1,,B,,,,,
2727,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,BAO_0000357,CHEMBL617287,17200,9606.0,Expert,1,,B,,Homo sapiens,,,
2728,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,BAO_0000357,CHEMBL617288,5088,,Expert,1,,B,,,,,
2729,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,BAO_0000357,CHEMBL617289,5088,,Autocuration,1,,B,,,,,
2730,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL872917,5088,,Autocuration,1,,B,,,,,
2731,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL617290,5088,,Autocuration,1,,B,,,,,
2732,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL617291,16659,,Autocuration,1,449.0,B,,,,,CHO
2733,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,BAO_0000219,CHEMBL617292,16659,,Autocuration,1,449.0,B,,,,,CHO
2734,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,CHEMBL617293,17451,,Autocuration,1,723.0,B,,,,,NIH3T3
2735,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,CHEMBL617294,6857,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
2736,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,CHEMBL617295,3857,,Expert,1,,B,,,,,
2737,,Binding activity radioligand.,,BAO_0000357,CHEMBL617296,12861,,Autocuration,1,,B,,,,,
2738,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,CHEMBL617297,12861,,Autocuration,1,,B,,,,,
2739,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,BAO_0000219,CHEMBL617298,5104,,Expert,1,449.0,B,,,,,CHO
2740,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,BAO_0000219,CHEMBL617299,5105,,Expert,1,449.0,B,,,,,CHO
2741,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,BAO_0000219,CHEMBL617300,5105,,Autocuration,1,449.0,B,,,,,CHO
2742,,Binding affinity against 5-HT2C receptor,,BAO_0000357,CHEMBL617454,5254,,Autocuration,1,,B,,,,,
2743,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,BAO_0000219,CHEMBL617505,13267,,Autocuration,1,722.0,B,,,,,HEK293
2744,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,BAO_0000219,CHEMBL617506,14157,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2745,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,BAO_0000219,CHEMBL617507,12936,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2746,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,BAO_0000357,CHEMBL617508,14068,,Expert,1,,B,,,,,
2747,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,BAO_0000219,CHEMBL857982,12936,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2748,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,BAO_0000219,CHEMBL617509,4540,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2749,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,BAO_0000219,CHEMBL617510,4540,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2750,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,CHEMBL617511,6166,,Autocuration,1,,B,,,,,
2751,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,CHEMBL617512,17296,,Autocuration,1,722.0,B,,,,,HEK293
2752,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,CHEMBL617749,17296,,Autocuration,1,722.0,B,,,,,HEK293
2753,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,CHEMBL617750,15779,,Autocuration,1,722.0,B,,,,,HEK293
2754,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,CHEMBL617751,15779,,Autocuration,1,722.0,B,,,,,HEK293
2755,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,CHEMBL617752,14391,,Expert,1,722.0,B,,,,,HEK293
2756,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,BAO_0000219,CHEMBL617753,15779,,Autocuration,1,722.0,B,,,,,HEK293
2757,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,BAO_0000219,CHEMBL617754,15851,,Expert,1,722.0,B,,,,,HEK293
2758,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,BAO_0000219,CHEMBL617755,15851,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2759,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,BAO_0000219,CHEMBL617756,15779,,Autocuration,1,722.0,B,,,,,HEK293
2760,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,BAO_0000219,CHEMBL617757,3832,,Expert,1,722.0,B,,,,,HEK293
2761,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,BAO_0000219,CHEMBL617758,3833,,Expert,1,722.0,B,,,,,HEK293
2762,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL617759,17451,,Autocuration,1,723.0,B,,,,,NIH3T3
2763,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,BAO_0000219,CHEMBL617760,4199,,Autocuration,1,722.0,B,,,,,HEK293
2764,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,BAO_0000219,CHEMBL617761,1883,,Expert,1,485.0,B,,,,,CHO-K1
2765,,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617762,4321,9606.0,Expert,1,,B,,Homo sapiens,,,
2766,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617763,14875,,Autocuration,1,,B,,,,,
2767,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,BAO_0000219,CHEMBL857983,15146,,Autocuration,1,722.0,B,,,,,HEK293
2768,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,BAO_0000219,CHEMBL617764,5213,,Autocuration,1,722.0,B,,,,,HEK293
2769,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,BAO_0000219,CHEMBL617765,16404,,Autocuration,1,308.0,B,,,,,HeLa
2770,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,BAO_0000019,CHEMBL617766,13267,,Autocuration,1,,F,,,,,
2771,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,BAO_0000221,CHEMBL617767,13267,,Autocuration,1,,F,,,,Hippocampus,
2772,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,BAO_0000219,CHEMBL617768,14818,,Autocuration,1,722.0,B,,,,,HEK293
2773,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,BAO_0000219,CHEMBL617769,4829,,Autocuration,1,722.0,B,,,,,HEK293
2774,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL858023,13463,,Autocuration,1,,B,,,,,
2775,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,BAO_0000019,CHEMBL617770,13463,,Autocuration,1,,B,,,,Stomach,
2776,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,BAO_0000019,CHEMBL617771,13463,,Autocuration,1,,B,,,,Stomach,
2777,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,BAO_0000219,CHEMBL617772,12652,,Autocuration,1,625.0,F,,,,,A9
2778,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,BAO_0000219,CHEMBL617773,4682,,Autocuration,1,723.0,B,,,,,NIH3T3
2779,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,BAO_0000219,CHEMBL617850,4682,,Autocuration,1,723.0,B,,,,,NIH3T3
2780,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,BAO_0000219,CHEMBL617851,4682,,Autocuration,1,723.0,B,,,,,NIH3T3
2781,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,BAO_0000019,CHEMBL617852,12652,,Autocuration,1,,F,,,,,
2782,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,BAO_0000019,CHEMBL858024,13463,10090.0,Autocuration,1,,B,,Mus musculus,,Stomach,
2783,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,BAO_0000019,CHEMBL617853,13463,10116.0,Expert,1,,B,,Rattus norvegicus,,Stomach,
2784,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,BAO_0000357,CHEMBL617854,13969,,Expert,1,,B,,,,,
2785,,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL873477,13392,9823.0,Expert,1,,B,,Sus scrofa,,,
2786,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617855,13392,,Expert,1,,B,,,,,
2787,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,CHEMBL617856,14430,,Expert,1,,B,,,,,
2788,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,BAO_0000019,CHEMBL617857,1742,,Autocuration,1,,B,,,,,
2789,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,BAO_0000249,CHEMBL617858,14286,,Autocuration,1,,B,,,,,
2790,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617859,5619,,Autocuration,1,,B,,,,,
2791,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617860,15086,,Autocuration,1,,B,,,,,
2792,,Binding activity radioligand.,,BAO_0000357,CHEMBL617861,12861,,Autocuration,1,,B,,,,,
2793,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,CHEMBL617862,12861,,Expert,1,,B,,,,,
2794,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,CHEMBL617863,12861,,Autocuration,1,,B,,,,,
2795,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,BAO_0000249,CHEMBL617864,12827,,Autocuration,1,,B,,,,,
2796,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,BAO_0000249,CHEMBL617649,12827,,Autocuration,1,,B,,,,,
2797,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,CHEMBL617650,12919,9823.0,Expert,1,,F,,Sus scrofa,,,
2798,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,CHEMBL617651,12919,9823.0,Expert,1,,F,,Sus scrofa,,,
2799,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,BAO_0000357,CHEMBL617652,16429,9823.0,Autocuration,1,,B,,Sus scrofa,,,
2800,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,BAO_0000019,CHEMBL857072,773,9823.0,Autocuration,1,,B,,Sus scrofa,,,
2801,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617653,5033,9823.0,Autocuration,1,,B,,Sus scrofa,,,
2802,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,CHEMBL617654,12861,,Autocuration,1,,B,,,,,
2803,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,BAO_0000019,CHEMBL617655,14093,,Autocuration,1,,F,,,,,
2804,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL617656,14970,,Expert,1,,B,,,,,
2805,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL617657,14970,,Autocuration,1,,B,,,,,
2806,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,BAO_0000357,CHEMBL617658,14970,,Autocuration,1,,B,,,,,
2807,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617659,14178,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2808,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617838,14178,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2809,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,BAO_0000249,CHEMBL617839,14229,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2810,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,BAO_0000357,CHEMBL617840,16532,,Autocuration,1,,B,,,,,
2811,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,BAO_0000019,CHEMBL617841,14826,,Autocuration,1,,B,,,,,
2812,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,BAO_0000019,CHEMBL875915,17211,,Autocuration,1,,B,,,,,
2813,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,BAO_0000219,CHEMBL617842,17211,,Expert,1,,B,In vitro,,,,
2814,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,BAO_0000219,CHEMBL617843,13246,,Expert,1,723.0,B,,,,,NIH3T3
2815,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,BAO_0000357,CHEMBL617844,13246,,Expert,1,,B,,,,,
2816,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617845,12457,,Expert,1,,B,,,,,
2817,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,BAO_0000219,CHEMBL617846,12457,,Expert,1,723.0,B,,,,,NIH3T3
2818,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,CHEMBL617847,4707,,Autocuration,1,,B,,,,,
2819,,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617848,13297,,Expert,1,,B,,,,,
2820,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,CHEMBL617849,16633,,Autocuration,1,,B,,,,,
2821,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL621507,16133,,Expert,1,,B,,,,,
2822,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,BAO_0000357,CHEMBL621508,16326,,Expert,1,,B,,,,,
2823,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,BAO_0000019,CHEMBL621509,14423,,Autocuration,1,,B,,,,,
2824,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,BAO_0000019,CHEMBL621510,15412,,Autocuration,1,,B,,,,,
2825,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,BAO_0000019,CHEMBL621511,15412,,Autocuration,1,,B,,,,,
2826,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,BAO_0000219,CHEMBL621512,15558,,Expert,1,625.0,B,,,,,A9
2827,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,CHEMBL621513,16633,,Autocuration,1,,B,,,,,
2828,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,BAO_0000357,CHEMBL621514,6013,,Expert,1,,B,,,,,
2829,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,BAO_0000219,CHEMBL621515,17175,,Expert,1,,B,In vitro,,,,
2830,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,BAO_0000219,CHEMBL621516,12469,,Autocuration,1,,B,,,,,
2831,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,BAO_0000019,CHEMBL621517,3682,,Autocuration,1,,B,,,,Caudate-putamen,
2832,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,BAO_0000357,CHEMBL621518,4932,,Autocuration,1,,B,,,,,
2833,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,BAO_0000019,CHEMBL621519,4932,,Autocuration,1,,B,,,,,
2834,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL621520,3935,,Autocuration,1,,B,,,,,
2835,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL621521,15818,,Autocuration,1,,B,,,,,
2836,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL621522,15818,,Autocuration,1,,B,,,,,
2837,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,BAO_0000219,CHEMBL621523,14749,,Expert,1,,B,,,,,
2838,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL621524,15740,,Autocuration,1,,B,,,,,
2839,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,BAO_0000357,CHEMBL621525,17133,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2840,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,BAO_0000357,CHEMBL872921,16532,,Autocuration,1,,B,,,,,
2841,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL621526,12369,,Autocuration,1,,B,,,,,
2842,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,BAO_0000219,CHEMBL621527,12369,,Expert,1,,B,,,,,
2843,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,CHEMBL617865,2309,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2844,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617866,12953,,Autocuration,1,,B,,,,,
2845,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,BAO_0000019,CHEMBL617867,12953,,Autocuration,1,,B,,,,,
2846,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,BAO_0000357,CHEMBL617487,12953,,Autocuration,1,,B,,,,,
2847,,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617488,12953,,Expert,1,,B,,,,,
2848,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,BAO_0000357,CHEMBL617489,17133,,Autocuration,1,,B,,,,,
2849,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,BAO_0000019,CHEMBL617490,17211,,Autocuration,1,,B,,,,,
2850,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,BAO_0000019,CHEMBL617491,17211,,Autocuration,1,,B,,,,,
2851,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,BAO_0000019,CHEMBL617492,14025,,Autocuration,1,,B,,,,,
2852,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,BAO_0000019,CHEMBL617493,14998,,Autocuration,1,,B,,,,,
2853,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,CHEMBL617494,4342,,Autocuration,1,,B,,,,,
2854,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,BAO_0000019,CHEMBL617495,13735,10116.0,Expert,1,,B,,Rattus norvegicus,,,
2855,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL617496,13181,,Autocuration,1,,B,,,,,
2856,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,BAO_0000219,CHEMBL617497,1883,,Autocuration,1,485.0,B,,,,,CHO-K1
2857,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL617498,15194,,Autocuration,1,,B,,,,,
2858,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,BAO_0000357,CHEMBL617499,15194,,Autocuration,1,,B,,,,,
2859,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,BAO_0000019,CHEMBL617500,14579,,Autocuration,1,,F,,,,,
2860,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617501,4639,,Autocuration,1,,B,,,,,
2861,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617502,4820,,Expert,1,,B,,,,,
2862,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,BAO_0000357,CHEMBL617503,14442,,Autocuration,1,,B,,,,,
2863,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,BAO_0000357,CHEMBL617504,14755,,Autocuration,1,,B,,,,,
2864,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,BAO_0000357,CHEMBL617406,14744,,Autocuration,1,,B,,,,,
2865,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,BAO_0000019,CHEMBL617407,6857,9606.0,Expert,1,,B,,Homo sapiens,,,
2866,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL617408,16209,,Autocuration,1,,B,,,,,
2867,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617409,15363,,Autocuration,1,,B,,,,,
2868,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617410,15363,,Autocuration,1,,B,,,,,
2869,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617411,15363,,Autocuration,1,,B,,,,,
2870,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,BAO_0000019,CHEMBL617412,17085,,Autocuration,1,,B,,,,,
2871,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,BAO_0000357,CHEMBL617774,17200,9606.0,Expert,1,,B,,Homo sapiens,,,
2872,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,BAO_0000219,CHEMBL617775,15851,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2873,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,BAO_0000219,CHEMBL617776,15851,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2874,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,CHEMBL617777,6857,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
2875,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,CHEMBL617778,6857,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
2876,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL617779,15779,,Autocuration,1,722.0,B,,,,,HEK293
2877,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,BAO_0000219,CHEMBL617780,15851,,Expert,1,722.0,B,,,,,HEK293
2878,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,BAO_0000219,CHEMBL617781,15779,,Autocuration,1,722.0,B,,,,,HEK293
2879,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,BAO_0000219,CHEMBL617782,14157,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2880,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,BAO_0000219,CHEMBL617783,4540,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2881,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,CHEMBL617784,6166,,Autocuration,1,,B,,,,,
2882,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,BAO_0000219,CHEMBL617785,15779,,Autocuration,1,722.0,B,,,,,HEK293
2883,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL857984,14391,,Expert,1,722.0,B,,,,,HEK293
2884,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,BAO_0000219,CHEMBL617786,3832,,Expert,1,722.0,B,,,,,HEK293
2885,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,BAO_0000219,CHEMBL617787,3833,,Expert,1,722.0,B,,,,,HEK293
2886,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,BAO_0000219,CHEMBL617788,15851,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2887,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,BAO_0000219,CHEMBL617789,15851,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
2888,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,BAO_0000219,CHEMBL617790,4199,,Autocuration,1,722.0,B,,,,,HEK293
2889,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,BAO_0000219,CHEMBL617791,1883,,Expert,1,485.0,B,,,,,CHO-K1
2890,,Binding affinity against 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617608,4321,,Expert,1,,B,,,,,
2891,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,BAO_0000219,CHEMBL617609,15146,,Autocuration,1,722.0,B,,,,,HEK293
2892,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,BAO_0000219,CHEMBL617610,5213,,Autocuration,1,722.0,B,,,,,HEK293
2893,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,BAO_0000219,CHEMBL617611,14818,,Autocuration,1,722.0,B,,,,,HEK293
2894,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL617612,4829,,Autocuration,1,722.0,B,,,,,HEK293
2895,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,CHEMBL617613,4829,,Autocuration,1,722.0,B,,,,,HEK293
2896,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,BAO_0000019,CHEMBL617614,14025,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
2897,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,BAO_0000019,CHEMBL617615,13463,,Expert,1,,B,,,,Stomach,
2898,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,BAO_0000357,CHEMBL858114,7259,,Expert,1,,B,,,,Stomach,
2899,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,BAO_0000357,CHEMBL617616,7259,,Autocuration,1,,B,,,,Stomach,
2900,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,BAO_0000019,CHEMBL617617,7185,10116.0,Expert,1,,F,,Rattus norvegicus,,Stomach,
2901,,Antagonistic against 5-hydroxytryptamine 2B receptor,,BAO_0000019,CHEMBL875914,7185,10116.0,Expert,1,,F,,Rattus norvegicus,,,
2902,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,BAO_0000019,CHEMBL617618,13267,,Autocuration,1,,F,,,,Stomach,
2903,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,BAO_0000357,CHEMBL617619,13735,10116.0,Expert,1,,B,,Rattus norvegicus,,Stomach,
2904,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,BAO_0000019,CHEMBL617620,15738,,Autocuration,1,,F,,,,,
2905,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,BAO_0000019,CHEMBL617621,15738,,Autocuration,1,,F,,,,,
2906,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,BAO_0000019,CHEMBL617622,15738,,Autocuration,1,,F,,,,,
2907,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617623,12936,10116.0,Expert,1,,B,,Rattus norvegicus,,Stomach,
2908,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617624,12936,10116.0,Expert,1,,B,,Rattus norvegicus,,Stomach,
2909,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617625,12936,10116.0,Expert,1,,B,,Rattus norvegicus,,Stomach,
2910,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617626,12936,10116.0,Expert,1,,B,,Rattus norvegicus,,Stomach,
2911,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,CHEMBL617627,16404,,Autocuration,1,,F,,,,Stomach,
2912,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,CHEMBL617628,16404,,Expert,1,,F,,,,Stomach,
2913,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,BAO_0000019,CHEMBL617629,16404,,Autocuration,1,,F,,,,Stomach,
2914,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,BAO_0000019,CHEMBL858115,16404,,Autocuration,1,,F,,,,Stomach,
2915,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,BAO_0000019,CHEMBL617630,16404,10116.0,Expert,1,,F,,Rattus norvegicus,,Stomach,
2916,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,BAO_0000019,CHEMBL617631,16404,,Autocuration,1,,F,,,,Thoracic aorta,
2917,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,CHEMBL617632,7483,,Autocuration,1,,B,,,,,
2918,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,BAO_0000357,CHEMBL617633,7483,,Expert,1,,B,,,,,
2919,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,CHEMBL617634,7483,,Autocuration,1,,B,,,,,
2920,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,CHEMBL617635,7483,,Autocuration,1,,B,,,,,
2922,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,CHEMBL617637,16404,10116.0,Autocuration,1,,F,,Rattus norvegicus,,Stomach,
2923,,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,CHEMBL617638,6347,,Autocuration,1,,B,,,,,
2924,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,CHEMBL617639,4373,,Autocuration,1,,B,,,,,
2925,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,CHEMBL617640,4373,,Autocuration,1,,B,,,,,
2926,,Evaluated for the binding affinity to 5-HT 2B receptor,,BAO_0000357,CHEMBL617641,4687,,Autocuration,1,,B,,,,,
2927,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617642,16946,,Autocuration,1,,B,,,,,
2928,,Binding affinities against 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617643,16633,,Autocuration,1,,B,,,,,
2929,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,BAO_0000357,CHEMBL617644,16633,,Autocuration,1,,B,,,,,
2930,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,BAO_0000357,CHEMBL617645,16633,,Autocuration,1,,B,,,,,
2931,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,CHEMBL617646,15026,,Expert,1,,B,,,,,
2932,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,CHEMBL617647,15738,9913.0,Autocuration,1,,B,,Bos taurus,,,
2933,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,BAO_0000357,CHEMBL617648,15738,9913.0,Autocuration,1,,B,,Bos taurus,,,
2934,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,BAO_0000357,CHEMBL617875,15738,9913.0,Autocuration,1,,B,,Bos taurus,,,
2935,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,BAO_0000357,CHEMBL617876,15738,9913.0,Autocuration,1,,B,,Bos taurus,,,
2936,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,BAO_0000357,CHEMBL617877,16404,9913.0,Expert,1,,B,,Bos taurus,,,
2937,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,CHEMBL617878,15026,9913.0,Expert,1,,B,,Bos taurus,,,
2938,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,CHEMBL617879,15738,9913.0,Autocuration,1,,B,,Bos taurus,,,
2939,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,BAO_0000019,CHEMBL617880,16312,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
2940,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,BAO_0000357,CHEMBL617881,5486,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
2941,,Binding affinity against 5-HT1A receptor,,BAO_0000357,CHEMBL857073,5254,,Autocuration,1,,B,,,,,
2942,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,BAO_0000219,CHEMBL617882,3857,,Expert,1,449.0,F,,,,,CHO
2943,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,CHEMBL617883,6857,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
2944,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,BAO_0000219,CHEMBL617884,4176,,Autocuration,1,,F,,,,,
2945,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,BAO_0000219,CHEMBL617885,6347,,Autocuration,1,449.0,B,,,,,CHO
2946,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,BAO_0000219,CHEMBL617886,6347,,Autocuration,1,449.0,B,,,,,CHO
2947,,Inhibition of human 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617887,16146,9606.0,Expert,1,,B,,Homo sapiens,,,
2948,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,BAO_0000357,CHEMBL617888,3805,,Autocuration,1,,B,,,,,
2949,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,CHEMBL617889,3857,,Autocuration,1,,B,,,,,
2950,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL617890,5635,,Autocuration,1,,B,,,,,
2951,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,CHEMBL617891,5635,,Autocuration,1,,B,,,,,
2952,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,CHEMBL617892,5635,,Autocuration,1,,B,,,,,
2953,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,BAO_0000219,CHEMBL617893,4012,,Expert,1,449.0,B,,,,,CHO
2954,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,BAO_0000219,CHEMBL617894,6366,,Expert,1,449.0,B,,,,,CHO
2955,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL617895,15949,,Expert,1,449.0,B,,,,,CHO
2956,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,BAO_0000219,CHEMBL617896,17211,,Autocuration,1,449.0,B,,,,,CHO
2957,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,BAO_0000357,CHEMBL617897,6491,9606.0,Expert,1,,B,,Homo sapiens,,,
2958,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,BAO_0000019,CHEMBL617898,14093,,Autocuration,1,,F,,,,,
2959,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000019,CHEMBL617899,13481,,Autocuration,1,,F,,,,,
2960,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,BAO_0000219,CHEMBL617900,6347,10116.0,Expert,1,449.0,B,,Rattus norvegicus,,,CHO
2961,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,BAO_0000019,CHEMBL617901,14093,,Autocuration,1,,F,,,,,
2962,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,BAO_0000019,CHEMBL617902,14093,,Autocuration,1,,F,,,,,
2963,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000019,CHEMBL617903,13481,,Autocuration,1,,F,,,,,
2964,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,BAO_0000357,CHEMBL617904,14442,,Autocuration,1,,B,,,,,
2965,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,BAO_0000357,CHEMBL617905,14442,,Autocuration,1,,B,,,,,
2966,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,BAO_0000357,CHEMBL617906,14442,,Autocuration,1,,B,,,,,
2967,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,BAO_0000357,CHEMBL617907,14755,,Autocuration,1,,B,,,,,
2968,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,BAO_0000357,CHEMBL617908,14744,,Autocuration,1,,B,,,,,
2969,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL620617,16659,,Expert,1,449.0,B,,,,,CHO
2970,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,BAO_0000019,CHEMBL620618,6857,9606.0,Expert,1,,B,,Homo sapiens,,,
2971,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,BAO_0000357,CHEMBL620619,5635,,Expert,1,,B,,,,,
2972,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL620620,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
2973,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,CHEMBL620621,16209,,Autocuration,1,,B,,,,,
2974,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,BAO_0000249,CHEMBL872920,5778,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2975,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,BAO_0000223,CHEMBL620622,5094,,Autocuration,1,,B,,,,,
2976,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,BAO_0000019,CHEMBL620623,809,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2977,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,BAO_0000019,CHEMBL620624,1578,,Autocuration,1,,B,,,,,
2978,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,BAO_0000019,CHEMBL620625,809,,Autocuration,1,,B,,,,,
2979,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,BAO_0000219,CHEMBL620626,12469,,Autocuration,1,,B,,,,,
2980,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,BAO_0000019,CHEMBL621307,14290,,Autocuration,1,,B,,,,,
2981,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,BAO_0000019,CHEMBL621308,14290,,Autocuration,1,,B,,,,,
2982,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,BAO_0000223,CHEMBL621309,10609,,Autocuration,1,,B,,,,,
2983,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,BAO_0000223,CHEMBL621310,10609,,Autocuration,1,,B,,,,,
2984,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,BAO_0000223,CHEMBL621311,10609,,Autocuration,1,,B,,,,,
2985,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,CHEMBL621502,15253,,Autocuration,1,,B,,,,,
2986,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,CHEMBL621503,15253,,Autocuration,1,,B,,,,,
2987,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,BAO_0000249,CHEMBL621504,11683,,Autocuration,1,,B,,,,,
2988,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL621505,12092,,Autocuration,1,,B,,,,,
2989,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,CHEMBL621506,1946,,Autocuration,1,,B,,,,,
2990,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,BAO_0000223,CHEMBL619781,11623,,Autocuration,1,,B,,,,,
2991,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,BAO_0000223,CHEMBL619782,11623,,Autocuration,1,,B,,,,,
2992,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,BAO_0000019,CHEMBL619783,14788,,Autocuration,1,,B,,,,,
2993,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,BAO_0000019,CHEMBL619784,5432,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
2994,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,CHEMBL619785,14826,,Autocuration,1,,B,,,,,
2995,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL619786,2222,,Autocuration,1,,B,,,,,
2996,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,BAO_0000019,CHEMBL619787,11963,,Autocuration,1,,B,,,,,
2997,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,BAO_0000019,CHEMBL872925,14145,,Autocuration,1,,B,,,,,
2998,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,BAO_0000019,CHEMBL619788,17819,,Autocuration,1,,B,,,,,
2999,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,CHEMBL619789,10394,,Autocuration,1,,B,,,,,
3000,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,CHEMBL619790,10394,,Autocuration,1,,B,,,,,
3001,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,CHEMBL619791,15034,,Autocuration,1,,B,,,,,
3002,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,CHEMBL619792,691,,Autocuration,1,,B,,,,,
3003,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,BAO_0000249,CHEMBL619793,12092,,Autocuration,1,,B,,,,,
3004,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL619794,11752,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3005,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,BAO_0000221,CHEMBL619795,11752,,Autocuration,1,,B,,,,Brain,
3006,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,BAO_0000019,CHEMBL619796,301,,Autocuration,1,,B,,,,,
3007,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,BAO_0000223,CHEMBL620448,16532,,Autocuration,1,,B,,,,,
3008,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,CHEMBL620449,16532,,Autocuration,1,,B,,,,,
3009,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,BAO_0000223,CHEMBL620450,12092,,Autocuration,1,,B,,,,,
3010,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,BAO_0000223,CHEMBL620451,11684,,Autocuration,1,,B,,,,,
3011,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,BAO_0000223,CHEMBL620631,11684,,Autocuration,1,,B,,,,,
3012,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,BAO_0000019,CHEMBL620632,12953,,Autocuration,1,,B,,,,,
3013,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,BAO_0000019,CHEMBL620633,12953,,Autocuration,1,,B,,,,,
3014,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,BAO_0000223,CHEMBL620634,12953,,Autocuration,1,,B,,,,,
3015,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,CHEMBL620635,12861,,Autocuration,1,,B,,,,,
3016,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620636,11454,,Autocuration,1,,F,In vivo,,,,
3017,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,CHEMBL620637,11454,,Autocuration,1,,F,In vivo,,,,
3018,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620638,11454,,Autocuration,1,,F,In vivo,,,,
3019,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620639,11454,,Autocuration,1,,F,In vivo,,,,
3020,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620640,11454,,Autocuration,1,,F,In vivo,,,,
3021,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,CHEMBL620641,11454,,Autocuration,1,,F,In vivo,,,,
3022,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620642,11454,,Autocuration,1,,F,In vivo,,,,
3023,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620643,11454,,Autocuration,1,,F,In vivo,,,,
3024,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620644,11454,,Autocuration,1,,F,In vivo,,,,
3025,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620645,11454,,Autocuration,1,,F,In vivo,,,,
3026,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,CHEMBL620646,11454,,Autocuration,1,,F,In vivo,,,,
3027,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620647,11454,,Autocuration,1,,F,In vivo,,,,
3028,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620648,11454,,Autocuration,1,,F,In vivo,,,,
3029,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620649,11454,,Autocuration,1,,F,In vivo,,,,
3030,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL620650,11454,,Autocuration,1,,F,In vivo,,,,
3031,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,CHEMBL620651,11454,,Autocuration,1,,F,In vivo,,,,
3032,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,CHEMBL872875,11454,,Autocuration,1,,F,In vivo,,,,
3033,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,CHEMBL620652,11454,,Autocuration,1,,F,In vivo,,,,
3034,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,BAO_0000019,CHEMBL620653,10609,,Autocuration,1,,F,,,,,
3035,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,BAO_0000019,CHEMBL857076,12861,,Autocuration,1,,B,,,,,
3036,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,CHEMBL620654,12861,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3037,,Binding activity radioligand.,,BAO_0000223,CHEMBL620655,12861,,Autocuration,1,,B,,,,,
3038,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,BAO_0000249,CHEMBL620656,10728,,Autocuration,1,,B,,,,,
3039,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,BAO_0000249,CHEMBL620657,10728,,Autocuration,1,,B,,,,,
3040,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,CHEMBL620658,5163,,Autocuration,1,,B,,,,,
3041,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,CHEMBL620659,5163,,Autocuration,1,,B,,,,,
3042,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,BAO_0000357,CHEMBL620660,6011,,Autocuration,1,,B,,,,,
3043,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL620661,5014,,Autocuration,1,,B,,,,,
3044,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL620662,5635,,Autocuration,1,,B,,,,,
3045,,Affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL620663,5163,,Expert,1,,B,,,,,
3046,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,CHEMBL620664,6841,,Autocuration,1,,B,,,,,
3047,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,BAO_0000357,CHEMBL620665,6119,,Expert,1,,B,,,,,
3048,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,CHEMBL620666,4373,,Autocuration,1,,B,,,,,
3049,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,BAO_0000357,CHEMBL620667,1633,,Autocuration,1,,B,,,,,
3050,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,BAO_0000357,CHEMBL620668,1633,,Expert,1,,B,,,,,
3051,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,CHEMBL620669,4373,,Autocuration,1,,B,,,,,
3052,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL620670,6576,,Expert,1,,B,,,,,
3053,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL620671,4687,,Autocuration,1,,B,,,,,
3054,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,BAO_0000357,CHEMBL620672,12146,,Autocuration,1,,B,,,,,
3055,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,BAO_0000357,CHEMBL620673,12146,,Autocuration,1,,B,,,,,
3056,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL620674,16946,,Autocuration,1,,B,,,,,
3057,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL620675,14159,,Autocuration,1,,B,,,,,
3058,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,BAO_0000357,CHEMBL620676,16700,,Autocuration,1,,B,,,,,
3059,,Affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL621382,3269,,Autocuration,1,,B,,,,,
3060,,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL621383,1274,9606.0,Expert,1,,B,,Homo sapiens,,,
3061,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,BAO_0000357,CHEMBL621384,1317,,Autocuration,1,,B,,,,,
3062,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,BAO_0000357,CHEMBL621385,5834,9913.0,Autocuration,1,,B,,Bos taurus,,,
3063,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,BAO_0000357,CHEMBL617989,11147,9913.0,Autocuration,1,,B,,Bos taurus,,,
3064,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,BAO_0000019,CHEMBL617990,14145,10141.0,Expert,1,,F,,Cavia porcellus,,,
3065,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,BAO_0000221,CHEMBL875085,10561,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3066,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,BAO_0000019,CHEMBL617991,15847,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3067,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,BAO_0000019,CHEMBL617992,15847,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3068,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,BAO_0000221,CHEMBL617993,10561,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3069,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,BAO_0000221,CHEMBL617994,11454,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3070,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,BAO_0000019,CHEMBL617995,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3071,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,BAO_0000019,CHEMBL617996,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3072,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,CHEMBL617997,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3073,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,BAO_0000019,CHEMBL617998,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3074,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,CHEMBL617999,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3075,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,CHEMBL618000,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3076,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,BAO_0000221,CHEMBL617815,15253,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3077,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,BAO_0000221,CHEMBL617816,15253,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3078,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,BAO_0000221,CHEMBL617817,11963,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3079,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,BAO_0000221,CHEMBL617818,1946,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3080,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,BAO_0000221,CHEMBL617819,1946,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3081,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,BAO_0000223,CHEMBL617820,12045,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
3082,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,CHEMBL617821,1559,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3083,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,CHEMBL617822,273,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3084,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,BAO_0000221,CHEMBL617823,273,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3085,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,BAO_0000221,CHEMBL617824,188,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3086,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,BAO_0000221,CHEMBL617825,12919,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3087,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,BAO_0000221,CHEMBL617826,12918,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3088,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,CHEMBL617827,1559,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3089,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,CHEMBL617828,273,10141.0,Autocuration,1,,F,,Cavia porcellus,,Ileum,
3090,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,CHEMBL617829,1559,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3091,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,BAO_0000221,CHEMBL617830,1559,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3092,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,BAO_0000221,CHEMBL617831,1559,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3093,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,BAO_0000221,CHEMBL617832,14424,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3094,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000019,CHEMBL617833,13181,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
3095,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,BAO_0000357,CHEMBL617834,5486,,Autocuration,1,,B,,,,,
3096,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,BAO_0000223,CHEMBL617835,6491,9606.0,Expert,1,,B,,Homo sapiens,,,
3097,,Binding affinity towards 5-HT3 receptor,,BAO_0000223,CHEMBL617836,6013,,Autocuration,1,,B,,,,,
3098,,Binding activity radioligand.,,BAO_0000223,CHEMBL617837,12861,,Autocuration,1,,B,,,,,
3099,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,CHEMBL620392,12861,,Autocuration,1,,B,,,,,
3100,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL620393,5104,,Autocuration,1,,B,,,,,
3101,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL620394,5105,,Autocuration,1,,B,,,,,
3102,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,BAO_0000223,CHEMBL620395,5104,,Autocuration,1,,B,,,,,
3103,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,BAO_0000019,CHEMBL620396,3935,,Autocuration,1,,B,,,,,
3104,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,BAO_0000219,CHEMBL620582,13657,,Expert,1,433.0,B,,,,,NG108-15
3105,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,BAO_0000218,CHEMBL620583,10369,,Autocuration,1,,B,In vivo,,,,
3106,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,CHEMBL620584,10369,,Autocuration,1,,B,,,,,
3107,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,BAO_0000224,CHEMBL620585,12918,,Autocuration,1,,B,,,,,
3108,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,BAO_0000224,CHEMBL620586,12918,,Autocuration,1,,B,,,,,
3109,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,CHEMBL620587,10369,,Autocuration,1,,B,,,,,
3110,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,CHEMBL620588,773,,Autocuration,1,,B,,,,,
3111,,5-hydroxytryptamine 3 receptor agonism in mouse,,BAO_0000218,CHEMBL620589,12918,,Autocuration,1,,F,,,,,
3112,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,BAO_0000219,CHEMBL620590,10561,,Autocuration,1,,B,,,,,
3113,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,CHEMBL617956,12827,,Autocuration,1,,B,,,,,
3114,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,CHEMBL617957,12827,,Autocuration,1,,B,,,,,
3115,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,BAO_0000224,CHEMBL617958,12918,,Autocuration,1,,B,,,,,
3116,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,CHEMBL617959,273,,Autocuration,1,,B,,,,,
3117,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,CHEMBL617960,273,,Autocuration,1,,B,,,,,
3118,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000224,CHEMBL617961,10561,,Autocuration,1,,B,,,,,
3119,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,BAO_0000219,CHEMBL617962,5033,,Autocuration,1,,B,In vitro,,,,
3120,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,BAO_0000219,CHEMBL617963,16429,,Autocuration,1,339.0,B,,,,,N1E-115
3121,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,CHEMBL617964,10322,,Autocuration,1,,B,,,,,
3122,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,BAO_0000219,CHEMBL617965,14331,,Autocuration,1,,B,,,,,
3123,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,BAO_0000357,CHEMBL617966,13462,10090.0,Autocuration,1,,B,,Mus musculus,,,
3124,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,CHEMBL857074,12861,,Autocuration,1,,B,,,,,
3125,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL617967,15086,9823.0,Autocuration,1,,B,,Sus scrofa,,,
3126,,Binding activity radioligand.,,BAO_0000357,CHEMBL617968,12861,9823.0,Autocuration,1,,B,,Sus scrofa,,,
3127,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,BAO_0000223,CHEMBL617969,10561,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
3128,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000223,CHEMBL617970,10561,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
3129,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,BAO_0000223,CHEMBL617971,10561,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
3130,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,CHEMBL617972,10561,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
3131,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,CHEMBL617973,273,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,,
3132,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,CHEMBL617974,273,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,,
3133,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,CHEMBL617975,273,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,Ileum,
3134,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,CHEMBL617976,273,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,,
3135,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,CHEMBL617977,273,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,,
3136,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,CHEMBL617978,273,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,,
3137,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,CHEMBL617979,273,9986.0,Autocuration,1,,F,,Oryctolagus cuniculus,,,
3138,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL617980,13047,9986.0,Autocuration,1,449.0,B,,Oryctolagus cuniculus,,,CHO
3139,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,BAO_0000019,CHEMBL617981,1650,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3140,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,BAO_0000019,CHEMBL617982,16288,,Autocuration,1,,B,,,,,
3141,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,BAO_0000357,CHEMBL617983,16288,,Autocuration,1,,B,,,,,
3142,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,BAO_0000019,CHEMBL617984,10254,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3143,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,BAO_0000019,CHEMBL617985,14532,,Autocuration,1,,B,,,,,
3144,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,BAO_0000218,CHEMBL617986,13392,,Autocuration,1,,F,In vivo,,,Heart,
3145,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,BAO_0000019,CHEMBL617987,13392,,Autocuration,1,,F,,,,Heart,
3146,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,BAO_0000019,CHEMBL617988,13392,,Autocuration,1,,F,,,,Heart,
3147,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,BAO_0000019,CHEMBL617792,13392,,Autocuration,1,,F,,,,Heart,
3148,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,BAO_0000019,CHEMBL617793,13392,,Autocuration,1,,F,,,,Heart,
3149,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,CHEMBL617794,13392,,Autocuration,1,,F,,,,,
3150,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,CHEMBL617795,13392,,Autocuration,1,,F,,,,,
3151,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,CHEMBL617796,13392,,Autocuration,1,,F,,,,,
3152,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,CHEMBL617797,13392,,Autocuration,1,,F,,,,,
3153,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000218,CHEMBL617798,1089,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
3154,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,BAO_0000218,CHEMBL617799,1089,,Autocuration,1,,F,In vivo,,,,
3155,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617800,11454,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
3156,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,BAO_0000019,CHEMBL617801,11454,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
3157,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,BAO_0000218,CHEMBL617802,12205,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
3158,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000019,CHEMBL617803,1089,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
3159,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,CHEMBL617804,5094,,Autocuration,1,,B,,,,,
3160,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,BAO_0000019,CHEMBL617805,2622,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3161,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL617806,245,,Autocuration,1,,B,,,,,
3162,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,BAO_0000019,CHEMBL617807,14788,,Autocuration,1,,B,,,,,
3163,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,BAO_0000019,CHEMBL617808,14788,,Autocuration,1,,B,,,,,
3164,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,BAO_0000249,CHEMBL617809,3020,,Autocuration,1,,B,,,,,
3165,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,BAO_0000019,CHEMBL617810,1742,,Autocuration,1,,B,,,,,
3166,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,BAO_0000249,CHEMBL617811,17394,,Autocuration,1,,B,,,,Brain,
3167,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,BAO_0000221,CHEMBL617812,17394,,Autocuration,1,,B,,,,Brain,
3168,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,CHEMBL617813,17394,,Autocuration,1,,B,,,,,
3169,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,CHEMBL617814,14286,,Autocuration,1,,B,,,,,
3170,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,BAO_0000019,CHEMBL617698,14178,,Autocuration,1,,B,,,,,
3171,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,BAO_0000019,CHEMBL617699,14178,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3172,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,BAO_0000019,CHEMBL617700,14178,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3173,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL617701,14178,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3174,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,CHEMBL617702,15034,,Autocuration,1,,B,,,,,
3175,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,BAO_0000249,CHEMBL617703,1089,,Autocuration,1,,B,,,,,
3176,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,BAO_0000019,CHEMBL617704,1089,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3177,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,CHEMBL617705,16532,,Autocuration,1,,B,,,,,
3178,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL617706,12801,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3179,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,BAO_0000219,CHEMBL617707,15194,,Autocuration,1,433.0,B,,,,,NG108-15
3180,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,BAO_0000219,CHEMBL617708,15194,,Autocuration,1,433.0,B,,,,,NG108-15
3181,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,BAO_0000019,CHEMBL617709,15194,,Autocuration,1,,B,,,,,
3182,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,BAO_0000019,CHEMBL617710,15194,,Autocuration,1,,B,,,,,
3183,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,BAO_0000019,CHEMBL882925,15194,,Autocuration,1,,B,,,,,
3184,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,BAO_0000019,CHEMBL617711,15194,,Autocuration,1,,B,,,,,
3185,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,BAO_0000019,CHEMBL617712,10610,,Autocuration,1,,F,,,,,
3186,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,BAO_0000019,CHEMBL617713,10355,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
3187,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,BAO_0000019,CHEMBL617714,691,,Autocuration,1,,F,,,,,
3188,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,BAO_0000218,CHEMBL617715,10611,,Autocuration,1,,F,,,,,
3189,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,BAO_0000218,CHEMBL617716,12801,,Autocuration,1,,F,In vivo,,,,
3190,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,BAO_0000218,CHEMBL617717,10609,,Autocuration,1,,F,,,,,
3191,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617718,11454,,Autocuration,1,,F,In vivo,,,,
3192,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617719,11454,,Autocuration,1,,F,In vivo,,,,
3193,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,BAO_0000218,CHEMBL617720,11454,,Autocuration,1,,F,In vivo,,,,
3194,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617721,11454,10116.0,Autocuration,1,,F,In vivo,Rattus norvegicus,,,
3195,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617722,11454,,Autocuration,1,,F,In vivo,,,,
3196,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,BAO_0000218,CHEMBL617723,11454,,Autocuration,1,,F,In vivo,,,,
3197,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617724,11454,,Autocuration,1,,F,In vivo,,,,
3198,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617725,11454,,Autocuration,1,,F,In vivo,,,,
3199,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617726,11454,,Autocuration,1,,F,In vivo,,,,
3200,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617727,11454,,Autocuration,1,,F,In vivo,,,,
3201,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617728,11454,,Autocuration,1,,F,In vivo,,,,
3202,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617729,11454,,Autocuration,1,,F,In vivo,,,,
3203,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617730,11454,,Autocuration,1,,F,In vivo,,,,
3204,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617731,11454,,Autocuration,1,,F,In vivo,,,,
3205,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617732,11454,,Autocuration,1,,F,In vivo,,,,
3206,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617733,11454,,Autocuration,1,,F,In vivo,,,,
3207,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617734,11454,,Autocuration,1,,F,In vivo,,,,
3208,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,BAO_0000218,CHEMBL872874,11454,,Autocuration,1,,F,In vivo,,,,
3209,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,BAO_0000218,CHEMBL617735,11454,,Autocuration,1,,F,In vivo,,,,
3210,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,BAO_0000218,CHEMBL617736,11454,,Autocuration,1,,F,In vivo,,,,
3211,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,BAO_0000218,CHEMBL617737,11454,,Autocuration,1,,F,In vivo,,,,
3212,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,BAO_0000218,CHEMBL617738,11454,,Autocuration,1,,F,In vivo,,,,
3213,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617739,11454,,Autocuration,1,,F,In vivo,,,,
3214,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617740,11454,,Autocuration,1,,F,In vivo,,,,
3215,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617741,11454,,Autocuration,1,,F,In vivo,,,,
3216,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617742,11454,,Autocuration,1,,F,In vivo,,,,
3217,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617743,11454,,Autocuration,1,,F,In vivo,,,,
3218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617744,11454,,Autocuration,1,,F,In vivo,,,,
3219,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,CHEMBL617745,11454,,Autocuration,1,,F,In vivo,,,,
3220,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,BAO_0000218,CHEMBL617746,670,,Autocuration,1,,F,,,,,
3221,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,BAO_0000218,CHEMBL617747,670,,Autocuration,1,,F,,,,,
3222,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,BAO_0000218,CHEMBL617748,10321,,Autocuration,1,,F,In vivo,,,,
3223,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,BAO_0000218,CHEMBL618909,10321,,Autocuration,1,,F,In vivo,,,,
3224,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,BAO_0000218,CHEMBL618910,10321,,Autocuration,1,,F,In vivo,,,,
3225,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,BAO_0000218,CHEMBL618911,10321,,Autocuration,1,,F,In vivo,,,,
3226,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,BAO_0000218,CHEMBL618912,10321,,Autocuration,1,,F,In vivo,,,,
3227,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,BAO_0000218,CHEMBL618913,10322,,Autocuration,1,,F,In vivo,,,,
3228,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,CHEMBL618914,15412,,Autocuration,1,,F,,,,,
3229,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,CHEMBL618915,15412,,Autocuration,1,,F,,,,,
3230,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL618916,15412,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3231,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,BAO_0000019,CHEMBL618917,15412,,Autocuration,1,,F,,,,,
3232,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,BAO_0000221,CHEMBL618918,15412,,Intermediate,1,,B,,,,Hippocampus,
3233,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,BAO_0000019,CHEMBL618919,15412,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3234,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000019,CHEMBL618920,17394,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3235,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL618921,12457,,Autocuration,1,,B,,,,,
3236,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,BAO_0000019,CHEMBL618922,12457,,Autocuration,1,,B,,,,,
3237,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,BAO_0000019,CHEMBL618923,12205,,Autocuration,1,,B,,,,,
3238,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,BAO_0000019,CHEMBL618924,14532,,Autocuration,1,,B,,,,,
3239,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,BAO_0000019,CHEMBL618925,1122,,Autocuration,1,,B,,,,,
3240,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,CHEMBL618926,5094,,Autocuration,1,,B,,,,,
3241,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,BAO_0000221,CHEMBL618927,809,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3242,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,BAO_0000221,CHEMBL618928,809,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3243,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,BAO_0000221,CHEMBL618929,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3244,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,BAO_0000221,CHEMBL618930,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3245,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,BAO_0000221,CHEMBL618931,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3246,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,BAO_0000221,CHEMBL619594,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3247,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,BAO_0000221,CHEMBL619595,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3248,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,BAO_0000221,CHEMBL619596,13961,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3249,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,BAO_0000221,CHEMBL619755,13961,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3250,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,BAO_0000221,CHEMBL619756,809,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3251,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,BAO_0000221,CHEMBL619757,809,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3252,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,BAO_0000221,CHEMBL619758,809,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3253,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,BAO_0000221,CHEMBL619759,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3254,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,BAO_0000221,CHEMBL619760,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3255,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,BAO_0000221,CHEMBL619761,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3256,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,BAO_0000221,CHEMBL619762,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3257,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,BAO_0000221,CHEMBL619763,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3258,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,BAO_0000221,CHEMBL617868,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3259,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,BAO_0000357,CHEMBL617869,15034,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3260,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,CHEMBL882926,5094,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3261,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,CHEMBL617870,5094,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3262,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,BAO_0000357,CHEMBL617871,5399,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3263,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,BAO_0000357,CHEMBL617872,17394,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3264,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,BAO_0000357,CHEMBL617873,17394,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3265,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,BAO_0000357,CHEMBL617874,17394,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3266,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,BAO_0000221,CHEMBL619067,13961,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3267,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,BAO_0000221,CHEMBL619068,13961,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3268,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,BAO_0000221,CHEMBL619069,13961,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3269,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,BAO_0000357,CHEMBL619070,16946,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3270,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,BAO_0000357,CHEMBL619071,16946,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3271,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,CHEMBL619072,15034,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
3272,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,BAO_0000019,CHEMBL619073,15034,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
3273,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,BAO_0000019,CHEMBL619074,12918,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
3274,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL619075,16946,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3275,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL619076,17394,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3276,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,BAO_0000357,CHEMBL619077,15034,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3277,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,CHEMBL619078,5094,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3278,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,CHEMBL619079,5094,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3279,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,BAO_0000221,CHEMBL619080,17358,10141.0,Intermediate,1,,B,,Cavia porcellus,,Ileum,
3280,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,BAO_0000357,CHEMBL619081,12953,10141.0,Expert,1,,B,,Cavia porcellus,,,
3281,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,CHEMBL619082,12953,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3282,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,BAO_0000357,CHEMBL619083,12953,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3283,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,CHEMBL619084,12953,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3284,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,CHEMBL859397,273,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3285,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,BAO_0000221,CHEMBL619085,12918,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3286,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,BAO_0000221,CHEMBL619086,12919,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3287,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,BAO_0000221,CHEMBL619087,273,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3288,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,CHEMBL619088,273,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3289,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,BAO_0000357,CHEMBL619089,13181,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3290,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL619090,13181,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
3291,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,CHEMBL619091,15034,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
3292,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL619092,5033,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3293,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,BAO_0000019,CHEMBL619093,1980,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3294,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,BAO_0000219,CHEMBL619094,13181,10141.0,Autocuration,1,722.0,B,,Cavia porcellus,,,HEK293
3295,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,BAO_0000019,CHEMBL619095,14287,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3296,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,BAO_0000357,CHEMBL857988,1317,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3297,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,BAO_0000357,CHEMBL619096,15316,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3298,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,BAO_0000357,CHEMBL619097,16429,10141.0,Intermediate,1,,B,,Cavia porcellus,,Striatum,
3299,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,BAO_0000221,CHEMBL619098,14818,10141.0,Intermediate,1,,B,,Cavia porcellus,,Hippocampus,
3300,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,BAO_0000357,CHEMBL619751,15194,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3301,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,BAO_0000357,CHEMBL619752,15194,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3302,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,BAO_0000221,CHEMBL875096,13961,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3303,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,BAO_0000357,CHEMBL619004,5486,,Autocuration,1,,B,,,,,
3304,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL619005,16209,,Autocuration,1,,B,,,,,
3305,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,BAO_0000019,CHEMBL619006,17085,,Autocuration,1,,B,,,,,
3306,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,BAO_0000219,CHEMBL619007,4199,,Autocuration,1,308.0,B,,,,,HeLa
3307,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL619008,15146,,Autocuration,1,,B,,,,,
3308,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL619009,5213,,Autocuration,1,,B,,,,,
3309,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,BAO_0000219,CHEMBL619010,4829,,Autocuration,1,308.0,B,,,,,HeLa
3310,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,BAO_0000357,CHEMBL619011,17358,,Autocuration,1,,B,,,,,
3311,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,BAO_0000357,CHEMBL619012,17358,,Autocuration,1,,B,,,,,
3312,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,BAO_0000219,CHEMBL619013,16946,,Autocuration,1,,B,,,,,
3313,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,BAO_0000357,CHEMBL619014,17358,,Autocuration,1,,B,,,,,
3314,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,BAO_0000019,CHEMBL857503,268,,Autocuration,1,,F,,,,Cardiac atrium,
3315,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,BAO_0000019,CHEMBL619015,268,,Autocuration,1,,F,,,,Cardiac atrium,
3316,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL619016,15086,,Autocuration,1,,B,,,,,
3317,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,BAO_0000221,CHEMBL619017,14875,,Autocuration,1,,B,,,,Hippocampus,
3318,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,BAO_0000221,CHEMBL619018,13267,9823.0,Autocuration,1,,B,,Sus scrofa,,Hippocampus,
3319,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,BAO_0000019,CHEMBL619019,13047,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
3320,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL619020,1650,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3321,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000019,CHEMBL619021,567,,Autocuration,1,,F,,,,,
3322,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,BAO_0000357,CHEMBL619022,17358,,Autocuration,1,,B,,,,,
3323,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,BAO_0000357,CHEMBL619023,188,,Autocuration,1,,B,,,,,
3324,,lntrinsic activity relative to 5-HT receptor,,BAO_0000019,CHEMBL619024,670,,Autocuration,1,,F,,,,,
3325,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,BAO_0000019,CHEMBL619025,204,,Autocuration,1,,F,,,,,
3326,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,BAO_0000019,CHEMBL619026,1946,,Expert,1,,F,,,,,
3327,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,BAO_0000019,CHEMBL619027,6398,,Autocuration,1,,F,,,,,
3328,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,BAO_0000019,CHEMBL619028,6398,,Autocuration,1,,F,,,,,
3329,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,BAO_0000019,CHEMBL619029,17358,,Autocuration,1,,F,,,,,
3330,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,BAO_0000019,CHEMBL619030,6398,,Autocuration,1,,F,,,,,
3331,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,BAO_0000357,CHEMBL619031,11752,,Expert,1,,B,,,,,
3332,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,BAO_0000019,CHEMBL619032,809,,Autocuration,1,,F,,,,,
3333,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL619033,14178,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3334,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000357,CHEMBL619034,567,,Autocuration,1,,B,,,,,
3335,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,BAO_0000357,CHEMBL619035,1946,,Autocuration,1,,B,,,,,
3336,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,BAO_0000357,CHEMBL619036,1946,,Autocuration,1,,B,,,,,
3337,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,BAO_0000019,CHEMBL619037,13961,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3338,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,BAO_0000249,CHEMBL619038,6238,,Autocuration,1,,B,,,,Striatum,
3339,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,BAO_0000249,CHEMBL619039,14290,,Autocuration,1,,B,,,,,
3340,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,BAO_0000249,CHEMBL619040,14290,,Expert,1,,B,,,,,
3341,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,BAO_0000019,CHEMBL619041,809,10116.0,Expert,1,,B,,Rattus norvegicus,,Striatum,
3342,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,BAO_0000019,CHEMBL619042,1578,,Autocuration,1,,B,,,,Striatum,
3343,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,BAO_0000249,CHEMBL619043,16709,,Expert,1,,B,,,,Striatum,
3344,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,BAO_0000019,CHEMBL619044,1946,,Expert,1,,B,,,,Striatum,
3345,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,BAO_0000249,CHEMBL619045,15253,,Expert,1,,B,,,,Striatum,
3346,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,BAO_0000249,CHEMBL619046,4535,,Expert,1,,B,,,,Striatum,
3347,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,BAO_0000249,CHEMBL619047,13961,,Expert,1,,B,,,,,
3348,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,BAO_0000221,CHEMBL619048,17358,,Autocuration,1,,F,,,,Brain,
3349,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,BAO_0000019,CHEMBL859398,15847,,Autocuration,1,,F,,,,,
3350,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,BAO_0000019,CHEMBL619049,15847,,Autocuration,1,,F,,,,,
3351,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,BAO_0000019,CHEMBL857886,670,,Autocuration,1,,F,,,,,
3352,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,BAO_0000019,CHEMBL619050,670,,Autocuration,1,,F,,,,,
3353,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,CHEMBL620591,1317,,Autocuration,1,,F,,,,,
3354,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL620592,12936,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3355,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,BAO_0000249,CHEMBL620593,4535,,Expert,1,,B,,,,Striatum,
3356,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,BAO_0000019,CHEMBL620594,14424,10116.0,Expert,1,,F,,Rattus norvegicus,,,
3357,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,BAO_0000019,CHEMBL875079,14424,,Expert,1,,F,,,,,
3358,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,CHEMBL620595,14424,,Expert,1,,F,,,,,
3359,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,BAO_0000019,CHEMBL620596,14424,10116.0,Expert,1,,F,,Rattus norvegicus,,,
3360,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,BAO_0000019,CHEMBL620597,14424,,Autocuration,1,,F,,,,,
3361,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,BAO_0000019,CHEMBL620598,14424,,Expert,1,,F,,,,,
3362,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,BAO_0000218,CHEMBL620599,14424,,Expert,1,,F,,,,,
3363,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,CHEMBL620600,14424,,Autocuration,1,,F,,,,,
3364,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,BAO_0000019,CHEMBL620601,1980,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
3365,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,BAO_0000019,CHEMBL620602,4639,,Autocuration,1,,F,,,,,
3366,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL620603,17358,,Autocuration,1,,B,,,,,
3367,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,BAO_0000357,CHEMBL620604,17358,,Autocuration,1,,B,,,,,
3368,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,BAO_0000357,CHEMBL620605,17358,,Autocuration,1,,B,,,,,
3369,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL620606,1558,,Autocuration,1,,B,,,,,
3370,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,CHEMBL620607,17358,,Autocuration,1,,F,,,,,
3371,,In vitro binding affinity towards 5-HT4 receptor was determined,,BAO_0000357,CHEMBL620608,16117,,Autocuration,1,,B,,,,,
3372,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,CHEMBL620609,17358,,Autocuration,1,,F,,,,,
3373,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,CHEMBL620610,17358,,Autocuration,1,,F,,,,,
3374,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL620611,17358,,Autocuration,1,,B,,,,,
3375,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,BAO_0000357,CHEMBL620612,17358,,Autocuration,1,,B,,,,,
3376,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,BAO_0000357,CHEMBL620613,17358,,Autocuration,1,,B,,,,,
3377,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,BAO_0000357,CHEMBL620614,17358,,Autocuration,1,,B,,,,,
3378,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL620615,1274,,Expert,1,,B,,,,,
3379,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,BAO_0000249,CHEMBL857075,10728,,Autocuration,1,,B,,,,,
3380,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,BAO_0000249,CHEMBL620616,11695,,Autocuration,1,,B,,,,,
3381,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,BAO_0000249,CHEMBL619411,11695,,Autocuration,1,,B,,,,,
3382,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,BAO_0000019,CHEMBL619412,12490,,Autocuration,1,,B,,,,,
3383,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,CHEMBL619413,11828,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3384,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,BAO_0000221,CHEMBL619414,12253,,Autocuration,1,,B,,,,Hippocampus,
3385,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,CHEMBL619415,10561,,Autocuration,1,,B,,,,,
3386,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,BAO_0000019,CHEMBL619416,10561,,Autocuration,1,,B,,,,,
3387,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,BAO_0000019,CHEMBL619417,14432,,Autocuration,1,,F,,,,,
3388,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL619418,12936,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3389,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL619419,1274,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3390,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,BAO_0000019,CHEMBL619420,1980,,Autocuration,1,,B,,,,,
3391,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,BAO_0000249,CHEMBL619421,670,,Autocuration,1,,B,,,,,
3392,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,BAO_0000019,CHEMBL619422,968,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3393,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,BAO_0000019,CHEMBL619423,14287,,Autocuration,1,,B,,,,,
3394,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,BAO_0000019,CHEMBL875080,567,,Autocuration,1,,B,,,,,
3395,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,CHEMBL619424,13267,,Autocuration,1,,B,,,,,
3396,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,BAO_0000249,CHEMBL619425,14826,,Autocuration,1,,B,,,,,
3397,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,BAO_0000223,CHEMBL619426,15194,,Autocuration,1,,B,,,,,
3398,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,BAO_0000223,CHEMBL619427,15194,,Autocuration,1,,B,,,,,
3399,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL619645,10394,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3400,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,BAO_0000249,CHEMBL619646,13657,,Expert,1,,B,,,,,
3401,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,BAO_0000221,CHEMBL619647,1879,,Autocuration,1,,F,,,,Brain,
3402,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,BAO_0000019,CHEMBL619648,1879,,Autocuration,1,,F,,,,,
3403,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,BAO_0000019,CHEMBL619165,1879,,Autocuration,1,,F,,,,,
3404,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,BAO_0000218,CHEMBL620719,204,,Autocuration,1,,F,In vivo,,,,
3405,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,CHEMBL872924,1879,,Autocuration,1,,B,,,,,
3406,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL620720,1879,,Autocuration,1,,B,,,,,
3407,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,CHEMBL620721,1879,,Autocuration,1,,B,,,,,
3408,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,BAO_0000019,CHEMBL620722,1879,,Autocuration,1,,B,,,,,
3409,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,BAO_0000019,CHEMBL620723,10641,,Autocuration,1,,B,,,,,
3410,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,CHEMBL620724,773,,Autocuration,1,,B,,,,,
3411,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,BAO_0000249,CHEMBL620725,11952,,Autocuration,1,,B,,,,,
3412,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,BAO_0000019,CHEMBL620726,14145,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
3413,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL620727,17066,,Expert,1,,B,,,,,
3414,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,BAO_0000223,CHEMBL620728,6398,,Autocuration,1,,B,,,,,
3415,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,CHEMBL620729,10321,,Autocuration,1,,B,,,,,
3416,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,BAO_0000019,CHEMBL858288,511,,Autocuration,1,,F,,,,,
3417,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL620730,4639,,Autocuration,1,,B,,,,,
3418,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL620731,4639,,Autocuration,1,,B,,,,,
3419,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,BAO_0000019,CHEMBL620732,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3420,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,CHEMBL618042,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3421,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,BAO_0000019,CHEMBL618043,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3422,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL618044,1558,,Autocuration,1,,B,,,,,
3423,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,BAO_0000019,CHEMBL618045,268,,Autocuration,1,,F,,,,,
3424,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,BAO_0000223,CHEMBL618046,2474,,Autocuration,1,,B,,,,,
3425,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,BAO_0000019,CHEMBL618047,5067,,Autocuration,1,,F,,,,,
3426,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,BAO_0000019,CHEMBL875084,5067,,Autocuration,1,,F,,,,,
3427,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,BAO_0000019,CHEMBL618048,5067,,Autocuration,1,,F,,,,,
3428,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,BAO_0000223,CHEMBL618049,5067,,Autocuration,1,,B,,,,,
3429,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,BAO_0000019,CHEMBL619764,5067,,Autocuration,1,,F,,,,,
3430,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,BAO_0000019,CHEMBL619765,5067,,Autocuration,1,,F,,,,,
3431,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,BAO_0000019,CHEMBL619766,5067,,Autocuration,1,,F,,,,,
3432,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,BAO_0000223,CHEMBL619767,5067,,Autocuration,1,,B,,,,,
3433,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,BAO_0000223,CHEMBL619768,5067,,Autocuration,1,,B,,,,,
3434,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,BAO_0000019,CHEMBL619769,5067,,Autocuration,1,,F,,,,,
3435,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,BAO_0000223,CHEMBL619770,5067,,Autocuration,1,,B,,,,,
3436,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL619771,5067,,Autocuration,1,,B,,,,,
3437,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,BAO_0000219,CHEMBL619772,14331,,Autocuration,1,,B,,,,,
3438,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,BAO_0000223,CHEMBL619773,5067,,Autocuration,1,,B,,,,,
3439,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,BAO_0000219,CHEMBL619774,6179,,Autocuration,1,433.0,B,,,,,NG108-15
3440,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,BAO_0000019,CHEMBL875083,4265,,Autocuration,1,,B,,,,,
3441,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,BAO_0000219,CHEMBL620718,4265,,Autocuration,1,433.0,B,,,,,NG108-15
3442,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,CHEMBL618127,17358,,Autocuration,1,,B,,,,,
3443,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,CHEMBL618128,17358,,Autocuration,1,,B,,,,,
3444,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,BAO_0000219,CHEMBL618129,13628,,Autocuration,1,,B,In vitro,,,,
3445,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000223,CHEMBL618130,4612,,Autocuration,1,,B,,,,,
3446,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,BAO_0000019,CHEMBL618131,17358,,Autocuration,1,,F,,,,,
3447,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,BAO_0000019,CHEMBL618132,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3448,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,BAO_0000019,CHEMBL618133,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3449,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,BAO_0000019,CHEMBL618134,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3450,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,CHEMBL618135,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3451,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,BAO_0000223,CHEMBL618136,511,,Autocuration,1,,B,,,,,
3452,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL618137,1479,,Autocuration,1,,B,,,,,
3453,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,BAO_0000223,CHEMBL618138,1317,,Autocuration,1,,B,,,,,
3454,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,BAO_0000223,CHEMBL618139,12146,,Autocuration,1,,B,,,,,
3455,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,BAO_0000223,CHEMBL618140,12146,,Autocuration,1,,B,,,,,
3456,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,BAO_0000223,CHEMBL618141,13969,,Autocuration,1,,B,,,,,
3457,,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,CHEMBL873478,13392,,Expert,1,,B,,,,,
3458,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL618142,13392,,Autocuration,1,,B,,,,,
3459,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL618143,14159,,Autocuration,1,,B,,,,,
3460,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL618144,1558,,Autocuration,1,,B,,,,,
3461,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL618145,16655,,Autocuration,1,,B,,,,,
3462,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,CHEMBL618146,13020,,Autocuration,1,,B,,,,,
3463,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,BAO_0000223,CHEMBL618147,13021,,Autocuration,1,,B,,,,,
3464,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,CHEMBL618148,13020,,Autocuration,1,,B,,,,,
3465,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,CHEMBL618149,10321,,Autocuration,1,,B,,,,,
3466,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL872927,15818,,Autocuration,1,,B,,,,,
3467,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL618150,15818,,Autocuration,1,,B,,,,,
3468,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000357,CHEMBL618151,17358,,Autocuration,1,,B,,,,,
3469,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000357,CHEMBL875094,2222,,Autocuration,1,,B,,,,,
3470,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,CHEMBL618152,10322,,Autocuration,1,,B,,,,,
3471,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000357,CHEMBL618153,16117,,Autocuration,1,,B,,,,,
3472,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,BAO_0000357,CHEMBL618888,17200,,Autocuration,1,,B,,,,,
3473,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,BAO_0000019,CHEMBL618889,17358,,Autocuration,1,,F,,,,,
3474,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,BAO_0000357,CHEMBL618890,16700,,Autocuration,1,,B,,,,,
3475,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,BAO_0000019,CHEMBL618891,1980,,Autocuration,1,,B,,,,,
3476,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,BAO_0000019,CHEMBL619054,1980,,Autocuration,1,,B,,,,,
3477,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,BAO_0000223,CHEMBL619055,12409,,Autocuration,1,,B,,,,,
3478,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,CHEMBL619056,4365,,Autocuration,1,,B,,,,,
3479,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,BAO_0000019,CHEMBL619057,4365,,Autocuration,1,,F,,,,,
3480,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,CHEMBL619058,4365,,Autocuration,1,,B,,,,,
3481,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,BAO_0000219,CHEMBL619059,6769,10116.0,Expert,1,,F,,Rattus norvegicus,,,Oocytes
3482,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,BAO_0000219,CHEMBL619060,6769,10116.0,Expert,1,,F,,Rattus norvegicus,,,Oocytes
3483,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,BAO_0000219,CHEMBL875095,6769,10116.0,Expert,1,,F,,Rattus norvegicus,,,Oocytes
3484,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,BAO_0000221,CHEMBL619061,809,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3485,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,BAO_0000221,CHEMBL619062,809,10141.0,Intermediate,1,,F,,Cavia porcellus,,Ileum,
3486,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,BAO_0000019,CHEMBL619063,14290,10141.0,Intermediate,1,,F,,Cavia porcellus,,,
3487,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,BAO_0000221,CHEMBL619064,17358,10141.0,Intermediate,1,,B,,Cavia porcellus,,Ileum,
3488,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,BAO_0000357,CHEMBL619065,17358,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
3489,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,BAO_0000221,CHEMBL619066,17358,10141.0,Intermediate,1,,B,,Cavia porcellus,,Ileum,
3490,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,BAO_0000221,CHEMBL619775,17386,,Autocuration,1,,B,,,,Ileum,
3491,,Affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619776,3269,,Autocuration,1,,B,,,,,
3492,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,CHEMBL619777,7721,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
3493,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,CHEMBL619778,7721,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
3494,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,BAO_0000221,CHEMBL619779,9117,10141.0,Autocuration,1,,B,,Cavia porcellus,,Ileum,
3495,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,CHEMBL619780,7721,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
3496,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,CHEMBL619166,7721,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
3497,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,CHEMBL619167,15796,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3498,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,CHEMBL619168,15796,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3499,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,BAO_0000219,CHEMBL619169,15650,9606.0,Expert,1,,B,,Homo sapiens,,Cardiac atrium,
3500,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,BAO_0000219,CHEMBL619170,15650,9606.0,Expert,1,,B,,Homo sapiens,,Cardiac atrium,
3501,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,BAO_0000019,CHEMBL619171,6866,9606.0,Autocuration,1,,F,,Homo sapiens,,,
3502,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,BAO_0000219,CHEMBL619172,15650,9606.0,Expert,1,,F,,Homo sapiens,,Cardiac atrium,
3503,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,BAO_0000019,CHEMBL619173,10063,10090.0,Autocuration,1,,B,,Mus musculus,,,
3504,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,BAO_0000019,CHEMBL619174,12665,10090.0,Autocuration,1,,B,,Mus musculus,,,
3505,,5-hydroxytryptamine receptor binding affinity was determined in rats,,BAO_0000019,CHEMBL619175,7504,,Autocuration,1,,B,,,,,
3506,,Binding affinity at rat 5-hydroxytryptamine receptor.,,BAO_0000224,CHEMBL619176,7504,,Autocuration,1,,B,,,,,
3507,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,BAO_0000019,CHEMBL619177,7038,,Autocuration,1,,B,,,,,
3508,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,BAO_0000224,CHEMBL619178,7626,,Autocuration,1,,B,,,,,
3509,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,BAO_0000224,CHEMBL619179,7626,,Autocuration,1,,B,,,,,
3510,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,BAO_0000019,CHEMBL619180,7185,,Autocuration,1,,F,,,,Stomach,
3511,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,BAO_0000019,CHEMBL619181,7185,,Autocuration,1,,F,,,,Stomach,
3512,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,CHEMBL619182,7185,,Autocuration,1,,F,,,,,
3513,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,BAO_0000224,CHEMBL619183,6960,,Autocuration,1,,B,,,,,
3514,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,BAO_0000224,CHEMBL619184,6960,,Autocuration,1,,B,,,,,
3515,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,BAO_0000221,CHEMBL619185,12416,,Autocuration,1,,B,,,,Hippocampus,
3516,,Binding affinity for rat 5-hydroxytryptamine transporter.,,BAO_0000357,CHEMBL619186,15753,,Expert,1,,B,,,,,
3517,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,BAO_0000019,CHEMBL619187,8062,,Autocuration,1,,B,,,,,
3518,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,BAO_0000019,CHEMBL619188,9036,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3519,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,BAO_0000224,CHEMBL619189,15067,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3520,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,BAO_0000019,CHEMBL619190,15753,10116.0,Expert,1,,F,,Rattus norvegicus,,Brain,
3521,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,BAO_0000221,CHEMBL619191,15753,10116.0,Expert,1,,F,,Rattus norvegicus,,Cerebellum,
3522,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,BAO_0000019,CHEMBL619192,15295,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3523,,Percent binding affinity against 5-hydroxytryptamine receptor,,BAO_0000224,CHEMBL619193,6347,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3524,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,BAO_0000019,CHEMBL619194,6763,,Autocuration,1,,B,,,,,
3525,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,BAO_0000224,CHEMBL619195,12092,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3526,,Affinity against 5-hydroxytryptamine receptor was determined,,BAO_0000224,CHEMBL619196,1579,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
3527,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,BAO_0000019,CHEMBL619197,1579,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Stomach,
3528,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,CHEMBL619198,5963,9606.0,Expert,1,,B,In vitro,Homo sapiens,,,
3529,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,CHEMBL875081,5963,9606.0,Expert,1,,B,In vitro,Homo sapiens,,,
3530,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,BAO_0000357,CHEMBL884712,5030,,Autocuration,1,,B,,,,,
3531,,Inhibition of 5-hydroxytryptamine reuptake,,BAO_0000357,CHEMBL884710,15796,,Expert,1,,B,,,,,
3532,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,CHEMBL619199,15413,,Autocuration,1,,F,,,,,
3533,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,BAO_0000019,CHEMBL619200,15413,,Autocuration,1,,F,,,,,
3534,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,BAO_0000019,CHEMBL619201,15413,,Autocuration,1,,F,,,,,
3535,,Tested for 5-hydroxytryptamine receptor uptake,,BAO_0000019,CHEMBL619202,12409,,Autocuration,1,,F,,,,,
3536,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,BAO_0000219,CHEMBL619203,16909,9606.0,Expert,1,449.0,B,,Homo sapiens,,,CHO
3537,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,BAO_0000019,CHEMBL619204,16909,9606.0,Expert,1,,F,,Homo sapiens,,,
3538,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,BAO_0000249,CHEMBL619205,15629,9606.0,Autocuration,1,,B,,Homo sapiens,,,
3539,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,BAO_0000357,CHEMBL619206,15629,,Autocuration,1,,B,,,,,
3540,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,CHEMBL619207,15629,,Expert,1,,B,,,,,
3541,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,BAO_0000019,CHEMBL619208,10034,,Autocuration,1,,F,,,,Striatum,
3542,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,BAO_0000019,CHEMBL619209,10034,,Autocuration,1,,F,,,,Striatum,
3543,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,BAO_0000019,CHEMBL619210,10034,,Autocuration,1,,F,,,,Striatum,
3544,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,BAO_0000019,CHEMBL619211,10034,,Autocuration,1,,F,,,,Striatum,
3545,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,BAO_0000019,CHEMBL619212,10034,,Autocuration,1,,F,,,,Striatum,
3546,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,BAO_0000019,CHEMBL620681,10034,,Autocuration,1,,F,,,,Striatum,
3547,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,BAO_0000019,CHEMBL620682,10034,,Autocuration,1,,F,,,,Striatum,
3548,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,BAO_0000019,CHEMBL620683,10034,,Autocuration,1,,F,,,,Striatum,
3549,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,BAO_0000019,CHEMBL620684,10034,,Autocuration,1,,F,,,,Striatum,
3550,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,BAO_0000019,CHEMBL620685,10034,,Autocuration,1,,F,,,,Striatum,
3551,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,BAO_0000019,CHEMBL620686,10034,,Autocuration,1,,F,,,,Striatum,
3552,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,BAO_0000019,CHEMBL620687,10034,,Autocuration,1,,F,,,,Limbic system,
3553,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,BAO_0000019,CHEMBL620688,10034,,Autocuration,1,,F,,,,Limbic system,
3554,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,BAO_0000019,CHEMBL620689,10034,,Autocuration,1,,F,,,,Limbic system,
3555,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,BAO_0000019,CHEMBL620690,10034,,Autocuration,1,,F,,,,Limbic system,
3556,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,BAO_0000019,CHEMBL620691,10034,,Autocuration,1,,F,,,,Limbic system,
3557,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,BAO_0000019,CHEMBL620692,10034,,Autocuration,1,,F,,,,Limbic system,
3558,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,BAO_0000019,CHEMBL620693,10034,,Autocuration,1,,F,,,,Limbic system,
3559,,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL620694,1274,,Expert,1,,B,,,,,
3560,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,CHEMBL857986,17358,,Autocuration,1,,F,,,,,
3561,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,BAO_0000357,CHEMBL620695,14532,,Autocuration,1,,B,,,,,
3562,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL620696,16989,,Expert,1,,B,,,,,
3563,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,BAO_0000357,CHEMBL620697,17200,,Autocuration,1,,B,,,,,
3564,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,CHEMBL620698,15779,,Autocuration,1,,B,,,,,
3565,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,CHEMBL620699,15779,,Autocuration,1,,B,,,,,
3566,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,CHEMBL620700,15779,,Autocuration,1,,B,,,,,
3567,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,BAO_0000219,CHEMBL620701,15650,,Autocuration,1,643.0,B,,,,,COS-7
3568,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,BAO_0000219,CHEMBL875082,15650,,Autocuration,1,643.0,B,,,,,COS-7
3569,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,BAO_0000219,CHEMBL620702,15650,,Autocuration,1,643.0,B,,,,,COS-7
3570,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,BAO_0000219,CHEMBL620703,15650,,Autocuration,1,643.0,B,,,,,COS-7
3571,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,BAO_0000219,CHEMBL620704,17046,,Autocuration,1,673.0,B,,,,,C6
3572,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,BAO_0000219,CHEMBL620705,17046,,Expert,1,673.0,B,,,,,C6
3573,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,BAO_0000219,CHEMBL620706,15650,,Expert,1,673.0,B,,,,,C6
3574,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,BAO_0000219,CHEMBL620707,17046,,Expert,1,673.0,B,,,,,C6
3575,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,BAO_0000357,CHEMBL620708,17066,,Expert,1,,B,,,,,
3576,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,BAO_0000357,CHEMBL620709,17200,,Autocuration,1,,B,,,,,
3577,,Binding affinity against 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL620710,16146,9606.0,Expert,1,,B,,Homo sapiens,,,
3578,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL620711,15250,,Autocuration,1,449.0,B,,,,,CHO
3579,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,BAO_0000357,CHEMBL620712,6491,9606.0,Expert,1,,B,,Homo sapiens,,,
3580,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL620713,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3581,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,BAO_0000357,CHEMBL620714,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3582,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL620715,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
3583,,Binding affinity towards 5-HT5A receptor,,BAO_0000357,CHEMBL620716,6013,,Autocuration,1,,B,,,,,
3584,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,CHEMBL620717,17175,,Expert,1,,B,,,,,
3585,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL618072,15818,,Autocuration,1,,B,,,,,
3586,,Binding affinity towards cloned human 5-HT5A receptor was determined,,BAO_0000357,CHEMBL857987,6166,,Autocuration,1,,B,,,,,
3587,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,CHEMBL618073,15779,,Autocuration,1,722.0,B,,,,,HEK293
3588,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,BAO_0000219,CHEMBL618074,15779,,Autocuration,1,722.0,B,,,,,HEK293
3589,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,BAO_0000219,CHEMBL618075,5213,,Autocuration,1,722.0,B,,,,,HEK293
3590,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL618076,17066,10090.0,Expert,1,,B,,Mus musculus,,,
3591,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,CHEMBL618077,17066,10090.0,Expert,1,,B,,Mus musculus,,,
3592,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,BAO_0000357,CHEMBL618078,17066,10090.0,Expert,1,,B,,Mus musculus,,,
3593,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,BAO_0000357,CHEMBL881821,17066,10090.0,Expert,1,,B,,Mus musculus,,,
3594,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL618079,17066,10090.0,Expert,1,,B,,Mus musculus,,,
3595,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,CHEMBL618080,17175,,Expert,1,,B,,,,,
3596,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,BAO_0000219,CHEMBL618081,16190,,Autocuration,1,722.0,B,,,,,HEK293
3597,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,BAO_0000219,CHEMBL618082,16190,,Autocuration,1,722.0,B,,,,,HEK293
3598,,Binding affinity towards 5-HT5a receptor,,BAO_0000357,CHEMBL618083,4820,,Expert,1,,B,,,,,
3599,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL618084,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3600,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL618085,17066,,Expert,1,,B,,,,,
3601,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,BAO_0000357,CHEMBL618086,17175,,Expert,1,,B,,,,,
3602,,Binding affinities against 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL875092,16633,,Autocuration,1,,B,,,,,
3603,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,CHEMBL618087,16633,,Autocuration,1,,B,,,,,
3604,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,BAO_0000357,CHEMBL872926,16700,,Autocuration,1,,B,,,,,
3605,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,CHEMBL618088,4639,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
3606,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,BAO_0000223,CHEMBL618089,5486,,Autocuration,1,,B,,,,,
3607,,Inhibition of human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL618090,16146,9606.0,Expert,1,,B,,Homo sapiens,,,
3608,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,BAO_0000357,CHEMBL618091,17273,9606.0,Expert,1,,B,,Homo sapiens,,,
3609,,Inhibition against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL618092,17687,,Autocuration,1,,B,,,,,
3610,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,BAO_0000357,CHEMBL618093,6491,9606.0,Expert,1,,B,,Homo sapiens,,,
3611,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,BAO_0000219,CHEMBL618094,16190,,Expert,1,308.0,B,,,,,HeLa
3612,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL618095,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3613,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL875093,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3614,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,CHEMBL618096,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3615,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,BAO_0000357,CHEMBL618118,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3616,,Binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL618119,3555,9606.0,Expert,1,,B,,Homo sapiens,,,
3617,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL618120,5808,,Expert,1,,B,,,,,
3618,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL618121,6013,,Autocuration,1,,B,,,,,
3619,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,BAO_0000219,CHEMBL618122,15818,,Expert,1,722.0,B,,,,,HEK293
3620,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,BAO_0000357,CHEMBL618123,16209,,Autocuration,1,,B,,,,,
3621,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,BAO_0000219,CHEMBL618124,3935,,Expert,1,722.0,B,,,,,HEK293
3622,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL618125,15818,,Autocuration,1,,B,,,,,
3623,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,BAO_0000219,CHEMBL618126,3805,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
3624,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,CHEMBL618236,16441,,Expert,1,,B,,,,,
3625,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,CHEMBL618237,16441,,Expert,1,,B,,,,,
3626,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,BAO_0000219,CHEMBL618238,6786,,Expert,1,643.0,B,,,,,COS-7
3627,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL618239,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
3628,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,BAO_0000019,CHEMBL618240,17085,,Autocuration,1,,B,,,,,
3629,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,BAO_0000357,CHEMBL618241,17200,,Autocuration,1,,B,,,,,
3630,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,BAO_0000219,CHEMBL859399,17451,,Autocuration,1,722.0,B,,,,,HEK293
3631,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,BAO_0000019,CHEMBL618242,3935,,Autocuration,1,,F,,,,,
3632,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL857991,5033,,Autocuration,1,,B,,,,,
3633,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL619951,4540,,Expert,1,,B,,,,,
3634,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,BAO_0000219,CHEMBL619952,4540,9606.0,Expert,1,308.0,B,,Homo sapiens,,,HeLa
3635,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,BAO_0000219,CHEMBL619953,4540,9606.0,Expert,1,308.0,B,,Homo sapiens,,,HeLa
3636,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,BAO_0000219,CHEMBL619954,17296,,Autocuration,1,308.0,B,,,,,HeLa
3637,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,CHEMBL619955,17296,,Autocuration,1,308.0,B,,,,,HeLa
3638,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,CHEMBL619956,17296,,Autocuration,1,308.0,B,,,,,HeLa
3639,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,CHEMBL619957,15779,,Autocuration,1,449.0,B,,,,,CHO
3640,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,CHEMBL619958,15779,,Autocuration,1,722.0,B,,,,,HEK293
3641,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,BAO_0000219,CHEMBL620627,15779,,Autocuration,1,722.0,B,,,,,HEK293
3642,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,BAO_0000219,CHEMBL620628,15779,,Autocuration,1,722.0,B,,,,,HEK293
3643,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,BAO_0000219,CHEMBL620629,15779,,Autocuration,1,308.0,B,,,,,HeLa
3644,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620630,6166,,Autocuration,1,,B,,,,,
3645,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,CHEMBL620782,17451,,Autocuration,1,308.0,B,,,,,HeLa
3646,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620783,15316,,Autocuration,1,,B,,,,,
3647,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620784,4199,,Expert,1,,B,,,,,
3648,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,BAO_0000219,CHEMBL620785,15146,,Expert,1,308.0,B,,,,,HeLa
3649,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,BAO_0000357,CHEMBL857992,5213,,Autocuration,1,,B,,,,,
3650,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,BAO_0000219,CHEMBL620786,16429,,Autocuration,1,,B,,,,,
3651,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,BAO_0000219,CHEMBL620787,14818,,Autocuration,1,308.0,B,,,,,HeLa
3652,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,BAO_0000219,CHEMBL620788,4829,,Autocuration,1,308.0,B,,,,,HeLa
3653,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,BAO_0000219,CHEMBL620789,4829,,Autocuration,1,308.0,B,,,,,HeLa
3654,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,BAO_0000219,CHEMBL620790,4829,,Autocuration,1,308.0,B,,,,,HeLa
3655,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL620791,15250,,Autocuration,1,449.0,B,,,,,CHO
3656,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,BAO_0000019,CHEMBL620792,14423,,Autocuration,1,,B,,,,,
3657,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620793,15086,,Autocuration,1,,B,,,,,
3658,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,CHEMBL620794,4342,,Autocuration,1,,B,,,,,
3659,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,BAO_0000219,CHEMBL620795,16190,9606.0,Autocuration,1,308.0,B,,Homo sapiens,,,HeLa
3660,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620796,4820,,Expert,1,,B,,,,,
3661,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,BAO_0000357,CHEMBL620797,4639,,Autocuration,1,,B,,,,,
3662,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,CHEMBL620798,17066,9606.0,Expert,1,,F,,Homo sapiens,,,
3663,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,BAO_0000357,CHEMBL620799,6011,,Autocuration,1,,B,,,,,
3664,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620800,17066,,Expert,1,,B,,,,,
3665,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,BAO_0000357,CHEMBL620801,17515,,Autocuration,1,,B,,,,,
3666,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL875100,5014,,Autocuration,1,,B,,,,,
3667,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,CHEMBL620802,4373,,Autocuration,1,,B,,,,,
3668,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,BAO_0000019,CHEMBL620803,17066,,Expert,1,,F,,,,,
3669,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,CHEMBL620804,17066,,Expert,1,,F,,,,,
3670,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,CHEMBL620805,4373,,Autocuration,1,,B,,,,,
3671,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620806,4687,,Autocuration,1,,B,,,,,
3672,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,BAO_0000357,CHEMBL620807,16946,,Autocuration,1,,B,,,,,
3673,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,BAO_0000357,CHEMBL620808,16946,,Autocuration,1,,B,,,,,
3674,,Binding affinities against 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620809,16633,,Autocuration,1,,B,,,,,
3675,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620810,16633,,Autocuration,1,,B,,,,,
3676,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620811,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3677,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,BAO_0000357,CHEMBL620812,16700,,Autocuration,1,,B,,,,,
3678,,Affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,CHEMBL620813,3269,,Autocuration,1,,B,,,,,
3679,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,BAO_0000357,CHEMBL620814,5486,,Autocuration,1,,B,,,,,
3680,,Inhibition of human 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620815,16146,9606.0,Expert,1,,B,,Homo sapiens,,,
3681,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,BAO_0000219,CHEMBL620816,5014,,Autocuration,1,722.0,B,,,,,HEK293
3682,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620817,15463,,Autocuration,1,,B,,,,,
3683,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,BAO_0000357,CHEMBL620818,3805,,Autocuration,1,,B,,,,,
3684,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,BAO_0000219,CHEMBL620819,5014,,Expert,1,722.0,B,,,,,HEK293
3685,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,BAO_0000357,CHEMBL620820,6491,9606.0,Expert,1,,B,,Homo sapiens,,,
3686,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,BAO_0000219,CHEMBL620821,16190,,Autocuration,1,449.0,B,,,,,CHO
3687,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620822,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3688,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620823,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3689,,Binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620824,3555,9606.0,Expert,1,,B,,Homo sapiens,,,
3690,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,BAO_0000219,CHEMBL620825,6588,,Expert,1,449.0,B,,,,,CHO
3691,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,BAO_0000357,CHEMBL872930,15463,,Autocuration,1,,B,,,,,
3692,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620826,6013,,Autocuration,1,,B,,,,,
3693,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL620827,16209,,Autocuration,1,,B,,,,,
3694,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620828,3935,,Autocuration,1,,B,,,,,
3695,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620829,15818,,Autocuration,1,,B,,,,,
3696,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,BAO_0000219,CHEMBL620830,5014,,Expert,1,722.0,B,,,,,HEK293
3697,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,CHEMBL620831,16441,,Expert,1,,B,,,,,
3698,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,CHEMBL620832,16441,,Expert,1,,B,,,,,
3699,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL621548,4234,9606.0,Expert,1,,B,,Homo sapiens,,,
3700,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,BAO_0000019,CHEMBL621549,17085,,Autocuration,1,,B,,,,,
3701,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,BAO_0000357,CHEMBL621550,17200,,Autocuration,1,,B,,,,,
3702,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,BAO_0000219,CHEMBL621551,17451,,Autocuration,1,449.0,B,,,,,CHO
3703,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,BAO_0000019,CHEMBL621552,17085,,Autocuration,1,,B,,,,,
3704,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL857077,5104,,Autocuration,1,,B,,,,,
3705,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,BAO_0000357,CHEMBL618158,5104,,Autocuration,1,,B,,,,,
3706,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,BAO_0000219,CHEMBL618159,5033,9606.0,Expert,1,643.0,B,,Homo sapiens,,,COS-7
3707,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,BAO_0000219,CHEMBL875101,5486,,Autocuration,1,643.0,B,,,,,COS-7
3708,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,BAO_0000219,CHEMBL618160,4540,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
3709,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,BAO_0000357,CHEMBL618161,6166,,Expert,1,,B,,,,,
3710,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,BAO_0000219,CHEMBL618162,17342,,Expert,1,722.0,B,,,,,HEK293
3711,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,BAO_0000357,CHEMBL618163,17342,,Expert,1,,B,,,,,
3712,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,BAO_0000357,CHEMBL618164,17296,,Autocuration,1,,B,,,,,
3713,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,BAO_0000219,CHEMBL618165,16429,,Expert,1,,B,,,,,
3714,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,BAO_0000219,CHEMBL618166,15779,,Autocuration,1,722.0,B,,,,,HEK293
3715,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,CHEMBL857989,15779,,Autocuration,1,722.0,B,,,,,HEK293
3716,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,CHEMBL619888,15779,,Autocuration,1,722.0,B,,,,,HEK293
3717,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,CHEMBL619889,15779,,Autocuration,1,722.0,B,,,,,HEK293
3718,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,CHEMBL619890,15779,,Autocuration,1,722.0,B,,,,,HEK293
3719,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,BAO_0000219,CHEMBL619891,17451,,Autocuration,1,449.0,B,,,,,CHO
3720,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,BAO_0000219,CHEMBL619892,4199,,Autocuration,1,722.0,B,,,,,HEK293
3721,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,BAO_0000219,CHEMBL619893,4199,,Expert,1,722.0,B,,,,,HEK293
3722,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,BAO_0000219,CHEMBL619894,4199,,Autocuration,1,722.0,B,,,,,HEK293
3723,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,BAO_0000219,CHEMBL619895,3680,,Intermediate,1,722.0,B,,,,,HEK293
3724,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,BAO_0000357,CHEMBL619896,3680,,Intermediate,1,,B,,,,,
3725,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,BAO_0000219,CHEMBL619897,15316,,Autocuration,1,643.0,B,,,,,COS-7
3726,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,BAO_0000219,CHEMBL619898,15146,,Autocuration,1,722.0,B,,,,,HEK293
3727,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,BAO_0000219,CHEMBL619899,5213,,Expert,1,722.0,B,,,,,HEK293
3728,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,BAO_0000219,CHEMBL619900,5213,,Autocuration,1,722.0,B,,,,,HEK293
3729,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,BAO_0000219,CHEMBL619901,14818,9606.0,Expert,1,722.0,B,,Homo sapiens,,,HEK293
3730,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,BAO_0000219,CHEMBL620580,14818,,Autocuration,1,722.0,B,,,,,HEK293
3731,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,BAO_0000219,CHEMBL620581,14818,,Autocuration,1,722.0,B,,,,,HEK293
3732,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,BAO_0000219,CHEMBL620733,4829,,Autocuration,1,722.0,B,,,,,HEK293
3733,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,BAO_0000357,CHEMBL620734,17200,9606.0,Autocuration,1,,B,,Homo sapiens,,,
3734,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL620735,17066,10090.0,Expert,1,,B,,Mus musculus,,,
3735,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,BAO_0000019,CHEMBL620736,14025,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
3736,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,BAO_0000219,CHEMBL620737,15250,,Autocuration,1,449.0,B,,,,,CHO
3737,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,BAO_0000219,CHEMBL620738,16372,,Autocuration,1,449.0,B,,,,,CHO
3738,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,BAO_0000219,CHEMBL620739,16372,,Autocuration,1,449.0,B,,,,,CHO
3739,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,BAO_0000219,CHEMBL620740,16372,,Autocuration,1,449.0,B,,,,,CHO
3740,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,BAO_0000219,CHEMBL620741,16372,,Autocuration,1,449.0,B,,,,,CHO
3741,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,BAO_0000219,CHEMBL620742,16372,,Autocuration,1,449.0,B,,,,,CHO
3742,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,BAO_0000219,CHEMBL620743,16372,,Autocuration,1,449.0,B,,,,,CHO
3743,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,BAO_0000219,CHEMBL620744,16372,,Autocuration,1,449.0,B,,,,,CHO
3744,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,BAO_0000219,CHEMBL620745,16372,,Autocuration,1,449.0,B,,,,,CHO
3745,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,BAO_0000219,CHEMBL620746,16372,,Autocuration,1,449.0,B,,,,,CHO
3746,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,BAO_0000219,CHEMBL620747,16372,,Autocuration,1,449.0,B,,,,,CHO
3747,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,BAO_0000219,CHEMBL620748,16372,,Autocuration,1,449.0,B,,,,,CHO
3748,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,BAO_0000219,CHEMBL620749,16372,,Autocuration,1,449.0,B,,,,,CHO
3749,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620750,17066,,Expert,1,,B,,,,,
3750,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL620751,17066,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3751,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620752,17386,,Expert,1,,B,,,,,
3752,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,BAO_0000019,CHEMBL872929,14423,,Autocuration,1,,B,,,,,
3753,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,BAO_0000357,CHEMBL620753,15874,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3754,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620754,15874,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3755,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,BAO_0000219,CHEMBL620755,16372,10116.0,Expert,1,449.0,B,,Rattus norvegicus,,,CHO
3756,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL620756,4622,,Autocuration,1,,B,,,,,
3757,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL620757,15086,,Autocuration,1,,B,,,,,
3758,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,BAO_0000219,CHEMBL620758,16372,,Autocuration,1,449.0,B,,,,,CHO
3759,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,BAO_0000219,CHEMBL620759,16372,,Autocuration,1,449.0,B,,,,,CHO
3760,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,BAO_0000219,CHEMBL620760,16372,,Autocuration,1,449.0,B,,,,,CHO
3761,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,BAO_0000219,CHEMBL620761,16372,,Autocuration,1,449.0,B,,,,,CHO
3762,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,BAO_0000221,CHEMBL620762,17386,,Autocuration,1,,F,,,,Ileum,
3763,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,BAO_0000221,CHEMBL620763,17386,,Autocuration,1,,F,,,,Ileum,
3764,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,BAO_0000221,CHEMBL620764,17386,,Autocuration,1,,F,,,,Ileum,
3765,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,BAO_0000249,CHEMBL857990,5831,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3766,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,CHEMBL620765,4342,,Autocuration,1,,B,,,,,
3767,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,BAO_0000357,CHEMBL620766,17319,,Expert,1,,B,,,,,
3768,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,BAO_0000019,CHEMBL620767,17342,,Expert,1,,B,,,,Hypothalamus,
3769,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,CHEMBL620768,17342,,Autocuration,1,,B,,,,,
3770,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,BAO_0000249,CHEMBL619051,3680,,Expert,1,,B,,,,Hypothalamus,
3771,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619052,3680,,Expert,1,,B,,,,,
3772,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,BAO_0000219,CHEMBL619053,17319,10116.0,Expert,1,722.0,F,,Rattus norvegicus,,,HEK293
3773,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,BAO_0000219,CHEMBL619703,17319,10116.0,Expert,1,722.0,F,,Rattus norvegicus,,,HEK293
3774,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,BAO_0000219,CHEMBL619704,17319,10116.0,Autocuration,1,722.0,F,,Rattus norvegicus,,,HEK293
3775,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619851,4820,,Expert,1,,B,,,,,
3776,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,BAO_0000357,CHEMBL619852,4639,,Autocuration,1,,B,,,,,
3777,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,BAO_0000357,CHEMBL619853,6011,,Autocuration,1,,B,,,,,
3778,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619854,17066,9606.0,Expert,1,,B,,Homo sapiens,,,
3779,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619855,17066,,Expert,1,,B,,,,,
3780,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,BAO_0000357,CHEMBL619856,17515,,Autocuration,1,,B,,,,,
3781,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,CHEMBL619857,4373,,Autocuration,1,,B,,,,,
3782,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,BAO_0000019,CHEMBL619858,17066,,Expert,1,,F,,,,,
3783,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,CHEMBL619859,4373,,Autocuration,1,,B,,,,,
3784,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,CHEMBL619860,4373,,Autocuration,1,,B,,,,,
3785,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619861,4687,,Autocuration,1,,B,,,,,
3786,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619862,17342,,Expert,1,,B,,,,,
3787,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,BAO_0000357,CHEMBL619863,16946,,Autocuration,1,,B,,,,,
3788,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,BAO_0000357,CHEMBL619864,16946,,Autocuration,1,,B,,,,,
3789,,Binding affinities against 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL872928,16633,,Autocuration,1,,B,,,,,
3790,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619865,16633,,Autocuration,1,,B,,,,,
3791,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,CHEMBL619866,17066,,Expert,1,,B,,,,,
3792,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,BAO_0000357,CHEMBL619867,16700,,Autocuration,1,,B,,,,,
3793,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,BAO_0000221,CHEMBL619868,17386,,Autocuration,1,,B,,,,Ileum,
3794,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,BAO_0000019,CHEMBL619869,14080,,Autocuration,1,,F,,,,,
3795,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,BAO_0000019,CHEMBL619870,14080,9606.0,Expert,1,,F,,Homo sapiens,,,
3796,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,BAO_0000357,CHEMBL619871,409,,Autocuration,1,,B,,,,,
3797,,In vitro inhibition of human recombinant lipoxygenase enzyme,,BAO_0000357,CHEMBL619872,409,,Autocuration,1,,B,,,,,
3798,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,BAO_0000357,CHEMBL619873,409,,Autocuration,1,,B,,,,,
3799,,Inhibition of 5-lipoxygenase in human whole blood.,,BAO_0000357,CHEMBL619874,11090,,Expert,1,,B,,,,Blood,
3800,,Inhibition of 5-lipoxygenase in human whole blood.,,BAO_0000357,CHEMBL619875,11090,,Expert,1,,B,,,,Blood,
3801,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,BAO_0000357,CHEMBL619876,948,,Autocuration,1,,B,,,,,
3802,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,BAO_0000357,CHEMBL619877,948,,Autocuration,1,,B,,,,,
3803,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,BAO_0000219,CHEMBL619878,13622,,Expert,1,,F,,,,,
3804,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,BAO_0000019,CHEMBL619879,13622,,Autocuration,1,,F,,,,Blood,
3805,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,BAO_0000357,CHEMBL619880,9637,,Autocuration,1,,B,,,,,
3806,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,BAO_0000357,CHEMBL619881,11320,,Autocuration,1,,B,,,,,
3807,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,BAO_0000357,CHEMBL619882,11320,,Expert,1,,B,,,,,
3808,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,BAO_0000357,CHEMBL619883,6838,,Autocuration,1,,B,,,,,
3809,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,BAO_0000357,CHEMBL619884,17667,9606.0,Expert,1,,B,,Homo sapiens,,Blood,
3810,,In vitro potency against human 5-Lipoxygenase,,BAO_0000357,CHEMBL619885,12703,,Autocuration,1,,B,,,,,
3811,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,BAO_0000019,CHEMBL619886,14312,9606.0,Expert,1,,F,,Homo sapiens,,,
3812,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,BAO_0000019,CHEMBL619887,14312,,Autocuration,1,,F,,,,Blood,
3813,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,CHEMBL875097,5364,,Autocuration,1,,F,,,,,
3814,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,BAO_0000219,CHEMBL618001,951,,Autocuration,1,,B,,,,,
3815,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,BAO_0000219,CHEMBL618002,951,,Autocuration,1,,B,,,,,
3816,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,BAO_0000219,CHEMBL618003,951,,Autocuration,1,,B,,,,,
3817,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,BAO_0000219,CHEMBL618004,951,,Autocuration,1,,B,,,,,
3818,,Inhibition of human 5-lipoxygenase in human cells,,BAO_0000219,CHEMBL618005,12365,,Autocuration,1,,B,,,,,
3819,,Inhibition of human neutrophil 5-lipoxygenase,,BAO_0000357,CHEMBL618006,10603,,Expert,1,,B,,,,,
3820,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,BAO_0000019,CHEMBL875086,10501,,Autocuration,1,,B,,,,,
3821,,Inhibition of 5-lipoxygenase from human whole blood,,BAO_0000357,CHEMBL618007,12281,,Expert,1,,B,,,,Blood,
3822,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,CHEMBL618008,2567,,Autocuration,1,,B,,,,,
3823,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,BAO_0000219,CHEMBL618009,2567,,Autocuration,1,,B,,,,,
3824,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,BAO_0000357,CHEMBL618010,10193,,Expert,1,,B,,,,,
3825,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,CHEMBL618011,10193,,Autocuration,1,,B,,,,,
3826,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,BAO_0000357,CHEMBL618012,13623,,Expert,1,,B,,,,,
3827,,Tested against 5-lipoxygenase,,BAO_0000357,CHEMBL882927,12780,,Autocuration,1,,B,,,,,
3828,,Tested for activity against 5-Lipoxygenase (5-LO),,BAO_0000357,CHEMBL618013,12780,,Autocuration,1,,B,,,,,
3829,,Tested for activity against 5-lipoxygenase,,BAO_0000357,CHEMBL618014,12780,,Autocuration,1,,B,,,,,
3830,,Tested for inhibition of 5-HPETE production by human 5-LO,,BAO_0000357,CHEMBL618015,11966,,Autocuration,1,,B,,,,,
3831,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,CHEMBL618016,5364,,Autocuration,1,,F,,,,,
3832,,Inhibition of Human 5-lipoxygenase,,BAO_0000357,CHEMBL618017,13165,,Expert,1,,B,,,,,
3833,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,BAO_0000019,CHEMBL618018,5364,,Autocuration,1,,B,,,,,
3834,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,CHEMBL875087,11311,,Autocuration,1,,B,,,,,
3835,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,CHEMBL618019,11311,,Autocuration,1,,B,,,,,
3836,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,BAO_0000019,CHEMBL618020,14863,,Autocuration,1,,B,,,,,
3837,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,BAO_0000019,CHEMBL618021,14863,,Autocuration,1,,B,,,,,
3838,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,BAO_0000357,CHEMBL618022,11087,,Autocuration,1,,B,,,,Blood,
3839,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,BAO_0000357,CHEMBL618023,455,,Autocuration,1,,B,,,,,
3840,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,CHEMBL618024,13183,,Autocuration,1,,B,,,,,
3841,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,BAO_0000019,CHEMBL873950,10319,,Expert,1,,B,,,,,
3842,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,CHEMBL618025,10193,,Autocuration,1,,B,,,,,
3843,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,BAO_0000219,CHEMBL618026,951,,Autocuration,1,,B,,,,,
3844,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,BAO_0000219,CHEMBL618027,951,,Autocuration,1,,B,,,,,
3845,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,BAO_0000219,CHEMBL618028,951,,Autocuration,1,,B,,,,,
3846,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,BAO_0000219,CHEMBL618029,951,,Autocuration,1,,B,,,,,
3847,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,BAO_0000357,CHEMBL618030,9859,,Expert,1,,B,,,,,
3848,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,BAO_0000357,CHEMBL618031,9859,,Expert,1,,B,,,,,
3849,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,BAO_0000357,CHEMBL618032,9859,,Autocuration,1,,B,,,,,
3850,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,CHEMBL618033,2567,,Autocuration,1,,B,,,,,
3851,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,BAO_0000357,CHEMBL618034,10193,,Autocuration,1,,B,,,,,
3852,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,CHEMBL875088,10193,,Autocuration,1,,B,,,,,
3853,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,BAO_0000019,CHEMBL618035,949,,Autocuration,1,,B,,,,,
3854,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,BAO_0000019,CHEMBL618036,949,,Autocuration,1,,B,,,,,
3855,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,CHEMBL618037,10603,,Expert,1,,B,,,,,
3856,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000357,CHEMBL618038,10603,,Expert,1,,B,,,,,
3857,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000019,CHEMBL618761,10603,,Autocuration,1,,F,,,,,
3858,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,CHEMBL618762,10603,,Expert,1,,B,,,,,
3859,,Inhibition of lipoxygenase at the concentration of 1 uM,,BAO_0000357,CHEMBL618763,10603,,Expert,1,,B,,,,,
3860,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,BAO_0000357,CHEMBL618764,10193,,Autocuration,1,,B,,,,,
3861,,Inhibition of 5-Lipoxygenase (5-LOX),,BAO_0000357,CHEMBL618765,14580,9606.0,Expert,1,,B,,Homo sapiens,,,
3862,,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,CHEMBL618766,11090,,Expert,1,,B,,,,,
3863,,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,CHEMBL618767,11090,,Expert,1,,B,,,,,
3864,,Inhibitory activity against lipoxygenase-2 in mice,,BAO_0000357,CHEMBL619380,6339,,Autocuration,1,,B,,,,,
3865,,Inhibitory activity against murine lipoxygenase-2.,,BAO_0000357,CHEMBL619381,6339,,Expert,1,,B,,,,,
3866,,Inhibition of 5-lipoxygenase from mouse macrophage,,BAO_0000357,CHEMBL619382,12281,10090.0,Expert,1,,B,,Mus musculus,,,
3867,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,BAO_0000357,CHEMBL619383,11311,,Autocuration,1,,B,,,,,
3868,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,CHEMBL619384,11089,9823.0,Autocuration,1,,B,,Sus scrofa,,,
3869,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,BAO_0000019,CHEMBL619385,10091,9823.0,Autocuration,1,,B,,Sus scrofa,,,
3870,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,BAO_0000019,CHEMBL882928,14352,9986.0,Autocuration,1,,B,,Oryctolagus cuniculus,,,
3871,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,BAO_0000019,CHEMBL619386,13329,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3872,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,BAO_0000019,CHEMBL619387,13329,,Autocuration,1,,B,,,,,
3873,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,CHEMBL619388,13329,,Autocuration,1,,B,,,,,
3874,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,BAO_0000019,CHEMBL619389,13329,,Autocuration,1,,B,,,,,
3875,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,BAO_0000019,CHEMBL619390,13329,,Expert,1,,B,,,,,
3876,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,BAO_0000019,CHEMBL619391,13329,,Expert,1,,B,,,,,
3877,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,BAO_0000019,CHEMBL619392,13329,,Autocuration,1,,B,,,,,
3878,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,BAO_0000019,CHEMBL619393,11311,,Autocuration,1,,B,,,,,
3879,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,BAO_0000019,CHEMBL619394,11311,,Autocuration,1,,B,,,,,
3880,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,BAO_0000219,CHEMBL619395,105,,Autocuration,1,702.0,B,,,,,RBL-1
3881,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,BAO_0000219,CHEMBL619396,105,,Autocuration,1,702.0,B,,,,,RBL-1
3882,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,BAO_0000357,CHEMBL619397,9138,,Autocuration,1,,B,,,,,
3883,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,BAO_0000357,CHEMBL619398,9138,,Autocuration,1,,B,,,,,
3884,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,BAO_0000357,CHEMBL619399,9138,,Autocuration,1,,B,,,,,
3885,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,CHEMBL619400,14427,,Autocuration,1,,B,,,,,
3886,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,CHEMBL619401,13329,,Autocuration,1,,B,,,,,
3887,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,BAO_0000019,CHEMBL619402,13329,,Autocuration,1,,B,,,,,
3888,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,BAO_0000219,CHEMBL619403,14427,10116.0,Expert,1,663.0,B,,Rattus norvegicus,,,RBL-2H3
3889,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,CHEMBL619404,14427,,Autocuration,1,,B,,,,,
3890,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,BAO_0000357,CHEMBL619405,14427,,Autocuration,1,,B,,,,,
3891,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,BAO_0000219,CHEMBL619406,10293,,Expert,1,702.0,B,,,,,RBL-1
3892,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,BAO_0000219,CHEMBL619407,338,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
3893,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,BAO_0000357,CHEMBL619408,303,,Autocuration,1,,B,,,,,
3894,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,BAO_0000219,CHEMBL619409,303,,Autocuration,1,702.0,B,,,,,RBL-1
3895,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,BAO_0000219,CHEMBL619410,9247,,Expert,1,702.0,B,,,,,RBL-1
3896,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,BAO_0000219,CHEMBL619753,9247,,Autocuration,1,702.0,B,,,,,RBL-1
3897,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,BAO_0000219,CHEMBL619754,137,,Autocuration,1,702.0,B,,,,,RBL-1
3898,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,CHEMBL619903,11481,,Expert,1,,B,,,,,
3899,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,BAO_0000357,CHEMBL619904,11481,,Expert,1,,B,,,,,
3900,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,BAO_0000357,CHEMBL619905,9029,,Expert,1,,B,,,,,
3901,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,BAO_0000019,CHEMBL619906,1701,,Autocuration,1,,B,,,,,
3902,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,BAO_0000019,CHEMBL619907,1701,,Autocuration,1,,B,,,,,
3903,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,BAO_0000019,CHEMBL619908,1701,,Autocuration,1,,B,,,,,
3904,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,BAO_0000019,CHEMBL619909,1701,,Autocuration,1,,B,,,,,
3905,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,BAO_0000219,CHEMBL619910,13358,,Expert,1,702.0,F,,,,,RBL-1
3906,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,BAO_0000219,CHEMBL882929,1175,,Expert,1,702.0,B,,,,,RBL-1
3907,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,BAO_0000219,CHEMBL619911,8797,,Expert,1,702.0,B,,,,,RBL-1
3908,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,BAO_0000019,CHEMBL619912,8797,,Autocuration,1,,B,,,,,
3909,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,CHEMBL619913,577,10116.0,Expert,1,,B,,Rattus norvegicus,,,
3910,,In vitro inhibitory activity against RBL-1 5-LO,,BAO_0000219,CHEMBL619914,9295,,Expert,1,702.0,B,,,,,RBL-1
3911,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,BAO_0000219,CHEMBL619915,9295,,Autocuration,1,702.0,B,,,,,RBL-1
3912,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,BAO_0000219,CHEMBL619916,9295,,Autocuration,1,702.0,B,,,,,RBL-1
3913,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,BAO_0000218,CHEMBL619917,9295,,Autocuration,1,,B,,,,,
3914,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,BAO_0000357,CHEMBL619918,9295,,Autocuration,1,,B,,,,,
3915,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,BAO_0000218,CHEMBL619919,216,,Autocuration,1,,B,,,,,
3916,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,BAO_0000219,CHEMBL883710,11090,,Autocuration,1,702.0,B,,,,,RBL-1
3917,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,BAO_0000019,CHEMBL619920,11090,,Autocuration,1,,B,,,,Blood,
3918,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,BAO_0000357,CHEMBL619921,10091,,Expert,1,,B,,,,,
3919,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,BAO_0000019,CHEMBL619922,10274,,Autocuration,1,,F,,,,,
3920,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,BAO_0000219,CHEMBL619923,13622,,Autocuration,1,,F,,,,,
3921,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,BAO_0000219,CHEMBL619924,12118,,Expert,1,702.0,B,,,,,RBL-1
3922,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,BAO_0000357,CHEMBL619925,12576,,Expert,1,,B,,,,,
3923,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,BAO_0000219,CHEMBL619926,9546,,Expert,1,702.0,B,,,,,RBL-1
3924,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,BAO_0000219,CHEMBL619927,9521,,Autocuration,1,702.0,B,,,,,RBL-1
3925,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,BAO_0000219,CHEMBL619928,10626,,Expert,1,702.0,B,,,,,RBL-1
3926,,In vitro inhibition of RBL-1 5-lipoxygenase,,BAO_0000219,CHEMBL619929,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3927,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,BAO_0000219,CHEMBL875089,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3928,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,BAO_0000219,CHEMBL619930,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3929,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,BAO_0000219,CHEMBL619931,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3930,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,BAO_0000219,CHEMBL619932,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3931,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,BAO_0000219,CHEMBL619933,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3932,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,BAO_0000219,CHEMBL619934,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3933,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,BAO_0000219,CHEMBL619935,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3934,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,BAO_0000219,CHEMBL619936,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3935,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,BAO_0000219,CHEMBL619937,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3936,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,BAO_0000219,CHEMBL619938,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3937,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,BAO_0000219,CHEMBL619939,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3938,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,BAO_0000219,CHEMBL619940,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3939,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,BAO_0000219,CHEMBL875090,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3940,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,BAO_0000219,CHEMBL619941,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3941,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,BAO_0000219,CHEMBL619942,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3942,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,BAO_0000219,CHEMBL883711,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3943,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,BAO_0000219,CHEMBL619943,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3944,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,BAO_0000219,CHEMBL619944,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3945,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,BAO_0000219,CHEMBL619945,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3946,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,BAO_0000219,CHEMBL619946,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3947,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,BAO_0000219,CHEMBL619947,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3948,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,BAO_0000219,CHEMBL619948,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3949,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,BAO_0000219,CHEMBL619949,9225,,Autocuration,1,702.0,B,,,,,RBL-1
3950,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,BAO_0000019,CHEMBL619950,9401,,Expert,1,,B,,,,,
3951,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,BAO_0000019,CHEMBL618050,10325,,Autocuration,1,,B,,,,,
3952,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,BAO_0000219,CHEMBL875091,1556,,Expert,1,663.0,F,,,,,RBL-2H3
3953,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,BAO_0000219,CHEMBL618051,1556,,Expert,1,663.0,F,,,,,RBL-2H3
3954,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,BAO_0000219,CHEMBL618052,961,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
3955,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,BAO_0000019,CHEMBL618053,6838,,Autocuration,1,,B,,,,,
3956,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,BAO_0000019,CHEMBL618054,10325,,Expert,1,,B,,,,,
3957,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,CHEMBL618055,9209,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
3958,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,BAO_0000219,CHEMBL618056,11520,,Expert,1,702.0,B,,,,,RBL-1
3959,,In vitro inhibitory activity against 5-lipoxygenase was determined,,BAO_0000357,CHEMBL618057,137,,Autocuration,1,,B,,,,,
3960,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,BAO_0000219,CHEMBL618058,4717,,Autocuration,1,702.0,B,,,,,RBL-1
3961,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,BAO_0000219,CHEMBL618059,10636,,Expert,1,702.0,B,,,,,RBL-1
3962,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,BAO_0000019,CHEMBL618060,14312,10116.0,Expert,1,,F,,Rattus norvegicus,,,
3963,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,BAO_0000219,CHEMBL618061,1203,,Autocuration,1,702.0,B,,,,,RBL-1
3964,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,BAO_0000019,CHEMBL618062,1203,,Autocuration,1,,B,,,,,
3965,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,BAO_0000219,CHEMBL618063,13622,,Expert,1,702.0,B,,,,,RBL-1
3966,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,BAO_0000357,CHEMBL618064,9793,,Autocuration,1,,B,,,,,
3967,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,BAO_0000219,CHEMBL618065,1143,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
3968,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,BAO_0000219,CHEMBL618066,11854,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
3969,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,CHEMBL618067,3595,,Autocuration,1,702.0,B,,,,,RBL-1
3970,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,BAO_0000219,CHEMBL618068,3595,,Autocuration,1,702.0,B,,,,,RBL-1
3971,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,CHEMBL618069,10501,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
3972,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,CHEMBL618070,12526,,Expert,1,702.0,B,,,,,RBL-1
3973,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,BAO_0000019,CHEMBL618071,10034,,Autocuration,1,,F,,,,Limbic system,
3974,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,BAO_0000019,CHEMBL619247,10034,,Autocuration,1,,F,,,,Limbic system,
3975,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,BAO_0000019,CHEMBL619248,10034,,Autocuration,1,,F,,,,,
3976,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,CHEMBL619249,10046,,Autocuration,1,,B,,,,Hippocampus,
3977,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,CHEMBL619250,10046,,Autocuration,1,,B,,,,Hippocampus,
3978,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,CHEMBL619251,10046,,Autocuration,1,,B,,,,,
3979,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,BAO_0000019,CHEMBL619252,12079,9615.0,Autocuration,1,,F,,Canis lupus familiaris,,Blood,
3980,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,BAO_0000019,CHEMBL619253,12079,,Autocuration,1,,F,,,,Blood,
3981,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,CHEMBL619254,11311,,Autocuration,1,,B,,,,,
3982,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,BAO_0000219,CHEMBL619255,12338,,Expert,1,,B,,,,,
3983,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,BAO_0000219,CHEMBL619256,12143,,Expert,1,,B,,,,,
3984,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,BAO_0000219,CHEMBL875418,12143,,Autocuration,1,,B,,,,,
3985,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,CHEMBL619257,12143,,Expert,1,,B,,,,,
3986,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,CHEMBL619258,12143,,Autocuration,1,,B,,,,,
3987,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,BAO_0000357,CHEMBL619259,12365,,Expert,1,,B,,,,,
3988,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,BAO_0000357,CHEMBL619260,13500,,Expert,1,,B,,,,,
3989,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619261,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3990,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619263,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3991,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619264,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3992,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619265,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3993,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619266,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3994,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619902,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3995,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620058,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3996,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620059,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3997,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620060,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3998,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620061,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
3999,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,CHEMBL620062,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4000,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620063,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4001,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,CHEMBL620064,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4002,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620065,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4003,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,CHEMBL620066,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4004,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620067,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4005,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,CHEMBL620068,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4006,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620069,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4007,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,CHEMBL620070,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4008,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620071,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4009,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,CHEMBL620072,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4010,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620036,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4011,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,CHEMBL857702,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4012,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620037,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4013,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,CHEMBL620038,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4014,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620039,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4015,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,CHEMBL620040,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4016,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620041,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4017,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,CHEMBL620042,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4018,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620043,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4019,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,CHEMBL620044,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4020,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620045,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4021,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,CHEMBL620046,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4022,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620047,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4023,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,CHEMBL620048,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4024,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL857703,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4025,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,CHEMBL620049,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4026,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620050,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4027,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620051,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4028,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619213,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4029,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619214,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4030,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619804,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4031,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619805,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4032,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619806,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4033,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619807,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4034,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL619808,12832,9615.0,Autocuration,1,,F,In vivo,Canis lupus familiaris,,Blood,
4035,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,BAO_0000218,CHEMBL619809,3595,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
4036,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,BAO_0000218,CHEMBL619810,3595,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
4037,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,BAO_0000218,CHEMBL619811,3595,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
4038,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,BAO_0000218,CHEMBL620769,3595,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
4039,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,BAO_0000218,CHEMBL620770,3595,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
4040,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,BAO_0000218,CHEMBL620771,3595,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
4041,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,BAO_0000218,CHEMBL620772,3595,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
4042,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,BAO_0000218,CHEMBL620773,3595,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
4043,,Ability to inhibit 5-lipoxygenase in guinea pig,,BAO_0000357,CHEMBL620774,9203,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4044,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,BAO_0000357,CHEMBL620775,82,10141.0,Expert,1,,B,,Cavia porcellus,,,
4045,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,BAO_0000357,CHEMBL620776,11090,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4046,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,CHEMBL620777,12832,10141.0,Autocuration,1,,B,,Cavia porcellus,,Blood,
4047,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,BAO_0000357,CHEMBL620778,1065,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4048,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,BAO_0000357,CHEMBL620779,1065,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4049,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,CHEMBL621500,12832,10141.0,Expert,1,,B,,Cavia porcellus,,,
4050,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,CHEMBL621501,12832,10141.0,Expert,1,,B,,Cavia porcellus,,,
4051,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,CHEMBL618098,12832,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4052,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,CHEMBL618099,10504,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4053,,Inhibitory activity against 5-lipoxygenase,,BAO_0000357,CHEMBL618100,7788,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4054,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,BAO_0000357,CHEMBL618101,10001,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4055,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,BAO_0000357,CHEMBL618102,10193,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4056,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,BAO_0000357,CHEMBL618103,13243,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4057,,Inhibitory activity uM,,BAO_0000357,CHEMBL618104,13243,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4058,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,BAO_0000219,CHEMBL883712,969,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4059,,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,CHEMBL618105,10001,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4060,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,CHEMBL618106,7788,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4061,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,BAO_0000357,CHEMBL618107,10001,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4062,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,CHEMBL618108,10193,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4063,,Inhibitory activity uM,,BAO_0000357,CHEMBL618109,13243,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4064,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,BAO_0000357,CHEMBL618110,13243,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4065,,Inhibitory activity uM,,BAO_0000357,CHEMBL618111,13243,10141.0,Expert,1,,B,,Cavia porcellus,,,
4066,,Inhibitory activity uM,,BAO_0000019,CHEMBL618112,13243,10141.0,Autocuration,1,,F,,Cavia porcellus,,,
4067,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,CHEMBL618113,10504,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4068,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,CHEMBL618114,7788,10141.0,Autocuration,1,,B,,Cavia porcellus,,,
4069,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,BAO_0000221,CHEMBL620871,10546,10141.0,Expert,1,,F,,Cavia porcellus,,Ileum,
4070,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,CHEMBL620872,13183,,Autocuration,1,,B,,,,,
4071,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,CHEMBL620873,13183,,Autocuration,1,,B,,,,,
4072,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,BAO_0000357,CHEMBL620874,2578,,Autocuration,1,,B,,,,,
4073,,In vitro inhibition of human 5-Lipoxygenase.,,BAO_0000357,CHEMBL620875,12780,,Expert,1,,B,,,,,
4074,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,BAO_0000251,CHEMBL620876,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4075,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,BAO_0000251,CHEMBL620877,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4076,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,BAO_0000251,CHEMBL857854,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4077,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,BAO_0000251,CHEMBL620878,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4078,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,BAO_0000251,CHEMBL620879,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4079,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,BAO_0000251,CHEMBL620880,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4080,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,BAO_0000251,CHEMBL620881,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4081,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,BAO_0000251,CHEMBL620882,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4082,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,BAO_0000251,CHEMBL620883,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4083,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,BAO_0000251,CHEMBL620884,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4084,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,BAO_0000251,CHEMBL620885,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4085,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,BAO_0000251,CHEMBL620886,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4086,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,BAO_0000251,CHEMBL620887,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4087,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,BAO_0000251,CHEMBL618039,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4088,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,BAO_0000251,CHEMBL618040,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4089,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,BAO_0000251,CHEMBL618041,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4090,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,BAO_0000251,CHEMBL618216,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4091,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,BAO_0000251,CHEMBL618217,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4092,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,BAO_0000251,CHEMBL618218,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4093,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,BAO_0000251,CHEMBL618219,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4094,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,BAO_0000251,CHEMBL618220,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4095,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,BAO_0000251,CHEMBL618221,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4096,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,BAO_0000251,CHEMBL618222,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4097,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,BAO_0000251,CHEMBL618223,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4098,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,BAO_0000251,CHEMBL618224,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4099,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,BAO_0000251,CHEMBL618225,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4100,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,BAO_0000251,CHEMBL618226,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4101,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,BAO_0000251,CHEMBL618227,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4102,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,BAO_0000251,CHEMBL618228,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4103,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,BAO_0000251,CHEMBL618229,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4104,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,BAO_0000251,CHEMBL618230,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4105,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,BAO_0000251,CHEMBL618231,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4106,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,BAO_0000251,CHEMBL618232,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4107,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,BAO_0000251,CHEMBL618233,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4108,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,BAO_0000251,CHEMBL618234,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4109,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,BAO_0000251,CHEMBL618235,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4110,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,BAO_0000251,CHEMBL618115,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4111,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,BAO_0000251,CHEMBL618116,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4112,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,BAO_0000251,CHEMBL618117,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4113,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,BAO_0000251,CHEMBL619968,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4114,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,BAO_0000251,CHEMBL619969,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4115,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,BAO_0000251,CHEMBL619970,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4116,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,BAO_0000251,CHEMBL619971,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4117,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,BAO_0000251,CHEMBL619972,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4118,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,BAO_0000251,CHEMBL619973,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4119,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,BAO_0000251,CHEMBL619974,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4120,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,BAO_0000251,CHEMBL619975,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4121,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,BAO_0000251,CHEMBL619976,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
4122,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,BAO_0000251,CHEMBL619977,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4123,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,BAO_0000251,CHEMBL619978,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4124,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,BAO_0000251,CHEMBL619979,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4125,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,BAO_0000251,CHEMBL619980,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4126,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,BAO_0000251,CHEMBL619981,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4127,,In vitro inhibition of 7226/S myeloma cancer cell line,,BAO_0000219,CHEMBL619982,10797,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
4128,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,BAO_0000219,CHEMBL619983,6881,9606.0,Intermediate,1,993.0,F,,Homo sapiens,,,BEL-7404 tumor cell line
4129,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,BAO_0000219,CHEMBL620031,3838,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4130,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,BAO_0000219,CHEMBL620032,3838,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4131,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,BAO_0000219,CHEMBL620033,12981,10029.0,Expert,1,505.0,F,,Cricetulus griseus,,,V79
4132,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,BAO_0000219,CHEMBL620034,12981,10029.0,Expert,1,505.0,F,,Cricetulus griseus,,,V79
4133,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,BAO_0000219,CHEMBL620035,7653,10116.0,Intermediate,1,1119.0,F,,Rattus norvegicus,,,7800C1 cell line
4134,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,BAO_0000219,CHEMBL618318,7653,10116.0,Intermediate,1,1119.0,F,,Rattus norvegicus,,,7800C1 cell line
4135,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,BAO_0000219,CHEMBL618319,7653,10116.0,Intermediate,1,1119.0,F,,Rattus norvegicus,,,7800C1 cell line
4136,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,BAO_0000219,CHEMBL618320,7653,10116.0,Intermediate,1,1119.0,F,,Rattus norvegicus,,,7800C1 cell line
4137,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,BAO_0000219,CHEMBL618321,7653,10116.0,Intermediate,1,1119.0,F,,Rattus norvegicus,,,7800C1 cell line
4138,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,BAO_0000219,CHEMBL883118,7653,10116.0,Intermediate,1,1119.0,F,,Rattus norvegicus,,,7800C1 cell line
4139,,In vitro antitumor activity against renal 786-0 tumor cell lines,,BAO_0000219,CHEMBL883795,17229,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4140,,Cytotoxic activity against 786-0 Renal cancer cell line,,BAO_0000219,CHEMBL618322,12858,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4141,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,BAO_0000219,CHEMBL618323,16325,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4142,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,BAO_0000219,CHEMBL618324,16325,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4143,,In vitro antitumor activity against human renal 786-0 cell line,,BAO_0000219,CHEMBL618325,5858,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4144,,Inhibition of Renal cancer in 786-0 cancer cell lines,,BAO_0000219,CHEMBL875416,16325,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4145,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,BAO_0000219,CHEMBL618326,14696,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4146,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,BAO_0000219,CHEMBL618327,3786,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4147,,inhibition of the growth of renal cancer(786-0) cell line,,BAO_0000219,CHEMBL619215,14696,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4148,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,BAO_0000219,CHEMBL619216,14769,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4149,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,BAO_0000219,CHEMBL619217,15354,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4150,,The IC50 value was measured on 786-0 cell line in ovarian tumor,,BAO_0000219,CHEMBL619218,14255,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4151,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,BAO_0000219,CHEMBL619219,14255,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4152,,The IC50 value was measured on 786-0 cell line in renal tumor type.,,BAO_0000219,CHEMBL619220,14255,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4153,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,BAO_0000219,CHEMBL619221,14696,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4154,,Tested for cytotoxic activity against renal cancer 786-0 cell line,,BAO_0000219,CHEMBL619222,12016,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4155,,Compound was tested for growth inhibitory activity against 786-0 cell line,,BAO_0000219,CHEMBL857454,2597,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
4156,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,BAO_0000219,CHEMBL619223,12526,,Autocuration,1,702.0,B,,,,,RBL-1
4157,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,BAO_0000219,CHEMBL619224,12526,,Autocuration,1,702.0,B,,,,,RBL-1
4158,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,CHEMBL619225,14799,,Autocuration,1,,B,,,,,
4159,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,CHEMBL619226,3595,,Expert,1,702.0,B,,,,,RBL-1
4160,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,BAO_0000219,CHEMBL619227,3595,,Expert,1,702.0,B,,,,,RBL-1
4161,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,BAO_0000357,CHEMBL619228,12767,,Autocuration,1,,B,,,,,
4162,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,CHEMBL619229,10997,,Autocuration,1,,B,,,,,
4163,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,BAO_0000219,CHEMBL619230,11388,,Autocuration,1,702.0,B,,,,,RBL-1
4164,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,BAO_0000357,CHEMBL619231,167,,Autocuration,1,,B,,,,,
4165,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,CHEMBL619232,167,,Autocuration,1,,B,,,,,
4166,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,BAO_0000357,CHEMBL619233,13744,,Expert,1,,B,,,,,
4167,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,CHEMBL619234,1630,,Autocuration,1,,B,,,,,
4168,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,BAO_0000357,CHEMBL619235,1630,,Autocuration,1,,B,,,,,
4169,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,BAO_0000019,CHEMBL619236,969,10116.0,Expert,1,,B,,Rattus norvegicus,,,
4170,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,CHEMBL619237,13621,,Autocuration,1,702.0,B,,,,,RBL-1
4171,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,BAO_0000357,CHEMBL619238,10089,,Autocuration,1,,B,,,,,
4172,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,CHEMBL619239,10193,,Expert,1,,B,,,,,
4173,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,BAO_0000357,CHEMBL619240,11966,,Autocuration,1,,B,,,,,
4174,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,CHEMBL875417,12251,,Autocuration,1,,B,,,,,
4175,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,BAO_0000219,CHEMBL619241,211,,Autocuration,1,702.0,B,,,,,RBL-1
4176,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,CHEMBL619242,12251,,Expert,1,,F,,,,,
4177,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,BAO_0000219,CHEMBL883796,12495,,Autocuration,1,702.0,B,,,,,RBL-1
4178,,Tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,CHEMBL619243,414,,Autocuration,1,,B,,,,,
4179,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,BAO_0000357,CHEMBL619244,414,,Autocuration,1,,B,,,,,
4180,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,BAO_0000019,CHEMBL619245,10325,,Expert,1,,B,,,,,
4181,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,CHEMBL619246,11966,,Expert,1,,B,,,,,
4182,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,CHEMBL619984,165,,Expert,1,702.0,B,,,,,RBL-1
4183,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,BAO_0000219,CHEMBL619985,165,,Autocuration,1,702.0,B,,,,,RBL-1
4184,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,CHEMBL619986,165,,Autocuration,1,702.0,B,,,,,RBL-1
4185,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,CHEMBL619987,165,,Expert,1,702.0,B,,,,,RBL-1
4186,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,BAO_0000218,CHEMBL619988,11311,,Autocuration,1,,B,,,,,
4187,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,BAO_0000219,CHEMBL619989,11311,,Autocuration,1,702.0,B,,,,,RBL-1
4188,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,CHEMBL619990,11311,,Autocuration,1,702.0,B,,,,,RBL-1
4189,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,CHEMBL619991,11311,,Autocuration,1,,B,,,,,
4190,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,BAO_0000219,CHEMBL619992,11311,,Autocuration,1,,B,,,,,
4191,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,BAO_0000218,CHEMBL619993,11311,,Autocuration,1,,B,In vivo,,,,
4192,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,BAO_0000219,CHEMBL619994,11311,,Autocuration,1,663.0,F,,,,,RBL-2H3
4193,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,BAO_0000219,CHEMBL619995,11311,,Autocuration,1,663.0,F,,,,,RBL-2H3
4194,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,BAO_0000019,CHEMBL619996,11311,,Autocuration,1,,B,,,,,
4195,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,BAO_0000019,CHEMBL619997,11732,,Autocuration,1,,B,,,,,
4196,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,BAO_0000019,CHEMBL619998,11732,,Expert,1,,B,,,,,
4197,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,CHEMBL619999,11087,,Expert,1,,B,,,,,
4198,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,CHEMBL620000,11087,,Autocuration,1,,B,,,,,
4199,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,BAO_0000219,CHEMBL620001,11087,,Autocuration,1,702.0,B,,,,,RBL-1
4200,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,BAO_0000357,CHEMBL620002,11087,10116.0,Expert,1,,B,,Rattus norvegicus,,,
4201,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,BAO_0000219,CHEMBL620003,496,,Autocuration,1,702.0,B,,,,,RBL-1
4202,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,BAO_0000219,CHEMBL620004,13986,,Expert,1,702.0,F,,,,,RBL-1
4203,,Compound was evaluated for the inhibition of 5-lipoxygenase,,BAO_0000357,CHEMBL874063,11520,,Autocuration,1,,B,,,,,
4204,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,BAO_0000219,CHEMBL620005,10293,,Autocuration,1,702.0,B,,,,,RBL-1
4205,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,BAO_0000219,CHEMBL620006,303,,Autocuration,1,702.0,B,,,,,RBL-1
4206,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,BAO_0000219,CHEMBL620007,303,,Autocuration,1,702.0,B,,,,,RBL-1
4207,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,BAO_0000219,CHEMBL620008,9247,,Autocuration,1,702.0,B,,,,,RBL-1
4208,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,BAO_0000219,CHEMBL620009,9247,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
4209,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,BAO_0000219,CHEMBL620010,9247,,Autocuration,1,702.0,B,,,,,RBL-1
4210,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,BAO_0000219,CHEMBL620011,9247,,Autocuration,1,702.0,B,,,,,RBL-1
4211,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,BAO_0000219,CHEMBL620677,9247,,Autocuration,1,702.0,B,,,,,RBL-1
4212,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,BAO_0000219,CHEMBL620678,9247,,Autocuration,1,702.0,B,,,,,RBL-1
4213,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,BAO_0000219,CHEMBL620679,9247,,Autocuration,1,702.0,B,,,,,RBL-1
4214,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,BAO_0000219,CHEMBL620680,9247,,Autocuration,1,702.0,B,,,,,RBL-1
4215,,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,CHEMBL620838,11481,10116.0,Expert,1,,B,,Rattus norvegicus,,,
4216,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,BAO_0000357,CHEMBL620839,105,,Autocuration,1,,B,,,,,
4217,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,BAO_0000357,CHEMBL620840,9029,,Expert,1,,B,,,,,
4218,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,BAO_0000219,CHEMBL620841,1175,,Expert,1,702.0,B,,,,,RBL-1
4219,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,BAO_0000219,CHEMBL620842,12118,,Autocuration,1,702.0,B,,,,,RBL-1
4220,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,BAO_0000219,CHEMBL620843,12118,,Autocuration,1,702.0,B,,,,,RBL-1
4221,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,BAO_0000219,CHEMBL620844,12118,,Autocuration,1,702.0,B,,,,,RBL-1
4222,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,BAO_0000219,CHEMBL620845,9225,,Autocuration,1,702.0,B,,,,,RBL-1
4223,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,BAO_0000019,CHEMBL620846,9401,,Autocuration,1,,B,,,,,
4224,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,CHEMBL873951,137,,Autocuration,1,,B,,,,,
4225,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,CHEMBL620847,137,,Autocuration,1,,B,,,,,
4226,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,BAO_0000219,CHEMBL620848,4717,,Autocuration,1,702.0,B,,,,,RBL-1
4227,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,BAO_0000219,CHEMBL620849,3595,,Autocuration,1,702.0,B,,,,,RBL-1
4228,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,BAO_0000219,CHEMBL620850,10501,,Autocuration,1,702.0,B,,,,,RBL-1
4229,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,BAO_0000219,CHEMBL620851,10501,,Autocuration,1,702.0,B,,,,,RBL-1
4230,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,BAO_0000219,CHEMBL620852,10501,,Autocuration,1,702.0,B,,,,,RBL-1
4231,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,CHEMBL875098,12526,,Autocuration,1,702.0,B,,,,,RBL-1
4232,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,BAO_0000219,CHEMBL620853,14799,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
4233,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,BAO_0000019,CHEMBL620854,14799,,Autocuration,1,,B,,,,,
4234,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,BAO_0000219,CHEMBL620855,3595,,Autocuration,1,702.0,B,,,,,RBL-1
4235,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,BAO_0000219,CHEMBL839884,3595,,Expert,1,702.0,B,,,,,RBL-1
4236,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,CHEMBL620856,12526,,Autocuration,1,702.0,B,,,,,RBL-1
4237,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,CHEMBL620857,12526,,Autocuration,1,702.0,B,,,,,RBL-1
4238,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,CHEMBL620858,10193,,Autocuration,1,,B,,,,,
4239,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,CHEMBL620859,10193,,Autocuration,1,,B,,,,,
4240,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,CHEMBL620860,10193,,Autocuration,1,,B,,,,,
4241,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,BAO_0000019,CHEMBL620861,10193,,Autocuration,1,,B,,,,,
4242,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,BAO_0000357,CHEMBL620862,9138,,Expert,1,,B,,,,,
4243,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,BAO_0000357,CHEMBL620863,9138,,Autocuration,1,,B,,,,,
4244,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,CHEMBL620864,11966,,Autocuration,1,,B,,,,,
4245,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,BAO_0000219,CHEMBL620865,165,,Autocuration,1,702.0,B,,,,,RBL-1
4246,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,BAO_0000219,CHEMBL620866,165,,Autocuration,1,702.0,B,,,,,RBL-1
4247,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,BAO_0000219,CHEMBL620867,11311,,Autocuration,1,663.0,B,,,,,RBL-2H3
4248,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,BAO_0000219,CHEMBL620868,11311,,Autocuration,1,663.0,B,,,,,RBL-2H3
4249,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,BAO_0000219,CHEMBL620869,11311,,Autocuration,1,663.0,F,,,,,RBL-2H3
4250,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,BAO_0000019,CHEMBL873952,11311,,Autocuration,1,,F,,,,,
4251,,The compound was tested for inhibition of isolated 5-lipoxygenase,,BAO_0000357,CHEMBL875099,11311,,Autocuration,1,,B,,,,,
4252,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,BAO_0000219,CHEMBL620870,11311,,Autocuration,1,663.0,F,,,,,RBL-2H3
4253,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,BAO_0000019,CHEMBL618261,11087,,Autocuration,1,,B,,,,,
4254,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,BAO_0000019,CHEMBL618262,11087,,Autocuration,1,,B,,,,,
4255,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,BAO_0000019,CHEMBL619428,11087,,Autocuration,1,,B,,,,,
4256,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,CHEMBL619429,11087,,Autocuration,1,,B,,,,,
4257,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,CHEMBL619430,11087,,Autocuration,1,,B,,,,,
4258,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,BAO_0000219,CHEMBL620017,496,,Autocuration,1,702.0,B,,,,,RBL-1
4259,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,BAO_0000219,CHEMBL620018,496,,Autocuration,1,702.0,B,,,,,RBL-1
4260,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,BAO_0000219,CHEMBL620019,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4261,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,BAO_0000219,CHEMBL620020,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4262,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,BAO_0000219,CHEMBL620021,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4263,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,BAO_0000219,CHEMBL620022,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4264,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,BAO_0000219,CHEMBL620023,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4265,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,BAO_0000219,CHEMBL620024,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4266,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,BAO_0000219,CHEMBL620025,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4267,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,BAO_0000219,CHEMBL620026,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4268,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,BAO_0000219,CHEMBL620027,13986,,Autocuration,1,702.0,F,,,,,RBL-1
4269,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,BAO_0000019,CHEMBL620028,13986,10116.0,Expert,1,,F,,Rattus norvegicus,,,
4270,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,CHEMBL620029,10193,,Autocuration,1,,B,,,,,
4271,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,BAO_0000357,CHEMBL620030,9295,,Autocuration,1,,B,,,,,
4272,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,BAO_0000219,CHEMBL875415,4717,,Autocuration,1,702.0,B,,,,,RBL-1
4273,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,BAO_0000219,CHEMBL618256,4717,,Autocuration,1,702.0,B,,,,,RBL-1
4274,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,BAO_0000219,CHEMBL618257,11854,,Autocuration,1,702.0,B,,,,,RBL-1
4275,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,BAO_0000219,CHEMBL618258,11854,,Autocuration,1,702.0,B,,,,,RBL-1
4276,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,BAO_0000219,CHEMBL618259,11854,,Autocuration,1,702.0,B,,,,,RBL-1
4277,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,CHEMBL618260,10193,,Autocuration,1,,B,,,,,
4278,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,BAO_0000219,CHEMBL618215,9295,,Autocuration,1,702.0,B,,,,,RBL-1
4279,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,BAO_0000219,CHEMBL618390,9295,,Autocuration,1,702.0,B,,,,,RBL-1
4280,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,BAO_0000219,CHEMBL618391,9295,,Autocuration,1,702.0,B,,,,,RBL-1
4281,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,BAO_0000219,CHEMBL618392,9295,,Autocuration,1,702.0,B,,,,,RBL-1
4282,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,BAO_0000219,CHEMBL618393,165,,Autocuration,1,702.0,B,,,,,RBL-1
4283,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,BAO_0000219,CHEMBL618394,11311,,Autocuration,1,,B,,,,,
4284,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,BAO_0000219,CHEMBL618395,10489,9606.0,Expert,1,702.0,B,,Homo sapiens,,,RBL-1
4285,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,BAO_0000219,CHEMBL618396,10489,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
4286,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,BAO_0000219,CHEMBL858253,10489,10116.0,Expert,1,702.0,B,,Rattus norvegicus,,,RBL-1
4287,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,CHEMBL618397,14799,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
4288,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,BAO_0000357,CHEMBL618398,9295,3847.0,Autocuration,1,,B,,Glycine max,,,
4289,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,BAO_0000019,CHEMBL618399,16811,,Autocuration,1,,B,,,,,
4290,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,BAO_0000357,CHEMBL618400,168,,Expert,1,,B,,,,,
4291,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,BAO_0000357,CHEMBL618401,6309,,Autocuration,1,,B,,,,,
4292,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,BAO_0000357,CHEMBL618402,6309,,Autocuration,1,,B,,,,,
4293,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,BAO_0000219,CHEMBL876400,3092,,Autocuration,1,702.0,B,,,,,RBL-1
4294,,Inhibitory activity against 5-lipoxygenase.,,BAO_0000357,CHEMBL618403,168,,Expert,1,,B,,,,,
4295,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,BAO_0000357,CHEMBL618404,168,,Autocuration,1,,B,,,,,
4296,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,BAO_0000357,CHEMBL618405,168,,Autocuration,1,,B,,,,,
4297,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,BAO_0000357,CHEMBL618406,168,,Autocuration,1,,B,,,,,
4298,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,BAO_0000019,CHEMBL618407,12338,,Expert,1,,F,,,,,
4299,,Tested for the inhibitory activity against 5-lipoxygenase,,BAO_0000357,CHEMBL618408,4501,,Autocuration,1,,B,,,,,
4300,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,CHEMBL618409,1132,,Autocuration,1,,B,,,,,
4301,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,BAO_0000357,CHEMBL618410,2117,,Autocuration,1,,B,,,,,
4302,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,BAO_0000357,CHEMBL618411,168,,Autocuration,1,,B,,,,,
4303,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,BAO_0000357,CHEMBL618412,168,,Autocuration,1,,B,,,,,
4304,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,BAO_0000219,CHEMBL618413,13575,,Autocuration,1,702.0,B,,,,,RBL-1
4305,,,,BAO_0000357,CHEMBL618414,11089,,Autocuration,1,,B,,,,,
4306,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,BAO_0000357,CHEMBL618415,216,,Autocuration,1,,B,,,,,
4307,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,BAO_0000019,CHEMBL618416,13165,,Autocuration,1,,B,,,,,
4308,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,BAO_0000357,CHEMBL876401,3278,,Autocuration,1,,B,,,,,
4309,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,BAO_0000357,CHEMBL618417,3278,,Expert,1,,B,,,,,
4310,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,BAO_0000357,CHEMBL618418,11966,,Autocuration,1,,B,,,,,
4311,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,BAO_0000357,CHEMBL618419,175,,Autocuration,1,,B,,,,,
4312,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,BAO_0000357,CHEMBL618420,175,,Autocuration,1,,B,,,,,
4313,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,BAO_0000357,CHEMBL618421,13449,,Autocuration,1,,B,,,,,
4314,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,BAO_0000019,CHEMBL618422,12014,,Autocuration,1,,B,,,,,
4315,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,BAO_0000019,CHEMBL618423,12014,,Autocuration,1,,B,,,,,
4316,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,BAO_0000019,CHEMBL618424,12014,,Autocuration,1,,B,,,,,
4317,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,BAO_0000220,CHEMBL618425,99,,Intermediate,1,,B,,,,,
4318,,The dark toxicity against 543 human galactophore carcinoma cells,,BAO_0000019,CHEMBL618426,4349,9606.0,Autocuration,1,,F,,Homo sapiens,,,
4319,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,BAO_0000219,CHEMBL618427,4071,9606.0,Expert,1,390.0,F,,Homo sapiens,,,Panel (56 tumour cell lines)
4320,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,BAO_0000219,CHEMBL618428,17589,9606.0,Expert,1,345.0,F,,Homo sapiens,,,5637
4321,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,BAO_0000219,CHEMBL618429,15002,9606.0,Intermediate,1,345.0,F,,Homo sapiens,,,5637
4322,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,BAO_0000219,CHEMBL618430,13958,9606.0,Intermediate,1,345.0,F,,Homo sapiens,,,5637
4323,,Growth inhibition against human 5637 cell lines,,BAO_0000219,CHEMBL618431,17589,9606.0,Expert,1,345.0,F,,Homo sapiens,,,5637
4324,,Antitumor activity against human bladder carcinoma 5637 cells.,,BAO_0000219,CHEMBL883799,16748,9606.0,Expert,1,345.0,F,,Homo sapiens,,,5637
4325,,Antitumor activity against human bladder carcinoma 5637 cells,,BAO_0000219,CHEMBL618432,16747,9606.0,Intermediate,1,345.0,F,,Homo sapiens,,,5637
4326,,Antitumor activity against human bladder carcinoma 5637 cells,,BAO_0000219,CHEMBL618433,16747,9606.0,Intermediate,1,345.0,F,,Homo sapiens,,,5637
4327,,In vitro inhibition of bovine trypsin(Trp).,,BAO_0000357,CHEMBL618434,15285,9913.0,Expert,1,,B,,Bos taurus,,,
4328,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,BAO_0000219,CHEMBL618435,3726,9527.0,Expert,1,407.0,B,,Cercopithecidae,,,CV-1
4329,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,BAO_0000357,CHEMBL876402,5033,,Autocuration,1,,B,,,,,
4330,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,BAO_0000019,CHEMBL618436,11756,,Autocuration,1,,F,,,,,
4331,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,BAO_0000218,CHEMBL618437,11953,,Autocuration,1,,F,In vivo,,,,
4332,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,BAO_0000357,CHEMBL618438,5033,10141.0,Intermediate,1,,B,,Cavia porcellus,,,
4333,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,BAO_0000251,CHEMBL883800,11347,10116.0,Expert,1,,A,,Rattus norvegicus,,,
4334,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,BAO_0000251,CHEMBL618439,11347,10116.0,Expert,1,,A,,Rattus norvegicus,,,
4335,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,CHEMBL618440,1229,,Intermediate,1,,F,,,,,
4336,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,CHEMBL618441,1229,,Intermediate,1,,F,,,,,
4337,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,BAO_0000019,CHEMBL618442,17588,5691.0,Expert,1,,B,,Trypanosoma brucei,,,
4338,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,BAO_0000019,CHEMBL618443,17588,5691.0,Autocuration,1,,B,,Trypanosoma brucei,,,
4339,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,BAO_0000019,CHEMBL619158,17588,9940.0,Expert,1,,B,,Ovis aries,,,
4340,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,BAO_0000019,CHEMBL620974,17588,9940.0,Autocuration,1,,B,,Ovis aries,,,
4341,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,BAO_0000357,CHEMBL620975,16485,,Autocuration,1,,B,,,,,
4342,,Average inhibitory concentration against 60 human cell lines was reported,,BAO_0000019,CHEMBL620976,4337,9606.0,Intermediate,1,,F,,Homo sapiens,,,
4343,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,BAO_0000019,CHEMBL620977,4112,9606.0,Expert,1,,F,,Homo sapiens,,,
4344,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,BAO_0000219,CHEMBL620978,16160,9606.0,Intermediate,1,542.0,F,,Homo sapiens,,,Panel NCI-60 (60 carcinoma cell lines)
4345,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,BAO_0000219,CHEMBL620979,16160,9606.0,Intermediate,1,542.0,F,,Homo sapiens,,,Panel NCI-60 (60 carcinoma cell lines)
4346,,In vitro mean growth inhibitory activity against 60-cell panel,,BAO_0000219,CHEMBL620980,17376,,Expert,1,542.0,F,,,,,Panel NCI-60 (60 carcinoma cell lines)
4347,,In vitro mean growth lethal concentration against 60-cell panel,,BAO_0000219,CHEMBL620981,17376,,Expert,1,542.0,F,,,,,Panel NCI-60 (60 carcinoma cell lines)
4348,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,BAO_0000219,CHEMBL620982,17376,,Expert,1,542.0,F,,,,,Panel NCI-60 (60 carcinoma cell lines)
4349,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,BAO_0000219,CHEMBL620983,17376,,Expert,1,542.0,F,,,,,Panel NCI-60 (60 carcinoma cell lines)
4350,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,CHEMBL620984,3241,,Autocuration,1,,F,,,,,
4351,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,CHEMBL620985,3241,,Autocuration,1,,F,,,,,
4352,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,BAO_0000357,CHEMBL620986,3725,,Expert,1,,B,,,,,
4353,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,BAO_0000218,CHEMBL620987,10805,5833.0,Expert,1,,F,,Plasmodium falciparum,,,
4354,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,BAO_0000218,CHEMBL620988,10805,5833.0,Expert,1,,F,,Plasmodium falciparum,,,
4355,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,CHEMBL620989,10805,5833.0,Expert,1,,F,,Plasmodium falciparum,,,
4356,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,CHEMBL620990,10805,5833.0,Expert,1,,F,,Plasmodium falciparum,,,
4357,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,CHEMBL620991,10805,5833.0,Intermediate,1,,F,,Plasmodium falciparum,,,
4358,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,CHEMBL620992,10144,10090.0,Intermediate,1,850.0,F,,Mus musculus,,,6C3HED
4359,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,CHEMBL620993,10144,10090.0,Intermediate,1,850.0,F,,Mus musculus,,,6C3HED
4360,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,BAO_0000218,CHEMBL620994,10144,10090.0,Intermediate,1,850.0,F,,Mus musculus,,,6C3HED
4361,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,CHEMBL620995,10144,10090.0,Intermediate,1,850.0,F,,Mus musculus,,,6C3HED
4362,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,CHEMBL620996,10144,10090.0,Intermediate,1,850.0,F,,Mus musculus,,,6C3HED
4363,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,BAO_0000218,CHEMBL875581,10144,10090.0,Intermediate,1,850.0,F,,Mus musculus,,,6C3HED
4364,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,BAO_0000218,CHEMBL620997,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4365,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,BAO_0000218,CHEMBL620998,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4366,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,CHEMBL620999,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4367,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,BAO_0000218,CHEMBL621000,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4368,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,BAO_0000218,CHEMBL621001,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4369,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,BAO_0000218,CHEMBL621002,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4370,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,BAO_0000218,CHEMBL621003,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4371,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,BAO_0000218,CHEMBL621004,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4372,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,CHEMBL621005,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4373,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,BAO_0000218,CHEMBL621006,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4374,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,BAO_0000218,CHEMBL621007,10685,10090.0,Autocuration,1,,F,In vivo,Mus musculus,,,
4375,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,CHEMBL621008,10144,10090.0,Autocuration,1,,F,,Mus musculus,,,
4376,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,CHEMBL621009,10144,10090.0,Autocuration,1,,F,,Mus musculus,,,
4377,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,CHEMBL857705,10144,10090.0,Autocuration,1,,F,,Mus musculus,,,
4378,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,CHEMBL619828,10144,10090.0,Autocuration,1,,F,,Mus musculus,,,
4379,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,CHEMBL619829,10685,10090.0,Autocuration,1,,F,,Mus musculus,,,
4380,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,BAO_0000218,CHEMBL619830,10685,10090.0,Autocuration,1,,F,,Mus musculus,,,
4381,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,CHEMBL619831,10685,10090.0,Autocuration,1,,F,,Mus musculus,,,
4382,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,CHEMBL619832,10685,10090.0,Autocuration,1,,F,,Mus musculus,,,
4383,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,BAO_0000218,CHEMBL619833,10685,10090.0,Autocuration,1,,A,,Mus musculus,,,
4384,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,BAO_0000218,CHEMBL619834,10685,10090.0,Autocuration,1,,A,,Mus musculus,,,
4385,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,BAO_0000218,CHEMBL619835,10685,10090.0,Autocuration,1,,A,,Mus musculus,,,
4386,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,BAO_0000218,CHEMBL619836,10685,10090.0,Autocuration,1,,A,,Mus musculus,,,
4387,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,BAO_0000218,CHEMBL619837,8831,10090.0,Intermediate,1,850.0,F,,Mus musculus,,,6C3HED
4388,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,BAO_0000218,CHEMBL619838,11704,,Autocuration,1,,F,In vivo,,,,
4389,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,BAO_0000218,CHEMBL619839,11704,10090.0,Intermediate,1,,A,,Mus musculus,,,
4390,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,BAO_0000218,CHEMBL619840,10685,10090.0,Intermediate,1,850.0,F,In vivo,Mus musculus,,,6C3HED
4391,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,BAO_0000218,CHEMBL619841,10685,10090.0,Intermediate,1,850.0,F,In vivo,Mus musculus,,,6C3HED
4392,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,BAO_0000218,CHEMBL857704,11368,10090.0,Expert,1,850.0,F,,Mus musculus,,,6C3HED
4393,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,BAO_0000218,CHEMBL619842,11368,10090.0,Intermediate,1,850.0,F,,Mus musculus,,,6C3HED
4394,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,BAO_0000218,CHEMBL619843,11368,10090.0,Expert,1,850.0,F,,Mus musculus,,,6C3HED
4395,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,BAO_0000019,CHEMBL619844,17763,1280.0,Autocuration,1,,B,,Staphylococcus aureus,,,
4396,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,BAO_0000251,CHEMBL857855,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4397,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,BAO_0000251,CHEMBL619845,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4398,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,BAO_0000251,CHEMBL619846,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4399,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,BAO_0000251,CHEMBL619847,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4400,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,BAO_0000251,CHEMBL619848,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4401,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,BAO_0000251,CHEMBL620893,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4402,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,BAO_0000251,CHEMBL620894,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4403,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,BAO_0000251,CHEMBL620895,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4404,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,BAO_0000251,CHEMBL620896,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4405,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,BAO_0000251,CHEMBL620897,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4406,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,BAO_0000251,CHEMBL620898,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4407,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,BAO_0000251,CHEMBL620899,7411,10116.0,Autocuration,1,,B,,Rattus norvegicus,,Liver,
4408,,The apparent total plasma clearance in monkey,,BAO_0000218,CHEMBL620900,347,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
4409,,Compound was evaluated for Hepatic clearance in monkey,,BAO_0000218,CHEMBL620901,3341,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4410,,Lower clearance in monkey (i.v.) at 0.5 mpk,,BAO_0000218,CHEMBL620902,17853,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4411,,Plasma clearance in rhesus monkey,,BAO_0000218,CHEMBL620903,4514,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4412,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL620904,6062,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4413,,Plasma clearance of compound was determined in monkey,,BAO_0000218,CHEMBL620905,6821,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4414,,Plasma clearance was calculated in rhesus monkey,,BAO_0000218,CHEMBL620906,6057,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4415,,Plasma clearance in rhesus monkey,,BAO_0000218,CHEMBL875420,5145,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4416,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL620907,6641,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4417,,Plasma clearance was evaluated in rhesus,,BAO_0000218,CHEMBL620908,5472,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4418,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,CHEMBL620909,4257,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4419,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,CHEMBL620910,5546,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4420,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,CHEMBL620911,5334,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4421,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,CHEMBL620912,5334,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4422,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,CHEMBL620913,17509,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4423,,Cmax in monkey after administration of 1 mg/kg iv,,BAO_0000218,CHEMBL620914,6535,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4424,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,CHEMBL620915,5668,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4425,,Cmax in cynomolgus monkey by iv administration,,BAO_0000218,CHEMBL620916,5922,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4426,,Cmax in cynomolgus monkey by po administration,,BAO_0000218,CHEMBL620917,5922,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4427,,Cmax value evaluated in monkey,,BAO_0000218,CHEMBL620918,6078,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4428,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,CHEMBL620919,2661,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4429,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,BAO_0000218,CHEMBL620920,3249,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
4430,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,BAO_0000218,CHEMBL620921,3249,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
4431,,Maximal plasma concentration in squirrel monkeys,,BAO_0000218,CHEMBL620922,5553,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
4432,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL620923,1916,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4433,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,BAO_0000218,CHEMBL620924,6227,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
4434,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,CHEMBL620925,4809,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4435,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,CHEMBL620926,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4436,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,CHEMBL620927,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4437,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,BAO_0000218,CHEMBL620928,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4438,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,BAO_0000218,CHEMBL620929,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4439,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,CHEMBL620930,6221,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
4440,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,BAO_0000218,CHEMBL620931,167,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4441,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,BAO_0000218,CHEMBL620932,167,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4442,,Absolute bioavailability was evaluated in monkey,,BAO_0000218,CHEMBL620933,4257,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4443,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,CHEMBL620934,6221,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4444,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,BAO_0000218,CHEMBL620935,17667,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4445,,Bioavailability of compound was determined in rhesus monkey,,BAO_0000218,CHEMBL620936,17267,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4446,,Bioavailability determined after oral administration in marmoset,,BAO_0000218,CHEMBL620937,4256,38020.0,Autocuration,1,,A,In vivo,marmosets,,,
4447,,Oral bioavailability in cynomolgus monkey,,BAO_0000218,CHEMBL620938,4256,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
4448,,Bioavailability in monkey (p.o.) at 2.0 mpk,,BAO_0000218,CHEMBL620939,17853,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4449,,Bioavailability was evaluated after oral administration in monkey,,BAO_0000218,CHEMBL620940,16365,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4450,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL620941,1916,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
4451,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,CHEMBL620942,5334,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4452,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,CHEMBL620943,5334,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4453,,Bioavailability of the compound was determined in monkey,,BAO_0000218,CHEMBL620944,17592,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4454,,Bioavailability in squirrel monkey (dose 5 mg/kg),,BAO_0000218,CHEMBL620945,1399,9521.0,Autocuration,1,,A,In vivo,Saimiri sciureus,,,
4455,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,CHEMBL620946,4809,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4456,,Oral bioavailability in monkey,,BAO_0000218,CHEMBL620947,3341,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4457,,Compound was tested for bioavailability in squirrel monkey,,BAO_0000218,CHEMBL620948,64,9521.0,Autocuration,1,,A,In vivo,Saimiri sciureus,,,
4458,,Oral bioavailability in Rhesus monkey,,BAO_0000218,CHEMBL620949,5005,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4459,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,BAO_0000218,CHEMBL620950,5005,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4460,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,BAO_0000218,CHEMBL620951,5237,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
4461,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,BAO_0000218,CHEMBL620952,5237,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
4462,,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,CHEMBL875421,5302,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4463,,Oral bioavailability of compound at 5 mg/kg in monkey,,BAO_0000218,CHEMBL620953,17667,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4464,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,CHEMBL873491,6161,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
4465,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,CHEMBL620954,6161,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
4466,,Plasma half life determined,,BAO_0000218,CHEMBL620955,3854,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
4467,,Plasma half life in dog,,BAO_0000218,CHEMBL618097,993,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
4468,,Plasma half-life in Beagle dogs,,BAO_0000218,CHEMBL618268,4514,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
4469,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,CHEMBL618269,5334,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
4470,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,BAO_0000218,CHEMBL618270,5334,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
4471,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,CHEMBL618271,1466,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
4472,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,CHEMBL873493,1466,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
4473,,Tested for the half life period in dog,,BAO_0000218,CHEMBL621031,5313,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
4474,,Tested for the half life period in dog at dosage of 10 mpk,,BAO_0000218,CHEMBL621032,5313,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
4475,,The compound was tested for half life in dog,,BAO_0000218,CHEMBL621033,3880,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
4476,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,BAO_0000218,CHEMBL621034,3639,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
4477,,The half life was determined,,BAO_0000218,CHEMBL621035,3880,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
4478,,The plasma half-life in dogs,,BAO_0000218,CHEMBL621036,3918,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
4479,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,BAO_0000218,CHEMBL621037,16452,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
4480,,Half life in dog,,BAO_0000218,CHEMBL619812,17796,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
4481,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,CHEMBL619813,5983,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
4482,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,CHEMBL873335,1466,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
4483,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619814,16456,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
4484,,Cmax in ferrets after 30 mg/kg oral dose,,BAO_0000218,CHEMBL619815,6113,9669.0,Expert,1,,A,In vivo,Mustela putorius furo,,,
4485,,Emesis in ferrets at 30 mg/kg oral dose,,BAO_0000218,CHEMBL619816,6113,9669.0,Expert,1,,F,In vivo,Mustela putorius furo,,,
4486,,Bioavailability in cynomolgus monkey,,BAO_0000218,CHEMBL619817,17796,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
4487,,Volume of distribution in cynomolgus,,BAO_0000218,CHEMBL619818,17796,9541.0,Intermediate,1,,A,In vivo,Macaca fascicularis,,,
4488,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,BAO_0000218,CHEMBL619819,5308,10141.0,Autocuration,1,,A,,Cavia porcellus,,Plasma,
4489,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,BAO_0000218,CHEMBL619820,4877,10141.0,Autocuration,1,,A,,Cavia porcellus,,,
4490,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,BAO_0000218,CHEMBL875419,4876,10141.0,Autocuration,1,,A,,Cavia porcellus,,,
4491,,AUC in guinea pig after 3mg/kg oral dose,,BAO_0000218,CHEMBL619821,4878,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,Plasma,
4492,,Bioavailability in guinea pig was tested,,BAO_0000218,CHEMBL619822,5308,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4493,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,BAO_0000218,CHEMBL619823,4877,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4494,,Tested for the oral bioavailability of the compound,,BAO_0000218,CHEMBL619824,4876,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4495,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,BAO_0000218,CHEMBL619825,4876,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4496,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,BAO_0000218,CHEMBL619826,5308,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4497,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,BAO_0000218,CHEMBL619827,4877,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,Lung,
4498,,Cmax in guinea pig after 3mg/kg oral dose,,BAO_0000218,CHEMBL618167,4878,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4499,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,CHEMBL618168,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,Blood,
4500,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,CHEMBL618169,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,Brain,
4501,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,CHEMBL618170,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,,
4502,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,CHEMBL618171,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,Intestine,
4503,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,CHEMBL618172,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,Kidney,
4504,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,CHEMBL618173,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,Liver,
4505,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,CHEMBL618174,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,,
4506,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,CHEMBL875408,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,Spleen,
4507,,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,CHEMBL839827,14465,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4508,,Partition coefficient was measured as -log (counts per min ),,BAO_0000019,CHEMBL618175,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,,
4509,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,CHEMBL618176,611,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4510,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,CHEMBL618177,611,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4511,,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,CHEMBL618178,14465,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4512,,"Tested for the half life period of the compound, intravenously",,BAO_0000218,CHEMBL618179,4876,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4513,,Half-life was measured,,BAO_0000019,CHEMBL873489,5689,10141.0,Autocuration,1,,A,,Cavia porcellus,,,
4514,,The time required for onset of inotropy after addition of a single dose of delta F75,,BAO_0000019,CHEMBL618180,7515,10141.0,Autocuration,1,,A,,Cavia porcellus,,,
4515,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,BAO_0000218,CHEMBL618181,17667,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4516,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,BAO_0000218,CHEMBL618182,17667,10141.0,Autocuration,1,,A,In vivo,Cavia porcellus,,,
4517,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,CHEMBL618183,4727,10029.0,Autocuration,1,,A,In vivo,Cricetulus griseus,,,
4518,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL618184,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4519,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,CHEMBL618185,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4520,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL618186,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4521,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL618187,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4522,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,BAO_0000218,CHEMBL618188,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4523,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL875409,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4524,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL618189,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4525,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618190,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
4526,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618191,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
4527,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL618192,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
4528,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618193,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
4529,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618194,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
4530,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL618195,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
4531,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618196,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
4532,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618197,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
4533,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL618198,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
4534,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618199,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
4535,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618200,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
4536,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL618201,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
4537,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618202,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
4538,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618203,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
4539,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL618204,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
4540,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618205,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
4541,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618206,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
4542,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL618207,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
4543,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618208,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
4544,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618932,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
4545,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL618933,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
4546,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618934,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
4547,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618935,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
4548,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL618936,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
4549,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL618937,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
4550,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL618938,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
4551,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL619104,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
4552,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL619105,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
4553,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL619106,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
4554,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL619107,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
4555,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,BAO_0000218,CHEMBL875410,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
4556,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,BAO_0000218,CHEMBL619108,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
4557,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,BAO_0000218,CHEMBL619109,3655,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
4558,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,CHEMBL619110,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4559,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,CHEMBL619111,16597,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4560,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,CHEMBL619112,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4561,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,CHEMBL619113,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4562,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,CHEMBL619114,17764,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4563,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,CHEMBL619115,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4564,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,BAO_0000219,CHEMBL619116,3830,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4565,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,BAO_0000219,CHEMBL619117,3829,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4566,,Compound was evaluated for cytotoxicity against A2780 cell lines.,,BAO_0000219,CHEMBL619118,2040,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4567,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,BAO_0000219,CHEMBL619119,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4568,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,BAO_0000219,CHEMBL619120,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4569,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,BAO_0000219,CHEMBL619121,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4570,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,BAO_0000219,CHEMBL619122,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4571,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,BAO_0000219,CHEMBL619123,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4572,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,BAO_0000219,CHEMBL619124,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4573,,Compound was evaluated for cytotoxicity against A2780 cell line,,BAO_0000219,CHEMBL619125,2859,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4574,,In vitro inhibitory activity against human tumor cell line A2780,,BAO_0000219,CHEMBL875411,5618,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4575,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,BAO_0000219,CHEMBL619126,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4576,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,BAO_0000219,CHEMBL619127,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4577,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,BAO_0000219,CHEMBL619128,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4578,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,BAO_0000219,CHEMBL619129,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4579,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,BAO_0000219,CHEMBL619130,2113,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4580,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,BAO_0000219,CHEMBL619131,2113,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4581,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,BAO_0000219,CHEMBL619132,16745,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4582,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,CHEMBL619133,16597,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
4583,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,BAO_0000219,CHEMBL619134,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4584,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,BAO_0000219,CHEMBL619135,15684,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4585,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,BAO_0000219,CHEMBL619136,2040,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4586,,Relative resistance factor in A2780 cisplatin-resistant line,,BAO_0000219,CHEMBL619137,2040,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4587,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,BAO_0000219,CHEMBL883713,16165,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4588,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,BAO_0000219,CHEMBL875412,16165,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4589,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,CHEMBL619138,16597,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
4590,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,CHEMBL619262,16597,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
4591,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,BAO_0000219,CHEMBL619139,3992,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4592,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,BAO_0000219,CHEMBL619140,10553,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4593,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,BAO_0000219,CHEMBL619141,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4594,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,BAO_0000219,CHEMBL619142,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4595,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,BAO_0000219,CHEMBL619143,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4596,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,BAO_0000219,CHEMBL619144,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4597,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,BAO_0000219,CHEMBL619145,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4598,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,BAO_0000219,CHEMBL619146,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4599,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,BAO_0000219,CHEMBL619147,15569,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4600,,Antiproliferative effect of compound on A2780/DX cell line,,BAO_0000219,CHEMBL619148,17420,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4601,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,BAO_0000219,CHEMBL619149,17420,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4602,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,BAO_0000219,CHEMBL619150,15099,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4603,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,BAO_0000219,CHEMBL619151,15099,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4604,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,BAO_0000219,CHEMBL883794,17672,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4605,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,BAO_0000219,CHEMBL619152,17672,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4606,,In vitro cytotoxicity against A2780ADR cell line,,BAO_0000219,CHEMBL619153,17270,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4607,,In vitro cytotoxicity against A2780CIS cell line,,BAO_0000219,CHEMBL619154,17270,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4608,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,BAO_0000219,CHEMBL619155,5574,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4609,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,BAO_0000219,CHEMBL619156,2113,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4610,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,CHEMBL619157,16913,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4611,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,CHEMBL619797,16913,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4612,,Oral bioavailability of compound in rhesus macaques,,BAO_0000218,CHEMBL619798,17839,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4613,,Oral bioavailability in monkey,,BAO_0000218,CHEMBL619799,6821,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4614,,Oral bioavailability evaluated in monkey,,BAO_0000218,CHEMBL619800,6078,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4615,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,BAO_0000218,CHEMBL619801,6535,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4616,,Oral bioavailability in Rhesus monkey,,BAO_0000218,CHEMBL619802,4449,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4617,,Oral bioavailability was calculated in rhesus monkey,,BAO_0000218,CHEMBL619803,6057,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4618,,Oral bioavailability in cynomolgus monkey,,BAO_0000218,CHEMBL619965,5922,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
4619,,Oral bioavailability in monkey,,BAO_0000218,CHEMBL619966,5940,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4620,,Oral bioavailability in monkey,,BAO_0000218,CHEMBL619967,6265,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4621,,Oral bioavailability in monkey (dose 1 mg/kg),,BAO_0000218,CHEMBL620073,6265,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4622,,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,CHEMBL620074,6265,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4623,,Oral bioavailability in monkey,,BAO_0000218,CHEMBL620075,5940,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4624,,Oral bioavailability in monkey,,BAO_0000218,CHEMBL620076,5940,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4625,,Oral bioavailability in rhesus monkey,,BAO_0000218,CHEMBL620077,4514,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4626,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,BAO_0000218,CHEMBL620078,5546,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4627,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,BAO_0000218,CHEMBL620079,5553,9521.0,Autocuration,1,,A,In vivo,Saimiri sciureus,,,
4628,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL620080,6641,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4629,,Oral bioavailability in Rhesus monkey,,BAO_0000218,CHEMBL620081,5472,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4630,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,BAO_0000218,CHEMBL620082,5668,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4631,,Oral bioavailability in monkey at 10 mg/kg of the compound,,BAO_0000218,CHEMBL620083,5711,9443.0,Autocuration,1,,A,In vivo,monkey,,,
4632,,Bioavailability in Rhesus monkey,,BAO_0000218,CHEMBL620084,5145,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4633,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL620085,3443,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4634,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL874595,3443,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4635,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,BAO_0000218,CHEMBL873352,3249,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4636,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,BAO_0000218,CHEMBL620086,3249,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4637,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,CHEMBL620087,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4638,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,CHEMBL620088,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4639,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,CHEMBL620089,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4640,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,CHEMBL620090,4809,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4641,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,CHEMBL620091,4809,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4642,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,CHEMBL620092,14294,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4643,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000251,CHEMBL620093,14294,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4644,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,BAO_0000251,CHEMBL620094,14294,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4645,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,CHEMBL620095,14294,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4646,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL620096,3443,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4647,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL620097,3443,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4648,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,BAO_0000019,CHEMBL620098,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4649,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL620099,3443,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4650,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL620100,3443,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4651,,Elimination Half-life of compound was determined in monkey,,BAO_0000019,CHEMBL620101,6821,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4652,,Half life of compound was determined in rhesus monkey,,BAO_0000019,CHEMBL620102,17267,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4653,,Half life in monkey plasma,,BAO_0000366,CHEMBL620103,5819,9527.0,Autocuration,1,,A,,Cercopithecidae,,Plasma,
4654,,Half life in monkey plasma; Not detected,,BAO_0000366,CHEMBL620104,5819,9527.0,Autocuration,1,,A,,Cercopithecidae,,Plasma,
4655,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL874596,1916,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4656,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,CHEMBL873490,17509,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4657,,Terminal half life of the compound.,,BAO_0000019,CHEMBL620105,1399,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4658,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL620780,1916,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4659,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,CHEMBL620781,4809,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4660,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,CHEMBL620956,5546,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4661,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL620957,3443,9527.0,Autocuration,1,,A,,Cercopithecidae,,Urine,
4662,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL620958,3443,9527.0,Autocuration,1,,A,,Cercopithecidae,,Urine,
4663,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,CHEMBL620959,4257,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4664,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,CHEMBL620960,6221,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4665,,Volume of distribution was evaluated in rhesus,,BAO_0000218,CHEMBL620961,5472,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4666,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,CHEMBL620962,4727,10029.0,Autocuration,1,,A,In vivo,Cricetulus griseus,,,
4667,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,BAO_0000218,CHEMBL620963,4727,10029.0,Autocuration,1,,A,In vivo,Cricetulus griseus,,,
4668,,Bioavailability in hamster was determined,,BAO_0000218,CHEMBL620964,4727,10029.0,Autocuration,1,,A,In vivo,Cricetulus griseus,,,
4669,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,BAO_0000218,CHEMBL620965,4727,10029.0,Autocuration,1,,A,In vivo,Cricetulus griseus,,,
4670,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,BAO_0000218,CHEMBL620966,4727,10029.0,Autocuration,1,,A,In vivo,Cricetulus griseus,,,
4671,,Half life of compound was determined in hamster blood,,BAO_0000221,CHEMBL620967,4727,10029.0,Autocuration,1,,A,,Cricetulus griseus,,Blood,
4672,,Michaelis-Menten constant of the compound.,,BAO_0000019,CHEMBL620968,1452,9823.0,Autocuration,1,,A,,Sus scrofa,,,
4673,,Vmax value was measured at 0 uM concentration of silyl ether.,,BAO_0000019,CHEMBL874597,1452,9823.0,Autocuration,1,,A,,Sus scrofa,,,
4674,,Vmax value was measured at 10 uM concentration of silyl ether.,,BAO_0000019,CHEMBL620969,1452,9823.0,Autocuration,1,,A,,Sus scrofa,,,
4675,,Vmax value was measured at 5 uM concentration of silyl ether.,,BAO_0000019,CHEMBL620970,1452,9823.0,Autocuration,1,,A,,Sus scrofa,,,
4676,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,BAO_0000357,CHEMBL620971,11706,9606.0,Expert,1,,B,,Homo sapiens,,,
4677,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,CHEMBL620972,1916,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4678,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,BAO_0000019,CHEMBL620973,17791,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4679,,Active metabolite of ifosfamide determined in humans; A-Active,,BAO_0000019,CHEMBL618243,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4680,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,BAO_0000019,CHEMBL618244,6567,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4681,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,BAO_0000019,CHEMBL618245,6567,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4682,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,BAO_0000019,CHEMBL618246,6567,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4683,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,BAO_0000019,CHEMBL618247,6567,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4684,,Compound was evaluated for oral bioavailability in human,,BAO_0000218,CHEMBL618248,17791,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4685,,Metabolite of ifosfamide determined in urine; NF-Not found,,BAO_0000019,CHEMBL618249,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4686,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,BAO_0000019,CHEMBL618250,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4687,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,BAO_0000019,CHEMBL874598,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4688,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,BAO_0000019,CHEMBL618251,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4689,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,BAO_0000019,CHEMBL618252,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4690,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,BAO_0000019,CHEMBL618253,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4691,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,BAO_0000019,CHEMBL618254,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4692,,Percent of compound in healthy individuals (Group D),,BAO_0000019,CHEMBL618255,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4693,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,BAO_0000251,CHEMBL618983,4397,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
4694,,Binding towards human plasma protein at 10 uM,,BAO_0000019,CHEMBL618984,17409,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4695,,Binding towards human plasma protein at 100 uM,,BAO_0000019,CHEMBL618985,17409,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4696,,Human plasma protein binding activity was determined,,BAO_0000019,CHEMBL618986,17176,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4697,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,BAO_0000019,CHEMBL618987,15444,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4698,,Percent binding of compound towards human plasma protein was determined,,BAO_0000019,CHEMBL618988,17267,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4699,,Plasma clearance in human liver microsomes,,BAO_0000251,CHEMBL618989,5944,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
4700,,In vitro intrinsic clearance in human liver microsome,,BAO_0000251,CHEMBL618990,5668,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
4701,,In vitro intrinsic clearance in human liver microsome,,BAO_0000251,CHEMBL618991,5669,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
4702,,In vitro microsome metabolism clearance in human was determined,,BAO_0000251,CHEMBL876725,5041,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,,
4703,,In vitro microsome metabolism clearance in human was determined; High,,BAO_0000251,CHEMBL618992,5041,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,,
4704,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,BAO_0000251,CHEMBL618993,5041,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,,
4705,,Pharmacokinetic property (clearance) in human liver microsome,,BAO_0000251,CHEMBL618994,5676,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
4706,,Plasma clearance in human liver microsomes,,BAO_0000251,CHEMBL618995,5944,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
4707,,In vitro clearance in human liver microsomes,,BAO_0000251,CHEMBL618996,17538,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
4708,,Intrinsic clearance in human liver microsomes was determined,,BAO_0000251,CHEMBL618997,6331,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
4709,,Intrinsic clearance in human liver microsomes was determined,,BAO_0000251,CHEMBL618998,5948,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
4710,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,CHEMBL618999,5965,9606.0,Autocuration,1,,A,In vivo,Homo sapiens,,,
4711,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,CHEMBL620223,1916,9606.0,Autocuration,1,,A,In vivo,Homo sapiens,,,
4712,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,CHEMBL620224,5965,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4713,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,BAO_0000019,CHEMBL620225,1299,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4714,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,BAO_0000019,CHEMBL620226,1299,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4715,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,CHEMBL620227,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4716,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,CHEMBL876726,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4717,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,CHEMBL620228,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4718,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,CHEMBL620229,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4719,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,CHEMBL620230,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4720,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,CHEMBL620231,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4721,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,CHEMBL620232,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4722,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,BAO_0000218,CHEMBL620233,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4723,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,BAO_0000218,CHEMBL620234,14294,10090.0,Intermediate,1,,A,,Mus musculus,,,
4724,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000218,CHEMBL620235,14294,10090.0,Intermediate,1,,A,,Mus musculus,,,
4725,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,CHEMBL620236,14294,10090.0,Intermediate,1,,A,,Mus musculus,,,
4726,,In vitro metabolic potential in mouse liver microsomes,,BAO_0000218,CHEMBL620237,6251,10090.0,Intermediate,1,,A,,Mus musculus,,Liver,
4727,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,BAO_0000218,CHEMBL620238,17582,10090.0,Intermediate,1,,A,,Mus musculus,,,
4728,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,BAO_0000218,CHEMBL620239,17811,10090.0,Intermediate,1,,A,,Mus musculus,,Adrenal gland,
4729,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,BAO_0000218,CHEMBL620240,17811,10090.0,Intermediate,1,,A,,Mus musculus,,Brain,
4730,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,BAO_0000218,CHEMBL620241,17811,10090.0,Intermediate,1,,A,,Mus musculus,,Brain,
4731,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,BAO_0000218,CHEMBL876727,17811,10090.0,Intermediate,1,,A,,Mus musculus,,,
4732,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,BAO_0000218,CHEMBL620242,17811,10090.0,Intermediate,1,,A,,Mus musculus,,Kidney,
4733,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,BAO_0000218,CHEMBL620243,17811,10090.0,Intermediate,1,,A,,Mus musculus,,,
4734,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,BAO_0000218,CHEMBL620244,5288,10090.0,Intermediate,1,,A,,Mus musculus,,,
4735,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,BAO_0000218,CHEMBL620245,2717,10090.0,Intermediate,1,,A,,Mus musculus,,Serum,
4736,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,BAO_0000218,CHEMBL620246,2717,10090.0,Intermediate,1,,A,,Mus musculus,,Serum,
4737,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,BAO_0000218,CHEMBL620247,2717,10090.0,Intermediate,1,,A,,Mus musculus,,Serum,
4738,,Half life of compound was determined in plasma of mice at 24 mg/Kg,,BAO_0000218,CHEMBL620248,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
4739,,Half life of compound was determined in plasma of mice at 40 mg/Kg,,BAO_0000218,CHEMBL873497,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
4740,,Half life of compound was determined in plasma of mice at 5 mg/Kg,,BAO_0000218,CHEMBL620249,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
4741,,Half life after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,CHEMBL620250,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4742,,Half life after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,CHEMBL620251,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4743,,Half life after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,CHEMBL620252,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4744,,Half life after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,CHEMBL620253,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4745,,Half life after intravenous administration in mice at 23 uM/kg,,BAO_0000218,CHEMBL620254,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4746,,Half life after intravenous administration in mice at 24 uM/kg,,BAO_0000218,CHEMBL620255,17764,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4747,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,CHEMBL620256,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4748,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,BAO_0000218,CHEMBL876728,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4749,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,BAO_0000218,CHEMBL620257,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4750,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,BAO_0000218,CHEMBL620258,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4751,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,BAO_0000218,CHEMBL620259,4890,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4752,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,BAO_0000218,CHEMBL620260,429,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4753,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,CHEMBL620261,17837,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
4754,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,CHEMBL620262,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4755,,Half life at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,CHEMBL620263,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4756,,Half life in ob/ob mice,,BAO_0000218,CHEMBL620264,6619,10090.0,Intermediate,1,,A,,Mus musculus,,,
4757,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,CHEMBL620265,4066,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4758,,Half-life was measured in mouse,,BAO_0000218,CHEMBL620266,4239,10090.0,Intermediate,1,,A,,Mus musculus,,,
4759,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,CHEMBL620267,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4760,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,BAO_0000218,CHEMBL619364,8999,10090.0,Intermediate,1,,A,,Mus musculus,,,
4761,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,BAO_0000218,CHEMBL619365,8999,10090.0,Intermediate,1,,A,,Mus musculus,,,
4762,,T2 in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL619366,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Brain,
4763,,T2 in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL619367,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Kidney,
4764,,T2 in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL619368,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Liver,
4765,,T2 in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL619369,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Lung,
4766,,T2 in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL876729,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Spleen,
4767,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,CHEMBL619370,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4768,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,BAO_0000218,CHEMBL619371,4890,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4769,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,BAO_0000218,CHEMBL619372,429,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4770,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,BAO_0000218,CHEMBL620012,429,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4771,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,CHEMBL620013,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4772,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,CHEMBL620014,16913,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4773,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,CHEMBL620015,16913,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4774,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,CHEMBL621010,16913,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4775,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,CHEMBL621011,16913,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4776,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,CHEMBL621012,16913,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4777,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,CHEMBL621013,16913,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4778,,In vitro cytotoxicity against A2780TAX cell line,,BAO_0000219,CHEMBL621014,17270,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4779,,In vitro inhibitory activity against human tumor cell line A2780cis,,BAO_0000219,CHEMBL618154,5618,9606.0,Intermediate,1,481.0,F,,Homo sapiens,,,A2780cisR
4780,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,BAO_0000219,CHEMBL618155,17777,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
4781,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,BAO_0000219,CHEMBL618156,16112,9606.0,Intermediate,1,481.0,F,,Homo sapiens,,,A2780cisR
4782,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,BAO_0000219,CHEMBL618157,15748,9606.0,Intermediate,1,481.0,F,,Homo sapiens,,,A2780cisR
4783,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,BAO_0000219,CHEMBL618328,6633,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4784,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,BAO_0000219,CHEMBL618329,16930,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4785,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,BAO_0000219,CHEMBL618330,17496,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4786,,In vitro antitumor activity against A2780cisR cell line.,,BAO_0000219,CHEMBL618331,12989,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
4787,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,BAO_0000219,CHEMBL618332,4840,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
4788,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,BAO_0000219,CHEMBL618333,12989,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
4789,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,BAO_0000219,CHEMBL618334,16745,9606.0,Intermediate,1,481.0,F,,Homo sapiens,,,A2780cisR
4790,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,BAO_0000219,CHEMBL618335,16597,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
4791,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,BAO_0000019,CHEMBL618336,16547,10116.0,Expert,1,,B,,Rattus norvegicus,,,
4792,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,CHEMBL618337,16547,,Expert,1,,F,,,,,
4793,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,CHEMBL618338,16547,10116.0,Expert,1,,F,,Rattus norvegicus,,,
4794,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,BAO_0000219,CHEMBL618339,15856,9606.0,Expert,1,722.0,F,,Homo sapiens,,,HEK293
4795,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,BAO_0000219,CHEMBL618340,15856,9606.0,Expert,1,722.0,F,,Homo sapiens,,,HEK293
4796,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,BAO_0000019,CHEMBL618341,16547,10090.0,Expert,1,,B,,Mus musculus,,,
4797,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,CHEMBL618342,16547,,Expert,1,,F,,,,,
4798,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,CHEMBL618343,16547,10090.0,Expert,1,,F,,Mus musculus,,,
4799,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,BAO_0000357,CHEMBL621038,17402,,Expert,1,,B,,,,,
4800,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,BAO_0000219,CHEMBL621039,11746,9606.0,Autocuration,1,574.0,F,,Homo sapiens,,,T-cells
4801,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,BAO_0000219,CHEMBL621040,11746,9606.0,Autocuration,1,574.0,F,,Homo sapiens,,,T-cells
4802,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,BAO_0000219,CHEMBL621041,5455,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
4803,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,BAO_0000219,CHEMBL621042,2068,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
4804,,In vitro antitumor activity against A375cell line extracted form melanoma,,BAO_0000219,CHEMBL621043,2683,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
4805,,Inhibition of cell growth in (A375) melan cell line,,BAO_0000219,CHEMBL621044,15313,9606.0,Expert,1,455.0,F,,Homo sapiens,,,A-375
4806,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,BAO_0000219,CHEMBL621045,13739,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
4807,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,BAO_0000219,CHEMBL621046,13739,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
4808,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,BAO_0000219,CHEMBL621047,14750,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
4809,,Antiproliferative activity measured against A427 human lung carcinoma,,BAO_0000219,CHEMBL621048,14777,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4810,,Antiproliferative activity measured against A427 human lung carcinoma,,BAO_0000219,CHEMBL883798,14777,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4811,,Cytotoxicity against lung carcinoma A427 tumor cell lines,,BAO_0000219,CHEMBL621049,17672,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4812,,Inhibition of large cell lung carcinoma (A427),,BAO_0000219,CHEMBL621050,14368,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4813,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,BAO_0000219,CHEMBL621051,14368,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4814,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,BAO_0000219,CHEMBL621052,13866,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4815,,Inhibitory concentration in human lung carcinoma A427 cell line,,BAO_0000219,CHEMBL621053,2545,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4816,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,BAO_0000219,CHEMBL621054,2545,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4817,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL621055,6062,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4818,,Tested for volume of distribution upon iv administration to african green monkey,,BAO_0000218,CHEMBL876398,4578,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4819,,Volume of distribution in monkey,,BAO_0000218,CHEMBL621056,17592,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4820,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,CHEMBL621057,5005,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4821,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,BAO_0000218,CHEMBL621058,5005,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,,
4822,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,BAO_0000218,CHEMBL621059,5922,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4823,,The distribution volume after intravenous administration in cynomolgus monkeys,,BAO_0000218,CHEMBL621060,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4824,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,CHEMBL621061,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4825,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,CHEMBL621062,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4826,,Volume displacement was calculated in rhesus monkey,,BAO_0000218,CHEMBL621063,6057,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4827,,Volume of distribution in steady state was determined in rhesus monkey,,BAO_0000218,CHEMBL621064,5145,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4828,,Volume of distribution of compound was determined in monkey,,BAO_0000218,CHEMBL621065,6821,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4829,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,CHEMBL621066,5334,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4830,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,CHEMBL621067,5334,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4831,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL621068,6641,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4832,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,CHEMBL876399,2661,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4833,,Volume distribution in monkey after administration of 1 mg/kg iv,,BAO_0000218,CHEMBL621069,6535,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4834,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,CHEMBL621070,4809,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4835,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL621071,6062,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4836,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL621072,3443,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4837,,Oral systemic bioavailability upon iv administration to african green monkey,,BAO_0000218,CHEMBL618209,4578,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4838,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,CHEMBL618210,4809,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4839,,Baboon plasma free fraction. ,,BAO_0000019,CHEMBL618211,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4840,,Area under the curve was calculated in rhesus monkey after iv administration,,BAO_0000218,CHEMBL618212,6057,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4841,,Area under the curve was calculated in rhesus monkey after peroral administration,,BAO_0000019,CHEMBL618213,6057,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4842,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,BAO_0000019,CHEMBL618214,17853,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4843,,Half life period in monkey after 5 mg/kg dose,,BAO_0000218,CHEMBL873492,5302,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4844,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,BAO_0000218,CHEMBL618272,4257,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4845,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,BAO_0000218,CHEMBL618273,4257,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4846,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,BAO_0000218,CHEMBL618274,13501,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
4847,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,BAO_0000218,CHEMBL618275,5394,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4848,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,CHEMBL618276,2661,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4849,,Compound was evaluated for terminal half life in monkey,,BAO_0000019,CHEMBL618277,3341,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4850,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,BAO_0000218,CHEMBL618278,3045,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4851,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,CHEMBL618279,5005,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,Plasma,
4852,,Half life of compound was determined in squirrel monkey,,BAO_0000019,CHEMBL618280,4847,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4853,,Half life after iv administration in cynomolgus monkey,,BAO_0000218,CHEMBL618281,4256,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
4854,,Half life in monkey plasma after administration of 1 mg/kg iv,,BAO_0000218,CHEMBL618282,6535,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
4855,,Half life was calculated in rhesus monkey,,BAO_0000019,CHEMBL618283,6057,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4856,,Half life in monkey,,BAO_0000019,CHEMBL618284,17592,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4857,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL618285,6641,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4858,,Half life was evaluated in rhesus,,BAO_0000019,CHEMBL618286,5472,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4859,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,CHEMBL618287,6221,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4860,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,CHEMBL618288,5668,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4861,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,CHEMBL876393,4809,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4862,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,CHEMBL618289,5546,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4863,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,BAO_0000218,CHEMBL618290,5553,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4864,,Half-life was calculated in monkey,,BAO_0000019,CHEMBL618291,6078,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4865,,Half-life in Squirrel monkey,,BAO_0000019,CHEMBL618292,5147,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4866,,Half-life in rhesus monkey,,BAO_0000019,CHEMBL618293,5145,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
4867,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL618294,6062,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4868,,Half-life period after intravenous administration in cynomolgus monkeys,,BAO_0000218,CHEMBL618295,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4869,,Half-life period after oral administration in cynomolgus monkeys,,BAO_0000218,CHEMBL618296,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4870,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,BAO_0000218,CHEMBL618297,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
4871,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,CHEMBL618298,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4872,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,CHEMBL618299,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4873,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,CHEMBL618300,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4874,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,CHEMBL618301,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4875,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,BAO_0000019,CHEMBL618302,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4876,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,BAO_0000019,CHEMBL876394,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4877,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,BAO_0000019,CHEMBL618303,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4878,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,BAO_0000019,CHEMBL618304,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4879,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,BAO_0000218,CHEMBL618305,1916,9606.0,Autocuration,1,,A,In vivo,Homo sapiens,,,
4880,,Oral bioavailability in human,,BAO_0000218,CHEMBL618306,16643,9606.0,Autocuration,1,,A,In vivo,Homo sapiens,,,
4881,,Compound was tested for human plasma protein binding,,BAO_0000019,CHEMBL618307,17248,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4882,,Compound was tested for human plasma protein binding; Not determined,,BAO_0000019,CHEMBL618308,17248,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4883,,Protein binding activity of compound in human plasma; % Free,,BAO_0000019,CHEMBL618309,6241,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4884,,Unbound fraction (plasma),,BAO_0000019,CHEMBL618310,17716,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4885,,Half life for the hydrolysis of compound in human blood serum,,BAO_0000366,CHEMBL873353,17605,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
4886,,Half life period in human plasma using phosphate buffer (0.08 M),,BAO_0000366,CHEMBL618311,17625,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
4887,,Half life period in human plasma using phosphate buffer (0.1 M),,BAO_0000366,CHEMBL618312,17625,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
4888,,Half-life in human plasma was determined,,BAO_0000366,CHEMBL618313,17747,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
4889,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,BAO_0000019,CHEMBL618314,15613,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4890,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,BAO_0000019,CHEMBL618315,354,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4891,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,BAO_0000019,CHEMBL618316,3741,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4892,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,BAO_0000019,CHEMBL618317,3741,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4893,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,BAO_0000019,CHEMBL620138,3741,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4894,,Partition coefficient (logP),,BAO_0000019,CHEMBL858280,17599,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4895,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,BAO_0000019,CHEMBL620139,5486,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4896,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,BAO_0000251,CHEMBL620140,5600,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4897,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,BAO_0000019,CHEMBL620141,14294,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4898,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,BAO_0000019,CHEMBL620142,14294,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4899,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,BAO_0000019,CHEMBL620143,14294,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4900,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,CHEMBL620144,14294,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4901,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,BAO_0000251,CHEMBL620145,14294,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4902,,Metabolism of compound in human microsomes; Trace,,BAO_0000251,CHEMBL620146,14294,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4903,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,BAO_0000251,CHEMBL620147,6260,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
4904,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,BAO_0000251,CHEMBL620148,6187,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4905,,In vitro metabolic potential in human liver microsomes,,BAO_0000251,CHEMBL620149,6251,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
4906,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,BAO_0000019,CHEMBL876412,3246,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4907,,Tested for human plasma protein binding of the compound; Not tested,,BAO_0000019,CHEMBL619352,17313,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4908,,Compound was tested for percent protein binding (PB) in human,,BAO_0000019,CHEMBL619353,6227,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4909,,Protein binding in human plasma,,BAO_0000019,CHEMBL619354,5530,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
4910,,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,CHEMBL619355,6108,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4911,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,BAO_0000019,CHEMBL619356,6108,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4912,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,BAO_0000019,CHEMBL619357,2774,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4913,,In vitro rate of absorption observed as Caco-2 permeability in humans,,BAO_0000019,CHEMBL619358,16643,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4914,,Cellular permeability of compound was determined in Caco-2 cells; High,,BAO_0000219,CHEMBL619359,17582,9606.0,Autocuration,1,495.0,A,,Homo sapiens,,,Caco-2
4915,,Permeability in Caco-2 cells of compound,,BAO_0000219,CHEMBL619360,6838,9606.0,Autocuration,1,495.0,A,,Homo sapiens,,,Caco-2
4916,,Permeability coefficient (A to B) in Caco-2 cell,,BAO_0000019,CHEMBL619361,6108,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4917,,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,CHEMBL619362,6108,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4918,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,BAO_0000019,CHEMBL619363,6108,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4919,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,BAO_0000019,CHEMBL618942,2146,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4920,,Compound was tested for protein binding in human plasma,,BAO_0000019,CHEMBL618943,4514,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4921,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,BAO_0000019,CHEMBL618944,6108,9606.0,Autocuration,1,,A,,Homo sapiens,,,
4922,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,BAO_0000019,CHEMBL618945,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
4923,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,CHEMBL618946,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4924,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,CHEMBL876413,3277,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4925,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,CHEMBL618947,3802,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4926,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,BAO_0000218,CHEMBL618948,2862,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
4927,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL618949,6348,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
4928,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,CHEMBL618950,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4929,,Tmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,CHEMBL618951,5781,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4930,,Tmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,CHEMBL618952,17764,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4931,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,CHEMBL618953,4066,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4932,,Tmax in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL618954,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
4933,,Tmax in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL618955,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
4934,,Tmax in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL618956,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
4935,,Tmax in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL618957,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
4936,,Tmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,CHEMBL618958,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4937,,Tmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,CHEMBL618959,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4938,,Tmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,CHEMBL618960,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4939,,Tmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,CHEMBL876723,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
4940,,Tmax in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL618961,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
4941,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,CHEMBL618962,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4942,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,CHEMBL618963,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4943,,Tmax value in IRC mice,,BAO_0000218,CHEMBL618964,5951,10090.0,Intermediate,1,,A,,Mus musculus,,,
4944,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,CHEMBL618965,5506,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4945,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,CHEMBL618966,5506,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4946,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,BAO_0000218,CHEMBL618967,429,10090.0,Intermediate,1,,A,,Mus musculus,,Urine,
4947,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,BAO_0000218,CHEMBL618968,429,10090.0,Intermediate,1,,A,,Mus musculus,,Urine,
4948,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,BAO_0000218,CHEMBL618969,4066,10090.0,Intermediate,1,,A,,Mus musculus,,Urine,
4949,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,CHEMBL618970,17734,10090.0,Intermediate,1,,A,,Mus musculus,,,
4950,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,CHEMBL618971,17734,10090.0,Intermediate,1,,A,,Mus musculus,,,
4951,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL618972,6062,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4952,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,CHEMBL618973,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4953,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,CHEMBL618974,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4954,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,CHEMBL618975,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4955,,Vd in mice,,BAO_0000218,CHEMBL618976,5980,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4956,,Volume of distribution in mouse,,BAO_0000218,CHEMBL618977,17592,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4957,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL876724,6348,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4958,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,BAO_0000218,CHEMBL618978,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4959,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,BAO_0000218,CHEMBL618979,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4960,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,BAO_0000218,CHEMBL618980,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4961,,Pharmacokinetic property (vdss) was measured in mouse,,BAO_0000218,CHEMBL618981,4239,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4962,,Value distribution upon iv administration in mouse,,BAO_0000218,CHEMBL618982,2862,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4963,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,CHEMBL620150,17734,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4964,,Volume of distribution was evaluated in mice after intravenous administration,,BAO_0000218,CHEMBL620151,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4965,,Volume of distribution was evaluated in mice after oral administration,,BAO_0000218,CHEMBL620152,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4966,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,CHEMBL620153,17837,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4967,,Steady state volume of distribution was determined in mice,,BAO_0000218,CHEMBL876395,5727,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4968,,Volume distribution (steady state) of compound was determined in mouse,,BAO_0000218,CHEMBL620154,17852,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4969,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,BAO_0000218,CHEMBL620155,17764,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4970,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,CHEMBL620156,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4971,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL620157,6062,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
4972,,Biodistribution of compound (oxidized form) in in kidney tissue,,BAO_0000218,CHEMBL620158,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
4973,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,CHEMBL620159,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
4974,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,CHEMBL620160,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
4975,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL620161,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
4976,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,BAO_0000219,CHEMBL620162,10708,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
4977,,Inhibition of A431 human squamous cell carcinoma cell proliferation,,BAO_0000219,CHEMBL620163,16597,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4978,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,BAO_0000219,CHEMBL620833,16062,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4979,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,BAO_0000219,CHEMBL876396,16062,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4980,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,BAO_0000219,CHEMBL620834,16958,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4981,,Inhibition of A431 human carcinoma cell proliferation,,BAO_0000219,CHEMBL620835,6700,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4982,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,BAO_0000219,CHEMBL620836,17226,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4983,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,BAO_0000219,CHEMBL620837,6828,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
4984,,In vitro cytotoxicity against epidermoid carcinoma cell line,,BAO_0000219,CHEMBL621017,12314,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
4985,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,BAO_0000218,CHEMBL621018,13412,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4986,,Antiproliferative activity of compound was measured on human tumor cell line A431.,,BAO_0000219,CHEMBL621019,13299,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
4987,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,BAO_0000219,CHEMBL621020,17420,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
4988,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,BAO_0000219,CHEMBL621021,13678,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
4989,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,BAO_0000219,CHEMBL621022,14171,,Expert,1,500.0,F,,,,,A-431
4990,,Tested for antiproliferative activity against human A431 cells,,BAO_0000219,CHEMBL621023,6333,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4991,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,BAO_0000219,CHEMBL621024,2356,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4992,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,BAO_0000219,CHEMBL621025,15578,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4993,,Inhibition of A431 cell proliferation,,BAO_0000219,CHEMBL621026,5126,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4994,,Cytotoxic effect on A431 human epidermoid carcinoma cells,,BAO_0000219,CHEMBL621027,6844,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4995,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,BAO_0000219,CHEMBL876397,6844,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
4996,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,BAO_0000219,CHEMBL883797,4925,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
4997,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,BAO_0000219,CHEMBL621028,4925,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
4998,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,BAO_0000219,CHEMBL621029,13978,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
4999,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,BAO_0000219,CHEMBL621030,16786,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5000,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,CHEMBL621147,13412,,Expert,1,500.0,F,,,,,A-431
5001,,In vivo antiproliferative activity against A431 cell line,,BAO_0000218,CHEMBL621148,17824,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5002,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,BAO_0000219,CHEMBL621149,12751,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5003,,Inhibition of A431 human epidermoid carcinoma cell proliferation,,BAO_0000219,CHEMBL621150,12380,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5004,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,BAO_0000219,CHEMBL621151,4959,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5005,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,BAO_0000219,CHEMBL621152,6333,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5006,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,BAO_0000219,CHEMBL621153,6333,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5007,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,BAO_0000219,CHEMBL884000,6333,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5008,,Inhibition of EGFR overexpressing A431 cell proliferation,,BAO_0000019,CHEMBL621154,5296,9606.0,Expert,1,,F,,Homo sapiens,,,
5009,,Inhibition of A431 cell proliferation,,BAO_0000219,CHEMBL621155,12624,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5010,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,BAO_0000219,CHEMBL621156,14926,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5011,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,BAO_0000219,CHEMBL621157,14926,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5012,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,BAO_0000219,CHEMBL621158,14926,,Expert,1,500.0,F,,,,,A-431
5013,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,BAO_0000219,CHEMBL621159,15144,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5014,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,BAO_0000219,CHEMBL621160,15144,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5015,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,BAO_0000219,CHEMBL621161,5245,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5016,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,BAO_0000219,CHEMBL621162,5245,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5017,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,BAO_0000219,CHEMBL621163,5245,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5018,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,BAO_0000219,CHEMBL621164,5245,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5019,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,BAO_0000219,CHEMBL621165,5245,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5020,,Half-life period in cynomolgus monkey,,BAO_0000019,CHEMBL619159,5922,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5021,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,BAO_0000366,CHEMBL619160,1116,9527.0,Autocuration,1,,A,In vitro,Cercopithecidae,,Plasma,
5022,,Longer half-life in monkey (i.v.) at 0.5 mpk,,BAO_0000218,CHEMBL619161,17853,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
5023,,Plasma half life in monkey,,BAO_0000366,CHEMBL619162,993,9527.0,Autocuration,1,,A,,Cercopithecidae,,Plasma,
5024,,Plasma half-life in rhesus monkey,,BAO_0000366,CHEMBL619163,4514,9527.0,Autocuration,1,,A,,Cercopithecidae,,Plasma,
5025,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,CHEMBL619164,5334,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
5026,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,CHEMBL619320,5334,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
5027,,Tested for half life upon iv administration to african green monkey,,BAO_0000218,CHEMBL619321,4578,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
5028,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,CHEMBL873336,2661,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
5029,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,CHEMBL619322,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
5030,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,CHEMBL619323,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
5031,,The time for peak concentration value after oral administration in cynomolgus monkeys,,BAO_0000218,CHEMBL619324,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
5032,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,CHEMBL619325,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5033,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,CHEMBL876411,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5034,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,CHEMBL619326,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5035,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,CHEMBL619327,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5036,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,CHEMBL619328,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5037,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,CHEMBL619329,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5038,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,CHEMBL619330,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5039,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,CHEMBL619331,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5040,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,CHEMBL619332,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5041,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,CHEMBL619333,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5042,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,CHEMBL619334,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5043,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,CHEMBL619335,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5044,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,CHEMBL619336,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5045,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,CHEMBL619337,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5046,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,CHEMBL619338,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5047,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,CHEMBL619339,11271,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5048,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,BAO_0000218,CHEMBL619340,5809,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
5049,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,CHEMBL873496,17720,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Plasma,
5050,,AUC value in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619341,3546,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Plasma,
5051,,AUC value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619342,3546,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Plasma,
5052,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619343,3546,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
5053,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619344,3546,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
5054,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619345,3546,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
5055,,Vc value in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619346,3546,10116.0,Intermediate,1,,A,,Rattus norvegicus,,,
5056,,Half life period in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619347,3546,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
5057,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,CHEMBL619348,10625,9557.0,Autocuration,1,,A,,Papio hamadryas,,,
5058,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,CHEMBL619349,10625,9557.0,Autocuration,1,,A,,Papio hamadryas,,,
5059,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,CHEMBL619350,10625,9557.0,Autocuration,1,,A,,Papio hamadryas,,,
5060,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,BAO_0000019,CHEMBL619351,10625,9557.0,Autocuration,1,,A,,Papio hamadryas,,,
5061,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,BAO_0000019,CHEMBL875953,10625,9557.0,Autocuration,1,,A,,Papio hamadryas,,,
5062,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,BAO_0000019,CHEMBL621716,10625,9557.0,Autocuration,1,,A,,Papio hamadryas,,,
5063,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,BAO_0000019,CHEMBL621717,10625,9557.0,Autocuration,1,,A,,Papio hamadryas,,,
5064,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,CHEMBL621718,10625,9557.0,Autocuration,1,,A,,Papio hamadryas,,,
5065,,Area under curve after 1 mpk peroral administration to beagles,,BAO_0000019,CHEMBL621719,3510,9615.0,Autocuration,1,,A,,beagle,,,
5066,,Area under curve after 2 mpk peroral administration to beagles,,BAO_0000019,CHEMBL621720,3510,9615.0,Autocuration,1,,A,,beagle,,,
5067,,Cmax value after 1 mpk peroral administration to beagles,,BAO_0000218,CHEMBL621721,3510,9615.0,Autocuration,1,,A,In vivo,beagle,,,
5068,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,BAO_0000019,CHEMBL621722,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
5069,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,BAO_0000019,CHEMBL621723,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
5070,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,BAO_0000019,CHEMBL621724,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
5071,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,BAO_0000019,CHEMBL623443,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
5072,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,BAO_0000019,CHEMBL623444,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
5073,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,BAO_0000019,CHEMBL623445,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
5074,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,BAO_0000019,CHEMBL623446,7766,9606.0,Autocuration,1,,A,,Homo sapiens,,Urine,
5075,,Metabolic stability observed at 30 min after administration in human liver microsomes,,BAO_0000251,CHEMBL623447,16643,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
5076,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,CHEMBL623448,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5077,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,CHEMBL623449,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5078,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,CHEMBL623450,6852,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5079,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,BAO_0000251,CHEMBL623451,6567,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
5080,,Metabolic stability (% remaining at 30 mins) in human S9.,,BAO_0000019,CHEMBL623452,6570,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5081,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,BAO_0000019,CHEMBL623453,6570,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5082,,Percent parent compound remaining after 20 min incubation with human liver microsomes,,BAO_0000251,CHEMBL623454,5237,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
5083,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,BAO_0000251,CHEMBL623455,5237,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
5084,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,BAO_0000251,CHEMBL624371,5237,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
5085,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,BAO_0000218,CHEMBL624372,5202,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5086,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,CHEMBL624373,5481,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5087,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,CHEMBL624374,5481,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5088,,The percent remaining in human plasma after 30 min was determined,,BAO_0000019,CHEMBL624556,3956,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5089,,Conversion rate of the prodrug in human plasma,,BAO_0000366,CHEMBL624557,5074,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5090,,Conversion rate of the prodrug in human plasma; ND means no data,,BAO_0000366,CHEMBL624558,5074,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5091,,Half life of compound was determined in human blood,,BAO_0000221,CHEMBL624559,4727,9606.0,Autocuration,1,,A,,Homo sapiens,,Blood,
5092,,Half life of compound was determined in man with once daily dosing,,BAO_0000019,CHEMBL624560,5965,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5093,,Half life in human microsomes,,BAO_0000251,CHEMBL624561,5732,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,,
5094,,Half life in human plasma,,BAO_0000366,CHEMBL624562,5819,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5095,,Half life in human plasma; Not detected,,BAO_0000366,CHEMBL624563,5819,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5096,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,CHEMBL624564,1916,9606.0,Autocuration,1,,A,In vivo,Homo sapiens,,,
5097,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,BAO_0000251,CHEMBL624565,6597,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
5098,,Half-life in human plasma,,BAO_0000366,CHEMBL875152,5229,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5099,,Half-life of the parent prodrug in plasma,,BAO_0000366,CHEMBL624566,5229,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5100,,In vitro half life in human plasma was determined,,BAO_0000366,CHEMBL873805,2192,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Plasma,
5101,,The compound was tested In Vitro for half life in human liver microsomes.,,BAO_0000251,CHEMBL624567,3032,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
5102,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,CHEMBL624568,1916,9606.0,Autocuration,1,,A,In vivo,Homo sapiens,,,
5103,,Observed volume of distribution,,BAO_0000218,CHEMBL624569,17716,9606.0,Autocuration,1,,A,In vivo,Homo sapiens,,,
5104,,Oral bioavailability in human,,BAO_0000218,CHEMBL624570,15778,9606.0,Autocuration,1,,A,In vivo,Homo sapiens,,,
5105,,Tested for human plasma protein binding of the compound,,BAO_0000019,CHEMBL624571,17313,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5106,,"First order rate constant, k was determined in human plasma",,BAO_0000019,CHEMBL624572,4231,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5107,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,CHEMBL624573,4755,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5108,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,CHEMBL875153,4755,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5109,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,BAO_0000251,CHEMBL624574,16907,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
5110,,The compound was tested for the plasma binding in human,,BAO_0000019,CHEMBL624575,10839,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5111,,Plasma protein binding (human),,BAO_0000019,CHEMBL624576,10839,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5112,,Compound was evaluated for half-life in human liver microsomes,,BAO_0000251,CHEMBL624577,3199,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
5113,,Half life measured in vitro for its stability in human blood,,BAO_0000221,CHEMBL624578,1345,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Blood,
5114,,Half life in human serum,,BAO_0000019,CHEMBL622796,4297,9606.0,Autocuration,1,,A,,Homo sapiens,,Serum,
5115,,Half life in human serum; ND=not determined,,BAO_0000019,CHEMBL622797,4297,9606.0,Autocuration,1,,A,,Homo sapiens,,Serum,
5116,,Half life were determined in CEM-SS cell extract in decomposition step 1,,BAO_0000019,CHEMBL622798,4297,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5117,,Half life were determined in CEM-SS cell extract in decomposition step 2,,BAO_0000019,CHEMBL622799,4297,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5118,,Half life of the in human plasma,,BAO_0000366,CHEMBL622800,4231,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5119,,Half life period in human hepatic S9 fraction was determined,,BAO_0000220,CHEMBL622801,5633,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,,
5120,,Half life period in human liver microsome was determined,,BAO_0000251,CHEMBL622802,5633,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
5121,,Half life period was determined; 6-7,,BAO_0000019,CHEMBL622803,17791,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5122,,Half life period was evaluated in human,,BAO_0000019,CHEMBL875154,17791,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5123,,Half life time in human plasma,,BAO_0000366,CHEMBL622804,3160,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5124,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622805,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
5125,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622611,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5126,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622612,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5127,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL875160,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5128,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,CHEMBL622613,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5129,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622614,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5130,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622615,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5131,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,CHEMBL622616,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5132,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622617,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5133,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,CHEMBL622618,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
5134,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,CHEMBL622619,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
5135,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622620,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
5136,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,CHEMBL622621,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
5137,,Biodistribution of compound (oxidized form) in blood tissue,,BAO_0000218,CHEMBL622622,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5138,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622623,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5139,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,CHEMBL622624,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5140,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,CHEMBL622625,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5141,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622626,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5142,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,CHEMBL622627,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5143,,Biodistribution of compound (oxidized form) in brain tissue of mice,,BAO_0000218,CHEMBL622628,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
5144,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622629,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
5145,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,CHEMBL622630,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
5146,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622631,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
5147,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,CHEMBL622632,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
5148,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,CHEMBL622633,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
5149,,Biodistribution of compound (oxidized form) in heart tissue of mice,,BAO_0000218,CHEMBL622634,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5150,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL622635,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5151,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL875161,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5152,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,CHEMBL622636,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5153,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL623335,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5154,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,CHEMBL623336,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5155,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL623337,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5156,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,CHEMBL623338,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5157,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,CHEMBL623339,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5158,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL623524,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5159,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,CHEMBL623525,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5160,,Biodistribution of compound (oxidized form) in liver tissue,,BAO_0000218,CHEMBL623526,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5161,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,CHEMBL623527,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5162,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,CHEMBL623528,16438,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5163,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,BAO_0000219,CHEMBL624615,5245,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5164,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,BAO_0000219,CHEMBL621672,5245,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5165,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,BAO_0000218,CHEMBL621673,16289,,Expert,1,500.0,F,,,,,A-431
5166,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,BAO_0000218,CHEMBL621674,16289,,Expert,1,500.0,F,,,,,A-431
5167,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,CHEMBL884002,16093,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5168,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,BAO_0000219,CHEMBL621850,16825,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5169,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,BAO_0000219,CHEMBL621851,4848,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5170,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,BAO_0000219,CHEMBL621852,14827,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5171,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,BAO_0000219,CHEMBL621853,14827,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5172,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,BAO_0000218,CHEMBL621854,16289,,Expert,1,500.0,F,,,,,A-431
5173,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,BAO_0000218,CHEMBL621855,16289,,Expert,1,500.0,F,,,,,A-431
5174,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,BAO_0000218,CHEMBL623724,16289,,Expert,1,500.0,F,,,,,A-431
5175,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,BAO_0000218,CHEMBL623725,16289,,Expert,1,500.0,F,,,,,A-431
5176,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,BAO_0000218,CHEMBL623726,16289,,Expert,1,500.0,F,,,,,A-431
5177,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,BAO_0000219,CHEMBL623727,16289,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5178,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,BAO_0000219,CHEMBL623728,16289,,Expert,1,500.0,F,,,,,A-431
5179,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,BAO_0000218,CHEMBL623729,16289,,Expert,1,500.0,F,,,,,A-431
5180,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,BAO_0000218,CHEMBL623730,16289,,Expert,1,500.0,F,,,,,A-431
5181,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,BAO_0000218,CHEMBL623731,16289,,Expert,1,500.0,F,,,,,A-431
5182,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,CHEMBL623732,14555,10090.0,Expert,1,500.0,F,,Mus musculus,,,A-431
5183,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,CHEMBL623733,14555,10090.0,Expert,1,500.0,F,,Mus musculus,,,A-431
5184,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,CHEMBL623734,14555,10090.0,Expert,1,500.0,F,,Mus musculus,,,A-431
5185,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,CHEMBL623735,14555,10090.0,Expert,1,500.0,F,,Mus musculus,,,A-431
5186,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,BAO_0000219,CHEMBL623736,1937,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5187,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,BAO_0000219,CHEMBL623737,13739,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5188,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,BAO_0000219,CHEMBL623738,3558,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5189,,Dose giving a 50% decrease in the living cell number (A437 cells),,BAO_0000219,CHEMBL875168,3558,9606.0,Intermediate,1,500.0,F,,Homo sapiens,,,A-431
5190,,In vitro inhibitory concentration against proliferation of A459 cell line.,,BAO_0000219,CHEMBL623739,17686,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5191,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,BAO_0000219,CHEMBL623740,5305,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5192,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,BAO_0000219,CHEMBL624424,3614,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5193,,In vitro antitumor activity against renal A498 tumor cell lines,,BAO_0000219,CHEMBL624425,17229,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5194,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,BAO_0000219,CHEMBL624426,15935,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5195,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,BAO_0000219,CHEMBL624427,15935,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5196,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,BAO_0000219,CHEMBL624428,15560,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5197,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,BAO_0000219,CHEMBL624429,13891,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5198,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,BAO_0000219,CHEMBL624620,13891,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5199,,Cytotoxicity on kidney carcinoma (A-498) cell line,,BAO_0000219,CHEMBL624621,13788,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5200,,Compound was evaluated against Human cell line renal A498,,BAO_0000219,CHEMBL624622,15403,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5201,,Compound was tested for inhibition of A498 human renal cancer cell line,,BAO_0000219,CHEMBL624623,1009,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5202,,Growth inhibitory activity against A498 human cancer cell line,,BAO_0000219,CHEMBL874365,1043,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5203,,In vitro antitumor activity against human renal A498 cell line,,BAO_0000219,CHEMBL624624,5858,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5204,,In vitro cytotoxic activity against renal (A498) cell line,,BAO_0000219,CHEMBL624625,5958,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5205,,In vitro cytotoxic activity against human renal cancer (A498) cell line,,BAO_0000219,CHEMBL624626,5506,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5206,,Tested for cytostatic activity against renal A498 cell line,,BAO_0000219,CHEMBL624627,12781,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5207,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,BAO_0000219,CHEMBL883157,14399,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5208,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,BAO_0000219,CHEMBL624628,5958,9606.0,Expert,1,624.0,F,,Homo sapiens,,,A498
5209,,Cmax value after 2 mpk peroral administration to beagles,,BAO_0000218,CHEMBL624629,3510,9615.0,Autocuration,1,,A,In vivo,beagle,,,
5210,,Bioavailability,,BAO_0000218,CHEMBL623551,3510,9615.0,Autocuration,1,,A,In vivo,Canis lupus familiaris,beagle,,
5211,,Bioavailability after 1 mpk peroral administration to beagles,,BAO_0000218,CHEMBL623552,3510,9615.0,Autocuration,1,,A,In vivo,Canis lupus familiaris,beagle,,
5212,,Bioavailability after 2 mpk peroral administration to beagles,,BAO_0000218,CHEMBL623553,3510,9615.0,Autocuration,1,,A,In vivo,Canis lupus familiaris,beagle,,
5213,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,BAO_0000019,CHEMBL623554,3085,9913.0,Autocuration,1,,A,,Bos taurus,,,
5214,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,BAO_0000019,CHEMBL623555,3085,9913.0,Autocuration,1,,A,,Bos taurus,,,
5215,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,CHEMBL623556,3085,9913.0,Autocuration,1,,A,,Bos taurus,,,
5216,,Solubility against bovine alpha-chymotrypsin,,BAO_0000019,CHEMBL623557,9372,9913.0,Autocuration,1,,A,,Bos taurus,,,
5217,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,CHEMBL623558,3085,9913.0,Autocuration,1,,A,,Bos taurus,,,
5218,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,CHEMBL623559,3085,9913.0,Autocuration,1,,A,,Bos taurus,,,
5219,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,BAO_0000221,CHEMBL623560,1469,9913.0,Autocuration,1,,A,,Bos taurus,,Spleen,
5220,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,BAO_0000019,CHEMBL623561,4297,9913.0,Autocuration,1,,A,,Bos taurus,,,
5221,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,BAO_0000019,CHEMBL623562,4297,9913.0,Autocuration,1,,A,,Bos taurus,,,
5222,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,BAO_0000019,CHEMBL623563,17585,9913.0,Autocuration,1,,A,,Bos taurus,,,
5223,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,BAO_0000221,CHEMBL623564,1336,9913.0,Autocuration,1,,A,,Bos taurus,,Spleen,
5224,,Half life in presence of 2 mg/mL BSA at pH 8.8,,BAO_0000019,CHEMBL873806,3085,9913.0,Autocuration,1,,A,,Bos taurus,,,
5225,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,BAO_0000019,CHEMBL623565,2857,9913.0,Autocuration,1,,A,,Bos taurus,,,
5226,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,BAO_0000019,CHEMBL623566,2857,9913.0,Autocuration,1,,A,,Bos taurus,,,
5227,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,BAO_0000019,CHEMBL623567,2857,9913.0,Autocuration,1,,A,,Bos taurus,,,
5228,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,BAO_0000019,CHEMBL623568,1540,9913.0,Autocuration,1,,A,,Bos taurus,,,
5229,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,BAO_0000218,CHEMBL623569,6316,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5230,,AUC after administration at 100 mg/kg/day in dogs,,BAO_0000218,CHEMBL623570,17594,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5231,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,BAO_0000218,CHEMBL624254,4953,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5232,,AUC value after 15 mg/kg iv dose in Dogs,,BAO_0000218,CHEMBL624255,16907,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5233,,AUC value after 30 mg/kg po dose in Dogs,,BAO_0000218,CHEMBL624256,16907,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5234,,AUC value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,CHEMBL624257,2959,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5235,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,CHEMBL624258,17594,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5236,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,BAO_0000218,CHEMBL875277,5356,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5237,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,BAO_0000218,CHEMBL622667,16807,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5238,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,BAO_0000218,CHEMBL622668,4527,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5239,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,CHEMBL622669,4527,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5240,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,BAO_0000218,CHEMBL622670,15660,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5241,,Area under curve determined in dogs after oral administration of 10 mg/kg,,BAO_0000218,CHEMBL622671,15660,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5242,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,CHEMBL622672,5802,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5243,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL622673,3598,9615.0,Expert,1,,A,,Canis lupus familiaris,,,
5244,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL622674,3598,9615.0,Expert,1,,A,,Canis lupus familiaris,,,
5245,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,CHEMBL622675,5944,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5246,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,CHEMBL622676,5944,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5247,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,CHEMBL622677,5944,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5248,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,CHEMBL622678,5944,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5249,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,CHEMBL622679,4186,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5250,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,CHEMBL622680,5007,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5251,,Area under curve was determine after peroral administration at 10 mpk in dog,,BAO_0000218,CHEMBL622681,5668,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5252,,Area under curve was determine after peroral administration at 5 mpk in dog,,BAO_0000218,CHEMBL875278,5668,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5253,,Area under curve was determined,,BAO_0000218,CHEMBL622682,5006,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5254,,Area under curve in dogs,,BAO_0000218,CHEMBL622683,5006,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5255,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,BAO_0000218,CHEMBL622684,3771,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5256,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,BAO_0000218,CHEMBL622685,3771,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5257,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,BAO_0000218,CHEMBL622686,3771,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5258,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL618344,1916,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5259,,Area under curve value in dog at a dose of 5 mg/kg,,BAO_0000218,CHEMBL875582,5302,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5260,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,CHEMBL618345,5600,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5261,,Area under curve was determined after 0.3 mg/kg po administration in dog,,BAO_0000218,CHEMBL618346,5600,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5262,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,CHEMBL618347,17764,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5263,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,CHEMBL618348,4368,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5264,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,BAO_0000019,CHEMBL618349,5318,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5265,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,CHEMBL618350,5318,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5266,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,BAO_0000019,CHEMBL618351,5318,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5267,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,BAO_0000019,CHEMBL618352,5318,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5268,,Time taken to reduce 50% of the concentration of compound in blood plasma,,BAO_0000221,CHEMBL873494,14518,9606.0,Autocuration,1,,A,,Homo sapiens,,Blood,
5269,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,BAO_0000366,CHEMBL618353,2209,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5270,,Half life in human plasma,,BAO_0000366,CHEMBL618354,6787,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5271,,Half life in human plasma was reported,,BAO_0000366,CHEMBL875583,4898,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5272,,Half life in human serum,,BAO_0000019,CHEMBL618355,6072,9606.0,Autocuration,1,,A,,Homo sapiens,,Serum,
5273,,Half life upon exposure to human plasma,,BAO_0000366,CHEMBL618356,16907,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5274,,t1/2 in human microsomes,,BAO_0000251,CHEMBL618357,5656,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,,
5275,,Half life period in 80% human plasma at 37 degree Centigrade,,BAO_0000366,CHEMBL618358,4755,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5276,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,BAO_0000221,CHEMBL618359,17503,9606.0,Autocuration,1,,A,,Homo sapiens,,Zone of skin,
5277,,Half-life measured in in vitro Cathepsin B assay in human plasma,,BAO_0000366,CHEMBL618360,12357,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Plasma,
5278,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,BAO_0000019,CHEMBL618361,3076,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5279,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,BAO_0000251,CHEMBL618362,6410,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
5280,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,BAO_0000366,CHEMBL618363,3741,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5281,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,BAO_0000366,CHEMBL618364,3741,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5282,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,BAO_0000366,CHEMBL875584,3741,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5283,,Half-life in the CEM cell extracts,,BAO_0000019,CHEMBL618365,1540,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5284,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,BAO_0000366,CHEMBL873495,2905,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5285,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,BAO_0000366,CHEMBL618366,2905,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5286,,Half-life was determined,,BAO_0000019,CHEMBL618367,5523,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5287,,Half-life (human blood stability),,BAO_0000221,CHEMBL618368,1499,9606.0,Autocuration,1,,A,,Homo sapiens,,Blood,
5288,,Half-life (human blood stability); no data,,BAO_0000221,CHEMBL618369,1499,9606.0,Autocuration,1,,A,,Homo sapiens,,Blood,
5289,,Half-life in human plasma,,BAO_0000366,CHEMBL618370,17065,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5290,,CYP3A4 metabolism half-life (t1/2),,BAO_0000019,CHEMBL618371,6861,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5291,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,BAO_0000221,CHEMBL618372,1499,9606.0,Autocuration,1,,A,,Homo sapiens,,Blood,
5292,,In vitro half life in human plasma,,BAO_0000366,CHEMBL618373,530,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Plasma,
5293,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,BAO_0000366,CHEMBL618374,1116,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Plasma,
5294,,In vitro hydrolysis in human plasma,,BAO_0000366,CHEMBL618375,6695,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Plasma,
5295,,In vitro hydrolysis in human plasma; no data,,BAO_0000366,CHEMBL618376,6695,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Plasma,
5296,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,BAO_0000251,CHEMBL618377,10,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,Liver,
5297,,Plasma half life in human,,BAO_0000366,CHEMBL618378,993,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5298,,Stability after incubation with human plasma (at 37 degree C),,BAO_0000366,CHEMBL618379,15429,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5299,,T1/2 was evaluated in human plasma,,BAO_0000366,CHEMBL618380,1675,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5300,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,BAO_0000366,CHEMBL618381,2209,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5301,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,BAO_0000366,CHEMBL618382,2209,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5302,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,CHEMBL618383,5318,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5303,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,BAO_0000019,CHEMBL618384,2412,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,,
5304,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,BAO_0000019,CHEMBL618385,2412,9606.0,Autocuration,1,,A,In vitro,Homo sapiens,,,
5305,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,BAO_0000366,CHEMBL619099,2906,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5306,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,BAO_0000366,CHEMBL619100,2906,9606.0,Autocuration,1,,A,,Homo sapiens,,Plasma,
5307,,Time taken for 50% to be consumed by serum PON1 was determined,,BAO_0000019,CHEMBL619101,5495,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5308,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,BAO_0000019,CHEMBL619102,5495,9606.0,Autocuration,1,,A,,Homo sapiens,,,
5309,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,BAO_0000251,CHEMBL619103,4397,9606.0,Autocuration,1,,A,,Homo sapiens,,Liver,
5310,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,CHEMBL619268,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5311,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL619269,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5312,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,CHEMBL619270,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5313,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL619271,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5314,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,CHEMBL875585,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5315,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,CHEMBL619272,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5316,,Compound tested for growth inhibition of renal cancer cell line 786-0,,BAO_0000219,CHEMBL619273,6058,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5317,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,BAO_0000219,CHEMBL619274,17708,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5318,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,BAO_0000219,CHEMBL619275,14017,9606.0,Expert,1,391.0,F,,Homo sapiens,,,786-0
5319,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,BAO_0000219,CHEMBL619276,16818,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5320,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,BAO_0000219,CHEMBL619277,16818,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5321,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,BAO_0000219,CHEMBL619278,16818,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5322,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,BAO_0000219,CHEMBL619279,11970,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5323,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,BAO_0000219,CHEMBL858458,12400,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5324,,Cytotoxic effect on renal cancer line 786-0,,BAO_0000219,CHEMBL619280,12888,9606.0,Expert,1,391.0,F,,Homo sapiens,,,786-0
5325,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,BAO_0000219,CHEMBL619281,15300,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5326,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,BAO_0000219,CHEMBL619282,14769,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5327,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,BAO_0000219,CHEMBL619283,15895,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5328,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,BAO_0000219,CHEMBL619284,17376,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5329,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,BAO_0000219,CHEMBL619285,14882,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5330,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,BAO_0000219,CHEMBL619286,14882,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5331,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,CHEMBL619287,15176,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5332,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,BAO_0000219,CHEMBL857455,12696,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5333,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,BAO_0000219,CHEMBL883801,2496,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5334,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,BAO_0000219,CHEMBL619288,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5335,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,BAO_0000219,CHEMBL619289,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5336,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,BAO_0000219,CHEMBL619290,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5337,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,BAO_0000219,CHEMBL619291,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5338,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,BAO_0000219,CHEMBL619292,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5339,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,BAO_0000219,CHEMBL619293,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5340,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,BAO_0000219,CHEMBL619294,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5341,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,BAO_0000219,CHEMBL619295,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5342,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,BAO_0000219,CHEMBL619296,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5343,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,BAO_0000219,CHEMBL619297,11831,9606.0,Intermediate,1,972.0,F,,Homo sapiens,,,791T cell line
5344,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,BAO_0000219,CHEMBL619298,12782,9606.0,Intermediate,1,391.0,F,,Homo sapiens,,,786-0
5345,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,BAO_0000019,CHEMBL619299,1229,,Intermediate,1,,F,,,,,
5346,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,BAO_0000219,CHEMBL619300,15313,9606.0,Expert,1,741.0,F,,Homo sapiens,,,RPMI-8226
5347,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,BAO_0000219,CHEMBL619301,15313,9606.0,Expert,1,741.0,F,,Homo sapiens,,,RPMI-8226
5348,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,BAO_0000219,CHEMBL619302,11544,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5349,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,CHEMBL619303,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5350,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,CHEMBL619304,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5351,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,CHEMBL857706,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5352,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,CHEMBL619305,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5353,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,CHEMBL619306,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5354,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,CHEMBL619307,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5355,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,CHEMBL619308,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5356,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,CHEMBL619309,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5357,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,CHEMBL619310,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5358,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,BAO_0000219,CHEMBL619311,14769,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5359,,Compound was tested for the growth inhibition of A498 renal tumor cell line,,BAO_0000219,CHEMBL619312,15354,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5360,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,BAO_0000219,CHEMBL619313,17445,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5361,,In vitro inhibitory concentration against renal cancer cell line A498,,BAO_0000219,CHEMBL619314,4337,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5362,,Cytotoxicity against A 498 tumor cell line,,BAO_0000219,CHEMBL619959,15277,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5363,,In vitro antitumor activity against A498 human cancer cell line,,BAO_0000219,CHEMBL619960,4812,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5364,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,BAO_0000219,CHEMBL619961,4812,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5365,,Inhibitory dose required against A498 human tumor cell lines,,BAO_0000219,CHEMBL619962,4995,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5366,,Anticancer activity against one renal cancer (A498 cell line),,BAO_0000219,CHEMBL875586,5847,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5367,,In vitro cytotoxicity against melanoma A498 cell line,,BAO_0000219,CHEMBL619963,6557,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5368,,Compound was tested for growth inhibitory activity against A498 cell line,,BAO_0000219,CHEMBL619964,2597,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5369,,Compound tested for growth inhibition of renal cancer cell line A498,,BAO_0000219,CHEMBL620108,6058,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5370,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,BAO_0000219,CHEMBL620109,17708,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5371,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,CHEMBL620110,15176,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5372,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,BAO_0000219,CHEMBL620111,15300,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5373,,Tested for cytotoxicity against A498 cell lines in renal cancer,,BAO_0000219,CHEMBL620112,11970,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5374,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,BAO_0000219,CHEMBL620113,12400,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5375,,Cytotoxic effect on renal cancer lines A498,,BAO_0000219,CHEMBL620114,12888,9606.0,Expert,1,624.0,F,,Homo sapiens,,,A498
5376,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,BAO_0000219,CHEMBL620115,3030,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5377,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,BAO_0000219,CHEMBL620116,14769,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5378,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,BAO_0000219,CHEMBL620117,17376,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5379,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,BAO_0000219,CHEMBL620118,16558,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5380,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,BAO_0000219,CHEMBL620119,5194,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5381,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,BAO_0000219,CHEMBL620120,10708,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5382,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,BAO_0000219,CHEMBL620121,16880,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5383,,Antitumor activity against A549 human lung carcinoma cell line,,BAO_0000219,CHEMBL620122,10196,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5384,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,BAO_0000219,CHEMBL620123,10196,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5385,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,BAO_0000219,CHEMBL620124,10196,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5386,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,BAO_0000219,CHEMBL620125,12083,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5387,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,BAO_0000219,CHEMBL620126,16464,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5388,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,CHEMBL883027,16464,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5389,,In vitro cytotoxic activity against human lung A549 cell line,,BAO_0000219,CHEMBL620127,16470,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5390,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,BAO_0000219,CHEMBL620128,16470,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5391,,In vitro cytotoxic activity against human lung A549 cell line),,BAO_0000219,CHEMBL620129,16470,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5392,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,BAO_0000219,CHEMBL620130,16470,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5393,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,BAO_0000219,CHEMBL620131,16582,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5394,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,BAO_0000219,CHEMBL620132,15935,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5395,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,BAO_0000219,CHEMBL620133,15935,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5396,,Inhibition of A549 human lung carcinoma cell proliferation,,BAO_0000219,CHEMBL620134,16597,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5397,,Inhibitory activity against A549 lung adenocarcinoma cell line,,BAO_0000219,CHEMBL620135,17376,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5398,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,BAO_0000219,CHEMBL620136,16496,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5399,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,BAO_0000219,CHEMBL620137,16152,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5400,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,BAO_0000219,CHEMBL620268,16152,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5401,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,CHEMBL620269,16464,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5402,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,BAO_0000219,CHEMBL620270,2288,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5403,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,BAO_0000219,CHEMBL620271,17350,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5404,,Inhibition of A549 cancer cell proliferation,,BAO_0000219,CHEMBL620272,4090,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5405,,Inhibition of A549 cancer cell proliferation (Not tested),,BAO_0000219,CHEMBL620273,4090,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5406,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,BAO_0000219,CHEMBL620274,17350,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5407,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,BAO_0000219,CHEMBL620275,4197,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5408,,Antiproliferative potency determined as inhibitory concentration against A549 cells,,BAO_0000219,CHEMBL620276,17072,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5409,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,BAO_0000219,CHEMBL620277,17072,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5410,,Cytotoxicity against Renal cell lines A549 was determined,,BAO_0000219,CHEMBL620278,5194,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5411,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,BAO_0000218,CHEMBL620279,4257,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5412,,Area under curve was determined in dog after oral administration at 1 mg/kg,,BAO_0000218,CHEMBL620280,6123,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5413,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,CHEMBL620281,1337,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5414,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,CHEMBL620282,1337,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5415,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,BAO_0000218,CHEMBL621134,8833,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5416,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,BAO_0000218,CHEMBL621135,8833,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5417,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,BAO_0000218,CHEMBL621136,8833,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5418,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,BAO_0000218,CHEMBL621137,8833,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5419,,Area under plasma concentration time curve in dog upon oral administration,,BAO_0000218,CHEMBL621138,17657,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5420,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,CHEMBL875587,17650,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5421,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,BAO_0000218,CHEMBL621139,1977,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5422,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,BAO_0000218,CHEMBL621140,1977,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5423,,Area under the curve for the compound was obtained when tested in dog,,BAO_0000218,CHEMBL621141,3132,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5424,,Area under the curve at a dose of 1 mg/kg,,BAO_0000218,CHEMBL621142,5473,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5425,,Area under the curve at a dose of 1 mg/kg (oral),,BAO_0000218,CHEMBL621143,5474,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5426,,Area under the curve at i.v. dose of 0.2 mg/kg,,BAO_0000218,CHEMBL621144,5474,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5427,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL621145,6062,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5428,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,BAO_0000218,CHEMBL621146,4709,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5429,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,BAO_0000218,CHEMBL622567,2652,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5430,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,BAO_0000218,CHEMBL622568,2652,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5431,,Compound was evaluated for area under the curve in dog blood.,,BAO_0000218,CHEMBL622569,2877,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5432,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,BAO_0000218,CHEMBL622570,5444,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5433,,AUC in dog after oral dose (1 mg/kg),,BAO_0000218,CHEMBL622571,5130,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5434,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,BAO_0000218,CHEMBL622572,6265,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5435,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,BAO_0000218,CHEMBL622573,4657,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5436,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,BAO_0000218,CHEMBL622574,16367,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5437,,Pharmacokinetic parameter AUC after oral administration to dogs,,BAO_0000218,CHEMBL622575,16367,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5438,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,BAO_0000218,CHEMBL622576,9579,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5439,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,BAO_0000218,CHEMBL622577,9579,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5440,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,CHEMBL622578,5983,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5441,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,BAO_0000218,CHEMBL622579,6241,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5442,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,BAO_0000218,CHEMBL622580,5313,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5443,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,BAO_0000218,CHEMBL622581,5313,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5444,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,CHEMBL622582,6642,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5445,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,CHEMBL622583,6642,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5446,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,CHEMBL622584,6641,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5447,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,CHEMBL622585,6642,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5448,,Compound was evaluated for oral bioavailability in dog; 90-100,,BAO_0000218,CHEMBL622586,17791,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5449,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,BAO_0000218,CHEMBL623281,17655,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5450,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,BAO_0000218,CHEMBL623282,17655,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5451,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,BAO_0000218,CHEMBL623283,6596,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5452,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623284,3880,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5453,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,BAO_0000218,CHEMBL623285,16367,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5454,,Plasma protein binding towards dog plasma at 10 uM,,BAO_0000218,CHEMBL623463,17409,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5455,,Plasma protein binding towards dog plasma at 100 uM,,BAO_0000218,CHEMBL875952,17409,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5456,,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,CHEMBL621705,2959,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5457,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,BAO_0000218,CHEMBL621706,13501,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5458,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,CHEMBL621707,4527,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5459,,Bioavailability in dogs,,BAO_0000218,CHEMBL621708,15145,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5460,,Bioavailability,,BAO_0000218,CHEMBL621709,4219,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5461,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,CHEMBL621710,17538,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5462,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,CHEMBL621711,17538,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5463,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,BAO_0000218,CHEMBL621712,1466,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5464,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,CHEMBL621713,17650,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5465,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,BAO_0000218,CHEMBL621714,3132,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5466,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL621715,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5467,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,CHEMBL623717,2413,10095.0,Autocuration,1,,A,,Mus sp.,,Liver,
5468,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,CHEMBL623718,2413,10095.0,Autocuration,1,,A,,Mus sp.,,Liver,
5469,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL623719,2413,10095.0,Autocuration,1,,A,,Mus sp.,,Liver,
5470,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,CHEMBL623720,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5471,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL623721,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5472,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,CHEMBL623722,2413,10095.0,Autocuration,1,,A,,Mus sp.,,Muscle tissue,
5473,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,CHEMBL623723,2413,10095.0,Autocuration,1,,A,,Mus sp.,,Muscle tissue,
5474,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL618543,2413,10095.0,Autocuration,1,,A,,Mus sp.,,Muscle tissue,
5475,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,CHEMBL618544,2413,10095.0,Autocuration,1,,A,,Mus sp.,,Spleen,
5476,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL875155,2413,10095.0,Autocuration,1,,A,,Mus sp.,,Spleen,
5477,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,CHEMBL618545,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5478,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,CHEMBL618546,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5479,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL623529,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5480,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,CHEMBL623530,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5481,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,CHEMBL621764,2413,10095.0,Autocuration,1,,A,,Mus sp.,,,
5482,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,CHEMBL621765,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5483,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,CHEMBL621766,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,Cerebellum,
5484,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,BAO_0000019,CHEMBL621767,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,Frontal cortex,
5485,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,BAO_0000019,CHEMBL621768,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5486,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,BAO_0000019,CHEMBL621769,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,Striatum,
5487,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,CHEMBL621770,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5488,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,CHEMBL621771,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,Cerebellum,
5489,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,BAO_0000019,CHEMBL621772,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,Frontal cortex,
5490,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,BAO_0000019,CHEMBL621773,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5491,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,CHEMBL621774,17827,9527.0,Autocuration,1,,A,,Cercopithecidae,,Striatum,
5492,,Compound was evaluated for oral bioavailability in rats,,BAO_0000218,CHEMBL621775,17791,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5493,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,BAO_0000218,CHEMBL621776,17667,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,Plasma,
5494,,Half life period was evaluated in monkey,,BAO_0000019,CHEMBL621777,17791,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
5495,,Half-life in rhesus monkeys by intravenous administration of dose,,BAO_0000218,CHEMBL875162,110,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
5496,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,CHEMBL621778,5781,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
5497,,AUC after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,CHEMBL621779,17734,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
5498,,AUC value was determined after oral administration,,BAO_0000218,CHEMBL622479,17718,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
5499,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,CHEMBL622480,4573,10090.0,Intermediate,1,,A,,Mus musculus,,,
5500,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,CHEMBL622481,3277,10090.0,Intermediate,1,,A,,Mus musculus,,,
5501,,Area under curve by ioral administration in mouse,,BAO_0000218,CHEMBL622482,2862,10090.0,Intermediate,1,,A,,Mus musculus,,,
5502,,Area under curve by iv administration in mouse,,BAO_0000218,CHEMBL622483,2862,10090.0,Intermediate,1,,A,,Mus musculus,,,
5503,,Area under curve at 0-8 hr in IRC mice after peroral administration,,BAO_0000218,CHEMBL622484,5951,10090.0,Intermediate,1,,A,,Mus musculus,,,
5504,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,BAO_0000218,CHEMBL622641,17729,10090.0,Intermediate,1,,A,,Mus musculus,,,
5505,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,CHEMBL622642,17728,10090.0,Intermediate,1,,A,,Mus musculus,,,
5506,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,CHEMBL622643,17728,10090.0,Intermediate,1,,A,,Mus musculus,,,
5507,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,BAO_0000218,CHEMBL622644,17729,10090.0,Intermediate,1,,A,,Mus musculus,,,
5508,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,CHEMBL622645,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5509,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,CHEMBL622646,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5510,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,CHEMBL621238,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5511,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,CHEMBL621239,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5512,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,CHEMBL621240,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5513,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,CHEMBL621241,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5514,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,CHEMBL621242,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5515,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,CHEMBL620350,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5516,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,CHEMBL620351,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5517,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,CHEMBL620352,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5518,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,CHEMBL620353,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5519,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,CHEMBL620354,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5520,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,CHEMBL620355,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5521,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,CHEMBL620356,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5522,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,CHEMBL620357,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5523,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,CHEMBL620358,9424,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5524,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,BAO_0000219,CHEMBL620359,9424,9606.0,Expert,1,741.0,F,,Homo sapiens,,,RPMI-8226
5525,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,BAO_0000219,CHEMBL620360,11544,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5526,,Cytotoxicity of compound against 8226/DOX1V cells,,BAO_0000219,CHEMBL620361,17378,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5527,,Cytotoxicity of compound against 8226/S cells,,BAO_0000219,CHEMBL620362,17378,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5528,,Inhibitory concentration against 8226 myeloma cancer cell line,,BAO_0000219,CHEMBL620363,17079,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5529,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,BAO_0000219,CHEMBL620364,17079,9606.0,Intermediate,1,741.0,F,,Homo sapiens,,,RPMI-8226
5530,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,BAO_0000219,CHEMBL620365,13466,9606.0,Intermediate,1,854.0,F,,Homo sapiens,,,833K
5531,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,BAO_0000219,CHEMBL620366,13466,9606.0,Intermediate,1,854.0,F,,Homo sapiens,,,833K
5532,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,BAO_0000219,CHEMBL620367,2392,9606.0,Expert,1,854.0,F,,Homo sapiens,,,833K
5533,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,BAO_0000219,CHEMBL620368,2392,9606.0,Intermediate,1,854.0,F,,Homo sapiens,,,833K
5534,,Inhibitory activity against caspase-1,,BAO_0000019,CHEMBL620369,6608,,Autocuration,1,,B,,,,,
5535,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,BAO_0000357,CHEMBL620370,10199,1351.0,Autocuration,1,,B,,Enterococcus faecalis,,,
5536,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,BAO_0000219,CHEMBL620371,17749,9606.0,Intermediate,1,705.0,F,,Homo sapiens,,,8701-BC
5537,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,BAO_0000219,CHEMBL620372,17749,9606.0,Intermediate,1,705.0,F,,Homo sapiens,,,8701-BC
5538,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,BAO_0000019,CHEMBL876492,1229,,Intermediate,1,,F,,,,,
5539,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,BAO_0000019,CHEMBL620373,1229,,Intermediate,1,,F,,,,,
5540,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,BAO_0000019,CHEMBL620374,1229,,Intermediate,1,,F,,,,,
5541,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,BAO_0000019,CHEMBL620375,6390,,Autocuration,1,,B,,,,,
5542,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,CHEMBL857902,16219,1314.0,Autocuration,1,,F,,Streptococcus pyogenes,,,
5543,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,CHEMBL620376,16219,1314.0,Autocuration,1,,F,,Streptococcus pyogenes,,,
5544,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,BAO_0000357,CHEMBL620377,17043,,Autocuration,1,,B,,,,,
5545,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,BAO_0000219,CHEMBL620378,6929,9606.0,Intermediate,1,324.0,F,,Homo sapiens,,,KB 
5546,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,BAO_0000219,CHEMBL620379,6929,9606.0,Intermediate,1,324.0,A,,Homo sapiens,,,KB 
5547,,In vitro cytotoxicity of compound was tested against 9KB cells.,,BAO_0000219,CHEMBL620380,7083,9606.0,Autocuration,1,,F,,Homo sapiens,,,
5548,,Cytotoxic concentration against 9L cells was determined on day 3,,BAO_0000219,CHEMBL884006,12446,10116.0,Intermediate,1,392.0,F,,Rattus norvegicus,,,9L
5549,,Tested in vitro for anticancer activity against 9L cells,,BAO_0000219,CHEMBL620381,15345,10116.0,Expert,1,392.0,F,,Rattus norvegicus,,,9L
5550,,Tested in vitro for anticancer activity against 9L cells; Not determined,,BAO_0000219,CHEMBL620382,15345,10116.0,Expert,1,392.0,F,,Rattus norvegicus,,,9L
5551,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,BAO_0000219,CHEMBL620383,6301,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5552,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,BAO_0000219,CHEMBL876493,4833,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5553,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,BAO_0000219,CHEMBL620384,4833,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5554,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,BAO_0000219,CHEMBL620385,4833,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5555,,Cytotoxicity against human lung carcinoma A549 cell line,,BAO_0000219,CHEMBL620386,13330,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5556,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,BAO_0000219,CHEMBL620387,17517,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5557,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,BAO_0000219,CHEMBL621404,17517,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5558,,"In vitro growth inhibition of A549, lung carcinoma",,BAO_0000219,CHEMBL621405,14425,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5559,,"In vitro growth inhibition of A549, lung carcinoma.",,BAO_0000219,CHEMBL621406,14425,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5560,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,CHEMBL621407,5228,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5561,,Cytotoxic activity against human lung cancer A549 cell line was determined,,BAO_0000219,CHEMBL621408,5351,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5562,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,BAO_0000219,CHEMBL885345,12198,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5563,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,BAO_0000219,CHEMBL621409,13891,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5564,,Cytotoxicity in A549 (human carcinoma) cell line.,,BAO_0000219,CHEMBL876034,5677,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5565,,Cytotoxicity on lung carcinoma (A-549) cell line,,BAO_0000219,CHEMBL621410,13788,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5566,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,BAO_0000219,CHEMBL621411,13384,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5567,,Effective dose of compound against replication of A549 cell line was evaluated,,BAO_0000219,CHEMBL621412,6726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5568,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,BAO_0000219,CHEMBL621413,3455,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5569,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,BAO_0000219,CHEMBL621414,5726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5570,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,BAO_0000219,CHEMBL621415,5726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5571,,The compound was evaluated for antiproliferative activity against A549 cell line,,BAO_0000219,CHEMBL621416,3936,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5572,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,BAO_0000219,CHEMBL621417,14991,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5573,,Concentration required for growth inhibition of human lung carcinoma cell line A549,,BAO_0000219,CHEMBL621418,5243,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5574,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,BAO_0000219,CHEMBL621419,12858,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5575,,Growth inhibition against A549 cell line was evaluated,,BAO_0000219,CHEMBL621420,6776,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5576,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,BAO_0000219,CHEMBL875823,16558,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5577,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,BAO_0000219,CHEMBL621421,4583,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5578,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,BAO_0000219,CHEMBL621422,13514,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5579,,Chemosensitivity against DT-diaphorase rich A549 cell lines,,BAO_0000219,CHEMBL884014,15166,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5580,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,BAO_0000219,CHEMBL621423,13873,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5581,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,BAO_0000219,CHEMBL621424,6447,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5582,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,BAO_0000219,CHEMBL621425,2068,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5583,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,BAO_0000219,CHEMBL621426,1863,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5584,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,BAO_0000219,CHEMBL621427,13873,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5585,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,BAO_0000219,CHEMBL621428,13873,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5586,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,BAO_0000219,CHEMBL621429,13873,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5587,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,BAO_0000219,CHEMBL621430,579,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5588,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,BAO_0000219,CHEMBL621431,579,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5589,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,BAO_0000219,CHEMBL621432,4584,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5590,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,BAO_0000219,CHEMBL621433,5421,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5591,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,BAO_0000219,CHEMBL875824,5421,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5592,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,BAO_0000219,CHEMBL621434,5421,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5593,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,BAO_0000219,CHEMBL621435,5421,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5594,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,BAO_0000219,CHEMBL621436,14188,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5595,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,BAO_0000219,CHEMBL621437,14188,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5596,,Compound was tested for the growth inhibition of A549 lung tumor cell line,,BAO_0000219,CHEMBL621438,15354,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5597,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,BAO_0000219,CHEMBL621439,14253,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5598,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,BAO_0000219,CHEMBL621440,13873,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5599,,Oral bioavailability in dog (conscious),,BAO_0000218,CHEMBL621441,3043,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5600,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,BAO_0000218,CHEMBL621442,3045,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5601,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,BAO_0000218,CHEMBL621443,3022,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5602,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621444,4453,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5603,,Oral bioavailability in dog,,BAO_0000218,CHEMBL625133,1696,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5604,,Oral bioavailability in dog,,BAO_0000218,CHEMBL625134,5045,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5605,,Oral bioavailability in dog (fasted),,BAO_0000218,CHEMBL625135,5356,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5606,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,CHEMBL625136,17764,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5607,,Oral bioavailability in dog,,BAO_0000218,CHEMBL625137,6448,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5608,,Oral bioavailability in dog,,BAO_0000218,CHEMBL625138,1475,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5609,,Percent bioavailability in dog,,BAO_0000218,CHEMBL625139,3788,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5610,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,BAO_0000218,CHEMBL872264,3639,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5611,,Oral bioavailability in dog,,BAO_0000218,CHEMBL625140,13397,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5612,,The compound was evaluated for bioavailability in dogs; 34-44,,BAO_0000218,CHEMBL624436,2137,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5613,,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,CHEMBL624437,2959,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5614,,Oral bioavailability in dog,,BAO_0000218,CHEMBL872261,6448,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5615,,8 hour trough Blood level in dog was measured after administration of compound,,BAO_0000218,CHEMBL624438,6084,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5616,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,BAO_0000218,CHEMBL624439,3639,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
5617,,C24 after oral administration at 5 mg/kg,,BAO_0000218,CHEMBL624440,6316,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5618,,Clearance after oral and iv dosing in dogs,,BAO_0000218,CHEMBL624441,5238,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5619,,Clearance of the drug was measured in the plasma of dog,,BAO_0000218,CHEMBL624442,17796,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
5620,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,BAO_0000218,CHEMBL624443,2652,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
5621,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,CHEMBL624444,5654,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5622,,Clearance of compound was determined in dogs,,BAO_0000218,CHEMBL624445,6621,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5623,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,CHEMBL624446,6505,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5624,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,CHEMBL624447,5802,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5625,,Plasma clearance in dog was determined,,BAO_0000218,CHEMBL624448,17267,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5626,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,CHEMBL624449,4521,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5627,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,BAO_0000218,CHEMBL624450,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5628,,Plasma clearance in dog after administration of 1 mg/kg iv,,BAO_0000218,CHEMBL875942,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5629,,Plasma clearance in dogs,,BAO_0000218,CHEMBL624451,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5630,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,CHEMBL624452,5542,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5631,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,CHEMBL624453,5199,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5632,,Plasma clearance after 15 mg/kg iv dose in Dogs,,BAO_0000218,CHEMBL624454,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5633,,Plasma clearance after 30 mg/kg po dose in Dogs,,BAO_0000218,CHEMBL624455,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5634,,Plasma administration to dogs,,BAO_0000218,CHEMBL624456,16367,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5635,,Plasma clearance was determined,,BAO_0000218,CHEMBL624457,5505,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5636,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,CHEMBL624458,6215,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5637,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,CHEMBL624459,1466,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5638,,Intrinsic clearance in human liver microsomes,,BAO_0000251,CHEMBL624460,5007,9606.0,Intermediate,1,,A,In vitro,Homo sapiens,,Liver,
5639,,Intrinsic clearance in human liver microsomes,,BAO_0000251,CHEMBL624461,5007,9606.0,Intermediate,1,,A,In vitro,Homo sapiens,,Liver,
5640,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,CHEMBL875943,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5641,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,CHEMBL624462,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5642,,Clearance in dog (dose 1 mg/kg i.v.),,BAO_0000218,CHEMBL624463,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5643,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,CHEMBL624464,6221,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5644,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,CHEMBL624465,5007,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5645,,Plasma clearance after peroral administration at 10 mpk in dog,,BAO_0000218,CHEMBL624466,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5646,,Plasma clearance after peroral administration at 5 mpk in dog,,BAO_0000218,CHEMBL624467,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5647,,Plasma clearance after peroral administration at 5 mg/kg in dog,,BAO_0000218,CHEMBL624468,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5648,,Plasma clearance was measured in dog,,BAO_0000218,CHEMBL624469,15660,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5649,,Plasma clearance was measured in dog,,BAO_0000218,CHEMBL624470,15660,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5650,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,CHEMBL624471,5983,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5651,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,CHEMBL624472,5600,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5652,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,CHEMBL622775,17764,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5653,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,CHEMBL622776,6039,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5654,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,CHEMBL622777,6039,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5655,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,CHEMBL622778,6039,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5656,,Clearance by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,CHEMBL622779,4368,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5657,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,CHEMBL622780,4305,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5658,,Clearance value was evaluated in dog plasma,,BAO_0000218,CHEMBL622781,1918,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
5659,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,CHEMBL622782,6005,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5660,,Compound was tested for plasma clearance in dog,,BAO_0000218,CHEMBL622783,4839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
5661,,Pharmacokinetic property (Plasma clearance) was measured in dog,,BAO_0000218,CHEMBL622784,4239,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5662,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,BAO_0000218,CHEMBL622785,17729,10090.0,Intermediate,1,,A,,Mus musculus,,,
5663,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,BAO_0000218,CHEMBL622786,17728,10090.0,Intermediate,1,,A,,Mus musculus,,,
5664,,Area under curve value in mouse at a dose of 10 mg/kg,,BAO_0000218,CHEMBL622787,5302,10090.0,Intermediate,1,,A,,Mus musculus,,,
5665,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,CHEMBL875949,5506,10090.0,Intermediate,1,,A,,Mus musculus,,,
5666,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,CHEMBL622788,5506,10090.0,Intermediate,1,,A,,Mus musculus,,,
5667,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,CHEMBL622789,17764,10090.0,Intermediate,1,,F,,Mus musculus,,,
5668,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,CHEMBL622790,17764,10090.0,Intermediate,1,,F,,Mus musculus,,,
5669,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,CHEMBL622791,17764,10090.0,Intermediate,1,,F,,Mus musculus,,,
5670,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,CHEMBL622792,17764,10090.0,Intermediate,1,,F,,Mus musculus,,,
5671,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,CHEMBL622793,17764,10090.0,Intermediate,1,,A,,Mus musculus,,,
5672,,Area under curve was determined for the compound at 24 mg/Kg,,BAO_0000218,CHEMBL622794,17753,10090.0,Intermediate,1,,A,,Mus musculus,,,
5673,,Area under curve was determined for the compound at 40 mg/Kg,,BAO_0000218,CHEMBL622795,17753,10090.0,Intermediate,1,,A,,Mus musculus,,,
5674,,Area under curve was determined for the compound at 5 mg/Kg,,BAO_0000218,CHEMBL621803,17753,10090.0,Intermediate,1,,A,,Mus musculus,,,
5675,,Area under the curve for the compound is obtained at dose 25 mg/kg,,BAO_0000218,CHEMBL621804,3132,10090.0,Intermediate,1,,A,,Mus musculus,,,
5676,,Area under the curve for the compound was obtained when tested in mouse,,BAO_0000218,CHEMBL621805,3132,10090.0,Intermediate,1,,A,,Mus musculus,,,
5677,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,CHEMBL621806,17837,10090.0,Intermediate,1,,A,,Mus musculus,,,
5678,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,CHEMBL621807,17837,10090.0,Intermediate,1,,A,,Mus musculus,,,
5679,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL621808,6062,10090.0,Intermediate,1,,A,,Mus musculus,,,
5680,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,CHEMBL621809,4066,10090.0,Intermediate,1,,A,,Mus musculus,,,
5681,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,CHEMBL621810,16597,10090.0,Intermediate,1,,A,,Mus musculus,,,
5682,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,BAO_0000218,CHEMBL875164,14239,10090.0,Intermediate,1,,A,,Mus musculus,,,
5683,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,BAO_0000218,CHEMBL621811,14239,10090.0,Intermediate,1,,A,,Mus musculus,,,
5684,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,BAO_0000218,CHEMBL621812,4890,10090.0,Intermediate,1,,A,,Mus musculus,,,
5685,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,BAO_0000218,CHEMBL621813,429,10090.0,Intermediate,1,,A,,Mus musculus,,,
5686,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,BAO_0000218,CHEMBL621814,429,10090.0,Intermediate,1,,A,,Mus musculus,,,
5687,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,CHEMBL621815,5969,10090.0,Intermediate,1,,A,,Mus musculus,,,
5688,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,CHEMBL621816,5969,10090.0,Intermediate,1,,A,,Mus musculus,,,
5689,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,CHEMBL621817,5969,10090.0,Intermediate,1,,A,,Mus musculus,,,
5690,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,BAO_0000218,CHEMBL621818,6091,10090.0,Intermediate,1,,A,,Mus musculus,,,
5691,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,BAO_0000218,CHEMBL621819,6091,10090.0,Intermediate,1,,A,,Mus musculus,,,
5692,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,BAO_0000218,CHEMBL621820,6091,10090.0,Intermediate,1,,A,,Mus musculus,,,
5693,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,BAO_0000218,CHEMBL621821,6091,10090.0,Intermediate,1,,A,,Mus musculus,,,
5694,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,CHEMBL621822,6178,10090.0,Intermediate,1,,A,,Mus musculus,,,
5695,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,CHEMBL619474,6178,10090.0,Intermediate,1,,A,,Mus musculus,,,
5696,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,CHEMBL619475,6619,10090.0,Intermediate,1,,A,,Mus musculus,,,
5697,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,CHEMBL619476,6619,10090.0,Intermediate,1,,A,,Mus musculus,,,
5698,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,CHEMBL619477,3760,10090.0,Intermediate,1,,A,,Mus musculus,,,
5699,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,CHEMBL619478,3760,10090.0,Intermediate,1,,A,,Mus musculus,,,
5700,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,CHEMBL619479,3760,10090.0,Intermediate,1,,A,,Mus musculus,,,
5701,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,CHEMBL619480,3760,10090.0,Intermediate,1,,A,,Mus musculus,,,
5702,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,BAO_0000218,CHEMBL619481,3192,10090.0,Intermediate,1,,A,,Mus musculus,,,
5703,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,BAO_0000218,CHEMBL619482,3192,10090.0,Intermediate,1,,A,,Mus musculus,,,
5704,,Area under the curve was evaluated in mice after intravenous administration,,BAO_0000218,CHEMBL619483,2675,10090.0,Intermediate,1,,A,,Mus musculus,,,
5705,,Area under the curve was evaluated in mice after oral administration,,BAO_0000218,CHEMBL619484,2675,10090.0,Intermediate,1,,A,,Mus musculus,,,
5706,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,CHEMBL619485,16597,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
5707,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,CHEMBL619486,16597,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
5708,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,CHEMBL619487,16597,10090.0,Intermediate,1,,A,,Mus musculus,,,
5709,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,CHEMBL619488,17734,10090.0,Intermediate,1,,A,,Mus musculus,,,
5710,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620106,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5711,,The compound was tested in vitro for anticancer activity against 9L cells,,BAO_0000219,CHEMBL620107,15345,,Intermediate,1,392.0,F,,,,,9L
5712,,Anti proliferation activity determined; Weak effect,,BAO_0000019,CHEMBL620283,2181,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
5713,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,CHEMBL875176,2181,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
5714,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,BAO_0000219,CHEMBL620284,2181,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
5715,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,CHEMBL623515,2181,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
5716,,The cytotoxic activity was in vitro tested by 9PS assay method,,BAO_0000019,CHEMBL623516,10486,10090.0,Autocuration,1,,F,,Mus musculus,,,
5717,,The cytotoxic activity was in vitro tested by 9PS assay method.,,BAO_0000019,CHEMBL623517,10486,10090.0,Autocuration,1,,F,,Mus musculus,,,
5718,,Partition coefficient (logD6.5),,BAO_0000019,CHEMBL857878,15508,,Autocuration,1,,A,,,,,
5719,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,BAO_0000219,CHEMBL623518,5242,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
5720,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,BAO_0000219,CHEMBL624195,16167,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
5721,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,BAO_0000219,CHEMBL624196,4782,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5722,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,CHEMBL624197,16093,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5723,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,BAO_0000219,CHEMBL624198,2596,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5724,,in vitro cytotoxicity against A 498 cancer cell line,,BAO_0000219,CHEMBL621287,2596,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5725,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,BAO_0000219,CHEMBL621288,3239,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5726,,Cytotoxic activity against A 498 renal cancer cell lines.,,BAO_0000219,CHEMBL876496,1847,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5727,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,BAO_0000219,CHEMBL621289,10553,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5728,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,CHEMBL621290,16219,1280.0,Autocuration,1,,F,,Staphylococcus aureus,,,
5729,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,CHEMBL621291,16219,1280.0,Autocuration,1,,F,,Staphylococcus aureus,,,
5730,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,CHEMBL621292,16219,1280.0,Autocuration,1,,F,,Staphylococcus aureus,,,
5731,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,CHEMBL621293,16219,1280.0,Autocuration,1,,F,,Staphylococcus aureus,,,
5732,,Inhibitory concentration required against A 549 lung cancer cell line,,BAO_0000219,CHEMBL621294,4782,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5733,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,BAO_0000219,CHEMBL621295,11805,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5734,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,BAO_0000219,CHEMBL884007,11805,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5735,,In vitro cytotoxicity against lung cancer A 549 cell lines,,BAO_0000219,CHEMBL621296,2007,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5736,,Compound was tested for its cytotoxicity against A 549 cell line,,BAO_0000219,CHEMBL621297,4594,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5737,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,BAO_0000219,CHEMBL839828,6018,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5738,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,BAO_0000219,CHEMBL620397,6018,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5739,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,BAO_0000219,CHEMBL620398,3599,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5740,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,BAO_0000219,CHEMBL620399,2551,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5741,,In vitro inhibition of A549 (human lung cancer) cell growth.,,BAO_0000219,CHEMBL620400,16132,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5742,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,BAO_0000219,CHEMBL620401,16132,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5743,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,BAO_0000219,CHEMBL620402,2551,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5744,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,BAO_0000219,CHEMBL620403,2551,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5745,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,BAO_0000218,CHEMBL620404,11913,,Autocuration,1,,F,,,,,
5746,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,BAO_0000218,CHEMBL620405,12621,,Autocuration,1,,F,In vivo,,,,
5747,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,CHEMBL620406,12621,,Autocuration,1,,F,In vivo,,,,
5748,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,BAO_0000218,CHEMBL620407,12621,,Autocuration,1,,F,In vivo,,,,
5749,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,CHEMBL620408,12621,,Autocuration,1,,F,In vivo,,,,
5750,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,BAO_0000218,CHEMBL620409,12621,,Autocuration,1,,F,In vivo,,,,
5751,,Inhibition of A-498 human Renal cell proliferation,,BAO_0000219,CHEMBL620410,3600,9606.0,Expert,1,624.0,F,,Homo sapiens,,,A498
5752,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,BAO_0000019,CHEMBL620411,1796,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
5753,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,BAO_0000019,CHEMBL620412,1796,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
5754,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,BAO_0000019,CHEMBL876596,1796,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
5755,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,BAO_0000219,CHEMBL620413,16464,9606.0,Expert,1,622.0,F,,Homo sapiens,,,A 172
5756,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,CHEMBL620414,16464,9606.0,Intermediate,1,622.0,F,,Homo sapiens,,,A 172
5757,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,CHEMBL620415,16464,9606.0,Intermediate,1,622.0,F,,Homo sapiens,,,A 172
5758,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,BAO_0000219,CHEMBL620416,13617,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5759,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,BAO_0000219,CHEMBL620417,4584,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5760,,Cytotoxic activity evaluated against A549 tumor cells,,BAO_0000219,CHEMBL620418,13799,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5761,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,BAO_0000219,CHEMBL620419,16726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5762,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,BAO_0000219,CHEMBL620420,16109,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5763,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,BAO_0000219,CHEMBL620421,16109,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5764,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,BAO_0000219,CHEMBL620422,15474,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5765,,Cytotoxicity of compound against A549 cell line,,BAO_0000219,CHEMBL620423,6851,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5766,,Cytotoxicity against human lung cell carcinoma A549 cell line,,BAO_0000219,CHEMBL620424,17534,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5767,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,BAO_0000219,CHEMBL620425,2621,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5768,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,BAO_0000219,CHEMBL620426,830,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5769,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,BAO_0000219,CHEMBL620427,14255,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5770,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,BAO_0000219,CHEMBL620428,14255,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5771,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,BAO_0000219,CHEMBL620429,1590,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5772,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,BAO_0000219,CHEMBL620430,6146,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5773,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,CHEMBL839887,17427,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5774,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,BAO_0000219,CHEMBL620431,5280,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5775,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,BAO_0000219,CHEMBL884010,16786,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5776,,In vitro cytotoxicity against A549 (human lung cancer),,BAO_0000219,CHEMBL620538,5895,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5777,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,CHEMBL620539,14297,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5778,,In vivo antiproliferative activity against A549 cell line,,BAO_0000218,CHEMBL623373,17824,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5779,,Inhibition of non-small-cell lung adenocarcinoma (A549),,BAO_0000219,CHEMBL623374,14368,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5780,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,BAO_0000219,CHEMBL623375,14368,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5781,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,BAO_0000219,CHEMBL623376,14254,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5782,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,BAO_0000219,CHEMBL623377,15897,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5783,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,BAO_0000219,CHEMBL623378,13866,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5784,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,BAO_0000219,CHEMBL623379,13370,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5785,,Inhibitory activity against A549 lung cancer cell line,,BAO_0000219,CHEMBL623380,4862,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5786,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,BAO_0000219,CHEMBL623381,4862,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5787,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,BAO_0000219,CHEMBL623382,4862,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5788,,Inhibitory concentration against A549 (lung cancer) cell line,,BAO_0000219,CHEMBL623383,15970,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5789,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,CHEMBL623384,17713,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5790,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,BAO_0000219,CHEMBL623385,4833,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5791,,Activity against A549 cancer cell line.,,BAO_0000219,CHEMBL623386,13736,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5792,,The compound was evaluated for cytotoxicity against A549 cell line,,BAO_0000219,CHEMBL884105,4312,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5793,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,BAO_0000219,CHEMBL623387,5421,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5794,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,BAO_0000219,CHEMBL621568,5421,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5795,,Growth inhibitory activity was measured for human A549 tumor cell line.,,BAO_0000219,CHEMBL621569,14717,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5796,,Inhibitory activity against A549 lung cancer cell line,,BAO_0000219,CHEMBL621570,4634,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5797,,Inhibitory activity against A549 cell line; inactive,,BAO_0000219,CHEMBL621571,1149,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5798,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,BAO_0000219,CHEMBL621572,5421,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5799,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,BAO_0000219,CHEMBL621573,5421,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5800,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,BAO_0000219,CHEMBL621574,5421,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5801,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,BAO_0000219,CHEMBL621575,3320,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5802,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,BAO_0000219,CHEMBL621576,3320,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5803,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,BAO_0000219,CHEMBL621577,3320,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5804,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,BAO_0000219,CHEMBL621578,3320,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5805,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,BAO_0000219,CHEMBL621579,3320,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5806,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,BAO_0000219,CHEMBL621580,5726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5807,,Plasma clearance (in vivo) in mongrel dogs was determined,,BAO_0000218,CHEMBL621581,17800,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5808,,Plasma clearance was measured in dog,,BAO_0000218,CHEMBL621582,5985,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5809,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,CHEMBL621583,5530,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5810,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,CHEMBL621584,5530,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5811,,Tested for plasma clearance in dog,,BAO_0000218,CHEMBL621585,4839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
5812,,The compound was tested for clearance in dog plasma.,,BAO_0000218,CHEMBL621586,3639,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5813,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,BAO_0000218,CHEMBL875835,4838,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5814,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,CHEMBL621587,4137,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5815,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,BAO_0000218,CHEMBL621588,5017,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
5816,,In vitro clearance in dog liver microsomes,,BAO_0000218,CHEMBL621589,17538,9615.0,Intermediate,1,,A,In vitro,Canis lupus familiaris,,Liver,
5817,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,CHEMBL621590,6161,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5818,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,CHEMBL621591,6161,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5819,,Plasma clearance in dog,,BAO_0000218,CHEMBL621592,1696,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5820,,Clearance rate in dog,,BAO_0000218,CHEMBL621593,6762,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5821,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,BAO_0000218,CHEMBL621594,5932,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
5822,,Clearance in dogs,,BAO_0000218,CHEMBL621595,6305,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5823,,Plasma clearance in dogs,,BAO_0000218,CHEMBL621596,4942,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5824,,Plasma clearance was determined,,BAO_0000218,CHEMBL621597,4219,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5825,,Lower clearance in dog (i.v.) at 0.5 mpk,,BAO_0000218,CHEMBL621598,17853,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5826,,Plasma clearance in Beagle dogs,,BAO_0000218,CHEMBL621599,4514,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5827,,Plasma clearance (Clp) in dog,,BAO_0000218,CHEMBL875836,6448,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5828,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,BAO_0000218,CHEMBL621600,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5829,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,BAO_0000218,CHEMBL621601,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5830,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL618474,6062,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5831,,Plasma clearance of compound was determined in dog,,BAO_0000218,CHEMBL618475,6821,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5832,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,BAO_0000218,CHEMBL624524,4709,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5833,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,CHEMBL624525,4521,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5834,,Plasma clearance in dog was determined,,BAO_0000218,CHEMBL624526,5374,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5835,,Plasma clearance was calculated in dog,,BAO_0000218,CHEMBL624527,6057,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5836,,Plasma clearance at the dose of 2 mg/kg in dog,,BAO_0000218,CHEMBL624528,4727,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5837,,Plasma clearance in dog,,BAO_0000218,CHEMBL624529,5145,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5838,,Plasma clearance in dog,,BAO_0000218,CHEMBL624530,17657,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5839,,Plasma clearance in dog; Unable to calculate,,BAO_0000218,CHEMBL624531,17657,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5840,,Plasma clearance in rhesus monkey,,BAO_0000218,CHEMBL624532,5145,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5841,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,CHEMBL624533,6642,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5842,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL624534,6641,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5843,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL624535,6642,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5844,,Plasma clearance was evaluated in dog,,BAO_0000218,CHEMBL624536,5472,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5845,,Plasma clearance was evaluated in dog; Not tested,,BAO_0000218,CHEMBL624537,5472,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5846,,Plasma clearance was evaluated in rhesus,,BAO_0000218,CHEMBL624538,5472,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5847,,Plasma clearance was evaluated in rhesus; Not tested,,BAO_0000218,CHEMBL624539,5472,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5848,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,CHEMBL624540,4257,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5849,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,CHEMBL624541,6679,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5850,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,CHEMBL624542,5546,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5851,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL624543,6348,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5852,,Clearance value at a dose of 0.2 mg/kg i.v.,,BAO_0000218,CHEMBL624544,5474,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5853,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,BAO_0000218,CHEMBL624545,6316,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
5854,,Cmax after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,CHEMBL624546,17594,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5855,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,CHEMBL875957,17594,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5856,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,CHEMBL624547,5802,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5857,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,CHEMBL624548,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5858,,Cmax in dog after administration of 1 mg/kg iv,,BAO_0000218,CHEMBL624549,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5859,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,CHEMBL624550,1466,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
5860,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,BAO_0000218,CHEMBL621613,6505,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5861,,Cmax was determine after peroral administration at 10 mpk in dog,,BAO_0000218,CHEMBL621614,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5862,,Cmax was determine after peroral administration at 5 mpk in dog,,BAO_0000218,CHEMBL623431,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5863,,Cmax was determine after peroral administration at 5 mg/kg in dog,,BAO_0000218,CHEMBL623432,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5864,,Cmax after 0.3 mg/kg po administration in dog,,BAO_0000218,CHEMBL623433,5600,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5865,,Cmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,CHEMBL623434,17764,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5866,,Cmax in dog after oral administration at 1 mg/kg,,BAO_0000218,CHEMBL623435,6123,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5867,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,BAO_0000218,CHEMBL623436,6123,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5868,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,BAO_0000218,CHEMBL875958,6757,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5869,,Cmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,CHEMBL623437,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5870,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623438,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5871,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623439,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
5872,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623440,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
5873,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623441,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
5874,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623442,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
5875,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623469,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
5876,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623470,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
5877,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623471,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
5878,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623472,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5879,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623473,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5880,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623474,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
5881,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623475,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5882,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623476,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5883,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL623477,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
5884,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL621896,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
5885,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL621897,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
5886,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL621898,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
5887,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL621899,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5888,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL621900,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5889,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL621901,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
5890,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL621902,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
5891,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL621903,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
5892,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL622587,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
5893,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620285,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
5894,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL875285,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
5895,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620286,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
5896,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620287,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
5897,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620288,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
5898,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620289,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
5899,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620290,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
5900,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620291,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
5901,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620292,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Intestine,
5902,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620293,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
5903,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL620294,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
5904,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL618614,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
5905,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL618615,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
5906,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL618616,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
5907,,Cytotoxicity against A-172 human tumor cell lines,,BAO_0000219,CHEMBL618617,2036,9606.0,Expert,1,622.0,F,,Homo sapiens,,,A 172
5908,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,BAO_0000219,CHEMBL618618,2357,9606.0,Intermediate,1,622.0,F,,Homo sapiens,,,A 172
5909,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,BAO_0000219,CHEMBL618619,1457,9606.0,Intermediate,1,623.0,F,,Homo sapiens,,,A204
5910,,Tested for antiproliferative activity against A-2780 tumoral cell line,,BAO_0000219,CHEMBL618620,4379,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
5911,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,BAO_0000219,CHEMBL618621,1093,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
5912,,Tested in vitro against A-375 cell line human melanoma,,BAO_0000219,CHEMBL618622,12152,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
5913,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,BAO_0000219,CHEMBL618623,16464,9606.0,Expert,1,797.0,F,,Homo sapiens,,,A-427
5914,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,CHEMBL618624,16464,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
5915,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,BAO_0000219,CHEMBL618625,16582,9606.0,Expert,1,797.0,F,,Homo sapiens,,,A-427
5916,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,CHEMBL618626,16464,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
5917,,Antitumor activity on A-427 lung carcinoma cell lines,,BAO_0000219,CHEMBL618627,10413,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
5918,,Cytotoxic activity against human A-427 lung tumor cell line,,BAO_0000219,CHEMBL618628,6418,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
5919,,In vitro antitumor effects against human A-427 cell lines.,,BAO_0000219,CHEMBL618629,17134,9606.0,Expert,1,797.0,F,,Homo sapiens,,,A-427
5920,,In vitro inhibition of A-427 (human lung cancer) cell growth.,,BAO_0000219,CHEMBL618630,16132,9606.0,Expert,1,797.0,F,,Homo sapiens,,,A-427
5921,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,BAO_0000219,CHEMBL618631,16132,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
5922,,Cytotoxic activity of compound against A-427 lung human tumor cell line,,BAO_0000219,CHEMBL618632,16780,9606.0,Intermediate,1,797.0,F,,Homo sapiens,,,A-427
5923,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,BAO_0000219,CHEMBL618633,4085,9606.0,Expert,1,500.0,F,,Homo sapiens,,,A-431
5924,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,BAO_0000219,CHEMBL619315,1276,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5925,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,BAO_0000219,CHEMBL619316,3498,9606.0,Expert,1,624.0,F,,Homo sapiens,,,A498
5926,,Cytotoxicity against human kidney carcinoma A-498cell lines,,BAO_0000219,CHEMBL619317,1169,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5927,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,BAO_0000219,CHEMBL619318,4450,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5928,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,BAO_0000219,CHEMBL619319,3311,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5929,,Antitumor cytotoxic activity against A-498 cell line was determined,,BAO_0000219,CHEMBL619739,4461,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5930,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,BAO_0000219,CHEMBL619740,3311,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5931,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,BAO_0000219,CHEMBL883158,3311,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5932,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,BAO_0000219,CHEMBL884012,1457,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5933,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,BAO_0000219,CHEMBL619741,3664,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5934,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,BAO_0000219,CHEMBL619742,15895,9606.0,Intermediate,1,624.0,F,,Homo sapiens,,,A498
5935,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,BAO_0000219,CHEMBL876610,11843,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5936,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,BAO_0000219,CHEMBL619743,11843,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5937,,In vitro antiproliferative activity against human A-549 NSCL cell line,,BAO_0000219,CHEMBL619744,17705,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5938,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,BAO_0000219,CHEMBL619745,17705,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5939,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,BAO_0000219,CHEMBL619746,4369,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5940,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,BAO_0000219,CHEMBL619747,4369,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5941,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,CHEMBL619748,4369,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5942,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,BAO_0000219,CHEMBL619749,4369,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5943,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,CHEMBL619750,4369,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5944,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,BAO_0000219,CHEMBL624014,4369,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5945,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,CHEMBL624015,4369,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5946,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,BAO_0000219,CHEMBL885344,4787,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5947,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,BAO_0000219,CHEMBL623224,4787,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5948,,Cytotoxic activity against A-549 cell line,,BAO_0000219,CHEMBL623225,6513,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5949,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,BAO_0000219,CHEMBL622698,6690,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5950,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,BAO_0000219,CHEMBL622699,6690,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5951,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,BAO_0000219,CHEMBL622700,12263,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5952,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,BAO_0000219,CHEMBL622701,1054,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5953,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,BAO_0000219,CHEMBL622702,1359,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5954,,Cytotoxic activity against human lung carcinoma (A-549) cell line,,BAO_0000219,CHEMBL622703,3547,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5955,,Cytotoxic activity towards A-549 cells,,BAO_0000219,CHEMBL622704,5771,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5956,,"In vitro percent inhibition of A549, lung carcinoma.",,BAO_0000219,CHEMBL622705,14425,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5957,,"In vitro percent inhibition of A549, lung carcinoma",,BAO_0000219,CHEMBL622706,14425,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5958,,"In vitro percent inhibition of A549, lung carcinoma.",,BAO_0000219,CHEMBL622707,14425,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5959,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,BAO_0000219,CHEMBL622708,14425,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5960,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,BAO_0000219,CHEMBL622709,5280,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5961,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,BAO_0000219,CHEMBL622710,15176,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5962,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,BAO_0000219,CHEMBL622711,15300,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5963,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,CHEMBL622712,17824,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5964,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,CHEMBL622713,17824,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5965,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,CHEMBL622714,17824,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5966,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,CHEMBL622715,17824,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5967,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,CHEMBL622716,17824,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5968,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,BAO_0000219,CHEMBL622717,17824,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5969,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,BAO_0000218,CHEMBL622718,17528,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5970,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,BAO_0000219,CHEMBL622719,6870,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5971,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,BAO_0000219,CHEMBL622720,6870,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5972,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,BAO_0000219,CHEMBL622721,6870,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5973,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,BAO_0000219,CHEMBL622722,6870,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5974,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,BAO_0000219,CHEMBL876030,16726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5975,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,BAO_0000219,CHEMBL620206,6170,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5976,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,BAO_0000219,CHEMBL620207,6583,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5977,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,BAO_0000219,CHEMBL620208,6583,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5978,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,BAO_0000219,CHEMBL620209,6583,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5979,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,BAO_0000219,CHEMBL620210,6583,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5980,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,BAO_0000219,CHEMBL621639,6583,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5981,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,BAO_0000219,CHEMBL621640,17321,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5982,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,BAO_0000219,CHEMBL621641,17528,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5983,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,BAO_0000219,CHEMBL621642,12888,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
5984,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,BAO_0000219,CHEMBL621643,4312,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5985,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,BAO_0000219,CHEMBL621644,4312,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5986,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,BAO_0000219,CHEMBL621645,4312,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
5987,,In vitro antiproliferative activity against A549 cell line,,BAO_0000219,CHEMBL621646,17737,10090.0,Intermediate,1,646.0,F,,Mus musculus,,,A549
5988,,Synergism with indomethacin in A549 cells,,BAO_0000219,CHEMBL621647,6630,,Intermediate,1,646.0,F,,,,,A549
5989,,Synergism with tolmetin in A549 cells,,BAO_0000219,CHEMBL621648,6630,,Intermediate,1,646.0,F,,,,,A549
5990,,Synergism with sulindac in A549 cells,,BAO_0000219,CHEMBL621649,6630,,Intermediate,1,646.0,F,,,,,A549
5991,,Antagonism of indomethacin in A549 cells,,BAO_0000219,CHEMBL621650,6630,,Intermediate,1,646.0,F,,,,,A549
5992,,Antagonism of sulindac in A549 cells,,BAO_0000219,CHEMBL621651,6630,,Intermediate,1,646.0,F,,,,,A549
5993,,Antagonism of tolmetin in A549 cells,,BAO_0000219,CHEMBL621652,6630,,Intermediate,1,646.0,F,,,,,A549
5994,,Synergism with indomethacin in A549 cells,,BAO_0000219,CHEMBL621653,6630,,Intermediate,1,646.0,F,,,,,A549
5995,,Synergism with sulindac in A549 cells,,BAO_0000219,CHEMBL621654,6630,,Intermediate,1,646.0,F,,,,,A549
5996,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,BAO_0000219,CHEMBL621655,6630,,Intermediate,1,646.0,F,,,,,A549
5997,,Cmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,CHEMBL621656,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5998,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,CHEMBL621657,5944,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
5999,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,CHEMBL621658,5944,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6000,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,CHEMBL621659,5944,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6001,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,CHEMBL621660,5944,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6002,,Cmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,CHEMBL621661,2959,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6003,,Cmax value in dog,,BAO_0000218,CHEMBL621662,6241,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6004,,Cmax value in dogs after oral administration at 1 mg/kg,,BAO_0000218,CHEMBL621663,6241,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6005,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,BAO_0000218,CHEMBL621664,2652,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6006,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,BAO_0000218,CHEMBL621665,1806,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6007,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,BAO_0000218,CHEMBL621666,1806,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6008,,Concentration maxima after oral dosing in dogs,,BAO_0000218,CHEMBL621667,1021,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6009,,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,CHEMBL876738,1021,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6010,,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,CHEMBL621668,1021,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6011,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,BAO_0000218,CHEMBL621669,5444,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6012,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,BAO_0000218,CHEMBL621670,5444,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6013,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,BAO_0000218,CHEMBL621671,5444,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6014,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,BAO_0000218,CHEMBL622360,5444,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6015,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,BAO_0000218,CHEMBL622361,5444,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6016,,Cmax in dog plasma after oral dose (1 mg/kg),,BAO_0000218,CHEMBL622362,5130,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6017,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,BAO_0000218,CHEMBL622363,3249,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6018,,Maximal plasma concentration at a dose of 1 mg/kg,,BAO_0000218,CHEMBL622364,5473,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6019,,Maximal plasma concentration at a dose of 1 mg/kg (oral),,BAO_0000218,CHEMBL622365,5474,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6020,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,BAO_0000218,CHEMBL622533,4657,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6021,,Maximum concentration of compound in dog was evaluated.,,BAO_0000218,CHEMBL622534,3031,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6022,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,CHEMBL622535,4527,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6023,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,CHEMBL876739,4186,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6024,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,CHEMBL622536,5007,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6025,,Maximum concentration obtained in dog plasma was determined,,BAO_0000218,CHEMBL622537,3132,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6026,,Maximum concentration was determined,,BAO_0000218,CHEMBL622538,5006,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6027,,Maximum concentration at the dose of 2 mg/kg in dog,,BAO_0000218,CHEMBL627867,4727,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6028,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL627868,1916,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6029,,Maximum concentration was evaluated in dog plasma,,BAO_0000218,CHEMBL627869,1918,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6030,,Maximum concentration was evaluated after 75 min after administration in dog,,BAO_0000218,CHEMBL627870,3045,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6031,,Maximum plasma concentration determined in dog after oral administration of 17b,,BAO_0000218,CHEMBL627871,9579,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6032,,Maximum plasma concentration determined in dog after oral administration of 2b,,BAO_0000218,CHEMBL627872,9579,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6033,,Maximum plasma concentration in dog,,BAO_0000218,CHEMBL627873,933,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6034,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,BAO_0000218,CHEMBL627874,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6035,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,BAO_0000218,CHEMBL627875,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6036,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,BAO_0000218,CHEMBL627876,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6037,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,BAO_0000218,CHEMBL627877,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6038,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL627878,6348,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6039,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,BAO_0000218,CHEMBL627879,16367,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6040,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,CHEMBL875355,1337,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6041,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,CHEMBL627880,1337,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6042,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,BAO_0000218,CHEMBL627881,5199,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6043,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,CHEMBL627882,17650,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6044,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL627883,6679,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6045,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,BAO_0000218,CHEMBL628526,5356,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6046,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,BAO_0000218,CHEMBL628527,5356,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6047,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,BAO_0000218,CHEMBL628528,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6048,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,BAO_0000218,CHEMBL628529,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6049,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,BAO_0000218,CHEMBL628530,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6050,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,BAO_0000218,CHEMBL625243,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6051,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL625244,3598,9615.0,Expert,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6052,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,CHEMBL625245,4368,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6053,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,CHEMBL625246,6265,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6054,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL625247,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
6055,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,CHEMBL625248,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Urine,
6056,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,BAO_0000218,CHEMBL625249,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Urine,
6057,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,BAO_0000218,CHEMBL625250,7767,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Urine,
6058,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,BAO_0000218,CHEMBL625251,17811,10090.0,Intermediate,1,,A,,Mus musculus,,,
6059,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,BAO_0000218,CHEMBL875356,17811,10090.0,Intermediate,1,,A,,Mus musculus,,,
6060,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,BAO_0000218,CHEMBL625252,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6061,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,BAO_0000218,CHEMBL625253,17827,10090.0,Intermediate,1,,A,,Mus musculus,,Blood,
6062,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,BAO_0000218,CHEMBL625254,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6063,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,BAO_0000218,CHEMBL625255,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6064,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,BAO_0000218,CHEMBL625256,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6065,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,BAO_0000218,CHEMBL625257,17827,10090.0,Intermediate,1,,A,,Mus musculus,,Blood,
6066,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,BAO_0000218,CHEMBL625258,17827,10090.0,Intermediate,1,,A,,Mus musculus,,Blood,
6067,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,BAO_0000218,CHEMBL625259,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6068,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,BAO_0000218,CHEMBL625260,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6069,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,CHEMBL625261,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6070,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,CHEMBL625262,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6071,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,CHEMBL622639,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6072,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,BAO_0000218,CHEMBL622640,17257,10090.0,Intermediate,1,,A,,Mus musculus,,,
6073,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,BAO_0000218,CHEMBL622812,17257,10090.0,Intermediate,1,,A,,Mus musculus,,,
6074,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,BAO_0000218,CHEMBL622813,17257,10090.0,Intermediate,1,,A,,Mus musculus,,,
6075,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,BAO_0000218,CHEMBL622814,17257,10090.0,Intermediate,1,,A,,Mus musculus,,,
6076,,Time at maximum activity in mice (Radiolabeled compound),,BAO_0000218,CHEMBL622815,17827,10090.0,Intermediate,1,,A,,Mus musculus,,,
6077,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,CHEMBL625342,3760,10090.0,Intermediate,1,,A,,Mus musculus,,,
6078,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,CHEMBL625343,3760,10090.0,Intermediate,1,,A,,Mus musculus,,,
6079,,Binding towards mouse plasma protein at 10 uM,,BAO_0000218,CHEMBL877591,17409,10090.0,Intermediate,1,,A,,Mus musculus,,,
6080,,Binding towards mouse plasma protein at 100 uM,,BAO_0000218,CHEMBL625344,17409,10090.0,Intermediate,1,,A,,Mus musculus,,,
6081,,Bioavailability was evaluated in mice after intravenous administration,,BAO_0000218,CHEMBL625345,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6082,,Bioavailability was evaluated in mice after oral administration,,BAO_0000218,CHEMBL625346,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6083,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,BAO_0000218,CHEMBL625347,3132,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6084,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,BAO_0000218,CHEMBL625348,3132,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6085,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,CHEMBL625349,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6086,,Oral bioavailability in mouse,,BAO_0000218,CHEMBL625350,2862,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6087,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,BAO_0000218,CHEMBL882952,17764,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6088,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL625351,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
6089,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL625352,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
6090,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL877592,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
6091,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL625353,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
6092,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL625354,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
6093,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL626019,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
6094,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL626020,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
6095,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL626021,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
6096,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL626022,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
6097,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL626192,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
6098,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,BAO_0000219,CHEMBL626193,1276,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6099,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,BAO_0000219,CHEMBL626194,3498,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6100,,Cytotoxicity against human lung carcinoma A-549 cell lines,,BAO_0000219,CHEMBL626195,1169,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6101,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,BAO_0000219,CHEMBL626196,4450,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6102,,In vitro cytotoxicity against human lung carcinoma cell line A-549,,BAO_0000219,CHEMBL626197,358,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6103,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,BAO_0000219,CHEMBL626198,358,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6104,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,BAO_0000219,CHEMBL626199,358,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6105,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,BAO_0000219,CHEMBL626200,358,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6106,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,BAO_0000219,CHEMBL626201,358,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6107,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,BAO_0000219,CHEMBL626202,358,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6108,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,BAO_0000219,CHEMBL626203,358,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6109,,In vitro cytotoxicity against A-549 human lung cancer cells,,BAO_0000219,CHEMBL626204,15167,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6110,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,BAO_0000219,CHEMBL624701,4139,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6111,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,BAO_0000219,CHEMBL624702,833,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6112,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,CHEMBL624703,15718,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6113,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,BAO_0000219,CHEMBL624704,12373,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6114,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,BAO_0000219,CHEMBL624705,637,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6115,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,BAO_0000219,CHEMBL624706,14867,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6116,,Antitumor cytotoxic activity against A-549 cell line was determined,,BAO_0000219,CHEMBL624707,4461,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6117,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,BAO_0000219,CHEMBL624708,5406,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6118,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,BAO_0000219,CHEMBL624709,4457,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6119,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,CHEMBL884107,1386,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6120,,Antitumoral activity was assayed against A-549 cell line,,BAO_0000219,CHEMBL624710,3265,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6121,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,BAO_0000219,CHEMBL624711,2359,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6122,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,BAO_0000219,CHEMBL624712,4457,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6123,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,CHEMBL624713,12454,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6124,,Compound was tested for inhibition of cell growth of A-549 cells,,BAO_0000219,CHEMBL624714,1481,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6125,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,BAO_0000219,CHEMBL624715,1750,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6126,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,BAO_0000219,CHEMBL624716,5065,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6127,,In vitro cytotoxicity against A549-human lung carcinoma cells.,,BAO_0000219,CHEMBL619505,808,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6128,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,BAO_0000219,CHEMBL619506,16364,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6129,,Cytotoxic activity against A-549 cell lines.,,BAO_0000219,CHEMBL619507,1847,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6130,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,BAO_0000219,CHEMBL619508,1747,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6131,,Cytotoxicity against human A549 non small cell lung cell lines,,BAO_0000219,CHEMBL619509,1003,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6132,,Inhibition of cell growth in (A-549) lung cell line,,BAO_0000219,CHEMBL619510,15313,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6133,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,BAO_0000219,CHEMBL619511,3122,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6134,,In vitro antitumor activity against A-549 tumor cells.,,BAO_0000219,CHEMBL619512,16049,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6135,,In vitro antitumor effects against human A-549 cell lines.,,BAO_0000219,CHEMBL619513,17134,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6136,,In vitro cytotoxic activity of compound against A-549 cell line,,BAO_0000219,CHEMBL619514,6406,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6137,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,BAO_0000219,CHEMBL619515,627,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6138,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,BAO_0000219,CHEMBL619516,12307,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6139,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,BAO_0000219,CHEMBL884005,17861,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6140,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,BAO_0000219,CHEMBL619517,6682,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6141,,Inhibitory concentration of compound against A-549 cell line,,BAO_0000219,CHEMBL619518,6663,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6142,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,BAO_0000219,CHEMBL619519,2454,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6143,,cytotoxic activity against leukemia (A-549) cancer cell line,,BAO_0000219,CHEMBL876489,14709,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6144,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,CHEMBL619520,15718,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6145,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,CHEMBL619521,15718,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6146,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,BAO_0000219,CHEMBL619522,17130,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6147,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,BAO_0000219,CHEMBL619523,17130,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6148,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,BAO_0000219,CHEMBL619524,17130,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6149,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,BAO_0000219,CHEMBL619525,17130,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6150,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,BAO_0000219,CHEMBL619526,6630,,Intermediate,1,646.0,F,,,,,A549
6151,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,BAO_0000219,CHEMBL619527,16726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6152,,Cytotoxicity against A549 cells; No cytotoxicity,,BAO_0000219,CHEMBL619528,17846,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6153,,Cytotoxicity against human lung carcinoma (A549) cell lines,,BAO_0000219,CHEMBL619529,3415,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6154,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,BAO_0000219,CHEMBL619530,3415,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6155,,In vitro anticancer activity against human lung (A549) cell line,,BAO_0000219,CHEMBL876490,5609,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6156,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,BAO_0000219,CHEMBL619531,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6157,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619532,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6158,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619533,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6159,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619534,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6160,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL620164,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6161,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL620165,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6162,,Inhibition of A549 human lung tumor cell proliferation,,BAO_0000219,CHEMBL620166,16295,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6163,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,BAO_0000219,CHEMBL620167,16825,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6164,,In vitro cytotoxicity against human tumor cell line A549,,BAO_0000219,CHEMBL620168,3439,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6165,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,BAO_0000219,CHEMBL620338,10870,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6166,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,BAO_0000219,CHEMBL620339,4845,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6167,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,BAO_0000219,CHEMBL620340,5822,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6168,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,BAO_0000219,CHEMBL620341,5822,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6169,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,BAO_0000219,CHEMBL876491,5822,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6170,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,BAO_0000219,CHEMBL620342,16381,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6171,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,BAO_0000219,CHEMBL620343,16381,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6172,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,BAO_0000219,CHEMBL620344,16381,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6173,,In vitro anticancer activity against human lung (A549) cell line,,BAO_0000219,CHEMBL620345,5609,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6174,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,BAO_0000219,CHEMBL620346,4644,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6175,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,BAO_0000219,CHEMBL620347,4644,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6176,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,BAO_0000219,CHEMBL620348,4644,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6177,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,BAO_0000219,CHEMBL620349,4644,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6178,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,BAO_0000219,CHEMBL618667,5822,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6179,,Percentage inhibition of human lung carcinoma (A549) cell lines,,BAO_0000219,CHEMBL618668,3415,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6180,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,BAO_0000219,CHEMBL876031,16726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6181,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,BAO_0000219,CHEMBL618759,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6182,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,BAO_0000219,CHEMBL618760,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6183,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,BAO_0000219,CHEMBL619000,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6184,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,BAO_0000219,CHEMBL619001,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6185,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,BAO_0000219,CHEMBL619002,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6186,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,BAO_0000219,CHEMBL619003,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6187,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,BAO_0000219,CHEMBL619597,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6188,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,BAO_0000219,CHEMBL619598,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6189,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,BAO_0000219,CHEMBL619599,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6190,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,BAO_0000219,CHEMBL619600,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6191,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,BAO_0000219,CHEMBL619601,16726,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6192,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619602,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6193,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619603,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6194,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619604,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6195,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619605,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6196,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,BAO_0000218,CHEMBL619606,6084,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6197,,Pharmacokinetic activity (Cmax) in dog,,BAO_0000218,CHEMBL876032,6084,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6198,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,CHEMBL619607,4809,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6199,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,CHEMBL619608,5983,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6200,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,CHEMBL619609,6251,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6201,,Cmax in dog plasma after 30mg/kg oral dose,,BAO_0000218,CHEMBL619610,5932,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6202,,Tested for the peak blood level in dog,,BAO_0000218,CHEMBL619611,4273,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Blood,
6203,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,BAO_0000218,CHEMBL619612,5313,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6204,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,BAO_0000218,CHEMBL619613,5313,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6205,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,BAO_0000218,CHEMBL619614,6221,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Blood,
6206,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,BAO_0000218,CHEMBL619615,4709,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6207,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,BAO_0000218,CHEMBL619616,167,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6208,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,BAO_0000218,CHEMBL619617,6241,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
6209,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,BAO_0000218,CHEMBL619618,344,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6210,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,BAO_0000218,CHEMBL876033,344,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6211,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,BAO_0000218,CHEMBL619619,344,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6212,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,BAO_0000218,CHEMBL619620,2189,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6213,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,BAO_0000218,CHEMBL619621,2189,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Urine,
6214,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,BAO_0000218,CHEMBL619622,2189,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Urine,
6215,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,BAO_0000218,CHEMBL618874,2189,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Urine,
6216,,Absolute bioavailability was evaluated in dog,,BAO_0000218,CHEMBL618875,4257,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6217,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,CHEMBL618876,6221,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6218,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,CHEMBL618877,6215,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6219,,Bioavailability in dog,,BAO_0000218,CHEMBL618878,17267,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6220,,Bioavailability in dog,,BAO_0000218,CHEMBL618879,6621,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6221,,Bioavailability after intravenous administration in dogs,,BAO_0000218,CHEMBL618880,3854,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6222,,Bioavailability after peroral administration in dogs,,BAO_0000218,CHEMBL618881,3854,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6223,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,CHEMBL618882,5007,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6224,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,BAO_0000218,CHEMBL624226,4333,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6225,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,BAO_0000218,CHEMBL624227,4333,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6226,,Bioavailability,,BAO_0000218,CHEMBL624228,5006,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6227,,Bioavailability,,BAO_0000218,CHEMBL624229,5199,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6228,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,CHEMBL624230,4368,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6229,,Bioavailability in dog,,BAO_0000218,CHEMBL624231,3771,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6230,,Bioavailability in dog,,BAO_0000218,CHEMBL624232,4953,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6231,,Bioavailability in dog,,BAO_0000218,CHEMBL625127,5064,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6232,,Bioavailability in dog,,BAO_0000218,CHEMBL625128,17657,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6233,,Bioavailability in dog,,BAO_0000218,CHEMBL621675,17796,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6234,,Bioavailability in dog (p.o.) at 2.0 mpk,,BAO_0000218,CHEMBL621676,17853,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6235,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,BAO_0000218,CHEMBL621677,4521,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6236,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,CHEMBL621678,4521,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6237,,Bioavailability in dog,,BAO_0000218,CHEMBL621679,5006,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6238,,Bioavailability was evaluated after oral administration in dog,,BAO_0000218,CHEMBL621680,16365,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6239,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL621681,1916,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6240,,Bioavailability was evaluated in dog,,BAO_0000218,CHEMBL876740,1918,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6241,,Bioavailability in dog,,BAO_0000218,CHEMBL621682,4239,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6242,,Bioavailability in dog,,BAO_0000218,CHEMBL621683,6505,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6243,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,CHEMBL621684,5334,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6244,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,CHEMBL621685,5334,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6245,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,CHEMBL621686,4809,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6246,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL621687,6348,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6247,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,BAO_0000218,CHEMBL621688,6005,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6248,,Bioavailability of compound in dog was determined after peroral administration,,BAO_0000218,CHEMBL621689,17804,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6249,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621690,3184,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6250,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,BAO_0000218,CHEMBL621691,1806,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6251,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,BAO_0000218,CHEMBL875941,1806,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6252,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,BAO_0000218,CHEMBL621692,1806,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6253,,Bioavailability in dog,,BAO_0000218,CHEMBL621693,4839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6254,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,BAO_0000218,CHEMBL621694,5017,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6255,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL621695,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
6256,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL621696,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
6257,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL621697,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
6258,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL621698,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
6259,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623420,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
6260,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623421,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
6261,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623422,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
6262,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623423,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
6263,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623424,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
6264,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623425,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
6265,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623426,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
6266,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623427,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
6267,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623428,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
6268,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL875947,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
6269,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623429,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
6270,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL623430,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
6271,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL622588,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
6272,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL622589,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
6273,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL622751,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
6274,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,CHEMBL622752,846,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
6275,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL622753,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6276,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL622647,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6277,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL875163,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6278,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL622648,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6279,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL622649,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6280,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL622650,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Brain,CCRF S-180
6281,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL622651,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Brain,CCRF S-180
6282,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL622652,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Brain,CCRF S-180
6283,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL622653,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Brain,CCRF S-180
6284,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL622654,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Brain,CCRF S-180
6285,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL622655,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6286,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL622656,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6287,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL622657,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6288,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL622658,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6289,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL622659,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6290,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL624630,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Kidney,CCRF S-180
6291,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL624631,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Kidney,CCRF S-180
6292,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL624632,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Kidney,CCRF S-180
6293,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,BAO_0000219,CHEMBL624633,17130,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6294,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,BAO_0000219,CHEMBL624634,17130,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6295,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,BAO_0000219,CHEMBL624635,17130,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6296,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,BAO_0000219,CHEMBL624636,17130,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6297,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,CHEMBL857055,3263,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6298,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,BAO_0000219,CHEMBL624637,6663,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6299,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,BAO_0000219,CHEMBL624638,6663,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6300,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,BAO_0000219,CHEMBL874366,6663,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6301,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,BAO_0000219,CHEMBL624639,6663,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6302,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,BAO_0000219,CHEMBL624640,6663,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6303,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,BAO_0000219,CHEMBL624641,6663,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6304,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,BAO_0000219,CHEMBL624642,6663,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6305,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,BAO_0000219,CHEMBL624643,6663,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6306,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,BAO_0000219,CHEMBL624644,6663,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6307,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,BAO_0000219,CHEMBL624645,6663,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6308,,The compound was evaluated for its cytotoxic potency against A-549 cell line,,BAO_0000219,CHEMBL619445,3983,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6309,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,BAO_0000219,CHEMBL839886,11141,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6310,,Cytotoxic activity of compound against A-549 tumor cell line.,,BAO_0000219,CHEMBL619446,5076,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6311,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,BAO_0000219,CHEMBL619447,3311,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6312,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,BAO_0000219,CHEMBL619448,3311,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6313,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,BAO_0000219,CHEMBL619449,3311,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6314,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,BAO_0000219,CHEMBL619450,5076,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6315,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,BAO_0000219,CHEMBL619451,4150,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6316,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,BAO_0000219,CHEMBL619452,2150,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6317,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,BAO_0000219,CHEMBL619453,4644,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6318,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,BAO_0000219,CHEMBL874367,263,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6319,,Cytotoxic concentration against A-549 tumor cells.,,BAO_0000219,CHEMBL619454,11333,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6320,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,BAO_0000219,CHEMBL619455,11333,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6321,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,BAO_0000219,CHEMBL619456,15895,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6322,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,BAO_0000218,CHEMBL619457,16677,470.0,Expert,1,,F,,Acinetobacter baumannii,,,
6323,,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,CHEMBL619458,10624,471.0,Intermediate,1,,F,,Acinetobacter calcoaceticus,,,
6324,,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,CHEMBL619459,16717,5059.0,Expert,1,,F,,Aspergillus flavus,,,
6325,,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,CHEMBL619460,16717,5059.0,Expert,1,,F,,Aspergillus flavus,,,
6326,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,BAO_0000218,CHEMBL619461,5513,746128.0,Intermediate,1,,F,,Aspergillus fumigatus,,,
6327,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,BAO_0000218,CHEMBL619462,15962,746128.0,Intermediate,1,,F,,Aspergillus fumigatus,,,
6328,,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,CHEMBL620388,15962,746128.0,Intermediate,1,,F,,Aspergillus fumigatus,,,
6329,,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,CHEMBL620389,15962,746128.0,Intermediate,1,,F,,Aspergillus fumigatus,,,
6330,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,CHEMBL620390,15962,746128.0,Intermediate,1,,F,,Aspergillus fumigatus,,,
6331,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,CHEMBL620391,16717,746128.0,Expert,1,,F,,Aspergillus fumigatus,,,
6332,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,CHEMBL621073,16717,746128.0,Expert,1,,F,,Aspergillus fumigatus,,,
6333,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,BAO_0000218,CHEMBL621074,8117,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6334,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,BAO_0000218,CHEMBL621075,8117,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6335,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,CHEMBL619554,15472,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6336,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,CHEMBL619555,15472,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6337,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,BAO_0000218,CHEMBL619556,16443,714.0,Intermediate,1,,F,,Aggregatibacter actinomycetemcomitans,,,
6338,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,BAO_0000218,CHEMBL619557,16443,714.0,Intermediate,1,,F,,Aggregatibacter actinomycetemcomitans,,,
6339,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,BAO_0000218,CHEMBL619558,16443,714.0,Intermediate,1,,F,,Aggregatibacter actinomycetemcomitans,,,
6340,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619559,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6341,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619560,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6342,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,BAO_0000219,CHEMBL619561,16381,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6343,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,BAO_0000219,CHEMBL619562,16381,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6344,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,BAO_0000219,CHEMBL619563,16381,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6345,,GI values against A549 cells (lung cancer),,BAO_0000219,CHEMBL857457,16381,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6346,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,BAO_0000219,CHEMBL619564,17206,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6347,,Inhibitory activity against A549 human adenocarcinoma,,BAO_0000219,CHEMBL619565,16325,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6348,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,BAO_0000218,CHEMBL619566,10708,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6349,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,BAO_0000218,CHEMBL619567,10708,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6350,,Inhibitory activity against A549 lung adenocarcinoma cell line,,BAO_0000219,CHEMBL619568,17376,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6351,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,BAO_0000219,CHEMBL619569,17376,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6352,,Cytotoxicity against human A549 lung cells,,BAO_0000219,CHEMBL619570,17488,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6353,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,BAO_0000218,CHEMBL619571,17404,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6354,,Growth inhibition of A549 (human lung carcinoma) cell line.,,BAO_0000219,CHEMBL619572,10958,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6355,,Effective dose required for inhibitory activity against A549 human tumor cell line.,,BAO_0000219,CHEMBL619573,17099,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6356,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,BAO_0000219,CHEMBL619574,17099,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6357,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,BAO_0000219,CHEMBL619575,4096,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6358,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,BAO_0000219,CHEMBL619576,4096,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6359,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,BAO_0000219,CHEMBL619577,4096,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6360,,In vitro inhibitory activity against A549 tumor cell culture,,BAO_0000219,CHEMBL619578,2525,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6361,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,BAO_0000219,CHEMBL884009,2525,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6362,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,BAO_0000219,CHEMBL619579,5302,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6363,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,BAO_0000219,CHEMBL619580,16325,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6364,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,BAO_0000219,CHEMBL619581,16939,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6365,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,BAO_0000219,CHEMBL619582,17229,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6366,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,BAO_0000219,CHEMBL619583,17380,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6367,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,BAO_0000219,CHEMBL876502,17380,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6368,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,BAO_0000219,CHEMBL619584,1903,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6369,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,BAO_0000219,CHEMBL619585,3838,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6370,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,BAO_0000219,CHEMBL619586,14696,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6371,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,BAO_0000219,CHEMBL619587,3838,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6372,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,BAO_0000219,CHEMBL619588,1522,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6373,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,BAO_0000219,CHEMBL619589,12400,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6374,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,BAO_0000219,CHEMBL619590,14696,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6375,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,BAO_0000219,CHEMBL619591,14769,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6376,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,BAO_0000219,CHEMBL619592,14696,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6377,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,BAO_0000219,CHEMBL619593,1888,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6378,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,BAO_0000219,CHEMBL620217,12016,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6379,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,BAO_0000219,CHEMBL620218,6058,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6380,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,BAO_0000219,CHEMBL620219,17708,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6381,,Antitumor activity against A549/ATCC cell line,,BAO_0000219,CHEMBL620220,12301,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6382,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,BAO_0000219,CHEMBL625141,11970,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6383,,In vitro cytotoxicity against A549/ATCC cell line.,,BAO_0000219,CHEMBL625142,11818,9606.0,Expert,1,646.0,F,,Homo sapiens,,,A549
6384,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,BAO_0000219,CHEMBL625143,12400,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6385,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,BAO_0000219,CHEMBL625144,3381,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6386,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,BAO_0000219,CHEMBL622474,17376,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6387,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,BAO_0000219,CHEMBL884104,10708,9606.0,Intermediate,1,646.0,F,,Homo sapiens,,,A549
6388,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,BAO_0000219,CHEMBL622475,2964,9606.0,Autocuration,1,,F,,Homo sapiens,,,
6389,,Compound was tested for oral bioavailability in dogs,,BAO_0000218,CHEMBL622476,5005,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6390,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,BAO_0000218,CHEMBL875831,6229,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6391,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,BAO_0000218,CHEMBL622477,6229,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6392,,Oral bioavailability in dog,,BAO_0000218,CHEMBL622478,5374,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6393,,Compound was tested for the oral bioavailability in dog; No availability,,BAO_0000218,CHEMBL623172,5374,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6394,,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,CHEMBL623173,6265,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6395,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,CHEMBL623174,5654,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6396,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,CHEMBL623175,5654,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6397,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,BAO_0000218,CHEMBL623340,16456,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6398,,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,CHEMBL623341,5302,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6399,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,BAO_0000218,CHEMBL623342,3624,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6400,,Oral bioavailability of active FTIs in dogs,,BAO_0000218,CHEMBL623343,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6401,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,CHEMBL623344,5802,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6402,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL623345,3598,9615.0,Expert,1,,A,In vivo,Canis lupus familiaris,,,
6403,,Oral bioavailability in dog,,BAO_0000218,CHEMBL875832,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6404,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623346,6762,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6405,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623347,6821,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6406,,Oral bioavailability of compound was determined in dog; Not tested,,BAO_0000218,CHEMBL623348,6821,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6407,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623349,5210,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6408,,Oral bioavailability (10 mg/kg) was determined in dog,,BAO_0000218,CHEMBL623350,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6409,,Oral bioavailability,,BAO_0000218,CHEMBL623351,761,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6410,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,BAO_0000218,CHEMBL623352,761,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6411,,Oral bioavailability administered in solution in rats,,BAO_0000218,CHEMBL623353,761,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6412,,Oral bioavailability after 30 mg/kg po dose in Dogs,,BAO_0000218,CHEMBL875833,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6413,,Oral bioavailability at a dose of 1 mg/kg in dogs,,BAO_0000218,CHEMBL623354,5474,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6414,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,BAO_0000218,CHEMBL623355,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6415,,Oral bioavailability in Dog; ND = not determined,,BAO_0000218,CHEMBL623356,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6416,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623357,3352,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6417,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623358,6168,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6418,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623359,5988,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6419,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623360,4942,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6420,,Oral bioavailability in dogs; No data,,BAO_0000218,CHEMBL623361,4942,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6421,,Oral bioavailability measured in dogs,,BAO_0000218,CHEMBL623362,14541,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6422,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623363,4449,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6423,,Oral bioavailability was calculated in dog,,BAO_0000218,CHEMBL623364,6057,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6424,,Oral bioavailability after 0.3 mg/kg po administration in dog,,BAO_0000218,CHEMBL875834,5600,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6425,,Oral bioavailability in dog (i.v. dosing),,BAO_0000218,CHEMBL623365,5542,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6426,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623366,5542,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6427,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,BAO_0000218,CHEMBL623367,5546,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6428,,Oral bioavailability in Beagle dogs,,BAO_0000218,CHEMBL623368,4514,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6429,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623369,3624,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6430,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623370,3854,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6431,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623371,5836,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6432,,Oral bioavailability in dog,,BAO_0000218,CHEMBL623372,5940,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6433,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621351,6168,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6434,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621352,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6435,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621353,6251,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6436,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621354,6448,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6437,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621355,6647,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6438,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621356,5940,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6439,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621357,933,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6440,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621358,5210,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6441,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,BAO_0000218,CHEMBL621359,6642,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6442,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,CHEMBL621360,6641,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6443,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,CHEMBL621361,6642,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6444,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621362,5472,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6445,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621363,5985,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6446,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621364,15660,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6447,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,BAO_0000218,CHEMBL621166,5530,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6448,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,CHEMBL621167,5530,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6449,,Oral bioavailability (F) in dogs,,BAO_0000218,CHEMBL621168,6305,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6450,,Oral bioavailability in dog,,BAO_0000218,CHEMBL621169,5210,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6451,,Bioavailability in dog,,BAO_0000218,CHEMBL875950,5238,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6452,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,CHEMBL621170,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6453,,Oral bioavailability after peroral administration at 5 mpk in Dog,,BAO_0000218,CHEMBL621171,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6454,,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,CHEMBL621172,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6455,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,CHEMBL621173,6084,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6456,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL621174,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Kidney,CCRF S-180
6457,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL621175,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Kidney,CCRF S-180
6458,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL621176,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6459,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL621177,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6460,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL621178,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6461,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL621179,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6462,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL621180,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6463,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL875951,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6464,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL621181,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6465,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL621182,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6466,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL621183,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6467,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL621184,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6468,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL621185,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6469,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL621186,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6470,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL621187,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6471,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL621188,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6472,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL621189,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6473,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL621190,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Spleen,CCRF S-180
6474,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL618520,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Spleen,CCRF S-180
6475,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL621739,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Spleen,CCRF S-180
6476,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL621740,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Spleen,CCRF S-180
6477,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL621741,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Spleen,CCRF S-180
6478,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL621742,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6479,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL621743,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6480,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL621744,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6481,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL621745,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6482,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL621746,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6483,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL621747,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6484,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL621748,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6485,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL621749,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6486,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL621750,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6487,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL621751,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6488,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL621752,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6489,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL621753,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6490,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL875955,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6491,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL621754,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6492,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL621755,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Heart,CCRF S-180
6493,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL621756,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6494,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL624199,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6495,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL624200,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6496,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL624375,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6497,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL624376,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Liver,CCRF S-180
6498,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL624377,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6499,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL624378,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6500,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,CHEMBL857901,12269,107673.0,Intermediate,1,,F,,aeinetobacter anitrotap,,,
6501,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,CHEMBL875274,12269,107673.0,Intermediate,1,,F,,Acinetobacter calcoaceticus subsp. anitratus,,,
6502,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,CHEMBL624379,12269,107673.0,Intermediate,1,,F,,Acinetobacter calcoaceticus subsp. anitratus,,,
6503,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,CHEMBL624380,12269,107673.0,Intermediate,1,,F,,aeinetobacter anitrotap,,,
6504,,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,CHEMBL624381,10624,471.0,Intermediate,1,,F,,Acinetobacter calcoaceticus,,,
6505,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,BAO_0000218,CHEMBL624382,17216,28377.0,Intermediate,1,,F,,Anolis carolinensis,,,
6506,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,BAO_0000218,CHEMBL624383,17216,28377.0,Intermediate,1,,F,,Anolis carolinensis,,,
6507,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,BAO_0000218,CHEMBL624384,9560,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6508,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,BAO_0000218,CHEMBL624385,9560,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6509,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,BAO_0000218,CHEMBL624386,9560,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6510,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,BAO_0000218,CHEMBL624387,9560,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6511,,Plaque bactericidal index against Actinomyces naeslundii 631,,BAO_0000218,CHEMBL624388,9560,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6512,,Plaque bactericidal index against Actinomyces naeslundii N/9,,BAO_0000218,CHEMBL624389,9560,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6513,,Plaque bactericidal index against Actinomyces naeslundii B74,,BAO_0000218,CHEMBL624390,9560,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6514,,Plaque bactericidal index against Actinomyces naeslundii N/3,,BAO_0000218,CHEMBL875275,9560,1655.0,Intermediate,1,,F,,Actinomyces naeslundii,,,
6515,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,BAO_0000218,CHEMBL624391,114,85549.0,Intermediate,1,,F,,Artemia salina,,,
6516,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,BAO_0000218,CHEMBL623636,114,85549.0,Intermediate,1,,F,,Artemia salina,,,
6517,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,CHEMBL623637,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6518,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,CHEMBL623638,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6519,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,CHEMBL623639,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6520,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,CHEMBL623640,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6521,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,CHEMBL623641,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6522,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,BAO_0000218,CHEMBL623642,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6523,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,CHEMBL623643,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6524,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,CHEMBL623644,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6525,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,CHEMBL623645,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6526,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,CHEMBL623646,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6527,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,CHEMBL623647,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6528,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,BAO_0000218,CHEMBL623648,10841,6253.0,Intermediate,1,,F,,Ascaris suum,,,
6529,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,CHEMBL623649,8117,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6530,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,CHEMBL623650,8117,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6531,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,BAO_0000218,CHEMBL623651,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6532,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,BAO_0000218,CHEMBL623652,9560,1656.0,Expert,1,,F,,Actinomyces viscosus,,,
6533,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,BAO_0000218,CHEMBL623653,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6534,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,BAO_0000218,CHEMBL623654,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6535,,Plaque bactericidal index against Actinomyces viscosus 8A06,,BAO_0000218,CHEMBL623655,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6536,,Plaque bactericidal index against Actinomyces viscosus M-100,,BAO_0000218,CHEMBL623656,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6537,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,BAO_0000218,CHEMBL623657,9560,1656.0,Expert,1,,F,,Actinomyces viscosus,,,
6538,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,CHEMBL623658,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6539,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,CHEMBL623659,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6540,,Plaque bactericidal index against Actinomyces viscosus 626,,BAO_0000218,CHEMBL623660,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6541,,Plaque bactericidal index against Actinomyces viscosus T14V,,BAO_0000218,CHEMBL623661,9560,1656.0,Intermediate,1,,F,,Actinomyces viscosus,,,
6542,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,BAO_0000218,CHEMBL875281,10986,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6543,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,BAO_0000218,CHEMBL623662,10986,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6544,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,BAO_0000218,CHEMBL623663,10986,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6545,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,BAO_0000218,CHEMBL623664,10986,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6546,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,BAO_0000218,CHEMBL623665,10986,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6547,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,BAO_0000219,CHEMBL621856,10708,9606.0,Intermediate,1,165.0,F,,Homo sapiens,,,A673
6548,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,BAO_0000219,CHEMBL620432,10708,9606.0,Intermediate,1,645.0,F,,Homo sapiens,,,A704
6549,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,BAO_0000219,CHEMBL620433,416,10116.0,Autocuration,1,,F,,Rattus norvegicus,,,
6550,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,BAO_0000219,CHEMBL620434,14354,10090.0,Intermediate,1,625.0,F,,Mus musculus,,,A9
6551,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,BAO_0000219,CHEMBL620435,14354,10090.0,Intermediate,1,625.0,F,,Mus musculus,,,A9
6552,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,BAO_0000219,CHEMBL620436,5116,9606.0,Intermediate,1,625.0,F,,Homo sapiens,,,A9
6553,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,BAO_0000219,CHEMBL876597,5116,9606.0,Intermediate,1,625.0,F,,Homo sapiens,,,A9
6554,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,BAO_0000219,CHEMBL620437,15694,9606.0,Expert,1,874.0,F,,Homo sapiens,,,Human ovarian carcinoma cell line
6555,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,BAO_0000219,CHEMBL620438,13038,10090.0,Expert,1,625.0,F,,Mus musculus,,,A9
6556,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,BAO_0000219,CHEMBL620439,13038,10090.0,Expert,1,625.0,F,,Mus musculus,,,A9
6557,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,BAO_0000219,CHEMBL619657,10923,10090.0,Expert,1,625.0,F,,Mus musculus,,,A9
6558,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,BAO_0000219,CHEMBL619658,10923,10090.0,Intermediate,1,625.0,F,,Mus musculus,,,A9
6559,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,BAO_0000219,CHEMBL619659,10923,10090.0,Intermediate,1,625.0,F,,Mus musculus,,,A9
6560,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,BAO_0000019,CHEMBL619660,10923,,Expert,1,,F,,,,,
6561,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,BAO_0000219,CHEMBL619661,10923,10090.0,Intermediate,1,625.0,F,,Mus musculus,,,A9
6562,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,BAO_0000219,CHEMBL619662,10923,10090.0,Intermediate,1,625.0,F,,Mus musculus,,,A9
6563,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,BAO_0000219,CHEMBL619663,8158,10029.0,Intermediate,1,975.0,F,,Cricetulus griseus,,,AA6
6564,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,BAO_0000219,CHEMBL619664,15494,9606.0,Autocuration,1,,F,,Homo sapiens,,,
6565,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,BAO_0000219,CHEMBL619665,15494,9606.0,Autocuration,1,,F,,Homo sapiens,,,
6566,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,BAO_0000219,CHEMBL883244,12348,9606.0,Intermediate,1,974.0,F,,Homo sapiens,,,AA5
6567,,Cytotoxicity was measured against AA5/HIV-1(IIIB),,BAO_0000219,CHEMBL884011,12348,9606.0,Intermediate,1,974.0,F,,Homo sapiens,,,AA5
6568,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,BAO_0000219,CHEMBL619666,2726,9606.0,Intermediate,1,974.0,F,,Homo sapiens,,,AA5
6569,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,BAO_0000219,CHEMBL619667,2726,9606.0,Intermediate,1,379.0,F,,Homo sapiens,,,U-937
6570,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,BAO_0000219,CHEMBL619668,10747,10029.0,Intermediate,1,274.0,F,,Cricetulus griseus,,,UV4
6571,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000219,CHEMBL619669,11005,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6572,,Average intracellular compound concentration when the hypoxic SER=1.6,,BAO_0000219,CHEMBL876608,12687,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6573,,Average intracellular compound concentration when the hypoxic SER=1.6.,,BAO_0000219,CHEMBL619670,12687,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6574,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,BAO_0000219,CHEMBL619671,12687,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6575,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,BAO_0000219,CHEMBL619672,12687,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6576,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,BAO_0000219,CHEMBL619673,12687,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6577,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,BAO_0000219,CHEMBL619674,13436,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6578,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,BAO_0000219,CHEMBL619675,13435,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6579,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,BAO_0000219,CHEMBL619676,13302,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6580,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,BAO_0000219,CHEMBL619677,12687,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6581,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,BAO_0000219,CHEMBL619678,12687,10029.0,Intermediate,1,185.0,A,,Cricetulus griseus,,,CHO-AA8
6582,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,BAO_0000219,CHEMBL619679,12687,10029.0,Intermediate,1,185.0,A,,Cricetulus griseus,,,CHO-AA8
6583,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,BAO_0000219,CHEMBL619680,12878,10029.0,Expert,1,185.0,A,,Cricetulus griseus,,,CHO-AA8
6584,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,BAO_0000219,CHEMBL621457,12878,10029.0,Intermediate,1,185.0,A,,Cricetulus griseus,,,CHO-AA8
6585,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,BAO_0000219,CHEMBL876609,14367,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6586,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,BAO_0000219,CHEMBL621458,14367,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6587,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,BAO_0000219,CHEMBL621459,12398,36483.0,Expert,1,185.0,F,,hampster,,,CHO-AA8
6588,,Aerobic growth inhibition in Chinese hamster cell line AA8,,BAO_0000219,CHEMBL621460,12878,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6589,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,BAO_0000219,CHEMBL621461,13820,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6590,,Inhibition of growth under aerobic conditions in AA8 cells,,BAO_0000219,CHEMBL621462,13436,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6591,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,CHEMBL621463,6084,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6592,,Oral bioavailability in dog at 10 mg/kg of the compound,,BAO_0000218,CHEMBL621464,5711,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6593,,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,CHEMBL621465,4353,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6594,,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,CHEMBL621466,4353,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6595,,Oral bioavailability in dog (mongrel),,BAO_0000218,CHEMBL621467,17800,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6596,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,CHEMBL621468,3994,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6597,,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,CHEMBL876734,3994,9615.0,Intermediate,1,,F,In vivo,Canis lupus familiaris,,,
6598,,Bioavailability in dog,,BAO_0000218,CHEMBL618476,5145,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6599,,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,CHEMBL618477,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6600,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,BAO_0000218,CHEMBL618478,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6601,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,CHEMBL618479,5983,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6602,,Bioavailability in dog,,BAO_0000218,CHEMBL618480,4273,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6603,,Bioavailability in dog (dose 3-10 mg/kg),,BAO_0000218,CHEMBL618481,12500,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6604,,The compound was tested for bioavailability of compound in plasma of dog; Complete,,BAO_0000218,CHEMBL618482,12500,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6605,,Oral bioavailability in dog,,BAO_0000218,CHEMBL618483,3639,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6606,,Oral bioavailability in dog,,BAO_0000218,CHEMBL618484,3880,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6607,,Bioavailability in dog,,BAO_0000218,CHEMBL618485,4838,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6608,,oral bioavailability was measured in dogs,,BAO_0000218,CHEMBL618486,15600,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6609,,Compound was tested for plasma protein binding in dog; Not determined,,BAO_0000218,CHEMBL618487,17248,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6610,,Compound was tested for plasma protein binding of dog,,BAO_0000218,CHEMBL618488,17248,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6611,,Compound was tested for plasma protein binding of dog; Not determined,,BAO_0000218,CHEMBL876735,17248,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6612,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,BAO_0000218,CHEMBL618489,17443,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6613,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,CHEMBL618490,4186,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6614,,Half life was determined,,BAO_0000218,CHEMBL618491,3749,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6615,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,BAO_0000218,CHEMBL618492,3249,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6616,,Half life was evaluated in dog,,BAO_0000218,CHEMBL873354,3022,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6617,,Half life was determined,,BAO_0000218,CHEMBL618493,3749,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6618,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,CHEMBL618494,2517,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6619,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,CHEMBL618495,2517,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Heart,
6620,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,CHEMBL618496,2517,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Kidney,
6621,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,CHEMBL618497,2517,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Liver,
6622,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,CHEMBL618498,2517,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Lung,
6623,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,CHEMBL618499,2517,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Spleen,
6624,,LogP in dog,,BAO_0000218,CHEMBL876736,3639,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6625,,Partition coefficient (logP),,BAO_0000218,CHEMBL618500,6227,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6626,,Partition coefficient in dog,,BAO_0000218,CHEMBL857831,6227,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6627,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,CHEMBL618501,17764,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6628,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,BAO_0000218,CHEMBL618502,4809,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6629,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,BAO_0000218,CHEMBL618503,5600,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6630,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000218,CHEMBL618504,14294,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6631,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,CHEMBL618505,14294,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6632,,Metabolism of compound in dog S9 microsomes; Trace,,BAO_0000218,CHEMBL618506,14294,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6633,,In vitro metabolic potential in dog liver microsomes,,BAO_0000218,CHEMBL618507,6251,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Liver,
6634,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,BAO_0000218,CHEMBL876737,3748,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6635,,Oral bioavailability in dog,,BAO_0000218,CHEMBL618508,2713,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6636,,Oral bioavailability in dog,,BAO_0000218,CHEMBL618509,6512,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6637,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,CHEMBL618510,6679,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6638,,The compound was tested for bioavailability in dogs,,BAO_0000218,CHEMBL618511,3749,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6639,,The compound was tested for oral bioavailability in dogs,,BAO_0000218,CHEMBL618512,3749,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6640,,Oral bioavailability in dog,,BAO_0000218,CHEMBL618513,6742,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6641,,Compound was tested for percent protein binding (PB) in dog,,BAO_0000218,CHEMBL618514,6227,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6642,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,BAO_0000218,CHEMBL620052,6874,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6643,,Compound was evaluated for plasma clearance.,,BAO_0000218,CHEMBL620053,2877,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6644,,The compound was tested for plasma clearance in dog,,BAO_0000218,CHEMBL620054,12500,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6645,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,BAO_0000218,CHEMBL620055,12500,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6646,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,BAO_0000218,CHEMBL620056,4709,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6647,,In vitro relative rate of metabolism was determined in dog liver microsomes,,BAO_0000218,CHEMBL620057,5542,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Liver,
6648,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,CHEMBL618939,17594,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6649,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,CHEMBL618940,2652,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6650,,Half life after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,CHEMBL618941,17764,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6651,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL624473,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6652,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL624474,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6653,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL624475,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,Lung,CCRF S-180
6654,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,BAO_0000218,CHEMBL624476,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6655,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,BAO_0000218,CHEMBL623478,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6656,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,BAO_0000218,CHEMBL623479,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6657,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,BAO_0000218,CHEMBL623480,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6658,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,BAO_0000218,CHEMBL623481,6599,10090.0,Intermediate,1,42.0,A,,Mus musculus,,,CCRF S-180
6659,,C2 in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623482,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Brain,
6660,,C2 in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623483,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Kidney,
6661,,C2 in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623484,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Liver,
6662,,C2 in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623485,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Lung,
6663,,C2 in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623486,17641,10090.0,Intermediate,1,,A,,Mus musculus,,Spleen,
6664,,Plasma clearance in mouse,,BAO_0000218,CHEMBL623487,17852,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6665,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,CHEMBL623488,17764,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6666,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,CHEMBL623489,17837,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6667,,Clearance was evaluated in mice after intravenous administration,,BAO_0000218,CHEMBL875157,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6668,,Clearance was evaluated in mice after oral administration,,BAO_0000218,CHEMBL623490,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6669,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,BAO_0000218,CHEMBL623491,4239,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6670,,Plasma clearance of compound was determined at 40 mg/Kg,,BAO_0000218,CHEMBL623492,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6671,,Plasma clearance of at 24 mg/Kg,,BAO_0000218,CHEMBL623493,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6672,,Plasma clearance at 24 mg/Kg,,BAO_0000218,CHEMBL623494,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6673,,Plasma clearance at 5 mg/Kg,,BAO_0000218,CHEMBL623495,17753,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6674,,Plasma clearance in mice,,BAO_0000218,CHEMBL623496,5727,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6675,,Plasma clearance value upon iv administration in mouse,,BAO_0000218,CHEMBL623497,2862,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6676,,Total plasma clearance in mice,,BAO_0000218,CHEMBL623498,5980,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6677,,Clearance in mouse,,BAO_0000218,CHEMBL623499,17592,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6678,,Clearance value was determined,,BAO_0000218,CHEMBL623500,17718,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6679,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,CHEMBL623501,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6680,,Calculated partition coefficient (clogP),,BAO_0000100,CHEMBL875158,17384,,Intermediate,1,,P,,,,,
6681,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL623502,6062,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6682,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,CHEMBL623503,17734,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6683,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL623504,6348,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6684,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,CHEMBL623505,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6685,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,CHEMBL623506,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6686,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,CHEMBL623507,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6687,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,BAO_0000218,CHEMBL623508,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6688,,Cmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,CHEMBL623509,5781,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6689,,Cmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,CHEMBL875159,17764,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6690,,Cmax in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623510,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Brain,
6691,,Cmax in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623511,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
6692,,Cmax in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623512,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
6693,,Cmax in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL623513,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
6694,,Cmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,CHEMBL623514,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
6695,,Cmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,CHEMBL622609,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
6696,,Cmax in mice at 24 uM/kg i.p. administration,,BAO_0000218,CHEMBL622610,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
6697,,Cmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,CHEMBL621823,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
6698,,Cmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,CHEMBL621824,17764,10090.0,Intermediate,1,,F,In vivo,Mus musculus,,,
6699,,Cmax in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,CHEMBL621825,17641,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
6700,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,CHEMBL621826,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6701,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,CHEMBL621827,16597,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6702,,Cmax value was determined,,BAO_0000218,CHEMBL621828,5727,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6703,,Cmax value in IRC mice,,BAO_0000218,CHEMBL621829,5951,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6704,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,CHEMBL621830,5506,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6705,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,CHEMBL621831,5506,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6706,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,BAO_0000218,CHEMBL621832,14239,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6707,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,BAO_0000218,CHEMBL624579,4890,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6708,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,BAO_0000218,CHEMBL624580,429,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6709,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,BAO_0000218,CHEMBL624581,10986,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6710,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,BAO_0000218,CHEMBL624582,10986,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6711,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,BAO_0000218,CHEMBL624583,10986,6277.0,Intermediate,1,,F,,Acanthocheilonema viteae,,,
6712,,Inhibitory activity against human tumor cell line A0375 melanoma.,,BAO_0000219,CHEMBL624584,13227,9606.0,Intermediate,1,455.0,F,,Homo sapiens,,,A-375
6713,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,BAO_0000249,CHEMBL624585,4481,10116.0,Expert,1,,B,,Rattus norvegicus,,,
6714,,Forskolin-induced cAMP production at human A1 adenosine receptor,,BAO_0000019,CHEMBL875165,16931,9606.0,Expert,1,,F,,Homo sapiens,,,
6715,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,BAO_0000219,CHEMBL619490,3850,,Autocuration,1,449.0,F,,,,,CHO
6716,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,BAO_0000219,CHEMBL619491,3850,,Autocuration,1,449.0,F,,,,,CHO
6717,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,BAO_0000219,CHEMBL619492,3850,,Expert,1,449.0,F,,,,,CHO
6718,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,BAO_0000219,CHEMBL619493,3850,,Expert,1,449.0,F,,,,,CHO
6719,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,BAO_0000219,CHEMBL619494,3850,,Autocuration,1,449.0,F,,,,,CHO
6720,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,BAO_0000219,CHEMBL619495,3850,,Autocuration,1,449.0,F,,,,,CHO
6721,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,CHEMBL619496,3850,,Autocuration,1,449.0,F,,,,,CHO
6722,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,BAO_0000219,CHEMBL619497,3850,9606.0,Expert,1,449.0,F,,Homo sapiens,,,CHO
6723,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,BAO_0000219,CHEMBL619498,3850,,Autocuration,1,449.0,F,,,,,CHO
6724,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,BAO_0000219,CHEMBL619499,3850,,Autocuration,1,449.0,F,,,,,CHO
6725,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,BAO_0000219,CHEMBL619500,3850,,Expert,1,449.0,F,,,,,CHO
6726,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,CHEMBL619501,3850,,Autocuration,1,449.0,F,,,,,CHO
6727,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,BAO_0000219,CHEMBL619502,3850,,Expert,1,449.0,F,,,,,CHO
6728,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,BAO_0000219,CHEMBL619503,3850,,Autocuration,1,449.0,F,,,,,CHO
6729,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,BAO_0000219,CHEMBL619504,3850,,Autocuration,1,449.0,F,,,,,CHO
6730,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,BAO_0000219,CHEMBL621298,3850,,Autocuration,1,449.0,F,,,,,CHO
6731,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,BAO_0000219,CHEMBL621299,3850,,Expert,1,449.0,F,,,,,CHO
6732,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,BAO_0000219,CHEMBL621300,3850,,Autocuration,1,449.0,F,,,,,CHO
6733,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,CHEMBL621301,3850,,Autocuration,1,449.0,F,,,,,CHO
6734,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,BAO_0000219,CHEMBL621302,3850,,Expert,1,449.0,F,,,,,CHO
6735,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,BAO_0000219,CHEMBL621303,12680,9986.0,Intermediate,1,164.0,F,,Oryctolagus cuniculus,,,A10
6736,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,BAO_0000219,CHEMBL621304,1313,10116.0,Autocuration,1,164.0,F,,Rattus norvegicus,,,A10
6737,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,BAO_0000219,CHEMBL621305,1313,10116.0,Autocuration,1,164.0,F,,Rattus norvegicus,,,A10
6738,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,BAO_0000219,CHEMBL621306,17567,10116.0,Intermediate,1,164.0,F,,Rattus norvegicus,,,A10
6739,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,BAO_0000219,CHEMBL618444,17567,10116.0,Intermediate,1,164.0,F,,Rattus norvegicus,,,A10
6740,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,BAO_0000219,CHEMBL618445,11819,10116.0,Intermediate,1,164.0,F,,Rattus norvegicus,,,A10
6741,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,BAO_0000219,CHEMBL618446,13436,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6742,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,BAO_0000219,CHEMBL618447,12687,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6743,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,BAO_0000219,CHEMBL618448,12651,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6744,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,BAO_0000219,CHEMBL618449,13300,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6745,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000219,CHEMBL618637,15296,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6746,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,BAO_0000219,CHEMBL618638,15328,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6747,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,BAO_0000219,CHEMBL618639,13302,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6748,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,BAO_0000219,CHEMBL618640,14367,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6749,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,BAO_0000219,CHEMBL618641,17002,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6750,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,BAO_0000219,CHEMBL618642,13436,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6751,,Inhibitory activity against aerobic growth of AA8 cells.,,BAO_0000219,CHEMBL618643,13435,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6752,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,CHEMBL884013,10503,10029.0,Intermediate,1,185.0,A,,Cricetulus griseus,,,CHO-AA8
6753,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,CHEMBL622723,10503,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6754,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,CHEMBL622724,10503,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6755,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,BAO_0000219,CHEMBL622725,15090,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6756,,Cytotoxicity against AA8 cell line,,BAO_0000219,CHEMBL622726,10368,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6757,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,BAO_0000219,CHEMBL622727,12651,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6758,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,CHEMBL622728,12687,10029.0,Intermediate,1,185.0,A,,Cricetulus griseus,,,CHO-AA8
6759,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,CHEMBL622729,12687,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6760,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,CHEMBL622730,12687,10029.0,Intermediate,1,185.0,A,,Cricetulus griseus,,,CHO-AA8
6761,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,BAO_0000219,CHEMBL622731,1890,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6762,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,BAO_0000219,CHEMBL622732,10747,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6763,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,BAO_0000219,CHEMBL622733,10747,10029.0,Intermediate,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6764,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,BAO_0000218,CHEMBL622734,11616,10029.0,Autocuration,1,,F,,Cricetulus griseus,,,
6765,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,BAO_0000219,CHEMBL622735,11616,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6766,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,BAO_0000219,CHEMBL618746,3471,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6767,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,BAO_0000219,CHEMBL618747,3471,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6768,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,BAO_0000219,CHEMBL620540,3471,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6769,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,BAO_0000219,CHEMBL620541,3471,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6770,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,BAO_0000219,CHEMBL620542,3471,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6771,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,BAO_0000219,CHEMBL620543,3471,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6772,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,BAO_0000219,CHEMBL618832,3471,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6773,,Concentration required to reduce AA8 cell survival by 10%,,BAO_0000219,CHEMBL618833,11616,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6774,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,BAO_0000219,CHEMBL618834,2656,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6775,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,BAO_0000219,CHEMBL618835,10518,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6776,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,BAO_0000219,CHEMBL618836,10518,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6777,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,BAO_0000219,CHEMBL618837,10518,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6778,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,BAO_0000219,CHEMBL618838,10518,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6779,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,BAO_0000219,CHEMBL618839,16156,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6780,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,BAO_0000219,CHEMBL618840,2656,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6781,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000019,CHEMBL618841,11005,10029.0,Autocuration,1,,F,,Cricetulus griseus,,,
6782,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,BAO_0000219,CHEMBL618842,11942,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6783,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,BAO_0000219,CHEMBL618843,2128,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6784,,Half life period after 15 mg/kg iv dose in Dogs,,BAO_0000218,CHEMBL618844,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6785,,Half life period after 30 mg/kg po dose in Dogs,,BAO_0000218,CHEMBL618845,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6786,,Half life was measured after oral 2b administration (tested in 6 dogs),,BAO_0000218,CHEMBL618846,9579,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6787,,Half life was measured in dog after oral 17b administration,,BAO_0000218,CHEMBL618847,9579,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6788,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,BAO_0000218,CHEMBL618848,9579,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6789,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,BAO_0000218,CHEMBL618849,9579,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6790,,Tmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,CHEMBL618850,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6791,,Tmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,CHEMBL618851,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6792,,Compound was evaluated for its half life when administered intravenously in dog,,BAO_0000218,CHEMBL873815,3184,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6793,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,BAO_0000218,CHEMBL618852,5017,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6794,,Elimination Half-life of compound was determined in dog,,BAO_0000218,CHEMBL618853,6821,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6795,,Half life of compound in dog following oral administration,,BAO_0000218,CHEMBL618854,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6796,,Half life of compound was determined in dog,,BAO_0000218,CHEMBL618855,17267,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6797,,Half life of compound was determined in dog blood,,BAO_0000218,CHEMBL618856,4727,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Blood,
6798,,Half life after oral and iv dosing in dogs,,BAO_0000218,CHEMBL875827,5238,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6799,,Half life in dogs in hours,,BAO_0000218,CHEMBL618857,4942,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6800,,Half life on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,CHEMBL618858,6505,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6801,,t1/2 in dog after oral dose (1 mg/kg),,BAO_0000218,CHEMBL618859,5130,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6802,,Half life was evaluated in dog,,BAO_0000218,CHEMBL618860,1475,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6803,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,BAO_0000218,CHEMBL618861,17804,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6804,,Half life period of compound was determined after peroral administration at 2 mg/kg,,BAO_0000218,CHEMBL622539,17804,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6805,,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,CHEMBL622540,6084,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6806,,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,CHEMBL873803,6084,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6807,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,CHEMBL873804,5542,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6808,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,CHEMBL624311,5542,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6809,,Half life period in dog,,BAO_0000218,CHEMBL624312,6084,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6810,,Half life period in dogs after oral administration at 1 mg/kg,,BAO_0000218,CHEMBL624313,6241,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6811,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL624314,1916,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6812,,Half-life of compound was determined in dogs,,BAO_0000218,CHEMBL624315,6621,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6813,,Half-life in dog plasma,,BAO_0000218,CHEMBL624316,1696,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
6814,,Half-life in mongrel dogs was determined,,BAO_0000218,CHEMBL624317,17800,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6815,,Half-life in dog upon oral administration,,BAO_0000218,CHEMBL624318,17657,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6816,,Half-life in dog upon oral administration; Unable to calculate,,BAO_0000218,CHEMBL624319,17657,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6817,,Half-life was measured in dog,,BAO_0000218,CHEMBL624496,4239,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6818,,Half-life was measured in dog,,BAO_0000218,CHEMBL624497,5985,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6819,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,BAO_0000218,CHEMBL624498,9932,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6820,,Oral half life was determined,,BAO_0000218,CHEMBL624499,5199,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6821,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,BAO_0000218,CHEMBL624500,5199,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6822,,Plasma half life was evaluated,,BAO_0000218,CHEMBL624501,1475,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
6823,,Plasma half life was evaluated in Dog,,BAO_0000218,CHEMBL623666,1475,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
6824,,Plasma half life was evaluated in dog,,BAO_0000218,CHEMBL623667,1475,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
6825,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,BAO_0000218,CHEMBL623668,6316,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6826,,Tested for the half life value in dog,,BAO_0000218,CHEMBL623669,4883,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6827,,Maximum time at the dose of 2 mg/kg in dog,,BAO_0000218,CHEMBL623670,4727,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6828,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL623671,1916,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6829,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,CHEMBL875945,1337,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Blood,
6830,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,CHEMBL623672,1337,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Blood,
6831,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,CHEMBL623673,6265,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6832,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,CHEMBL623674,4809,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6833,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,CHEMBL623675,5983,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6834,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,BAO_0000218,CHEMBL872526,5313,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6835,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,BAO_0000218,CHEMBL623676,5313,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6836,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,CHEMBL623677,17650,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6837,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,BAO_0000218,CHEMBL623678,5199,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6838,,Time taken for maximum plasma concentration in dog,,BAO_0000218,CHEMBL623679,933,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
6839,,Time to reach Cmax after oral administration to dogs,,BAO_0000218,CHEMBL623680,16367,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6840,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL623681,6348,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
6841,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,BAO_0000218,CHEMBL623682,6316,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6842,,Tmax after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,CHEMBL623683,6215,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6843,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL623684,3598,9615.0,Expert,1,,A,In vivo,Canis lupus familiaris,,,
6844,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,CHEMBL622745,4527,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6845,,Tmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,CHEMBL622746,17764,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6846,,In vivo Cmax in mice at dose of 100 mg/kg,,BAO_0000218,CHEMBL622747,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6847,,In vivo Cmax in mice at dose of 50 mg/kg,,BAO_0000218,CHEMBL622748,5969,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6848,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,CHEMBL622749,4573,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6849,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,CHEMBL622750,3277,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6850,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,CHEMBL623411,17734,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6851,,Maximum concentration obtained in mouse plasma was determined,,BAO_0000218,CHEMBL875946,3132,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6852,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,BAO_0000218,CHEMBL623412,3132,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6853,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL623413,6348,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6854,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,BAO_0000218,CHEMBL623414,17729,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6855,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,BAO_0000218,CHEMBL623415,17729,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6856,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,BAO_0000218,CHEMBL623416,17729,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6857,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,BAO_0000218,CHEMBL623417,17728,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6858,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,BAO_0000218,CHEMBL623418,17728,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6859,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,BAO_0000218,CHEMBL623419,17728,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6860,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,CHEMBL622816,4066,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6861,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,CHEMBL623313,6178,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6862,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,CHEMBL623314,6178,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6863,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,BAO_0000218,CHEMBL876788,3760,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6864,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,CHEMBL623315,3760,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6865,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,BAO_0000218,CHEMBL623316,3760,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6866,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,CHEMBL623317,3760,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6868,,Cmax in male mice after 2 mg/kg oral dose,,BAO_0000218,CHEMBL623319,5961,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6869,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,BAO_0000218,CHEMBL623320,6137,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6870,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,CHEMBL623321,3802,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
6871,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,BAO_0000218,CHEMBL623322,3535,10090.0,Intermediate,1,,A,,Mus musculus,,,
6872,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,BAO_0000218,CHEMBL623323,3535,10090.0,Intermediate,1,,A,,Mus musculus,,,
6873,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,BAO_0000218,CHEMBL623324,3535,10090.0,Intermediate,1,,A,,Mus musculus,,,
6874,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,BAO_0000218,CHEMBL623325,3535,10090.0,Intermediate,1,,A,,Mus musculus,,,
6875,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,BAO_0000218,CHEMBL623326,3535,10090.0,Intermediate,1,,A,,Mus musculus,,,
6876,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,BAO_0000218,CHEMBL623327,3535,10090.0,Intermediate,1,,A,,Mus musculus,,,
6877,,Maximum concentration in plasma upon oral administration in mouse,,BAO_0000218,CHEMBL623328,2862,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
6878,,Maximum plasma concentration was evaluated in mice after oral administration,,BAO_0000218,CHEMBL623329,2675,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
6879,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,BAO_0000218,CHEMBL623330,2675,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Plasma,
6880,,Dose at which the compound induced fecal excretion in mice,,BAO_0000218,CHEMBL876789,5399,10090.0,Intermediate,1,,A,,Mus musculus,,,
6893,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,BAO_0000219,CHEMBL623333,11819,10116.0,Expert,1,164.0,F,,Rattus norvegicus,,,A10
6894,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,BAO_0000219,CHEMBL623334,11819,10116.0,Expert,1,164.0,F,,Rattus norvegicus,,,A10
6895,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,BAO_0000219,CHEMBL627536,11819,10116.0,Expert,1,164.0,F,,Rattus norvegicus,,,A10
6896,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,BAO_0000219,CHEMBL627537,11819,10116.0,Expert,1,164.0,F,,Rattus norvegicus,,,A10
6897,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,BAO_0000219,CHEMBL627538,16361,10116.0,Intermediate,1,164.0,F,,Rattus norvegicus,,,A10
6898,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,BAO_0000219,CHEMBL884106,2288,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6899,,Anticancer activity against human ovarian carcinoma A121 cells,,BAO_0000219,CHEMBL625294,10404,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6900,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,BAO_0000219,CHEMBL625295,14790,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6901,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,BAO_0000219,CHEMBL625296,14790,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6902,,Growth inhibition of human ovarian carcinoma (A121) cell line,,BAO_0000219,CHEMBL625297,14253,9606.0,Expert,1,393.0,F,,Homo sapiens,,,A121
6903,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,BAO_0000219,CHEMBL625298,13617,9606.0,Expert,1,393.0,F,,Homo sapiens,,,A121
6904,,Cytotoxicity against human A121 ovarian cells,,BAO_0000219,CHEMBL625960,1003,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6905,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,BAO_0000219,CHEMBL625961,830,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6906,,In vitro cytotoxicity against human ovarian carcinoma A21,,BAO_0000219,CHEMBL625962,12307,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6907,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,BAO_0000219,CHEMBL624717,14254,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6908,,Inhibitory activity of compound against human A121 ovarian cell line.,,BAO_0000219,CHEMBL624718,13370,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6909,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,BAO_0000219,CHEMBL624719,14790,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6910,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,BAO_0000219,CHEMBL624720,3614,9606.0,Intermediate,1,393.0,F,,Homo sapiens,,,A121
6911,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,BAO_0000219,CHEMBL624721,2664,9606.0,Intermediate,1,622.0,F,,Homo sapiens,,,A 172
6912,,In vitro cytotoxicity against A172 human tumor cell lines.,,BAO_0000219,CHEMBL624722,2037,9606.0,Expert,1,622.0,F,,Homo sapiens,,,A 172
6913,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,BAO_0000219,CHEMBL877597,14539,9606.0,Intermediate,1,622.0,F,,Homo sapiens,,,A 172
6914,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,BAO_0000219,CHEMBL624723,2836,9606.0,Intermediate,1,622.0,F,,Homo sapiens,,,A 172
6915,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,BAO_0000219,CHEMBL624724,10708,9606.0,Intermediate,1,622.0,F,,Homo sapiens,,,A 172
6916,,Association constant against A2 adenosine receptor,,BAO_0000224,CHEMBL624725,8975,9615.0,Autocuration,1,,B,,Canis lupus familiaris,,,
6917,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,BAO_0000219,CHEMBL624726,7645,,Intermediate,1,1085.0,F,,fish,,,A2
6918,,Ratio of Ki for adenosine A2 and A1 receptor binding,,BAO_0000224,CHEMBL857535,11377,10116.0,Autocuration,1,,B,,Rattus norvegicus,,,
6919,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,BAO_0000219,CHEMBL624727,13528,9606.0,Expert,1,623.0,F,,Homo sapiens,,,A204
6920,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,BAO_0000219,CHEMBL624728,10160,9606.0,Expert,1,623.0,F,,Homo sapiens,,,A204
6921,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,BAO_0000219,CHEMBL624729,15144,9606.0,Intermediate,1,404.0,F,,Homo sapiens,,,A2058
6922,,Growth inhibition against Human squamous cell line(A 253),,BAO_0000219,CHEMBL624730,13160,9606.0,Intermediate,1,973.0,F,,Homo sapiens,,,A253 cell line
6923,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,BAO_0000219,CHEMBL624731,12898,9606.0,Intermediate,1,973.0,F,,Homo sapiens,,,A253 cell line
6924,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,BAO_0000219,CHEMBL624732,13069,9606.0,Intermediate,1,973.0,F,,Homo sapiens,,,A253 cell line
6925,,Growth inhibition of A253 cell lines.,,BAO_0000219,CHEMBL883245,15984,9606.0,Intermediate,1,973.0,F,,Homo sapiens,,,A253 cell line
6926,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,BAO_0000219,CHEMBL624733,15564,9606.0,Intermediate,1,973.0,F,,Homo sapiens,,,A253 cell line
6927,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,BAO_0000219,CHEMBL624734,15564,9606.0,Intermediate,1,973.0,F,,Homo sapiens,,,A253 cell line
6928,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,BAO_0000219,CHEMBL624735,15564,9606.0,Intermediate,1,973.0,F,,Homo sapiens,,,A253 cell line
6929,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,BAO_0000219,CHEMBL621780,4720,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
6930,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,BAO_0000219,CHEMBL877598,16112,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
6931,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,BAO_0000219,CHEMBL621781,16597,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
6932,,Cytotoxicity against human cancer cell lines A2780 (ovarian),,BAO_0000219,CHEMBL621782,16378,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
6933,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,BAO_0000219,CHEMBL621783,16085,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
6934,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,BAO_0000219,CHEMBL621784,16317,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
6935,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,BAO_0000219,CHEMBL621785,15748,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
6936,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,BAO_0000219,CHEMBL621968,16597,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
6937,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,BAO_0000219,CHEMBL621969,16597,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
6938,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,BAO_0000219,CHEMBL621970,16597,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
6939,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,BAO_0000219,CHEMBL621971,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
6940,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,BAO_0000219,CHEMBL621972,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
6941,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,BAO_0000219,CHEMBL884108,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
6942,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000019,CHEMBL623826,15296,10029.0,Autocuration,1,,F,,Cricetulus griseus,,,
6943,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,BAO_0000219,CHEMBL623827,10251,10029.0,Autocuration,1,185.0,A,,Cricetulus griseus,,,CHO-AA8
6944,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,BAO_0000219,CHEMBL623828,10251,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6945,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,BAO_0000219,CHEMBL623829,10251,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6946,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,BAO_0000219,CHEMBL623830,10251,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6947,,Growth inhibition against CHO-derived cell line AA8,,BAO_0000019,CHEMBL623831,11858,10029.0,Autocuration,1,,F,,Cricetulus griseus,,,
6948,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,BAO_0000219,CHEMBL623832,11858,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6949,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,BAO_0000219,CHEMBL623833,11616,36483.0,Expert,1,185.0,F,,hampster,,,CHO-AA8
6950,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,BAO_0000219,CHEMBL623834,11616,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6951,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,BAO_0000219,CHEMBL623835,10518,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6952,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,BAO_0000219,CHEMBL623836,11396,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6953,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,BAO_0000219,CHEMBL623837,10518,10029.0,Autocuration,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6954,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,BAO_0000219,CHEMBL623838,11616,10029.0,Expert,1,185.0,F,,Cricetulus griseus,,,CHO-AA8
6955,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,BAO_0000019,CHEMBL623839,14837,,Autocuration,1,,F,,,,,
6956,,Number of binding sites (n) of isolated serum protein AAG,,BAO_0000019,CHEMBL623840,14837,,Autocuration,1,,F,,,,,
6957,,Association constant for binding to AATT duplex,,BAO_0000225,CHEMBL623841,16037,,Intermediate,1,,B,,,,,
6958,,Inhibition of ABAE human fibroblast cell proliferation,,BAO_0000219,CHEMBL623842,16597,9606.0,Expert,1,416.0,F,,Homo sapiens,,,ABAE
6959,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,BAO_0000218,CHEMBL623843,8831,10090.0,Intermediate,1,1064.0,F,,Mus musculus,,,AC755
6960,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,BAO_0000218,CHEMBL618669,13419,9986.0,Expert,1,,F,,Oryctolagus cuniculus,,,
6961,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,BAO_0000218,CHEMBL618670,13419,9986.0,Expert,1,,F,In vivo,Oryctolagus cuniculus,,,
6962,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,BAO_0000357,CHEMBL618671,15778,,Autocuration,1,,B,,,,,
6963,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,BAO_0000357,CHEMBL618672,15778,,Autocuration,1,,B,,,,,
6964,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,BAO_0000219,CHEMBL618673,12988,9606.0,Intermediate,1,978.0,F,,Homo sapiens,,,ACH-2 cell line
6965,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,CHEMBL618674,12988,9606.0,Intermediate,1,978.0,F,,Homo sapiens,,,ACH-2 cell line
6966,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,BAO_0000219,CHEMBL618675,12988,11676.0,Autocuration,1,998.0,F,,Human immunodeficiency virus 1,,,T cell line
6967,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,CHEMBL618676,12988,11676.0,Autocuration,1,998.0,F,,Human immunodeficiency virus 1,,,T cell line
6968,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,CHEMBL618677,12988,11676.0,Autocuration,1,998.0,F,,Human immunodeficiency virus 1,,,T cell line
6969,,Inhibition of growth of renal cancer ACHN cell line,,BAO_0000219,CHEMBL618678,11843,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6970,,Inhibition of growth of ACHN renal cancer cell line,,BAO_0000219,CHEMBL618679,16939,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6971,,Inhibitory concentration required against ACHN renal cancer cell line,,BAO_0000219,CHEMBL618680,4782,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6972,,Concentration required to inhibit growth of human renal (ACHN) cell line,,BAO_0000219,CHEMBL618681,6310,9606.0,Expert,1,626.0,F,,Homo sapiens,,,ACHN
6973,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,BAO_0000219,CHEMBL618682,6310,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6974,,Cytotoxic activity against ACHN Renal cancer cell line,,BAO_0000219,CHEMBL618683,12858,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6975,,Cytotoxicity evaluation against ACHN renal cancer cells,,BAO_0000219,CHEMBL618684,17380,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6976,,In vitro antitumor activity against human renal ACHN cell line,,BAO_0000219,CHEMBL618685,5858,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6977,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,BAO_0000219,CHEMBL876499,3838,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6978,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,BAO_0000219,CHEMBL618686,3838,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6979,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,BAO_0000219,CHEMBL618687,5406,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6980,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,BAO_0000219,CHEMBL618688,4071,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6981,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,BAO_0000219,CHEMBL618689,4071,9606.0,Expert,1,626.0,F,,Homo sapiens,,,ACHN
6982,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,BAO_0000219,CHEMBL618690,4071,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6983,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,BAO_0000219,CHEMBL618691,15002,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6984,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,BAO_0000219,CHEMBL619373,14769,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6985,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,BAO_0000219,CHEMBL884008,13958,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6986,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,BAO_0000219,CHEMBL619374,1665,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6987,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,BAO_0000219,CHEMBL619375,15354,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6988,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,BAO_0000219,CHEMBL619376,15354,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6989,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,BAO_0000219,CHEMBL619377,13978,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6990,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,BAO_0000219,CHEMBL619378,6798,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
6991,,Tmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,CHEMBL872527,2959,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6992,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,BAO_0000218,CHEMBL876500,9932,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6993,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,CHEMBL619379,5546,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
6994,,Volume distribution after 15 mg/kg iv dose in Dogs,,BAO_0000218,CHEMBL619538,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6995,,Volume distribution after 30 mg/kg po dose in Dogs,,BAO_0000218,CHEMBL619539,16907,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6996,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,CHEMBL619540,4257,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6997,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,CHEMBL619541,4305,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6998,,Volume of distribution was evaluated in dog,,BAO_0000218,CHEMBL619542,5472,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
6999,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL619543,6062,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7000,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL619544,3598,9615.0,Expert,1,,A,,Canis lupus familiaris,,,
7001,,The compound was tested for volume of distribution in dog,,BAO_0000218,CHEMBL619545,12500,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7002,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,BAO_0000218,CHEMBL619546,12500,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7003,,Vd (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,CHEMBL619547,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7004,,Vd in dog,,BAO_0000218,CHEMBL619548,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7005,,Volume distribution was determined,,BAO_0000218,CHEMBL619549,4219,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7006,,Volume of distribution in dog,,BAO_0000218,CHEMBL619550,1696,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7007,,Volume of distribution by as 4 fold increase by iv administration in dogs,,BAO_0000218,CHEMBL876501,5542,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7008,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,CHEMBL619551,5199,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7009,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL619552,6348,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7010,,Volume distribution at the dose of 2 mg/kg in dog,,BAO_0000218,CHEMBL619553,4727,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7011,,Steady state volume of distribution was determined,,BAO_0000218,CHEMBL618722,16367,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7012,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,BAO_0000218,CHEMBL618723,2652,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7013,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,CHEMBL618724,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7014,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,CHEMBL618725,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7015,,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,CHEMBL618726,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7016,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,CHEMBL618727,5334,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7017,,Pharmacokinetic property (vdss) was measured in dog,,BAO_0000218,CHEMBL624233,4239,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7018,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,BAO_0000218,CHEMBL624234,4709,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7019,,Vdss was determined after iv 0.1 mg/kg administration in dog,,BAO_0000218,CHEMBL624235,5600,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7020,,Volume displacement was calculated in dog,,BAO_0000218,CHEMBL624236,6057,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7021,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,CHEMBL624237,5654,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7022,,Volume distribution constant was determined,,BAO_0000218,CHEMBL624238,5505,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7023,,Volume distribution at a dose of 1 uM/kg in dog was determined,,BAO_0000218,CHEMBL624239,4527,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7024,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,CHEMBL875829,4521,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7025,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,CHEMBL624240,4521,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7026,,Volume distribution (Vdss) was measured in dog,,BAO_0000218,CHEMBL624241,15660,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7027,,Volume distribution (Vdss) was measured in dog,,BAO_0000218,CHEMBL624242,15660,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7028,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,CHEMBL624243,6679,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7029,,Volume of distribution in steady state was determined in dog,,BAO_0000218,CHEMBL624244,5145,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7030,,Volume of distribution of compound was determined in dog,,BAO_0000218,CHEMBL624245,6821,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7031,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,CHEMBL624246,4137,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7032,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,CHEMBL624247,5334,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7033,,Volume of distribution (Vdss) was measured in dog,,BAO_0000218,CHEMBL624248,15660,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7034,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,CHEMBL624249,6642,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7035,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL624250,6641,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7036,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL624251,6642,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7037,,Maximum rate of depolarization of the upstroke of the action potential,,BAO_0000218,CHEMBL624252,11659,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7038,,Steady state volume distribution in dog,,BAO_0000218,CHEMBL624253,6448,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7039,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,BAO_0000218,CHEMBL624950,5474,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7040,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,CHEMBL624951,1466,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7041,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,CHEMBL875830,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7042,,Volume distribution in dog after administration of 1 mg/kg iv,,BAO_0000218,CHEMBL624952,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7043,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,CHEMBL624953,17764,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7044,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,CHEMBL624954,6215,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7045,,Vss on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,CHEMBL624955,6505,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7046,,Vss was determined,,BAO_0000218,CHEMBL624956,3639,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7047,,Vss in dog,,BAO_0000218,CHEMBL625129,3639,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7048,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL625130,6062,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7049,,Volume distribution in dogs,,BAO_0000218,CHEMBL625131,4942,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7050,,Volume of distribution in dog,,BAO_0000218,CHEMBL625132,17796,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7051,,Tested for the oral bioavailability in dog,,BAO_0000218,CHEMBL872263,4883,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7060,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,CHEMBL624336,17837,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7061,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,BAO_0000218,CHEMBL624337,17729,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7062,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,BAO_0000218,CHEMBL624338,17729,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7063,,Bioavailability was measured in mouse,,BAO_0000218,CHEMBL624339,4239,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7064,,Bioavailability in mouse,,BAO_0000218,CHEMBL624340,17592,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7065,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL624341,6348,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7066,,Bioavailability in mouse,,BAO_0000218,CHEMBL624342,2801,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7067,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,BAO_0000218,CHEMBL624343,2801,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7068,,Oral bioavailability in mouse,,BAO_0000218,CHEMBL624344,17718,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7069,,Oral availability at 50 mg/kg po in male mice,,BAO_0000218,CHEMBL624345,5727,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7070,,Oral bioavailability in mouse (dose 10 mg/kg),,BAO_0000218,CHEMBL624346,5302,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7071,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL624347,3598,10090.0,Expert,1,,A,In vivo,Mus musculus,,,
7072,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,BAO_0000218,CHEMBL624348,5961,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7074,,Oral bioavailability in mouse,,BAO_0000218,CHEMBL622754,6091,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7075,,Oral bioavailability in vivo in mice;ND=Not determined,,BAO_0000218,CHEMBL622755,6091,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7076,,Oral bioavailability in mouse at 10 mg/kg of the compound,,BAO_0000218,CHEMBL622756,5711,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7077,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,BAO_0000218,CHEMBL622757,17728,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7078,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,BAO_0000218,CHEMBL622758,17728,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7079,,Tested for bioavailability of the compound,,BAO_0000218,CHEMBL622759,3802,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7080,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,BAO_0000218,CHEMBL622760,3802,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,,
7081,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,BAO_0000218,CHEMBL622761,14029,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
7082,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,BAO_0000218,CHEMBL622762,14029,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
7083,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,BAO_0000218,CHEMBL622763,14029,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
7084,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,BAO_0000218,CHEMBL622764,14029,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
7085,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,BAO_0000218,CHEMBL622765,14029,10090.0,Intermediate,1,,A,,Mus musculus,,Plasma,
7086,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,BAO_0000218,CHEMBL622766,17753,10090.0,Intermediate,1,,F,,Mus musculus,,,
7087,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,BAO_0000218,CHEMBL622767,17753,10090.0,Intermediate,1,,A,,Mus musculus,,,
7088,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,BAO_0000218,CHEMBL622768,17753,10090.0,Intermediate,1,,A,,Mus musculus,,,
7089,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL875948,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
7090,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,CHEMBL622769,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
7091,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL622770,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
7092,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL622771,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
7093,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL622772,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
7094,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL622773,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
7095,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL622774,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Blood,
7096,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL621725,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
7097,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,CHEMBL621726,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
7098,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,BAO_0000219,CHEMBL621727,15608,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7099,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,CHEMBL622413,3290,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7100,,Compound was evaluated for cytotoxicity against A2780 cell line,,BAO_0000219,CHEMBL622414,2859,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7101,,Inhibition of A2780 cell clonogenic assay,,BAO_0000219,CHEMBL622415,15688,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7102,,Cytotoxic effect on ovarian cancer cell line (A2780),,BAO_0000219,CHEMBL884001,5642,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7103,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,BAO_0000219,CHEMBL622416,6633,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7104,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,BAO_0000219,CHEMBL622417,3906,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7105,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,BAO_0000219,CHEMBL622590,6788,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7106,,Antiproliferative activity against human A2780 cells,,BAO_0000219,CHEMBL622591,17582,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7107,,Inhibition of human A2780 cell proliferation,,BAO_0000219,CHEMBL622592,17764,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7108,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,BAO_0000219,CHEMBL622593,17764,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7109,,Inhibition of human A2780 cell proliferation (No data),,BAO_0000219,CHEMBL622594,17764,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7110,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,BAO_0000219,CHEMBL622595,2815,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7111,,Compound was evaluated against human Ovarian carcinoma cell line A2780,,BAO_0000219,CHEMBL622596,16930,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7112,,Growth inhibition against A2780 wild-type ovarian cell lines,,BAO_0000219,CHEMBL622597,17777,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7113,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,BAO_0000219,CHEMBL622598,17777,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7114,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,BAO_0000019,CHEMBL622599,16936,9606.0,Autocuration,1,,F,,Homo sapiens,,,
7115,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,BAO_0000219,CHEMBL622600,13759,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7116,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,BAO_0000219,CHEMBL622601,13759,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7117,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,BAO_0000219,CHEMBL622602,13759,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7118,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,BAO_0000219,CHEMBL622603,13759,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7119,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,BAO_0000219,CHEMBL622604,15292,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7120,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,BAO_0000219,CHEMBL622605,15292,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7121,,In vitro inhibition of human ovarian cell line A2780,,BAO_0000219,CHEMBL622606,15069,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7122,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,BAO_0000219,CHEMBL619463,15069,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7123,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,BAO_0000219,CHEMBL619464,14073,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7124,,Concentration required to inhibit A2780-cell growth by 50%,,BAO_0000219,CHEMBL619465,14553,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7125,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,BAO_0000219,CHEMBL619466,13040,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7126,,Cytotoxic effect on human ovarian (A2780) cancer cell line,,BAO_0000219,CHEMBL619467,6891,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7127,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,BAO_0000219,CHEMBL619468,15569,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7128,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,BAO_0000219,CHEMBL619469,14190,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7129,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,CHEMBL619470,15014,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7130,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,CHEMBL619471,15014,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7131,,Cytotoxicity against human ovarian carcinoma A2780 cell line,,BAO_0000219,CHEMBL619472,17496,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7132,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,BAO_0000219,CHEMBL619473,13617,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7133,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,BAO_0000219,CHEMBL874368,13617,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7134,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,BAO_0000219,CHEMBL884003,13617,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7135,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,BAO_0000219,CHEMBL622690,13617,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7136,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,BAO_0000219,CHEMBL622691,17672,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7137,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,BAO_0000219,CHEMBL622692,4544,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7138,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,BAO_0000219,CHEMBL623406,4544,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7139,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,BAO_0000219,CHEMBL884004,16317,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7140,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,BAO_0000219,CHEMBL623407,15099,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7141,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,BAO_0000219,CHEMBL623408,13978,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7142,,In vitro antitumor activity against A2780 cell line.,,BAO_0000219,CHEMBL623409,12989,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7143,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,BAO_0000219,CHEMBL623410,5574,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7144,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,BAO_0000219,CHEMBL623576,13528,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7145,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,BAO_0000219,CHEMBL623577,12782,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7146,,The IC50 value was measured on ACHN cell line in renal tumor type.,,BAO_0000219,CHEMBL623578,14255,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7147,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,BAO_0000219,CHEMBL623579,16364,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7148,,In vitro lethal concentration against most sensitive ACHN cell line,,BAO_0000219,CHEMBL623580,17376,9606.0,Expert,1,626.0,F,,Homo sapiens,,,ACHN
7149,,Tested for cytotoxic activity against renal cancer ACHN cell line,,BAO_0000219,CHEMBL623581,12016,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7150,,Compound tested for growth inhibition of renal cancer cell line ACHN,,BAO_0000219,CHEMBL857456,6058,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7151,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,BAO_0000219,CHEMBL623582,17708,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7152,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,CHEMBL623583,15176,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7153,,In vitro anticancer activity against ACHN renal cancer cell line,,BAO_0000219,CHEMBL623584,2806,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7154,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,BAO_0000219,CHEMBL623585,15300,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7155,,Percent selectivity was evaluated in renal ACHN cell lines,,BAO_0000219,CHEMBL623586,16364,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7156,,In vitro inhibitory activity against renal ACHN cancer cell line,,BAO_0000219,CHEMBL623587,13859,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7157,,Tested for cytotoxicity against ACHN cell lines in renal cancer,,BAO_0000219,CHEMBL875279,11970,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7158,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,BAO_0000219,CHEMBL623588,2450,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7159,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,BAO_0000219,CHEMBL623589,12696,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7160,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,BAO_0000219,CHEMBL623590,12400,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7161,,Cytotoxic effect on renal cancer line ACHN,,BAO_0000219,CHEMBL623591,12888,9606.0,Expert,1,626.0,F,,Homo sapiens,,,ACHN
7162,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,BAO_0000219,CHEMBL623592,3156,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7163,,In vitro inhibition of Renal Cancer ACHN cell lines,,BAO_0000219,CHEMBL623593,3381,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7164,,Antitumor activity against human renal adenocarcinoma ACHN cells,,BAO_0000219,CHEMBL623594,16747,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7165,,Antitumor activity against human renal adenocarcinoma ACHN cells.,,BAO_0000219,CHEMBL621833,16748,9606.0,Expert,1,626.0,F,,Homo sapiens,,,ACHN
7166,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,BAO_0000219,CHEMBL621834,12062,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7167,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,BAO_0000219,CHEMBL621835,14769,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7168,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,BAO_0000219,CHEMBL621836,15895,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7169,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,BAO_0000219,CHEMBL621837,17376,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7170,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,BAO_0000219,CHEMBL875280,14882,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7171,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,BAO_0000219,CHEMBL621838,14882,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7172,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,BAO_0000219,CHEMBL621839,15661,9606.0,Intermediate,1,626.0,F,,Homo sapiens,,,ACHN
7173,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,CHEMBL621840,9680,,Autocuration,1,,A,,,,,
7174,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,BAO_0000019,CHEMBL621841,14579,,Autocuration,1,,F,,,,,
7175,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,BAO_0000218,CHEMBL622979,17290,10358.0,Expert,1,468.0,F,,Cytomegalovirus,,,HEL
7176,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,BAO_0000218,CHEMBL876595,17290,10358.0,Intermediate,1,,F,,Cytomegalovirus,,,
7177,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,BAO_0000357,CHEMBL620221,15891,,Autocuration,1,,B,,,,,
7178,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,BAO_0000357,CHEMBL620222,15890,,Autocuration,1,,B,,,,,
7179,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,BAO_0000219,CHEMBL620506,3801,9913.0,Intermediate,1,979.0,F,,Bos taurus,,,ADDP cell line
7180,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,BAO_0000219,CHEMBL620507,9222,10090.0,Intermediate,1,980.0,F,,Mus musculus,,,ADJ/PC6
7181,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,BAO_0000219,CHEMBL620508,9222,10090.0,Intermediate,1,980.0,F,,Mus musculus,,,ADJ/PC6
7182,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,BAO_0000219,CHEMBL620509,7257,10090.0,Intermediate,1,980.0,F,,Mus musculus,,,ADJ/PC6
7183,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,BAO_0000219,CHEMBL620510,7257,10090.0,Intermediate,1,980.0,F,,Mus musculus,,,ADJ/PC6
7184,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,BAO_0000219,CHEMBL620511,7257,10090.0,Intermediate,1,980.0,A,,Mus musculus,,,ADJ/PC6
7185,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,BAO_0000219,CHEMBL620512,8084,10090.0,Intermediate,1,980.0,F,,Mus musculus,,,ADJ/PC6
7186,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,BAO_0000019,CHEMBL620513,14943,10090.0,Autocuration,1,,F,,Mus musculus,,,
7187,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,BAO_0000019,CHEMBL620514,14943,10090.0,Autocuration,1,,F,,Mus musculus,,,
7188,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,BAO_0000019,CHEMBL620515,14943,10090.0,Autocuration,1,,F,,Mus musculus,,,
7189,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,CHEMBL620516,10524,1423.0,Autocuration,1,,A,In vivo,Bacillus subtilis,,,
7190,,AUC value in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,CHEMBL620517,3546,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
7191,,AUC value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,CHEMBL620518,3546,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
7192,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,CHEMBL620519,3546,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7193,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,CHEMBL621386,3546,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7194,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,CHEMBL621387,3546,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7195,,Compound was evaluated for its clearance when administered intravenously in dog,,BAO_0000218,CHEMBL621388,3184,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7196,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL621389,16456,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7197,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,CHEMBL621390,4809,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7198,,Calculated partition coefficient (clogP),,BAO_0000100,CHEMBL621391,4219,,Intermediate,1,,P,,,,,
7199,,Half life in dog,,BAO_0000218,CHEMBL621392,3748,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7200,,Time taken for EC90 was determined when tested in dog,,BAO_0000218,CHEMBL621393,3132,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7201,,Half life (iv) was determined,,BAO_0000218,CHEMBL621394,4219,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7202,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,BAO_0000218,CHEMBL621395,16907,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Liver,
7203,,Area under the curve was calculated in dog after iv administration,,BAO_0000218,CHEMBL621396,6057,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7204,,Area under the curve was calculated in dog after peroral administration,,BAO_0000218,CHEMBL621397,6057,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7205,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,BAO_0000218,CHEMBL621398,17853,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7206,,pKa was evaluated in dog,,BAO_0000218,CHEMBL618818,3639,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7207,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,BAO_0000218,CHEMBL618819,14541,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7208,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL618820,16456,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7209,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,CHEMBL873810,16456,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7210,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,CHEMBL876606,2652,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7211,,Compound was evaluated for the half-life (t 1/2) in hours,,BAO_0000218,CHEMBL618821,3624,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7212,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,CHEMBL618822,1337,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Blood,
7213,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,CHEMBL618823,1337,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Blood,
7214,,Half life after intravenous administration of 1 mg/kg in dog,,BAO_0000218,CHEMBL618824,4709,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7215,,Half life was measured in dog,,BAO_0000218,CHEMBL618825,15660,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7216,,Half life period in dog after 5 mg/kg dose,,BAO_0000218,CHEMBL618826,5302,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7217,,Half life period was evaluated in dog; 4-4.8,,BAO_0000218,CHEMBL618827,17791,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7218,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,CHEMBL618828,6348,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7219,,Half-life was determined in dog after a3 mg/kg of iv dose,,BAO_0000218,CHEMBL618829,4257,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7220,,Half-life was determined,,BAO_0000218,CHEMBL618830,3771,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7221,,Half life in dogs,,BAO_0000218,CHEMBL618831,6305,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7222,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,BAO_0000218,CHEMBL619489,13501,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
7223,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,CHEMBL619649,17594,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7224,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,BAO_0000218,CHEMBL876607,3045,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7225,,Compound was evaluated for the half life period after oral administration in conscious dog.,,BAO_0000218,CHEMBL619650,3043,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7226,,Compound was tested for half life in dog,,BAO_0000218,CHEMBL619651,4839,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7227,,Compound was tested for its half life in dog,,BAO_0000218,CHEMBL619652,4839,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7228,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,CHEMBL619653,5802,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7229,,Half life of compound in dog was determined,,BAO_0000218,CHEMBL619654,17839,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7230,,Half life (iv) was determined,,BAO_0000218,CHEMBL619655,4219,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7231,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,BAO_0000218,CHEMBL619656,13966,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Blood,
7232,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,BAO_0000218,CHEMBL873812,3994,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
7233,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,BAO_0000218,CHEMBL621365,3994,9615.0,Intermediate,1,,F,In vivo,Canis lupus familiaris,,Plasma,
7234,,Half life in dog,,BAO_0000218,CHEMBL621366,4453,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7235,,Half life in dog plasma,,BAO_0000218,CHEMBL621367,6535,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
7236,,Half life in dog plasma after administration of 0.25 mg/kg iv,,BAO_0000218,CHEMBL621368,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
7237,,Half life in dog plasma after administration of 1 mg/kg iv,,BAO_0000218,CHEMBL621369,6535,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
7238,,Half life in dog plasma was determined at dose 10 mg/kg,,BAO_0000218,CHEMBL621370,3132,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,Plasma,
7239,,Half life in dog was determined,,BAO_0000218,CHEMBL621371,5374,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7240,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,CHEMBL621372,5007,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7241,,Half life upon exposure to human plasma,,BAO_0000218,CHEMBL621373,16907,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
7242,,Half life was calculated in dog,,BAO_0000218,CHEMBL621374,6057,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7243,,Half life was determined,,BAO_0000218,CHEMBL621375,5006,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7244,,Half life was determined,,BAO_0000218,CHEMBL621376,5473,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7245,,Half life by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,CHEMBL619624,4368,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7246,,Half life in dog,,BAO_0000218,CHEMBL875840,6448,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7247,,Half life in dog after intra venous administration of the compound,,BAO_0000218,CHEMBL619625,4353,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7248,,Half life in dog after intra venous administration of the compound; ND means Not determined,,BAO_0000218,CHEMBL619626,4353,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7249,,Half life in dog after po administration of the compound,,BAO_0000218,CHEMBL619627,4353,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7250,,Half life in dog after po administration of the compound; ND means Not determined,,BAO_0000218,CHEMBL873817,4353,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7251,,Half life in dog at the single oral dose of 1 mg/kg,,BAO_0000218,CHEMBL619628,6265,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7252,,Half life in dogs,,BAO_0000218,CHEMBL619629,5006,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7253,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,BAO_0000218,CHEMBL619630,5356,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7254,,Half life in rat,,BAO_0000218,CHEMBL619631,405,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7255,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,CHEMBL619632,6642,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7256,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL619633,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
7257,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL875841,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
7258,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL619634,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
7259,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL619635,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
7260,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL619636,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Bone,
7261,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL619637,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Gut,
7262,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,CHEMBL619638,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Gut,
7263,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL619639,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Gut,
7264,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL619640,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Gut,
7265,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL619641,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Gut,
7266,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL619642,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Gut,
7267,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL619643,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Gut,
7268,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL619644,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
7269,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,CHEMBL621112,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
7270,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL621113,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
7271,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL621114,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
7272,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL621115,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
7273,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL621116,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
7274,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL621117,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Heart,
7275,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL621118,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
7276,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,CHEMBL621119,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
7277,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL621120,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
7278,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL621757,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
7279,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL621758,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
7280,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL621759,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
7281,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL621760,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Kidney,
7282,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL621761,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
7283,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,CHEMBL621762,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
7284,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL621763,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
7285,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL624502,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
7286,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL624503,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
7287,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL624504,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
7288,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL624505,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Liver,
7289,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL624506,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
7290,,In vitro cytotoxicity against A2780 (human ovarian cancer),,BAO_0000219,CHEMBL624507,5895,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7291,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,BAO_0000219,CHEMBL624508,6338,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7292,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,BAO_0000219,CHEMBL624509,15163,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7293,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,BAO_0000219,CHEMBL624510,15163,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7294,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,BAO_0000219,CHEMBL875956,15000,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7295,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,BAO_0000219,CHEMBL839885,15000,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7296,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,BAO_0000219,CHEMBL624511,14729,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7297,,In vitro cytotoxicity against A2780 cell line,,BAO_0000219,CHEMBL624512,17270,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7298,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,BAO_0000219,CHEMBL624513,5685,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7299,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,BAO_0000219,CHEMBL624514,3563,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7300,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,BAO_0000218,CHEMBL618547,17753,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7301,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,BAO_0000219,CHEMBL618548,16317,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7302,,Inhibition of tubulin polymerization in analogy of ca.,,BAO_0000219,CHEMBL618549,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7303,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,BAO_0000219,CHEMBL618550,3801,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7304,,Cytotoxic effect in ovarian cancer cell line (A2780),,BAO_0000219,CHEMBL618551,6181,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7305,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,BAO_0000219,CHEMBL618552,5318,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7306,,Tested for the cytotoxicity in A2780 ovarian cell line,,BAO_0000219,CHEMBL618553,4840,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7307,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,BAO_0000219,CHEMBL618554,15748,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7308,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,BAO_0000219,CHEMBL618555,15748,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7309,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,BAO_0000219,CHEMBL618556,15748,,Intermediate,1,481.0,F,,,,,A2780cisR
7310,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,BAO_0000219,CHEMBL618557,15748,,Intermediate,1,481.0,F,,,,,A2780cisR
7311,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,BAO_0000219,CHEMBL618558,15748,,Intermediate,1,481.0,F,,,,,A2780cisR
7312,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,BAO_0000219,CHEMBL618559,15748,,Intermediate,1,481.0,F,,,,,A2780cisR
7313,,In vivo log of cells killed after administration of compound in A2780 cell line,,BAO_0000218,CHEMBL618560,17753,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7314,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,BAO_0000218,CHEMBL618561,17753,9606.0,Intermediate,1,478.0,F,In vivo,Homo sapiens,,,A2780
7315,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,BAO_0000219,CHEMBL618562,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7316,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,BAO_0000219,CHEMBL618563,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7317,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,BAO_0000219,CHEMBL618564,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7318,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,BAO_0000219,CHEMBL618565,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7319,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,BAO_0000218,CHEMBL618566,17528,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7320,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,BAO_0000219,CHEMBL618567,6633,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7321,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,BAO_0000219,CHEMBL618568,15000,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7322,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,BAO_0000219,CHEMBL618569,17528,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7323,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,BAO_0000219,CHEMBL621857,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7324,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,BAO_0000219,CHEMBL621858,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7325,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,BAO_0000219,CHEMBL621859,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7326,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,BAO_0000219,CHEMBL621860,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7327,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,BAO_0000219,CHEMBL621861,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7328,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,BAO_0000219,CHEMBL621862,16936,9606.0,Expert,1,478.0,F,,Homo sapiens,,,A2780
7329,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,CHEMBL621863,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7330,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,CHEMBL621864,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7331,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,CHEMBL621865,16936,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7332,,In vitro antiproliferative activity against A2780 cell line,,BAO_0000219,CHEMBL621866,17737,10090.0,Intermediate,1,478.0,F,,Mus musculus,,,A2780
7333,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,BAO_0000219,CHEMBL621867,17764,10090.0,Expert,1,478.0,F,,Mus musculus,,,A2780
7334,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,BAO_0000219,CHEMBL621868,3830,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7335,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,BAO_0000219,CHEMBL875282,3829,9606.0,Intermediate,1,478.0,F,,Homo sapiens,,,A2780
7336,,Vc value in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,CHEMBL621869,3546,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7337,,Half life period in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,CHEMBL621870,3546,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7338,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000019,CHEMBL621871,5668,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7339,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL621243,3443,9527.0,Autocuration,1,,A,,Cercopithecidae,,Plasma,
7340,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL621244,3443,9527.0,Autocuration,1,,A,,Cercopithecidae,,Plasma,
7341,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,CHEMBL621245,4256,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
7342,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,BAO_0000218,CHEMBL621246,4256,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
7343,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,CHEMBL621247,4256,9541.0,Autocuration,1,,A,In vivo,Macaca fascicularis,,,
7344,,Oral Bioavailability in rat,,BAO_0000218,CHEMBL618386,4256,10116.0,Autocuration,1,,A,In vivo,Rattus norvegicus,,,
7345,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,CHEMBL618387,1916,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7346,,Area under curve value in monkey at a dose of 5 mg/kg,,BAO_0000218,CHEMBL618388,5302,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7347,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,BAO_0000218,CHEMBL618389,4257,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7348,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,BAO_0000019,CHEMBL618574,5355,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7349,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,BAO_0000019,CHEMBL618575,5355,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7350,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,BAO_0000019,CHEMBL618576,5355,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7351,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,BAO_0000218,CHEMBL618577,6078,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7352,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,BAO_0000218,CHEMBL876487,6078,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7353,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL618578,6062,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7354,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,CHEMBL618579,2661,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7355,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000019,CHEMBL618580,2661,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7356,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,BAO_0000218,CHEMBL618581,5394,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7357,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,BAO_0000218,CHEMBL618582,4397,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7358,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,CHEMBL618583,17509,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7359,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,CHEMBL618584,17509,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7360,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,BAO_0000218,CHEMBL618585,6641,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7361,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,BAO_0000218,CHEMBL618586,5355,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7362,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL618587,3443,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7363,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,CHEMBL618588,3443,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7364,,Binding towards monkey plasma protein at 10 uM,,BAO_0000019,CHEMBL618589,17409,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7365,,Binding towards monkey plasma protein at 100 uM,,BAO_0000019,CHEMBL618590,17409,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7366,,Apparent bioavailability in squirrel monkey was determined,,BAO_0000218,CHEMBL872262,1052,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7367,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,BAO_0000218,CHEMBL618591,13501,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7368,,Bioavailability in monkey (dose 2 mg/kg),,BAO_0000218,CHEMBL618592,17509,9443.0,Autocuration,1,,A,In vivo,monkey,,,
7369,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,BAO_0000218,CHEMBL876488,5394,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7370,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,CHEMBL618593,2661,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7371,,Bioavailability in monkey (i.d. dosing),,BAO_0000218,CHEMBL618594,11219,9443.0,Autocuration,1,,A,In vivo,monkey,,,
7372,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,BAO_0000218,CHEMBL618595,3045,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7373,,Clearance of the drug was measured in cynomolgus,,BAO_0000019,CHEMBL621469,17796,9527.0,Autocuration,1,,A,,Cercopithecidae,,,
7374,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,BAO_0000218,CHEMBL621470,1399,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7375,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,CHEMBL621471,2661,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7376,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,CHEMBL621472,5005,9544.0,Autocuration,1,,A,In vivo,Macaca mulatta,,Plasma,
7377,,Plasma clearance in rhesus monkey was determined,,BAO_0000218,CHEMBL621473,17267,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7378,,Plasma clearance in monkey after administration of 1 mg/kg iv,,BAO_0000218,CHEMBL621474,6535,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7379,,Plasma clearance in cynomolgus monkey,,BAO_0000218,CHEMBL621475,5922,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7380,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,CHEMBL621476,6221,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7381,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,BAO_0000218,CHEMBL624290,5668,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7382,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,CHEMBL624291,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7383,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,CHEMBL624292,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7384,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,CHEMBL624293,5355,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7385,,Tested for Clearance upon iv administration to african green monkey,,BAO_0000218,CHEMBL624294,4578,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7386,,Clearance in monkey,,BAO_0000218,CHEMBL624295,17592,9527.0,Autocuration,1,,A,In vivo,Cercopithecidae,,,
7387,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL624296,6641,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7388,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,CHEMBL624297,6642,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7389,,Half life was evaluated after intravenous administration to dogs,,BAO_0000218,CHEMBL624298,16367,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7390,,Half life was evaluated in dog,,BAO_0000218,CHEMBL624299,5472,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7391,,Half life was evaluated in dog,,BAO_0000218,CHEMBL624300,5474,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7392,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,CHEMBL624301,5654,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7393,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,CHEMBL624302,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7394,,Half life period after intravenous administration in dog,,BAO_0000218,CHEMBL876026,6227,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7395,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,CHEMBL624303,6221,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7396,,Half life period at a dose of 1 uM/kg in dog was determined,,BAO_0000218,CHEMBL624304,4527,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7397,,Half life period was determine after peroral administration at 10 mpk in dog,,BAO_0000218,CHEMBL624305,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7398,,Half life period was determine after peroral administration at 5 mpk in dog,,BAO_0000218,CHEMBL624306,5668,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7399,,Half life period was determined,,BAO_0000218,CHEMBL624307,3854,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7400,,Half life period was determined,,BAO_0000218,CHEMBL624308,5505,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7401,,Half life period by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,CHEMBL624309,6251,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7402,,Half life period was evaluated in dog,,BAO_0000218,CHEMBL624310,1918,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7403,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,CHEMBL625003,5546,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7404,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,CHEMBL625004,4809,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7405,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,CHEMBL625005,6215,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7406,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,CHEMBL873813,4527,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7407,,Half-life after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,CHEMBL625006,17594,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7408,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,BAO_0000218,CHEMBL625007,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7409,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,BAO_0000218,CHEMBL876027,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7410,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,BAO_0000218,CHEMBL625008,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7411,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,BAO_0000218,CHEMBL625009,17839,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7412,,Half-life of compound in plasma of dog was determined,,BAO_0000218,CHEMBL625010,5210,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
7413,,Half-life of compound was determined in dogs,,BAO_0000218,CHEMBL625011,5210,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7414,,Half-life after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,CHEMBL621553,2959,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7415,,Half-life after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,CHEMBL621554,4137,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7416,,Half-life in Dog,,BAO_0000218,CHEMBL621555,5064,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7417,,Half-life in Dog,,BAO_0000218,CHEMBL621556,5147,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7418,,Half-life in dog,,BAO_0000218,CHEMBL621557,5145,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7419,,Half-life in dog after oral administration at 1 mg/kg,,BAO_0000218,CHEMBL621558,6123,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7420,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,BAO_0000218,CHEMBL621559,6123,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7421,,Half-life in dogs,,BAO_0000218,CHEMBL621560,4333,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7422,,Half-life in dogs; ND indicates not determined,,BAO_0000218,CHEMBL876028,4333,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7423,,Half-life in plasma of dog,,BAO_0000218,CHEMBL621561,12500,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
7424,,Half-life in plasma of dog at dose of 3-10 mgkg,,BAO_0000218,CHEMBL621562,12500,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,Plasma,
7425,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,CHEMBL621563,6005,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7426,,Half-life was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,CHEMBL621564,6062,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7427,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,CHEMBL621565,17650,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7428,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,CHEMBL621566,5530,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7429,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,CHEMBL621567,5530,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7430,,Half-life of the compound after 0.3 mg/kg po administration in dog,,BAO_0000218,CHEMBL622978,5600,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7431,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,CHEMBL873814,6039,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7432,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,CHEMBL623219,6039,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7433,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,CHEMBL624477,6039,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7434,,t1/2 in dog,,BAO_0000218,CHEMBL624478,6227,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7435,,Half-life period measured in dogs,,BAO_0000218,CHEMBL624479,14541,9615.0,Intermediate,1,,A,,Canis lupus familiaris,,,
7436,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,CHEMBL624480,4521,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7437,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,CHEMBL623595,4521,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7438,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,CHEMBL623596,6679,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7439,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,BAO_0000218,CHEMBL623597,1116,9615.0,Intermediate,1,,A,In vitro,Canis lupus familiaris,,Plasma,
7440,,In vivo half life period was calculated at 1 mg/kg in dog,,BAO_0000218,CHEMBL623598,5444,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7441,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,BAO_0000218,CHEMBL623599,5444,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7442,,Longer half-life in dog (i.v.) at 0.5 mpk,,BAO_0000218,CHEMBL623600,17853,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7443,,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,CHEMBL623601,4353,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7444,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,CHEMBL623602,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7445,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,CHEMBL623603,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7446,,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,CHEMBL623604,16452,9615.0,Intermediate,1,,A,In vivo,Canis lupus familiaris,,,
7447,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,CHEMBL623605,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
7448,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL623606,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
7449,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL623607,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
7450,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL623608,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
7451,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL623609,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
7452,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL623610,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Lung,
7453,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL623611,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
7454,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,CHEMBL623612,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
7455,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL623613,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
7456,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL623614,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
7457,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL623615,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
7458,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL623616,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
7459,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL623617,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Muscle tissue,
7460,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL875944,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Zone of skin,
7461,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,CHEMBL623618,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Zone of skin,
7462,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL623619,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Zone of skin,
7463,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL623620,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Zone of skin,
7464,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL623621,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Zone of skin,
7465,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL623622,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Zone of skin,
7466,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL623623,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Zone of skin,
7467,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL623624,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
7468,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,CHEMBL618521,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
7469,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL618522,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
7470,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL618523,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
7471,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL618524,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
7472,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL618525,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
7473,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL624586,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Spleen,
7474,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,CHEMBL624587,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
7475,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,CHEMBL624588,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
7476,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,CHEMBL624589,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
7477,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,CHEMBL624590,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
7478,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,CHEMBL624591,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
7479,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,CHEMBL624592,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
7480,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,CHEMBL624593,10107,10090.0,Intermediate,1,,A,In vivo,Mus musculus,,Stomach,
7481,,Oral bioavailability in rat,,BAO_0000218,CHEMBL624594,4689,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7482,,Tested for the bioavailability in rat,,BAO_0000218,CHEMBL624595,4950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7483,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,CHEMBL624596,5328,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7484,,Bioavailability in rat,,BAO_0000218,CHEMBL624597,406,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7485,,Bioavailability in rat,,BAO_0000218,CHEMBL624598,12500,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7486,,Bioavailability in rat (dose 3-10 mg/kg),,BAO_0000218,CHEMBL624599,12500,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7487,,Bioavailability in rat,,BAO_0000218,CHEMBL875166,5247,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7488,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,CHEMBL624600,4186,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Plasma,
7489,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,BAO_0000218,CHEMBL624601,4186,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Plasma,
7490,,Half life after oral administration was determined in rats at 6 mg/kg,,BAO_0000218,CHEMBL624602,6647,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7491,,Half life was determined,,BAO_0000218,CHEMBL624603,6484,10116.0,Intermediate,1,,A,,Rattus norvegicus,,,
7492,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,BAO_0000218,CHEMBL624604,3249,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,,
7493,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,BAO_0000218,CHEMBL624605,6281,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Plasma,
7494,,Half life in rats,,BAO_0000218,CHEMBL624606,3307,10116.0,Intermediate,1,,A,,Rattus norvegicus,,,
7495,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,BAO_0000218,CHEMBL624607,12058,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Blood,
7496,,Hill coefficient of the compound,,BAO_0000218,CHEMBL624608,8833,10116.0,Intermediate,1,,A,,Rattus norvegicus,,,
7497,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,BAO_0000218,CHEMBL624609,3193,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Blood,
7498,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,BAO_0000218,CHEMBL624610,3193,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Blood,
7499,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,BAO_0000218,CHEMBL624611,3193,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Blood,
7500,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,BAO_0000218,CHEMBL624612,3193,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Blood,
7501,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,BAO_0000218,CHEMBL875167,3193,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Blood,
7502,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,BAO_0000218,CHEMBL624613,3193,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Blood,
7503,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,BAO_0000218,CHEMBL624614,3193,10116.0,Intermediate,1,,A,,Rattus norvegicus,,Blood,
7504,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,BAO_0000218,CHEMBL624392,5960,10116.0,Intermediate,1,,A,,Rattus norvegicus,,,
7505,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624393,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Brain,
7506,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624394,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Brain,
7507,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624395,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Brain,
7508,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624396,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Brain,
7509,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624397,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Brain,
7510,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624398,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Thyroid gland,
7511,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624399,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Thyroid gland,
7512,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624400,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Thyroid gland,
7513,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624401,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Thyroid gland,
7514,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,BAO_0000218,CHEMBL624402,13950,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Thyroid gland,
7515,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,CHEMBL624403,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Blood,
7516,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,CHEMBL624404,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Blood,
7517,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,CHEMBL624405,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Blood,
7518,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,CHEMBL624406,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Bone,
7519,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,CHEMBL624407,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Bone,
7520,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,CHEMBL624408,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Bone,
7521,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,CHEMBL618644,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Heart,
7522,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,CHEMBL618645,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Heart,
7523,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,CHEMBL618646,9866,10116.0,Intermediate,1,,A,In vivo,Rattus norvegicus,,Heart,
